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Mitochondrial disease can be caused by pathogenic variants in either nuclear DNA or 
mitochondrial DNA (mtDNA). Affected patients present with a considerable genetic, clinical 
and biochemical heterogeneity, thereby complicating the diagnostic pathways. For pathogenic 
mtDNA variants, this is further compounded by heteroplasmy – the mixture of both wild-type 
and mutated mtDNA existing within a single cell. When the proportion of mutant mtDNA 
exceeds a critical threshold of mutated mtDNA molecules, the cell becomes biochemically 
dysfunctional. This dysfunction can be identified using a recently described quadruple 
immunofluorescent assay through the assessment of Complex I, Complex IV and porin 
protein expression in individual fibres within 10µm skeletal muscle sections from patients. 
The assessment of Complex I dysfunction is crucial, as deficiency of this particular 
respiratory chain complex is the most common form of mitochondrial dysfunction observed in 
mitochondrial disease. This thesis describes two studies that have utilised this assay with the 
aim of i) improving the diagnosis of mitochondrial disease and ii) understanding the 
molecular mechanisms underlying mitochondrial disease and the expression of a biochemical 
defect.  
Given the lack of histochemical tests to interrogate Complex I in skeletal muscle, the viability 
of the quadruple immunofluorescent assay in detecting Complex I deficiency was assessed in 
a heterogeneous cohort of patients with genetically-proven pathogenic variants within 
mtDNA-encoded or nuclear-encoded (structural Complex I subunits or assembly factors) 
genes. Clear diagnostic potential was evident, particularly for patients with nuclear-encoded 
gene defects whilst highlighting the necessity of complete mitochondrial genome sequencing 
in the diagnostic work up of patients.  
The quadruple immunofluorescent assay was also used to characterise –at a single cell level - 
the biochemical status of skeletal muscle fibres from patients harbouring the m.3243A>G 
mutation, the most prevalent, pathogenic heteroplasmic mtDNA point mutation. Two groups 
of patients were identified: those showing a predominance of Complex I deficiency and those 
expressing no biochemical defect in their skeletal muscle. Isolation of single muscle fibres 
enabled investigation of the relationship between the biochemical deficiency and single fibre 
m.3243A>G heteroplasmy, identifying differences in the biochemical threshold for Complex I 
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1.1.  Introduction  
Mitochondria are essential intracellular organelles which are present in the cytoplasm of all 
nucleated mammalian cells. They are predominantly known for their principle role of 
generating cellular energy in the form of adenosine triphosphate (ATP) (Hatefi, 1985). 
However, mitochondria are also involved in multiple biological processes and pathways for 
example, the regulation of cell death via apoptosis, cytosolic calcium handling, iron-sulphur 
(Fe-S) cluster and haem biogenesis and the generation of reactive oxygen species. Most 
interestingly, mitochondria are unique in that they are the only organelle, other than the 
nucleus, that contain their own genome; the mitochondrial DNA (mtDNA). This genome 
accommodates the essential genes required for the production of ATP and mitochondrial 
function. However, the vast majority of mitochondrial proteins (1,158 proteins according to 
the MitoCarta2.0) (Calvo et al. 2016), are encoded for by the nuclear DNA. Such, the 
mitochondria is under the dual control of both the nuclear DNA and mtDNA, thereby any 
defects occurring in these genomes can lead to complicated disease. One particular tissue that 
is frequently affected by mitochondrial disease in patients is the skeletal muscle – a post-
mitotic tissue that has high metabolic demand due to its critical function in controlling 
voluntary movement. Therefore, skeletal muscle is a major source of resource for both 
diagnostic investigation and research into mitochondrial disease. 
  
This section of the thesis will introduce basic mitochondrial biology and genetics, linking the 
latter to mitochondrial disease and current diagnostic processes. Areas of this introduction 
which are of particular interest and relevance to the studies described in this thesis, will be 
highlighted and detailed further in the relevant Results chapters (Chapters 3, 4 and 5).   
 
1.2.  Mitochondrial biology  
1.2.1. Origins and evolution of mitochondria 
The first identification of mitochondria dates back to the 1800s, where intracellular structures 
known as “bioblasts” were founded in the cytoplasm of nucleated cells (Altmann 1894). 
Thereafter, the organelle was named mitochondria (singular; mitochondrion), taken from the 
Greek terms “mito” which means thread and “khondrion” meaning granule.   
The origins of mitochondria in eukaryotic cells has been proposed by two theories. The first 
and most well-known theory is the endosymbiotic theory. The mitochondria was said to have 
an endosymbiotic origin, whereby a free living Eubacteria (believed to be a prokaryotic 
ancestor related to alpha-proteobacteria) was engulfed by a primordial eukaryotic cell 
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(Margulis 1971). It was proposed that the endosymbiosis event occurred after the emergence 
of the cell nucleus (Margulis 1971). The second theory which has been proposed is known as 
the “hydrogen hypothesis”, in which it was postulated that both the nucleus and mitochondria 
were formed after the fusion of a hydrogen dependent Archaebacterium and a hydrogen-
producing Eubacterium (Martin and Muller 1998). Both of these theories are in agreement 
that during the expansive and reductive evolution process, most of the genes from the 
bacterial genome were lost or transferred to the nuclear genome of the eukaryotic host cell, 
leaving a compact mtDNA, during a process called the endosymbiotic gene transfer (EGT) 
during mitochondrial evolution (Gray et al. 1999). 
Mitochondria have retained features of a bacterial ancestry which is reflected in the double 
membrane, circular genome (mtDNA), machinery for protein synthesis in the matrix and the 
ability to move, divide and fuse. Additionally, the respiratory chain complexes involved in 
Oxidative Phosphorylation (OXPHOS) is evident of the evolutionally conservation between 
the mitochondrion and the primitive Eurbacterium (Gray et al. 1999).  
1.2.2. Structure of mitochondria 
With the use of electron microscopy (EM), two pioneering studies in the 1950s were able to 
show that the mitochondria was a double membraned organelle, containing the outer 
mitochondrial membrane (OMM) and the inner mitochondrial membrane (IMM) (Palade 
1952; Sjostrand 1953). However, these studies differed in their proposed models of 
mitochondrial structures. Palade proposed the “baffle model” of cristae structure in which the 
inner membrane formed baffles that projected into the matrix, termed cristae mitochondriales. 
Sjostrand’s alternative model proposed a third membrane forming septa that divided the 
matrix into many compartments. Both theories were proven to be inaccurate when a study 
using EM tomography and isolated mitochondria from rat liver, showed that narrow tubular 
invaginations of the IMM form the cristae (Mannella et al. 1997).  
As shown in Figure 1.1 (A and B), the membranes of the mitochondrion confine two aqueous 
compartments; the intermembrane space (IMS) and the matrix. The IMS is a ~20nm gap 
between the OMM and the IMM. Within the matrix, mtDNA is present alongside proteins 
involved in DNA replication, transcription and translation as well as proteins involved in 
biosynthetic reactions, namely the Tricarboxylic acid cycle (TCA cycle) or fatty acid (β) 
oxidation. The mitochondrial matrix has been found to have a pH of 7.8 which is believed to 
have a role in creating a transmembrane electrochemical gradient that drives ATP synthase 
(Complex IV) to produce ATP (Llopis et al. 1998).   
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The OMM is smooth and porous as it contains a high abundance of the beta-barrel protein 
called porin (also known as VDAC), a voltage gated anion which allows for the passage of 
low molecular weight molecules (under 10KDa) from the cytoplasm to the IMS. These 
molecules include lipid, sugars, amino acids and ions (Szabo and Zoratti 2014; Villinger et al. 
2010). Larger molecules, such as proteins, require translocases to be transported across the 
membrane.  
The IMM is much less permeable than the OMM. This ion selectivity leads to an 
electrochemical membrane potential of approximately 180 millivolts (mV) to build across the 
membrane. Additionally, in comparison to the OMM, the IMM has a high amount of 
membrane associated proteins with studies stating a 3:1 ratio for protein: lipid association 
(Shaikh et al., 2012). This high protein content is largely due to the proteins involved in 
OXPHOS. The IMM is rich in the phospholipid cardiolipin, which accounts for 20% of the 
lipid constitution. Cardiolipin has been shown to have an important role in the architecture of 
the IMM, as well as having a role in the maintenance of the membrane potential and 
providing an essential structural and functional support to the OXPHOS proteins (Bazan et al. 
2013).  
The IMM forms invaginations called cristae that extend deeply into the matrix. Cristae can be 
found in different morphologies including lamellar sheets and tubular enlarged bag-like-
extensions (Frey and Mannella 2000). The cristae are connected to the IMS by the tubular 
cristae junctions (Daems and Wisse 1966; Mannella et al. 1997). The IMM can be subdivided 
into two parts; the inner boundary membrane (IBM) and the cristae membrane (CM). The 
IBM is found adjacent to the outer membrane and is enriched with proteins which are 
responsible for mitochondrial fusion and nuclear-encoded protein transport. The CM is 
enriched in proteins including the fully assembled complexes of the electron transport chain 
(ETC) and other proteins involved in OXPHOS, protein synthesis, mtDNA- encoded protein 
transport and Fe-S cluster biogenesis (Gilkerson et al. 2003; Vogel et al. 2006). At the 
junction between the IBM and CM is the large protein complex known as the ‘Mitochondrial 
contact site and cristae organising system’ (MICOS), which serves to anchor the cristae (the 





Figure 1.1: The mitochondrial structure. 
A) Transmission electron microscopy image of a mitochondrion (provided by Dr Amy Vincent, 
Wellcome Centre for Mitochondrial Research, Newcastle University) and B) a schematic diagram 
showing the key structures of mitochondria. C)  The proteins associated with the inner boundary 
membrane (IBM) and the cristae membrane (CM) that are involved with mitochondrial fusion (OPA1), 
nuclear- encoded protein transport complexes (TIM, SAM, TOM), the fully assembled complexes of 
the electron transport chain (ETC) which include Complex I, II, III, IV which then in conjunction with 
Complex V completes the oxidative phosphorylation (OXPHOS) system. The ‘Mitochondrial contact 
site and cristae organising system’ (MICOS) which anchors the CM to OMM.  
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1.2.3. The import of mitochondrial proteins 
According to the recently published MitoCarta2.0, the mitochondria contains 1,158 proteins 
of which 99% are encoded by the nDNA (Calvo et al. 2016; Pagliarini et al. 2008; Sickmann 
et al. 2003). Therefore, these proteins are synthesised by the cytosolic ribosomes in a 
precursor form and then subsequently imported into the mitochondria (Schmidt et al. 2010). 
These cytosolic ribosomes have been found to be in close proximity to the OMM (Kellems et 
al. 1975). The import of the precursors and the following intra-mitochondrial sorting is 
mediated by membrane protein complexes, termed translocases, founded in the outer and 
inner membranes. Further soluble factors are found within the cytosol, intermembrane space 
and matrix.  
The precursors contain targeting signals that are recognised by receptors on the mitochondrial 
surface, which assist in directing them to their functional destinations in the mitochondrial 
sub-compartments. There are 2 main groups of targeting signals and the first is the amino-
terminal cleavable pre-sequence which is found in 60% of all precursors (Schatz and 
Dobberstein 1996; Schulz et al. 2015). These sequences are usually proteolytically cleaved off 
after import. The remaining 40% of precursors are termed non-cleavable precursor proteins as 
they contain an internal targeting signal that remains part of the mature protein (Chacinska et 
al. 2009).  
All precursors must be translocated into or across the outer membrane of the mitochondria. 
The translocases responsible for most precursors are the translocases of the outer membrane 
(TOM), consisting of Tom40, Tom22, Tom5, Tom6, Tom7, Tom20 and Tom70 (Endo and 
Yamano 2010; Ryan et al. 2000; Schmidt et al. 2010). Once translocated through the TOM 
complex, precursors follow four different protein import pathways dependent on their sub-
compartment role. Figure 1.2 highlights the pathways by which the nuclear-encoded proteins 
are imported into the mitochondria.  
Pre-sequence Pathway 
The first pathway is the pre-sequence pathway which leads cleavable precursors from the 
TOM complex to the translocase of the inner membrane (TIM) complex – indicated by 3 in 
Figure 1.2 (Schmidt et al. 2010; Straub et al. 2016; Vogtle et al. 2009). The mitochondrial 
processing peptidase (MPP) cleaves the pre-sequence (Hawlitschek et al. 1988; Mossmann et 
al. 2012). The precursors are imported to the inner membrane and matrix with the assistance 





The second pathway is the carrier pathway (indicated by 7 in Figure 1.2) which involves the 
import of non-cleavable precursors of metabolite carriers (ADP and ATP carriers). The 
precursors are imported firstly through the TOM complex then transferred to chaperone 
complexes of the IMS - the small TIM complex (Rehling et al. 2003). From this, the 
precursors are inserted into the inner membrane through the translocases of the TIM22 
complex (Schmidt et al. 2010). 
Oxidative pathway for intermembrane space precursors 
The third pathway is the oxidative pathway of the IMS precursors (indicated by 5 in Figure 
1.2). Many of the IMS precursors contain cysteine motifs and these precursors are imported 
through the TOM complex. They then interact with the mitochondrial IMS import and 
assembly (MIA) machinery which oxidises the cysteine motifs (Chacinska et al. 2004; Straub 
et al. 2016).  
Beta-barrel protein pathway  
The final pathway is the transport pathway of beta-barrel proteins of the OMM (indicated by 6 
in Figure 1.2). The precursors for these proteins are translocated through the TOM complex 
and transported to the small TIM chaperones (Tim9-Tim10 and Tim8-13). They are then 
inserted into the outer membrane by the sorting and assembly machinery (SAM) which is 
embedded in the OMM. Beta-barrel proteins are the most abundant type of proteins of the 
OMM including porin. Sam50, the core component of the complex, recognises beta-barrel 
proteins through an amino acid sequence near their C-termini leading to the folding and 
insertion into the OMM (Dudek et al. 2013; Riezman et al. 1983; Schmidt et al. 2010; 




Figure 1.2: Import pathways for nuclear encoded mitochondrial proteins. 
(1-2) 99% of proteins in the mitochondrial proteome are encoded for by nuclear DNA and synthesised 
on cytosolic ribosomes. Proteins are imported to the mitochondria through the translocase of outer 
membrane (TOM) complex. Thereafter, precursors can use different sorting machineries. (3) Pre-
sequence pathway – pre-sequence precursors belonging to the matrix are imported by the translocase 
of the inner membrane (TIM23) complex and the pre-sequence translocase-associated motor (PAM). 
The mitochondrial processing peptidase (MPP) removes the pre-sequence. (4) Some precursors are 
laterally released from the TIM23 complex into the inner membrane. (5) Precursors which are for the 
intermembrane space are imported by the mitochondrial intermembrane space assembly (MIA). (6) 
Hydrophobic precursor proteins are transferred by the Tim9-Tim10 chaperones complex through the 
intermembrane space to the sorting and assembly machinery (SAM) in the case of the beta-barrel 
proteins of the outer membrane complex or (7) through the carrier pathway to the TIM22 complex. 










1.2.4.  Mitochondrial dynamics  
Mitochondria are dynamic organelles that are continually undergoing fission and fusion 
(Westermann 2010). These act concurrently to allow the mitochondrial network to be 
remodelled in terms of morphology, size, number and content in accordance to the metabolic 
demand and changes (Westermann 2012).   
1.2.4.1.  Mitochondrial Fission 
Fission involves the separation of both the outer and inner mitochondrial membrane and so 
the organelle becomes two separate entities (Figure 1.3). DRP1 (Dynamin-related protein 1), 
predominantly found in the cytosol of the cell, is the protein regulating the fission of the 
OMM (Smirnova et al. 2001). It is recruited to the mitochondria by four integral membrane 
proteins found in the OMM; mitochondrial fission protein 1 (Fis1 – an adapter protein 
anchored to the membrane by a c-terminal transmembrane domain), mitochondrial fission 
factor (Mff), MiD49 and MiD50 (Loson et al. 2013; Otera et al. 2010; Palmer et al. 2011; 
Scott and Youle 2010). Once translocated from the cytoplasm to the OMM, DRP1 
oligomerises into ring-like structures at the sites of division which are marked by endoplasmic 
reticulum (ER) and actin cytoskeleton. GTP binding and hydrolysis promotes a 
conformational change in DRP1, resulting in constriction and severing of the OMM 
(Friedman et al. 2011; Mears et al. 2011; Smirnova et al. 2001). The fission of the IMM 
remains unclear, however recent studies have suggested two IMM proteins; S-OPA1 (short 
form OPA1 - generated from the proteolytic cleavage of L-OPA1 at sites S1 or S2) (Anand et 
al. 2014; Belenguer and Pellegrini 2013; Mishra et al. 2014) and MTP-18 (mitochondrial 





Figure 1.3: Regulation of mitochondrial fission. 
Dynamin-related protein 1 (DRP1; red) is recruited from the cytosol to the outer mitochondrial 
membrane (OMM) by MFF (dark blue), MiD49 (dark green) and MiD59 (pink) and Fis1 (yellow). DRP1 
oligomerises into ring-like structures at the site of division which are marked by endoplasmic reticulum 
(ER - green). The binding and hydrolysis promotes a conformational change in DRP1, resulting in 
constriction and severing of the outer membrane. Figure has been adapted from (Wai and Langer 2016).      
 
1.2.4.2. Mitochondrial fusion 
Fusion is the process by which two mitochondria and their outer and inner membrane merge 
to result in one large mitochondria (Figure 1.4). The fusion of the OMM is regulated by the 
mitofusin proteins 1 and 2 (Mfn1 and Mfn2) which are localised to the OMM and have a role 
in tethering two mitochondria during the early stage of fusion. OPA1 mediates the fusion of 
the IMM (Meeusen et al. 2004; Meeusen et al. 2006). OPA1 exists in two forms, a long OPA1 
(L-OPA1) and a short form (S-OPA1). Both are localised in the IMS, however L-OPA1 is 
anchored to the IMM whereas S-OPA1 is not (Mishra et al. 2014). It was found that both 





Figure 1.4: Regulation of mitochondrial fusion. 
Mitochondrial fusion is facilitated by interactions between MFN1 (blue) and MFN2 (yellow) at the outer 
mitochondrial membrane (OMM) and L-OPA1 (green) in the inner mitochondrial membrane (IMM). 
Black arrows represent the emergence of two mitochondria Figure has been adapted from (Wai and 
Langer 2016).      
 
1.2.4.3.  Mitochondrial biogenesis  
Mitochondrial biogenesis is the process by which the mitochondrial copy number and activity 
increases within a cell as a response to metabolic stress (such as exercise) or an environmental 
stimuli, such as caloric restriction (Kelly and Scarpulla 2004). A major regulator of 
mitochondrial biogenesis is the peroxisome proliferator-activated receptor gamma coactivator 
1-alpha (PGC-1α) (Puigserver et al. 1998). It is a co-transcriptional regulator factor that 
induces biogenesis through the activation of different transcription factors including both 
nuclear respiratory factor 1 and 2 (NRF-1 and NRF-2), which promote the expression of 
TFAM, thus driving the replication and transcription of mtDNA (Virbasius and Scarpulla 
1994). Other transcriptor factors include estrogen related receptor alpha (ERRα) and 
peroxisome proliferator-activated receptor alpha (PPARα). 
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1.3. Mitochondrial function  
1.3.1. Oxidative Phosphorylation (OXPHOS) and ATP synthesis 
Mitochondria are the principle generators of cellular energy in the form of ATP, hence why 
they are commonly known as the “powerhouse of the cells” (Hatefi 1985).   
1.3.1.1. The tricarboxylic acid (TCA) cycle  
The generation of ATP is a multistep process which begins with glycolysis in the cytosol of 
the cell, where glucose is broken down into two molecules of pyruvate and two molecules of 
water (H2O), as shown by Equation 1.1  (Berg 2011). Pyruvate can also be a by-product of 
fatty acid β-oxidation.  
Glucose + 2[NAD+] + 2[ADP] + 2[Pi] → 2 [pyruvate] 2[NADH] + 2[H+] + 2[ATP] + 
2[H2O] 
Equation 1.1: Glycolysis  
 
The pyruvate is imported into the mitochondria via the mitochondrial pyruvate carrier (MPC) 
and is converted to acetyl-coenzyme (CoA) by the enzyme pyruvate decarboxylation 
(Equation 1.2).  
Pyruvate + CoA + NAD+ → Acetyl-CoA + NADH + H+ + CO2  
 
Equation 1.2: Pyruvate decarboxylation  
 
Acetyl-coenzyme (CoA), alongside NAD+ and FAD are major substrates in the tricarboxylic 
acid (TCA) cycle, also known as the Kreb’s cycle (Krebs and Johnson 1937) – highlighted by 
Figure 1.5. Here, the carbon atoms of the acetyl group of CoA are oxidized, producing citrate 
(catalysed by citrate synthase). Oxaloacetate is also converted to citrate. The TCA cycle is a 
series of reactions that produces one molecule of ATP and CO2, as well as NADH 
(nicotinamide adenine dinucleotide) and FADH2 (flavin adenine dinucleotide) which are 
electron carriers that are subsequently involved in the initial stage of OXPHOS. It also returns 
citrate to oxaloacetate (Berg 2011). Equation 1.3 highlights the complete TCA cycle.  
 
Acetyl-CoA + 3[NAD+ + FAD+ ADP + Pi + 2[H2O] → CoA + 3[NADH] + 2[H
+] + FADH2 + 
ATP + 2[CO2]  
 





Figure 1.5: The TCA (Krebs) Cycle. 
Eight intermediate redox reactions required for the conversion of Acetyl-CoA to CoA. A single 
molecule of GTP (red) or ATP is generated when inorganic phosphate (Pi) is transferred from 
Succinyl-CoA to either GDP or ADP. Essential electron carriers for the electron transfer chain are 
also produced; NADH and FADH2.  
 
1.3.1.2. Oxidative phosphorylation 
The final stage of cellular respiration is OXPHOS where the vast majority of ATP is 
synthesised. The OXPHOS system is embedded in the IMM. At the core of the OXPHOS 
system is the ETC (also known as the mitochondrial respiratory chain) which consists of a 
series of complexes (Complex I -IV) in conjunction with ATP synthase (Complex V), which 
completes the OXPHOS system. Approximately 90 protein components make up OXPHOS – 
13 of which are coded for by the mtDNA. The four complexes of the ETC catalyse the 
movement of electrons along the chain, as well as the translocation of protons from the matrix 
into the IMS, creating a proton motive force which drives the synthesis of ATP from ADP via 
complex V (Smeitink et al. 2001). The proton gradient across the IMM of the mitochondria is 
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180mV. This proton motive force is also essential for other processes such as ion transport 
across the inner membrane, protein import and Fe-S cluster biogenesis.  
As shown in Figure 1.6, the electron carrying substrates NADH and FADH2 enter the ETC 
via Complex I and II and are reduced to NAD/FAD. The electrons are transferred to 
ubiquinone (Q), a soluble electron carrier found within the IMS. Ubiquinone is reduced to 
ubiquinol (QH2) by Complex III and the electrons are transferred to cytochrome c (cyt c), a 
water-soluble carrier. Complex IV then catalyses the final transfer of electrons to produce 
molecular oxygen (O2) and water (H2O). During this series of electron transfer, protons are 
translocated from the matrix into the IMS by complex I, III and IV. This coupled movement 
of electrons and translocation of protons creates the proton motive force which then drives the 
production of ATP from ADP and Pi via Complex V. This coupling of electron transfer and 
ATP production is known as the chemiosmotic theory, as first described by Mitchell (1961).  
 
 
Figure 1.6: Oxidative Phosphorylation. 
The five protein complexes (CI-CV) are embedded in the inner membrane of the mitochondria. Oxidative 
phosphorylation couple’s electron transport and proton translocation to generate ATP. Electrons (in 
red) enter the electron transport chain through either Complex I or Complex II and are moved along to 
Complex III and Complex IV, via cytochrome c. This transfer of electrons generates the proton transfer 
from the matrix to the intermembrane space (IMS). Complex V utilises the proton gradient to produce 




1.3.1.3. Complex I (NADH: Ubiquinone Oxidoreductase)  
With a relative molecular mass of 1MDa, the mitochondrial Complex I (also known as 
NADH: ubiquinone oxidoreductase), is the first and largest complex of the ETC. This 
complex is the first entry point for electrons in the OXPHOS system (Brandt 2006; Hirst 
2013). The main function is to oxidize NADH (derived from the breakdown of carbohydrates, 
amino acids and fatty acids) to NAD+, as well as playing a central role in both electron 
transfer and in ATP production through establishing the proton motive force (also known as 
the mitochondrial electrochemical proton gradient (ΔΨ)).   
The movement of electrons through Complex I, as shown in Figure 1.7, is initiated when 
NADH is oxidised to NAD+.  Two electrons and two hydrogen ions are released from this 
reaction and are transferred to the primary electron acceptor known as flavin mononucleotide 
(FMN) protein which is consequently reduced to FMNH2. The two electrons from FMNH2 are 
then shuttled through a series of eight Fe-S clusters, each of which have an increased 
reduction potential. When electrons reach the final Fe- S cluster (N2 Fe-S cluster), they are 
transferred to the final electron acceptor known as ubiquinone (CoQ10) which is reduced to 
ubiquinol (QH2). This electron carrier is able to diffuse within the IMM to the next electron 
acceptor within Complex III of the ETC. The reduction reaction of CoQ10 is coupled with the 
translocation of four protons (H+) from the mitochondrial matrix into the IMS (Ripple et al. 
2013). This proton movement coupled with the electron movement contributes to the proton 
motive force, which leads to the eventual synthesis of ATP via ATP synthase (Complex IV) 
(Guerrero-Castillo et al. 2017; Lazarou et al. 2009; Mitchell 1961; Stroud et al. 2016). To 
summarise, with every two electrons which are transferred from NADH to ubiquinone, four 
protons are translocated (Galkin et al. 2006) - (Equation 1.4). It has been found that Complex 
I provides 40% of the proton motive force to drive the energy production (Giachin et al. 
2016), hence it’s importance in the synthesis of ATP. 
 
NADH + Q + 5[H+] matrix → NAD
+ + QH2 + 4[H
+] cytoplasm  
 
Equation 1.4: Complex I reaction  







Figure 1.7: The movement of electrons through Complex I. 
A-D indicate the order in which electrons move through the complex. A) Two electrons accepted from 
NADH B) and transferred to the flavin mononucleotide (FMN) and then shuttled through a series of 
eight iron-sulphur (Fe-S) clusters (black). C) They are passed to the final acceptor ubiquinone ((Q10) 
which is reduced to ubiquinol (Q10H2), D) consequently causing the release of 4 protons (H
+) into the 
intermembrane space of the mitochondria. Figure adapted from (Hirst and Roessler 2016).  
 
1.3.1.4. Complex II - Succinate-ubiquinone oxidoreductase 
Complex II, is the only complex which is completely encoded by the nDNA. At ~260 kDa in 
size, the complex has a dual role in ATP synthesis; firstly, within the TCA cycle where it 
oxidises the metabolite succinate to fumarate, generating FADH2 in the process (Equation 
1.5) and secondly within the ETC where it transfers electrons from FADH2 to ubiquinone 
which is reduced to ubiquinol (Cecchini 2003; Sun et al. 2005). Therefore, with its 
involvement with the TCA cycle, Complex II links the TCA cycle to the respiratory chain.   
 
Succinate + FAD + 2[H+] +Q → fumarate + FADH2 + Q → fumarate + FAD +QH2  
 




Complex II consists of four nuclear encoded subunits – the two hydrophilic catalytic subunits 
SDHA (flavoprotein (Fp); 70 kDa) and SDHB (iron-sulphur (Ip); 35 kDa) and the two 
hydrophobic subunits SDHC and SDHD (Figure 1.8). SDHA and SDHB project into the 
matrix of the mitochondria whilst SDHC and SDHD are embedded within the inner 
membrane, helping to stabilise the complex (Sun et al. 2005). SDHA harbours a covalently 
bound prosthetic group called flavin adenine dinucleotide (FAD) which acts as the initial 
acceptor of electrons donated by FADH2 that is then consequently oxidised to FAD
+, 
releasing two electrons. These electrons are then sequentially transferred through three Fe-S 
clusters within SDHB to ubiquinone at the Q binding site found between SDHC and SDHD 
(Lee et al. 1995).  Ubiquinone is consequently reduced to ubiquinol. The haem group (heme b 
moiety) within SDHD stabilises the electrons adjacent to ubiquinol in the reduction process. 
Ubiquinol dissociates from SDHC to transfer electrons to Complex III (McNeil and Fineran 
2013; Quinlan et al. 2012). The movement of electrons from FADH2 to ubiquinone does not 
contribute towards the proton motive force.  
There are two main assembly factors associated with Complex II; SDHAF1 which inserts the 
Fe-S clusters into SDHB (Ghezzi et al. 2009) and SDHAF2 which inserts FAD into SDHA 
(Hao et al. 2009).  
 
Figure 1.8: A schematic structure and function of Complex II.  
The two hydrophilic catalytic subunits SDHA and SDHB project into the matrix of the mitochondria. 
The two hydrophobic subunits SDHC and SDHD are embedded within the inner membrane. The 
FADH2 is oxidised to FAD
+, releasing two electrons. Fe-S clusters in SDHB transfer the electrons to 
the haem group in SDHD and to ubiquinone in SDHC which is reduced to ubiquinol (QH2). This 
dissociates from SDHC to transfer to CIII.  
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1.3.1.5. Complex III - Ubiquinol-cytochrome c oxidoreductase 
Complex III is ~480 kDa in size and consists of 11 subunits. Cytochrome b is the only 
mtDNA encoded subunit whilst the remaining 10 are encoded by the nuclear DNA (Iwata et 
al. 1998; Xia et al. 1997; Yu et al. 1999). The catalytic centre of the complex is comprised of 
cytochrome b (MTCYB), cytochrome CI (CYC1), two haem moieties (cytochrome bL and 
cytochrome bH) and a Fe-S cluster known as the Rieske Fe-S cluster (UQCRFS1). The 
complex functions as a homodimer and has the role of catalysing the transfer of electrons 
from the reduced ubiquinol (QH2), from Complex I and II, to cytochrome b and then to 
cytochrome c (Figure 1.9), as part of the process known as the ‘Q cycle’ (Mitchell 1975, 
1976; Rieske 1976) – which processes two QH2 molecules in succession, as shown in 
Equation 1.6 and Figure 1.9.  
The ‘Q cycle’ starts with the transfer of two electrons from ubiquinol (QH2) to the Q0 site. 
One electron is passed to the Rieske Fe-S cluster and cytochrome C1 which in turn leads to 
the reduction of one cytochrome c (cyt c) molecule. During this, two hydrogen protons are 
pumped from the mitochondrial matrix to the IMS. The alternative electron is passed to haem 
bL and haem bH and then to the Q1 site where ubiquinone is reduced to semi-ubiquinone 
radical (Q−·). This process is repeated, allowing haem bH to reduce the semi-ubiquinone to 
ubiquinol and in doing so removes an additional two protons from the matrix to the IMS. In 
total, this process is therefore coupled with the translocation of four hydrogen ions into the 
intermembrane space, thus contributing the proton motive force.  
2[QH2] + Q + 2[Cyt c]ox + 2[H
+]matrix → 2 [Q] +QH2 + 2[Cyt c]red +4[H
+]cytoplasm 







Figure 1.9: A schematic structure and function of Complex III. 
The transfer of electrons in Complex III (process known as the Q cycle).  Overall, four electrons (2x 
2e-) are required for the reduction of two cytochrome c (2CytC). 4 hydrogen protons (H+) are pumped 
into the intermembrane space (IMS). The path of electrons is shown with red dashed line and the 
Rieske Fe-S cluster (red oval), cytochrome C1, haem moieties BL
 and BH and the two binding sites Q0 
and Q1.  
 
1.3.1.6. Complex IV - Cytochrome c Oxidase 
Complex IV, also known as cytochrome c oxidase (COX), is the terminal complex of the ETC 
and is embedded into the IMM. The complex has a molecular weight of 204 kDa and 
comprises of 13 subunits, of which three are mtDNA encoded (Tsukihara et al. 1996). These 
three subunits – COX-I, COX-II and COX-III are the largest subunits and form the functional 
core of Complex IV (Capaldi 1990; Rubin and Tzagoloff 1973). The complex is active as a 
dimer and has the role in oxidising cytochrome c (cyt c) and transferring the electrons to 
molecular oxygen (O2) (Shoubridge 2001). The oxygen molecule is subsequently reduced to 
H2O. Overall, four cytochrome c molecules are oxidised, thereby four electrons are required 
for one molecule of oxygen to be reduced to H2O.  
The crystal structure of Complex IV was resolved by Tsukihara and colleagues in 1996 and 
showed that the core subunits contain the prosthetic groups which are required for the 
catalytic function of the complex. COX-I contains the two haem moieties; a and a3 and copper 
centre CuB. COX-II contains the copper centre CuA. It also contains a magnesium and zinc ion 
(Tsukihara et al. 1996). COX-III is also associated with proton translocation (Wilson and 
Prochaska 1990).   
20 
 
The electron movement through Complex IV is shown in the schematic Figure 1.10 and is as 
follows; each electron from reduced cytochrome c is transferred to the binuclear CuA site and 
haem a. They are then transferred to haem a3 and CuB site which forms the oxygen binding 
site (binuclear site) known as haem a3-CuB. This is reduced, consequently producing in total, 
two molecules of H2O (Capaldi et al. 1995; Faxen et al. 2005). The transfer of electrons is 
coupled with the translocation of four protons from the matrix to the IMS, per oxidised 
molecule (Equation 1.7) (Belevich et al. 2006).  
The nuclear-encoded subunits are known as the accessory subunits and have been found to 
have a role in the regulation and stability of the fully assembled complex (Galati et al. 2009). 
They also have the role of protecting the core subunits from oxidative damage (Diaz et al. 
2006; Shoubridge 2001; Soto et al. 2012). 
Briefly, the assembly of Complex IV has been found to initiate with the synthesis of COX-1, 
followed by COX-II and COX-III. The assembly factor Surf-1 has a role in inserting the haem 
groups (Pacheu-Grau et al. 2015).  
4[Cyt c]red + 8[H
+]matrix +O2 → 4[Cyt c]ox + 2H2O + 4[H
+]cytoplasm 










Figure 1.10: A schematic structure and function of Complex IV.   
A simplified structure of Complex IV showing the movement of electrons and translocation of protons. 
The three mitochondrial DNA encoded subunits contain the prosthetic groups – COX-1 (yellow) 
contains the two haem moieties, COX-2 (subunit II - blue) contains the copper centre CuA and COX-3 
(subunit III = purple) is involved in proton translocation. Electrons reduced from cytochrome c are 
transferred to the CuA site, then to haem (cyt) a, and lastly to the oxygen binding site haem (cyt) a3-
CuB, producing H2O. The transfer of electrons is coupled with the translocation of four protons from 
the matrix to the intermembrane space, per oxidised molecule. Figure is taken from (Nelson et al. 
2008).  
 
1.3.1.7.  Complex V - ATP Synthase 
Complex V (ATP synthase), utilises the proton motive force generated by Complex I, III and 
IV to drive the conversion of ADP and inorganic phosphate (Pi) to ATP. The complex is ~600 
kDa in size and comprises of 13 structural subunits, of which two are mtDNA encoded 
(ATPase 6 and 8) (Pogoryelov et al. 2009).  
The structure, as schematically shown in Figure 1.11, is divided into two functional regions - 
the F0 and F1 regions, which are joined together by a central and peripheral stalk. The F1 
region protrudes into the matrix and is the catalytic unit of Complex V. It is formed by five 
polypeptide chains; β (x3), α (x3), δ, γ and ε. Both α and β chains form a hexameric α3β3 ring 
structure which catalyses the synthesis of ATP through binding ADP and Pi. However only 
the β subunits have catalytic activity (Abrahams et al. 1994). The δ and γ polypeptides form 
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the central stalk of Complex V and connects both regions together. The F0 region is embedded 
into the IMM and is organised into a c-ring structure (12 ‘c’ subunits) that forms a proton 
channel, allowing for the movement of protons across the IMS to the matrix.  
The proton gradient generates a proton motive force. The movement of protons through the c-
ring is coupled with the rotation of the rotary motors; c ring and δ, γ and ε subunits. As F1 
rotates, the β subunit undergoes a structural conformational change (Noji et al. 1997). The 
complete 360° rotation catalyses ATP synthesis in a proton dependent manner (Abrahams et 
al. 1994) – a full rotation is coupled to the transfer of eight protons and the production of three 
ATP molecules (Watt et al. 2010).  
 
 
Figure 1.11: A schematic diagram of Complex V (ATP synthase). 
The diagram illustrates the structural arrangement of subunits of Complex V. The complex has the 
role of generating ATP from ADP and inorganic phosphate (Pi) which is achieved through the use of 
the electrochemical gradient generated from Complexes I-IV. Protons flow through the C-ring along 
the electrochemical gradient, leading to the rotation of the αβ ring of the F1 unit. This causes the 






Individual respiratory chain complexes can be organised into supercomplexes, which are also 
known as ‘respirasomes’. These were first postulated following the analysis of yeast and 
bovine heart mitochondria using Blue Native Polyacrylamide gel (BN-PAGE) (Schagger and 
Pfeiffer 2000, 2001) and were further confirmed using EM (Dudkina et al. 2005). There are 
various types of supercomplexes which are found in co-existence with single ETC complexes 
in the IMM; CI/CIII2/CIV, CI/CIII2, and CIII2/CIV1-2. The most well studied of these is the 
CICII2CIV supercomplex (Complex I monomer, Complex III dimer and Complex IV 
monomer) for which the spatial arrangement has been deduced as shown in Figure 1.12 
(Dudkina et al. 2005; Gu et al. 2016; Letts et al. 2016; Wu et al. 2016). It has been estimated 
that approximately 85%–100% of Complex I molecules are found in supercomplexes, 55%–
65% of Complex III and only 15%–25% of Complex IV (Greggio et al. 2017; Schagger and 
Pfeiffer 2001). The three individual complexes pass electrons from NADH to O2 (NADH:O2 
oxidoreduction) through the ETC, contributing to the proton motive force, therefore, the 
supercomplex can undertake respiration in the presence of ubiquinone and cytochrome c, 
hence the term ‘respirasomes’. Supercomplexes have been found to be important for the 
stability of ETC complexes (Acin-Perez et al. 2008) and protecting the complexes from ROS 
(Maranzana et al. 2013). In terms of assembly, it was believed that the supercomplex provided 
a scaffolding for the completion of Complex I assembly whereby the final part of the 
peripheral arm of the complex (the N module) was added only when the remainder of the 
complex had been assembled into the supercomplex. The theory behind this notion was so 
that Complex I was not activated before the supercomplex was completely assembled 
(Moreno-Lastres et al. 2012). However, this has been proven otherwise by Guerrero-Castillo 
and colleagues (2017), who showed that Complex I was fully assembled in a stepwise manner 
before it combined with Complex III and IV into a supercomplex. The assembly of Complex I 





Figure 1.12: Crystal structure of ovine supercomplex. 
The CI/CIII2/CIV respirasome supercomplex. Complex I: blue, Complex III: green, Complex IV: pink. 
Figure has been adapted from Letts et al. (2016).   
 
1.3.2. Other functions of Mitochondria 
1.3.2.1.  Reactive oxygen species (ROS) production  
It was initially believed that ROS production was a major cause of cell damage, however it 
has now been shown that ROS signalling has roles in cell differentiation, regulation of 
autophagy (Scherz-Shouval et al. 2007), apoptosis (Pierce et al. 1991) and immune cell 
activity (Sena et al. 2013; West et al. 2011).  
The ETC, in particular Complex I –III, is a major source of ROS in cells (Boveris et al. 1972; 
Turrens and Boveris 1980). This was first reported in 1966 (Jensen 1966), followed by the 
work presented by Chance and colleagues who demonstrated the production of H2O2 in 
isolated mitochondria (Loschen et al. 1971). During the movement of electrons along the 
ETC, some electrons leak out and react with O2 leading to the production of the most 
common ROS; superoxide anion (O2•-) – the precursor for other ROS, through partial 
reduction. Complex I produces O2•- in the matrix and Complex III produces O2•- on both 
sides of the IMM. Complex I is a vast producer of O2•-, influenced by either a high proton 
gradient caused by a decrease in ATP synthesis or a high NADH/NAD+ ratio in the matrix 
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(Murphy 2009). The O2•- is converted to hydrogen peroxide (H2O2) by superoxide dismutase 
(SOD) in the matrix (catalysed by SOD2) and IMS (catalysed by SOD1) (Sabharwal and 
Schumacker 2014). H2O2 is usually converted to H2O by the antioxidant molecule glutathione 
peroxidase (Turrens 2003). However, when there is an excessive production of ROS or the 
antioxidant system fails to counteract the ROS, H2O2 can leak into the IMS and cytosol where 
it can oxidise proteins, lipids or mtDNA, leading to eventual cell death (Murphy et al. 2011).  
1.3.2.2.  Apoptosis  
Apoptosis, or programmed cell death is a critical process for tissue homeostasis in multi-
cellular organisms. First described by Kerr et al. (1972), the process is defined by the 
morphological changes which occur in dying cells including blebbing, chromatin 
condensation, nuclear fragmentation and cell shrinkage.  
There are two major apoptotic pathways; the intrinsic pathway and the extrinsic pathways. 
Firstly, the intrinsic pathway, also known as the mitochondrial pathway due to the essential 
role of mitochondria (Wang and Youle 2009). This role was first established by biochemical 
studies identifying several mitochondrial proteins that can activate apoptosis directly, 
particularly cytochrome c and the mitochondrial apoptosis inducing factor (AIF) (Liu et al. 
1996; Susin et al. 1999). These proteins reside in the IMS but in response to variable 
apoptotic signals, they are released into the cytosol of the cells. Cytochrome c, released after 
signal from Bid, initiates the activation of procaspase-9 which activates downstream caspases 
such as caspase-3, leading to the eventual apoptotic changes in the cell after further cleavage 
of substrates. Chromatin and large scale DNA fragmentation occurs due to the AIF protein, 
which translocate from the mitochondria to the nucleus of the cell (Liu et al. 1996; Susin et al. 
1999; Wang 2001). The alternative apoptotic pathway is independent of mitochondria, known 
as the extrinsic pathway (or the death receptor-dependent pathway) and is activated by death 
receptors of the tumour necrosis factor (TNF) receptor superfamily.  
1.3.2.3.  Haem biogenesis and Fe-S cluster biogenesis  
Haem is the major functional form of iron and is synthesised in mitochondria. The molecule is 
found within a tetrapyrrole which allows for the haem to function as an electron carrier and a 
catalyst for redox reactions. The mitochondrial membrane associated enzyme ferrochelatase 
catalyses the insertion of the ferrous iron into the protoporphyrin IX (a tetrapyrrole) to form 
haem (Ajioka et al. 2006; Wu et al. 2001).  
Fe-S clusters are essential for the movement of electrons through the ETC and it has been 
shown that the mitochondria is the main site of Fe-S cluster assembly (Lill et al. 2012). For 
26 
 
biogenesis to occur, there is a requirement for a supply of iron which is imported from the 
cytosol, involving monothiol glutaredoxins (GrX) as iron donors and the inner membrane iron 
carrier Mrs3 and Mrs4. These carriers require the proton motive force to allow for membrane 
passage. The Fe-S cluster biogenesis is initiated by the mitochondrial iron sulphur cluster 
(ISC) complex which comprises 17 mitochondrial proteins including the following; IscU 
which acts as a scaffold protein for Fe-S cluster synthesis, NFS1 (cysteine desulfurase) which 
is a sulphur donor, GRP75 (mitochondrial Hsp70 chaperone) which transfer Fe-S cluster from 
the scaffold protein and FXN (frataxin) which is an iron donor in the initial stage of 
biogenesis (Lill et al. 2012; Stehling and Lill 2013).  
1.3.2.4.  Calcium (Ca2+) signalling and handling  
Calcium (Ca2+) is an important cellular signal and mitochondria have been shown to have an 
important role in cytosolic Ca2+ homeostasis due to their ability to uptake and buffer Ca2+ 
(Carafoli 2003; Cohen and Fields 2004; Rossi and Lehninger 1964). Calcium enters the 
mitochondrion through porin found in the OMM and the mitochondrial Ca2+ uniporter (MCU) 
(De Stefani et al. 2011). In the process of entering the mitochondrion through both the OMM 
and IMM, it travels down an electrochemical gradient leading to the reduction of cytoplasmic 
calcium.  
Calcium is a major modulator of many cellular functions. For example, an increase in the 
uptake of Ca2+ has been shown to stimulate the function of the electron transport chain and 
thereby increasing ATP production (Denton and McCormack 1980; Griffiths and Rutter 
2009). But an excessive accumulation of Ca2+ is toxic for the mitochondria and can lead to the 
induction of apoptosis (Mattson and Chan 2003; Orrenius et al. 2003).  
In addition, the control of intracellular Ca2+ is important for the normal function of skeletal 
muscle. This is due to the fact that Ca2+ is the signalling messenger that triggers all processes 
underlying muscle excitation-contraction, particularly in neuromuscular junctions (MacIntosh 







1.4. Mitochondrial DNA 
1.4.1. The Mitochondrial genome  
Aside from the nucleus, mitochondria are the only other organelle which contains genomic 
information. The human mitochondrial genome (mtDNA), as schematically shown in Figure 
1.13, is found in the matrix of the mitochondria and is organised into a compact circular, 
double-stranded DNA (dsDNA) with a heavy (H strand – outer circle) and a light (L-strand – 
inner circle) stand. These two strands are distinguished by their nucleotide composition (G 
and T base) which result in the different buoyant densities. The H strand is guanine rich 
whilst the L strand is cytosine rich.   
The genome was originally sequenced by Anderson et al. (1981) and later revised by Andrews 
et al. (1999), which is known as the Revised Cambridge Reference Sequence (rCRS). The 
genome is comprised of 16,569 base pairs and contains 37 genes; 28 genes on the H strand 
and nine genes on the L strand.  Of these 37 genes, 13 encode essential hydrophobic proteins 
of the OXPHOS system and the remaining 24 genes encode the RNA machinery consisting of 
two RNAs (16S RNA (the large ribosome) and 12S RNA (the small ribosome)) and 22 
tRNAs (Anderson et al. 1981).  
In comparison to the nuclear genome, the genome is highly compact with no introns within 
the mtDNA genes, nor any intergenic regions between the encoded proteins. However, the 
only exception to this is the major non-coding region (NCR) which spans 1.1kb of the 
molecule and includes the displacement loop (D-loop) which extends from the OH to the 
termination-associated sequence (TAS) (Nicholls and Minczuk 2014). The D-loop contains 
the origin of heavy strand replication (OH) and the H strand transcription promoters HSP1 and 
HSP2 – the sites at which replication and transcription are initiated from respectively.  
The mitochondrial genome is a multi-copy genome meaning there are numerous copies of the 
molecule in a mitochondrion. It has been estimated that mammalian cells can contain between 
5,000 to 10,000 copies of the genome; the exact number varying on a cell-type specific basis 
depending on the cellular energy demand of the cell (Lightowlers et al. 1997; Miller et al. 
2003). For example, a mature oocyte contains between 100,000 to 600,000 copies of mtDNA 
(Shoubridge and Wai 2007; Wai et al. 2010) whilst fibroblasts contain very few due to their 
capability of relying on anaerobic glycolysis for ATP. In addition, cardiomyocytes and 
skeletal muscle have been shown to have approximately 7,000 and 3,600 mtDNA molecules 
respectively (Miller et al. 2003). Unlike the nuclear genome which is organised in 
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nucleosomal array structures, the mtDNA has been shown to be packed in a nucleoprotein 
complexes known as nucleoids (Wang and Bogenhagen 2006).  
 
Figure 1.13: The Human Mitochondrial Genome. 
The circular double stranded DNA (dsDNA) encodes for 37 genes, including 13 polypeptides of the 
OXPHOS system, 22 tRNAs and 2 rRNAs. All but one protein coding gene is located on the Heavy (H) 
strand (outer circle) and MTND6 located on the light (L) strand (inner circle). The genes that encode 
the subunits of CI (NDI-ND6 and ND4-L) are shown in purple, Cytochrome c oxidase (COX-I –III) is 
shown in yellow, Cytochrome b of complex II shown in dark orange, and the subunits of ATP 
synthase/CV (ATP6 and 8) are shown in blue. Genes encoding for the ribosomal RNA genes (2 rRNAs) 
are shown in light orange and the tRNAs (22 tRNAs) are green. The major non-coding region (NCR) 
contains the displacement loop (D-loop. It contains sequences required for translation and 
transcription – origins of heavy (OH) strand replication and HPS1 and HSP2 for transcription. The 
origins of light (OL) strand is also shown. Also, within the NCR are; hypervariable segments (HVS1 
and HVS2), three conserved sequence blocks (CSB1, CSB2, CSB3) located between LSP and OH, 
termination associated sequence (TAS) and the third linear strand of DNA which is often incorporated 
in NCR called 7S DNA. Figure has been provided by Dr Amy Vincent (Wellcome Centre for 
Mitochondrial Research, Newcastle University) and adapted from (Nicholls and Minczuk 2014). 
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1.4.2. Replication of mitochondrial DNA 
Replication of the mtDNA genome occurs in the matrix of the mitochondria. Unlike the 
replication of nuclear DNA which occurs only once during cell division, the replication of the 
mtDNA occurs continuously and is independent of the cell cycle in replicative and post-
mitotic cells such as skeletal muscle and nerve cells of the central nervous system 
(Bogenhagen and Clayton 1977). This is known as a relaxed replication and this process has 
been found to take approximately 60-75 minutes (Clayton 1982; Korr et al. 1998). Another 
difference between the replication of the nuclear DNA and mtDNA is that the proteins 
included in the mtDNA replication machinery (as described below) are distinct and many are 
related to replication factors founded in bacteriophages (Shutt and Gray 2006). 
1.4.2.1.  The replication machinery  
Mitochondria contain their own DNA replication machinery comprising of at least four key 
proteins - often referred to as the ‘mitochondrial DNA minimal replisome’ (Korhonen et al. 
2004). These proteins include the mitochondria DNA polymerase gamma (POLG), mtDNA 
helicase TWINKLE and mitochondrial single stranded DNA binding protein (mtSSB) and the 
mitochondrial DNA polymerase POLRMT which is likely to synthesise the RNA primers 
needed for replication (Falkenberg et al. 2007; Fuste et al. 2010; Gustafsson et al. 2016; 
Milenkovic et al. 2013; Wanrooij et al. 2008). This is schematically shown in Figure 1.14. 
At the core of the machinery is POLG which is the only replicative polymerase in the 
mitochondria. This heterometric protein consists of a catalytic subunit POLG-A which 
contains a 3’ to 5’ exonuclease domain, allowing for an efficient proofreading of the newly 
synthesised DNA strand. The two identical POLG-B (also called POLG2) subunits have 
dsDNA binding activity as well as the ability to increase the catalytic and processing activity 
of POLG-A through enhancing the interaction with the DNA substrates (Gray and Wong 
1992; Gustafsson et al. 2016; Milenkovic et al. 2013). TWINKLE is a hexameric protein 
which catalyses the 5’ to 3’ nucleotide trisphosphate dependent unwinding of the dsDNA to a 
single stranded DNA (ssDNA) molecule (Korhonen et al. 2004; Spelbrink et al. 2001). It has 
been shown that POLG requires TWINKLE to synthesise dsDNA (Korhonen et al. 2004). 
TWINKLE moves with POLG to the replication fork where it initiates the unwinding of the 
DNA (Gustafsson et al. 2016). The tetrameric mtSSB protein has a role in stabilising the 
single stranded regions of the mtDNA at the replication fork and protects it from nucleolysis. 
It also enhances primer recognition during replication and has a stimulatory effect on 
TWINKLE unwinding activity (Korhonen et al. 2004; Milenkovic et al. 2013). Finally, the 
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POLRMT protein forms primers to initiate DNA synthesis of the heavy strand (Chang and 
Clayton 1985).  
 
Figure 1.14: A schematic diagram of the mitochondrial DNA replication machinery. 
Twinkle (purple) unwinds the mtDNA into a single stranded DNA which is stabilised by mtSSB 
(orange). PolγA and B (green and yellow respectively) synthesises the nascent leading complementary 
strand (red, direction shown by red arrow). Figure is adapted from Tsai and John, 2016.  
 
1.4.2.2.  Models of mtDNA replication; 
There is currently no scientific consensus on a single mechanism for the mode of replication 
of mtDNA, therefore there are several models that exist. Currently, there are two prevailing 
models that are proposed; strand-displacement (asynchronous) and strand-couple 
(synchronous) replication (Holt and Reyes 2012).  
 The Strand-displacement model  
One model is the ‘Strand-displacement model’ which is also known in the literature as the 
‘asynchronous strand displacement’ model. This was first described by Robberson et al. 
(1972) and later refined by Clayton (1982) who used EM images to demonstrate that 
replication is initiated at the OH within the D- loop, causing a displacement of the L strand. As 
shown schematically in Figure 1.15(A), the H strand is replicated from 5’ to 3’ and during the 
synthesis of the new H strand, mtSSB covers the displaced parental H strand and blocks 
POLRMT, preventing random initiation of RNA primer synthesis. Replication of the H strand 
is 70% completed before the origin of replication of the L strand (OL) is exposed, thus 
initiating the replication of the L strand which occurs from 3’ to 5’ (Clayton 1982; Gustafsson 
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et al. 2016; Robberson et al. 1972). Replication is terminated once the H strand is complete. 
Since the H strand is first replicated, this is often called the leading strand and thus, the L 
strand is termed the lagging strand.  
The Strand Coupled model  
The second model was suggested by Holt et al., 2000 and is called the ‘Strand couple model’ 
(also known as the coupled leading lagging strand model) – shown in Figure 1.15(B). The 
analysis of 2-dimensional agarose gel electrophoresis (2D-AGE) showed partially single 
stranded replication intermediates and so the model suggested that replication is initiated at 
the zone of replication (OriZ) which is a stretch of mtDNA encompassing the genes MT-ND5, 
MT-ND6 and MT-CYTB. In contrast to the strand displacement model, replication terminates 
at the OH. The replication of the H strand is followed by replication of the L strand in the 
same direction, hence why the model is referred to as ‘Strand coupled’ (Bowmaker et al. 
2003; Holt et al. 2000). 
The RITOLS model 
The third model is the ‘RNA-incorporated throughout the lagging strand’ – RITOLS – model 
which is based on the findings of extended RNA tracts incorporated into replication 
intermediates and RNA hybridised to the parental H strand (Yang et al. 2002; Yasukawa et al. 
2006) – shown in Figure1.15(C). In the RITOLS model, replication is initiated at either 
within the non-coding region close to the OH or at the OH. The replication of the H strand 
progresses until OL is exposed and the replication of the L strand is initiated with the 
simultaneous incorporation of RNA onto the L strand. The RNA is either replaced by DNA or 
converted to DNA (maturation) – this either occurs when the entire strand is incorporated 
with RNA or two-thirds completed (Yasukawa et al. 2006). The replication is unidirectional. 
The RITOLS model is essentially similar to the strand displacement model whereby both 
models suggest that replication is initiated at the OH and the two strands are replicated 
separately. However, a major difference in the models is that within the RITOLS model, the 




Figure 1.15: The current models of replication of mammalian mitochondrial DNA. 
Three models of replication have been proposed starting with the (A) Strand-displacement model - 
replication of mtDNA starts at the origin of replication for H strand (OH) within the D-Loop. 
Displacement of light stand occurs. 70% into replication of nascent H strand, origin of light stand (OL) 
is exposed and replication can commence in the opposite direction until both strands have been 
replicated. (B) The strand couple model - replication begins from the zone of replication (OriZ) on the 
genome and replication of both strands occur bidirectionally. (C) The RNA incorporation throughout 
the lagging strand (RITOLS) model - replication is initiated at or close to the OH, displacing the L 
strand. The model is very similar to the strand-displacement model only RNA intermediates are 
incorporated into the L strand (dashed lines) which are then replaced by or converted (matured) to 
DNA. Figured has been adapted from (Krishnan et al. 2008). 
 
1.4.3. Transcription of mitochondrial DNA 
The D-loop contains three promoters required for the transcription of mtDNA; HSP1, HSP2 
and LSP (Chang and Clayton 1984; Montoya et al. 1982; Zollo et al. 2012). Transcription 
occurs bi-directionally and gives rise to polycistronic transcripts – mRNA transcripts which 
encode several genes. Transcription of mtDNA is mediated by at least four key proteins; 
POLMRT (Ringel et al. 2011; Tiranti et al. 1997), mitochondrial transcription factor A 
(TFAM) (Fisher and Clayton 1988; Shi et al. 2012), mitochondrial transcription factor B2 
(TFB2M) (Falkenberg et al. 2002) and the mitochondrial termination factor 1 (MTERF-1) 
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(Gaspari et al. 2004; Kruse et al. 1989; Yakubovskaya et al. 2010). Promoter recognition and 
transcription initiation requires the simultaneous presence of the first three factors.   
The transcription of the H strand is initiated at HSP1 and HSP2 and the L strand transcription 
occurs from LSP. HSP1 is located upstream from the tRNAPhe gene and the transcripts of this 
H strand promoter contain two tRNA genes (tRNAPhe and tRNAVal) and two rRNA genes (12S 
rRNA and 16S rRNA). The HSP2 promoter is located approximately 100 base pairs (bps) 
further downstream within the D loop at the boundary between tRNAPhe and the 12S rRNA 
genes. Transcription from this promoter proceeds along almost the entire length of the H 
strand and so contains majority of the genes located on the strand. Transcription from LSP 
generates a single transcript containing all genes contained on the L strand – MTND6 and 8 
tRNAs (Kuhl et al. 2016; Montoya et al. 1982). 
The sequence of transcription can be briefly described as the following. Firstly, TFAM 
initiates transcription by sequence specific binding to a region 10 to 15bp upstream of the 
HSP and LSP (Fisher et al. 1987), causing the DNA to unwind and a structural alteration of 
the promoter region to occur (Hallberg and Larsson 2011). This recruits POLRMT to the 
promoters where it binds to TFAM and subsequently recruits TFB2M, completing the 
transcription complex (Rebelo et al. 2011). TFB2M executes the elongation step after 
initiation. The termination of transcription (characterised for HSP1 transcripts) is executed by 
MTERF-1 which binds to a specific 28bp region in the tRNALeu (UUR), resulting in DNA helix 
unwinding and base flipping leading to termination (Roberti et al. 2006; Yakubovskaya et al. 
2010).   
The resulting transcripts undergo post-transcriptional processing through the process of 
‘tRNA punctuation model’ (Ojala et al. 1981), which states that tRNAs flanking the 
transcripts provide the signals for the endonucleolytic excision of the tRNAs, leading to the 
release of individual tRNAs, rRNAs and mRNAs. It has been shown that processing takes 
place in distinct speckles named the mitochondrial RNA granules (Antonicka et al. 2013; 
Jourdain et al. 2013) and these contain the enzyme RNase P (consisting of 3 subunits – 
mitochondrial RNase P proteins (MRPP) 1 -3). RNase P cleaves the transcript at the 5’ end of 
the tRNAs (Rossmanith and Karwan 1998). On the other hand, the enzyme RNase Z (coded 
by the ELAC2 gene) which cleaves the 3’ end of the tRNAs (Schiffer et al. 2002) are not 





1.4.4. Translation of mitochondrial DNA 
The mitochondrial genome only encodes for 13 proteins, all of which are components of the 
OXPHOS system. These genes are translated by the mitochondrial ribosomes at the matrix 
face of the inner membrane (Hallberg and Larsson 2014; Herrmann et al. 2013; Lightowlers et 
al. 2014). 
Mitochondrial ribosomes (known as mitoribosomes), contain two mtDNA- encoded proteins, 
the 12S rRNA and the 16S rRNA alongside a further 80 nDNA-encoded proteins. 
Mitoribsomes have a sedimentation coefficient of 55s and are comprise of a large subunit 
(mtLSU, also known as 39S) and a small subunit (mtSSU, also known as 28S). The 39S 
subunit is involved in the catalysis of peptidyl-transferase and the 28S subunit binds the 
mRNA and is involved in the initiation of translation and decoding. This subunit also 
undergoes a conformational change during the elongation stage of translation. The 12S rRNA 
is found in the 28S subunit and the 16S rRNA is found in the 39S subunit. The mitoribosomes 
differ from the cytoplasmic ribosomes as they are characterised by a higher protein content 
rather than rRNA (ratio of rRNA/protein) (Amunts et al. 2015; Brown et al. 2014; Greber et 
al. 2014; Kaushal et al. 2014).  
The translation process includes three phases – initiation, elongation and termination, as 
shown by Figure 1.16. 
Initiation:  
Initiation occurs through two mitochondrial initiation factors; MtIF2 and MtIF3 (Koc and 
Spremulli 2002; Ma et al. 1995). MtIF3 aligns the start codon (AUG or AUA) of the mRNA 
at the peptidyl (P) site of the mitochondrial small subunit (mtSSU or 28S). MtIF3 also 
prevents the association of the mtSSU to the mitochondrial large subunit (mtLSU – 39S) 
(Bhargava and Spremulli 2005; Haque and Spremulli 2008). Following this, MtIF2 directs the 
N-formylmethionine-tRNA (fMet-tRNAMet) to also bind to the start codon of the mRNA, 
forming a stable complex. MtIF2 also stimulates the recombination of mtSSU and mtLSU by 
directing the dissociation of the mtIF3 and GTP hydrolysis complex (GTP-bound IF2mt). 
This then allows for the re-association of the mitoribosome subunits.  
Elongation:  
Following this, translation thereby enters the elongation phase in which the elongation factor 
MtEFTu (Ling et al. 1997) forms a ternary complex with GTP and an aminoacylated- tRNA. 
MtEFTu transfers the tRNA to the aminoacyl/acceptor (A) site in the mitoribosome – the site 
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at which mtDNA is decoded through codon-anticodon recognition on the 28S subunit. The 
recognition causes GTP hydrolysis of mtEFTu instigating the release of the elongation factor 
from the mitoribosome. The 3’end of the aminoacylated tRNA moves into the peptidyl 
transferase centre (P site) in the 39S subunit where peptide bond formation is catalysed, 
adding one amino acid to the growing peptide. The movement of the tRNA from the A and P 
site to the P and exit (E) site occurs after conformational changes in both the second 
elongation factor mtEFG1 and the mitoribosome. The mRNA is advanced by one codon and 
the tRNA leaves the mitoribosome, initiating a new elongation cycle.  
Termination:  
The elongation of the polypeptide continues until a stop codon (either UAA or UAG) is 
reached and thereafter the termination of translation is undertaken by the mitochondrial 
release factor 1a (MtRF1a) which recognises the stop codons (Soleimanpour-Lichaei et al. 
2007; Zhang and Spremulli 1998). MtRF1a triggers a hydrolysis cleavage of the ester bond 
between the terminal tRNA in the P-site and the last amino acid of the nascent polypeptide 
chain causing the release of the polypeptide from 39S subunit. Following this step, the 
dissociation of the mitoribosome and release of the uncharged mt-tRNA and mRNA occurs 
through two mitoribosome recycling factors; mitochondrial release factor 1 (mt-RRF1) and 




Figure 1.16: Mitochondrial translation. 
Translation is undertaken in 3 steps; initiation, elongation and termination. Prior to the start of the 
initiation stage, ribosomal recycling occurs and the mitochondrial small subunit (mt-SSU in blue) 
remains bound to the initial factor 3 (mt-IF3 in green). The first step of initiation involves the bindings 
of mtIF2 (light orange) to a GTP molecule (red) which now joins the previous complex. The 
recruitment of mt-mRNA occurs to the mt-SSU and fMet-tRNAMet in the P-site anchors it to the start 
codon. This causes GTP is hydrolysed to GDP (purple) and the initiation factors are released. The 
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mitochondrial large subunit (mt-LSU in darker blue) associates. During the elongation stage (centre 
illustration), the nascent polypeptide chain is bound to the P-site and the A-site hold charged mt-
tRNAs which are delivered by the mitochondrial elongation factor-Tu (mtEF-Tu in yellow). When GTP 
is hydrolysed and mtEF-Tu is released, the GDP is replaced by another GTP molecule mediated by 
mtEF-Ts (red). The charged A-site mt-tRNA changes its conformation which facilitates peptide bond 
formation and transferring the polypeptide chain onto the A-site mt-tRNA. The elongation factor 
mtEF-G1 (dark orange) promotes ribosome movement that repositions the mt-mRNA within the 55S so 
that the mt-tRNAs move from the A- and P-sites to the P- and E-sites. This cycle repeats until the 
completion of the polypeptide initiated by a stop codon at the A site. This termination step occurs after 
the recognition of the stop codon by a release factor protein (mtRF1a in pink), which after undergoing 
conformational change, promotes hydrolysis of the ester bond anchoring the nascent chain to the final 
mt-tRNA. After the release of the polypeptide chain, the two recycling factors, mtRRF1 (dark red) and 
mtRRF2 (red), promote the dissociation of the ribosomal subunits and premature re-association is 
prevented by the formation of an mtIF3/mt-SSU complex. Figure has been provided by Dr Amy 
Vincent (Wellcome Centre for Mitochondrial Research, Newcastle University) - legend and figure 

















1.5. Mitochondrial Genetics  
Given that both the nuclear DNA and mtDNA are involved in the mitoproteom, mitochondrial 
dysfunction can be caused by defects on either of the genomes. This dual genetics introduces 
the unique features of mitochondrial genetics which forms an essential basis for the 
understanding of the aetiology and pathogenesis of mitochondrial disease. For example, the 
unique inheritance patterns and the effects of having multiple copies of mtDNA in different 
cells and tissues.  
1.5.1. Heteroplasmy 
The polyploid nature of the mtDNA means that there are multiple copies of the genome in 
each individual cell (Holt et al. 1988; Zeviani et al. 1988). This gives rise to fundamental 
aspect of mitochondrial genetics; the state of homoplasmy and heteroplasmy within a cell.  
Homoplasmy refers to the state in which all copies of the mtDNA are identical in their 
genotype -either all normal (wild-type) or all mutated. Conversely, heteroplasmy, which is 
further described in Chapters 4 and 5, refers to the co-existence of the two mtDNA 
genotypes (wild-type and mutated) in the same single cell (Holt et al. 1988). The proportion 
of mutated mtDNA in the total mtDNA population is known as the heteroplasmy level, which 
is generally expressed as a percentage (can vary between 0-100%). This heteroplasmy level 
can vary between different tissues and organs within the same patient (Shanske et al. 2004) 
and it is an important feature of mitochondria genetics in terms of phenotypic expression of 
the causative mtDNA mutation. This will be described further in the next section of this 
chapter.   
1.5.2. Threshold effect 
Most heteroplasmic mutations exist in low levels and therefore do not typically cause an 
observable biochemical dysfunction or phenotype, due to the compensatory effect of the high 
proportion of wild-type mtDNA. Thereby, a minimum percentage of mutated mtDNA must be 
present in a cell for OXPHOS dysfunction to occur – termed the critical threshold level, 
which is highlighted in Figure 1.17. When the pathogenic mutation reaches this critical 
threshold and beyond, the wild-type mtDNA population can no longer act as a compensatory 
mechanism in upholding a normal mitochondrial function against the mutated mtDNA 
(Rossignol et al. 2003). Thereby a biochemical defect and associated clinical phenotype is 
observed due to respiratory chain deficiency. This is referred to as the ‘threshold effect’ 





Figure 1.17: Heteroplasmy and the threshold effect. 
The polyploidy nature of mitochondria means there are multiple copies of mtDNA. A mix of both wild-
type and mutant mtDNA is termed heteroplasmy, which can be between 0 to 100% (as indicated by the 
blue dotted arrow on X-axis).  The mitochondria remains biochemically normal (beige mitochondria) 
until a particular heteroplasmy level is reached (red dashed line), after which the cell becomes 
biochemically deficient due to OXPHOS dysfunction (grey mitochondria). This heteroplasmy level is 
called the critical threshold (red dashed line). 
 
Threshold levels vary greatly amongst different tissues and between different mutation types. 
Tissues which are highly dependent on OXPHOS, such as skeletal muscle, are reported to 
have threshold levels between 50% (Porteous et al. 1998) and 90% (Sciacco et al. 1994). 
Although, threshold levels have been found to vary across different regions of the skeletal 
muscle due to variation in COX-deficiency across the myofibre (Elson et al. 2007; Murphy 
2009). 
The threshold level for point mutations involving mt-tRNA genes has been estimated as 90%, 
according to studies using transmitochondrial cybrids cell lines – described further in 
Chapter 4 (Chomyn et al. 1992; Yoneda et al. 1992). Studies using patient muscle fibres have 
also shown threshold levels of approximately 80% - 90% for the m.8344A>G (MT-TK gene) 
and m.3243A>G (MT-TL1 gene) (Jeppesen et al. 2017; Shoffner et al. 1990). However, a 
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lower estimate of 50% heteroplasmy has been suggested as the threshold level for 
m.3243A>G in skeletal muscle (Jeppesen et al. 2006) and 60% in cells (Miyabayashi et al. 
1992). This variation highlights that the threshold level is not entirely known for the different 
tRNA pathogenic variants, particularly with regard to the m.3243A>G mutation. This aspect 
will be described in further details in section 1.5.5 of this current chapter as well as in 
Chapters 4 and 5.  
In comparison, single large scale mtDNA deletions are thought to cause biochemical defect at 
a lower threshold level of 50-60% based on transmitochondrial cybrid cell lines (Hayashi et 
al. 1991; Porteous et al. 1998). Although, higher threshold levels of 70-90% have been 
reported in patient skeletal muscle (Sciacco et al. 1994).  
1.5.3. Maternal inheritance 
It is widely accepted that mtDNA is inherited strictly through the maternal line – referred to 
as maternal inheritance (Giles et al. 1980). There are a few processes which can be used to 
explain this uniparental inheritance, which involve the elimination of the paternal 
mitochondria. The sperm contains only 50-70 copies of mtDNA compared to 100,000 to 
600,000 in the unfertilised egg (Jacobs et al. 2006; Lopez-Lluch et al. 2008; Shoubridge and 
Wai 2007; Wai et al. 2010). Once fertilisation has occurred, the paternal mtDNA (from 
sperm) is diluted away by the excessive oocyte (maternal) mtDNA – this model is termed the 
‘simple dilution model’ (Ankel-Simons and Cummins 1996; Gyllensten et al. 1991). 
Moreover, maternal inheritance is also driven by the active destruction of paternal 
mitochondria after fertilisation by proteosomal degradation. It has been shown that ubiquitin 
tagging of the paternal mitochondrial membrane occurs within the fertilised egg, resulting in 
selective degradation by lysosomes and/or proteasomes (Sutovsky et al. 2000). Lastly, a 
significant downregulation of mtDNA copy number occurs during spermatogenesis (Larsson 
et al. 1997). 
Cases of paternal inheritance have been reported in patients. Evidence of paternal inheritance 
was found in a patient with muscle specific mitochondrial disease, caused by a 2-base pair 
(bp) deletion in the MTND2 gene. The muscle biopsy showed that 90% of the mtDNA was 
paternally derived and also contained the mutation on the MTND2 gene. This findings 
suggested that this occurrence was likely to be resulting from the failure of eliminating the 
mtDNA within the sperm (Schwartz and Vissing 2002). A recent study has shown evidence 
for biparental transmission of mtDNA in three unrelated families (Luo et al. 2018). By 
undertaking whole mtDNA sequencing using Next Generation Sequencing (NGS) of 
seventeen individuals, Lou and colleagues identified high levels of heteroplasmic and 
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homoplasmic non-pathogenic mtDNA variants that were likely to be transmitted from the 
father. This paternal transmission of the variants was also observed in the siblings and the 
mother. The study concluded that whilst maternal inheritance remained dominant, the 
mechanisms driving bilateral transmission needs to be investigated to further understand 
mitochondrial inheritance, most particularly the potential paternal inheritance and its 
contribution to the disease pathogenicity of mitochondrial disease (Luo et al. 2018).  
1.5.4. The mitochondrial bottleneck 
During mitosis, both wild type and mutated mtDNA from the maternal mtDNA pool are 
believed to be randomly distributed to the daughter cells, resulting in a large amount of 
variability in the number of mutated mtDNA molecules passed on to offspring’s. Thus, 
siblings from the same mother can end up with very different heteroplasmy levels. This 
variation is due to a phenomena termed ‘the mitochondrial bottleneck’; the restriction and 
then re-amplification of mtDNA copy number that leads to random shifts of heteroplasmy 
from one generation to the next (Cree et al. 2008; Jenuth et al. 1996; Taylor and Turnbull 
2005). Genetic bottleneck is a result of the rapid replication that occurs after fertilisation 
(Cree et al. 2008; Howell et al. 2003).  
Heteroplasmy levels in offspring’s are thought to be determined by random genetic drift 
during replication in the oocyte (Brown et al. 2001). 
1.5.5. Segregation of mtDNA mutations  
As a result of continuous replication, the segregation of mtDNA mutations is possible in both 
mitotic and post mitotic tissues. Macmillan et al. (1993) proposed random segregation to 
explain the tissue specific segregation observed in many mutations. However, evidence that 
segregation is not random has been shown and rather that nuclear genes influence segregation 
pattern (Raap et al. 2012). In addition, Chinnery et al. (1999) showed that specific tissues 
demonstrate consistent alteration from the average heteroplasmy level of an individual, for 
example, the m.3243A>G heteroplasmy level is found to be higher in muscle and urine than 
blood or hair. The tissue specific segregation of the m.3243A>G mutation in embryogenesis 
was later exemplified by Frederiksen et al. (2006). Specific nuclear encoded mitochondrial 
proteins that affect this segregation are beginning to be identified, for example the GIMAP3, 
an outer mitochondrial membrane GTPase (Jokinen et al. 2010). 
An offspring would inherit a proportion of mutated mtDNA from their mother, but this load 
may not be enough to cause an immediate OXPHOS deficiency in cells. As the individual 
ages, a genetic drift occurs during cell proliferation which results in variable levels of mutated 
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mtDNA between cells. Only the cells or tissues that reach the threshold and above exhibit a 
biochemical defect (Mishra and Chan 2014). Thus, mutation segregation can influence and 
affect both the disease expression as well as inheritance. 
1.5.6. Clonal expansion 
Clonal expansion is the term used to describe the process by which a single mutated mtDNA 
(caused by either a point mutation or deletions), expands in proportion in a given cell, thus 
increasing the level of heteroplasmy. Eventually, this accumulation leads to the mutated 
mtDNA population outnumbering the wild-type mtDNA population, subsequently exceeding 
the necessary threshold required to induce a biochemical respiratory chain deficiency and the 
consequent functional impairment of a cell. Therefore the clonal expansion of mutated 
mtDNA may play an important role in both inherited diseases and ageing (Greaves et al. 
2014).  
A number of models have been proposed in aid of explaining how clonal expansion occurs 
within a cell. The first model was called the “survival of the smallest” by Wallace (1992) in 
which it was hypothesised that a smaller mtDNA genome, caused by a deletion, replicated 
faster than the wild-type, allowing for a selective and replicative advantage which leads to an 
accumulation of the mutated mtDNA. This model was initially supported by studies in which 
it was shown that cells containing high levels of mtDNA deletions replicated faster or were 
able to repopulate their mtDNA copy number faster than wild-type cell lines, although these 
studies were undertaken in non-physiological conditions (Diaz et al. 2002; Fukui and Moraes 
2009; Hayashi et al. 1991). Opposing studies refuted the hypothesis by showing that there was 
no replicative advantage of smaller genomes (Campbell et al. 2014). It was also apparent that 
the theory did not offer an explanation for the clonal expansion of mtDNA molecules 
damaged due to point mutations, as these did not alter the size of the genomes, yet 
significantly increased in frequency with age (Greaves et al. 2014). 
The second theory was termed the “survival of the slowest” by de Grey (1997). Also based on 
the notion of selective advantage, the theory proposed that mutated mtDNA produce a 
reduced level of ROS after a reduction in the OXPHOS process, compared to wild type 
mtDNA which are consequently degraded at a higher rate. However, this theory was not 
accepted as a sufficient explanation of clonal expansion because in order to impact the 
respiratory capacity of the mitochondria, there would need to be a sufficient amount of 
mutated mtDNA present in the mitochondria via clonal expansion.   
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Unlike the first two theories, which were based on the selective advantages of mutated 
mtDNA, the third hypothesis proposed was termed “random genetic drift” by Elson et al. 
(2007), where no selective advantage is required for clonal expansion. The hypothesis was 
based on the theory of relaxed replication by Bogenhagen and Clayton, 1997 (theory in which 
the mtDNA replication occurs independently to the nuclear DNA, which is linked to the cell 
cycle) and it was argued to be sufficient to explain clonal expansion. A population of mtDNA 
molecules in non-dividing cells were stimulated, with relaxed replication, over the maximum 
accepted human life span of 120 years. It was shown that the vast majority of mutations 
present after 80 years were found to have occurred before 30 years of ages, with 46% 
occurring before the age of 15. The study concluded that any mutation events which occurred 
after this, would not have sufficient time to accumulate. This study defined a COX-deficient 
fibre (described in section 1.8.1 of this chapter) as cells that contained more than 60% 
mutated mtDNA at the end of the simulation. Although this model is supported by 
mathematical models, there is some dispute between the predictions of COX-deficiency and 
physiological observations (Campbell et al. 2014).  
A more recent model has been proposed to explain clonal expansion, particularly within 
skeletal muscle fibres (Vincent et al. 2018). The study performed in depth imaging and 
molecular studies of skeletal muscle from patients with genetically confirmed mitochondrial 
disease (multiple mtDNA deletions) to determine how clonal expansion proceeded through 
highly organised and spatially restricted mitochondrial populations within these cell types 
(see section 1.7.2 of this chapter). The clonal expansion model by Vincent and colleagues 
proposes that mtDNA deletions, which first arise in the perinuclear region of the cell 
(opposite the myonuclei), preferentially accumulate due to an increase in mitochondrial 
biogenesis in the region. This gives rise to the first visible signs of a focal mitochondrial 
respiratory chain deficiency in the cell, indicating that the mtDNA have exceeded the 
biochemical threshold in this region. The mutant mitochondria then expand transversely from 
the site of the foci through to the remainder of the muscle fibre, driven by increased 
mitochondrial biogenesis. Whilst this study was unable to investigate the clonal nature of the 
deletions and the role of mtDNA replication, it has provided an insight into how fully COX-






1.6. Mitochondrial Disease 
Mitochondrial disease is the umbrella term used for a group of disorders that are characterised 
by a chronic loss of cellular energy and this failure to meet the energy demands consequently 
results in a clinical phenotype. The clinical spectrum for the diseases is extremely 
heterogeneous in terms of age of onset, the clinical manifestations, inheritance and prognosis. 
Tissues which have a high-energy demand, such as the brain, skeletal muscle, heart and the 
central nervous system (CNS) are typically most affected. Mitochondrial diseases can affect a 
single organ in isolation, such as pure myopathy, cardiomyopathy or optic neuropathy. 
Alternatively, they can be multisystem, in which several organs are affected. Due to this 
clinical heterogeneity, the prevalence of mitochondrial diseases is hard to quantify. However, 
it has been recently shown that approximately 12.5 per 100,000 adults (Gorman et al. 2015a) 
and 4.7 per 100,000 children are affected (Koenig 2008; Skladal et al. 2003).  
Common clinical features of mitochondrial disease, as shown in Figure 1.18 include ptosis, 
proximal myopathy, exercise intolerance, cardiomyopathy, external ophthalmoplegia, 
deafness, optic atrophy and diabetes (Gorman et al. 2016), Owing to the high metabolic 
demand, muscle is commonly affected in mitochondrial patients, either exclusively or 
predominantly.      
As mitochondria are under the dual control of both the mitochondrial genome and nuclear 
genome, genetic lesions can lie in either, giving rise to either defects caused by mtDNA 
mutations (primary defect) or defects of the nDNA-encoded mitochondrial protein (secondary 
defect).  For mitochondrial disease in general, pathogenic variants have been reported in all 
37 mtDNA genes and more than 300 nDNA-encoded genes (as reviewed by (Thompson et al. 











Figure 1.18: The clinical spectrum of mitochondrial diseases. 
Schematic diagram showing the organs affected in mitochondrial disease and the corresponding 
clinical manifestations. Organs that require a high-energy demand, such as the brain, heart, nervous 









1.6.1. Mitochondrial DNA pathogenic variants 
The mtDNA is significantly more vulnerable to mutations than the nuclear DNA, with a 
mutation rate that is 10-20 times higher (Brown et al. 1979; Richter et al. 1988). This is 
thought to be for a number of reasons; i) the mtDNA genome consists almost entirely of 
coding regions and therefore mutations are more likely to occur in a coding region, ii) the lack 
of protective histones found on the mtDNA molecule, iii) the close proximity to damaging 
ROS produced by the ETC within the IMM, iv) a nucleotide imbalance in the mitochondria 
results in the mtDNA polymerase POLG having a much lower fidelity and higher mtDNA 
mutation rates than that of the nuclear polymerase (Kunkel and Loeb 1981; Song et al. 2005) 
and v) the continuous replication of mtDNA which leads to the increase in the chances of 
error being made during the process (Bogenhagen and Clayton 1977).  
Primary mtDNA mutations are due to two common causes; point mutations (a single base pair 
substitution) and mtDNA rearrangements (typically single large-scale deletions but can also 
be insertions). These were first reported in 1988 when a point mutation in the ND4 gene was 
found to cause Leber’s hereditary optic neuropathy (LHON) (Wallace et al. 1988) and a 
deletion of up to ~7kb was reported in patients with mitochondrial myopathy (Holt et al. 
1988). Both point mutations and single large-scale deletions can be maternally inherited or 
arise as a de novo during embryonic development.  
1.6.1.1.  mtDNA point mutations 
Mitochondrial DNA point mutations (occurring in mt-tRNA, mt-rRNA and mt-mRNA) have 
become a significant cause of mitochondrial disease, with a prevalence of approximately 1 in 
5,000 in the adult population (Schaefer et al. 2008). The majority of defects have been 
reported in tRNA genes (accounting for 50%), which consequently cause an overall reduction 
in mitochondrial protein synthesis, a decline in oxygen consumption rate and a decreased 
activity of multiple respiratory chain complexes (Mariotti et al. 1994). The remaining 
mutations are founded in structural genes with only 2% in rRNA genes (Schon et al. 2012).  
Point mutations are heritable and follow a strict maternal inheritance pattern. They are usually 
highly recessive and heteroplasmic, however homoplasmic mutations have also been reported, 
for examples the m.11778G>A mutation in the ND4 gene and the m.4300A>G mutation in the 
mt-tRNAIle gene (Nakamura et al. 1993; Taylor et al. 2003; Yen et al. 2002). In heteroplasmic 
cases, point mutations have been shown to require a high threshold to induce a biochemical 
defect (Chomyn et al. 1992; Mariotti et al. 1994). However, some mutations have been shown 
to cause a biochemical defect, thereby clinical disease, with substantially lower thresholds as 
proposed. For example, Sacconi et al. (2008), reported a young patient harbouring the 
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m.5545C>T mutation within the MT-TW gene (tryptophan tRNA - tRNAtrp), which caused 
severe multisystemic disorder and marked respiratory chain deficiency at low levels of 
heteroplasmy (25%) in clinically affected tissue (muscle). Additionally, the m.14723T>C 
within the tRNAGlu (MT-TE) gene (glutamic acid tRNA) was shown to cause CPEO at low 
levels of heteroplasmy in muscle tissue of the patient (7% in initial biopsy, 34% in second 
biopsy) (Alston et al. 2010).   
The most common point mutation in mitochondrial disease is the m3243A>G mutation – a 
transition of A to G nucleotide at position 3243 of the mtDNA, within the dihydrouridine loop 
(D-loop) of the mt-tRNA Leu(UUR) (MT-TL1 gene) (Goto et al. 1990). This pathogenic variant 
is a key topic for interest in this thesis and will be descried in greater detail in Chapters 4 and 
5. Another common point mutation is the m.8344A>G in the MT-TK gene (mitochondrial 
tRNA lysine (Lys)), which was first identified in patients with MERFF (myoclonic epilepsy 
with ragged red fibres) (Shoffner et al. 1990). The prevalence for this point mutation within 
the North East of England has been shown to be 0.7 in 100,000 (Gorman et al. 2015a), 
therefore is much rarer in comparison to the m.3243A>G mutation.  
Further pathogenic point mutations that have been identified in mtDNA genes encoding 
subunits of Complex I, IV and V. For example, the three most commonly found mutations 
causing LHON; m.3460G>A within the MTND1 gene (Howell et al. 1991), m.11778G>A 
within the MTND4 gene (Wallace et al. 1988) and m.14484T>C within the MTND6 gene 
(Johns et al. 1992; Mackey and Howell 1992). These last three pathogenic variants, along 
with other variants related to Complex I, will be described again in Chapter 3.  
1.6.1.2. Single, large-scale mtDNA deletions 
The second cause of primary mitochondrial disease is single, large-scale mtDNA deletions, 
which Gorman et al., 2015, estimated the frequency to be 1.5 in 100,000 (12% of adult 
mitochondrial disease cases). These mutations are not heritable and instead usually occur 
sporadically during embryogenesis due to errors in either mtDNA replication or repair 
(Chinnery et al. 2004). In comparison to point mutations, patients affected show a lower 
threshold of approximately 50-60% (Rossignol et al. 2003). Deletions have been found to 
result from defects in mtDNA replication, maintenance and repair and occur frequently 
between OH and OL (origin of replication) and regions flanked by tandem repeats (Krishnan et 
al. 2008; Rossignol et al. 2003; Schon et al. 1989; Spelbrink et al. 2001). Deletions vary in 
size (1.3-10kb), however the most frequently reported deletion size is the so called “common 
deletion” which spans 4,977bp (approximately 5kB); extending from base 8,470 in MT-AT8 
to base 13,477 in MT-ND5 genes and flanked by a 13bp direct repeat  (Pitceathly et al. 2012; 
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Zeviani et al. 1988). A study by Grady et al. (2014), showed that there is a correlation 
between deletion size, heteroplasmy and severity of disease. Using a single cell approach 
(single muscle fibres), Rocha et al. (2018), provided an insight into the pathological 
mechanism underlying single large –scale deletions by showing that the removal of mtDNA 
genes is directly linked to the expression and severity of the consequential respiratory chain 
deficiency.  
Single large-scale deletions predominantly cause syndromes which comprise of; CPEO 
(Chronic progressive external ophthalmoplegia) which is present in ~ 65% of cases, KKS 
(Kearns Sayre Syndrome) accounting for 30% of cases and Pearson syndrome in the 
remaining ~ 5% of cases (Mancuso et al. 2015).  Pearson syndrome is the most severe 
disorder, affecting the bone marrow and pancreas thereby leading to the characteristic 
sideroblastic anaemia and exocrine pancreas diabetes. Neutropenia (low white blood cells) 
and thrombocytopenia (low platelets) are also observed. The disorder is often associated with 
death occurring at infancy. KKS is defined by clinical onset before the age of 20 years and 
affects mainly the eyes through a progressive external ophthalmoplegia (weakness or 
paralysis of the eye muscles - extraocular). This consequently leads to the impairment of eye 
movement and patients often present with ptosis. Pigmentary retinopathy is also observed in 
patients and additional features for KKS include cerebellar ataxia, impaired cognitive function 
such as dementia, muscle weakness, deafness, liver and kidney involvements. Finally, CPEO 
is characterised by ptosis, impaired eye movement due to paralysis of the extraocular. 
Proximal limb muscle weakness and exercise intolerance are also important findings in these 
patients.   
1.6.2. Nuclear DNA mutations 
As stated, the nDNA encodes 99% of mitochondrial proteins (1,158) and to date, over 300 
genes have now been reported to cause mitochondrial disease (Thompson et al. 2019), owed 
to the progress and application of high-throughput molecular genetic analysis. Mutations 
follow a Mendelian inheritance pattern which include autosomal dominant, recessive and X-
linked (Fernandez-Moreira et al. 2007; Harel et al. 2016; Sperl et al. 2015; Tang et al. 2011). 
The nuclear DNA encodes genes that are crucial for multiple mitochondrial functions, such as 
the structure and assembly of complexes in the OXPHOS system, the regulation of 
mitochondrial dynamics through fusion and fission, the import of nuclear-encoded RNA and 
proteins into the mitochondria, the proteins required for the maintenance of the mtDNA and 
also protein synthesis (Schon et al. 2012). Therefore, pathogenic variants can potentially 
disrupt any of these complexes and functions. Figure 1.19 highlights a list of nuclear DNA 
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genes (and mtDNA genes) that are currently known to be associated with mitochondrial 
disease.  
Nuclear DNA mutations often have secondary effects on the mtDNA which results in multiple 
mtDNA deletions of varying size and position to occur. This is predominantly due to 
pathogenic variants on nuclear genes encoding proteins involved in mtDNA transcription, 
replication and maintenance machinery (Kaukonen et al. 2000; Spelbrink et al. 2001; Van 
Goethem et al. 2001). 
The first nuclear gene mutation that was found to give rise to mitochondrial disease involved 
SDHA in two sisters with Complex II deficiency and Leigh syndrome (LS) (Bourgeron et al. 
1995). This particularly mutation was found to be recessive. Other examples include 
mutations in POLG which leads to mtDNA depletion syndrome or PEO (progressive external 
ophthalmoplegia) (Naviaux et al. 1999; Van Goethem et al. 2001). Another example would be 
mutations in PEO1 which is the gene encoding TWINKLE and pathogenic variants have also 
been associated with mtDNA depletion and multiple deletions (Spelbrink et al. 2001). 
Nuclear mutations can lead to an isolated disorder where only one complex of the respiratory 
chain is affected or a combined dysfunction of several complexes. The latter is usually a 






Figure 1.19: List of genes currently associated with mitochondrial disease. Genes have been listed 
according to their function.  
To date, pathogenic variants have been founded in 36/37 mitochondrial‐encoded genes and 295 
nuclear‐encoded mitochondrial genes which are associated with a wide range of mitochondrial 
functions. This figure has been taken from (Thompson et al. 2019) who has used broad categories of 
mitochondrial functions in order to appropriately assign these genes with more than one function to 
their most appropriate one. The list also takes into account the causative genes that have been shown 
to have a primary or secondary impact on OXPHOS and does not include genes where variants have 
been described in cancer, but not a mitochondrial disorder (e.g. SDHC).  
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1.7. Muscle and mitochondria  
The primary function of the skeletal muscle is to generate force and movement through 
contraction, for which it requires mitochondria to continuously synthesise ATP. The muscle is 
therefore known to be a tissue which has a high demand for energy, thus clinical phenotypes 
associated with the muscle are commonly found in mitochondrial patients. 
1.7.1. Structure of skeletal muscle  
Skeletal muscle has a highly organised architecture, as depicted in Figure 1.20. The smallest 
contractile unit is the multinucleated elongated cell which is called the muscle fibre (also 
known as a myofibre). Each of these muscle fibres are formed from densely arranged, parallel 
array of cylindrical elements called myofibrils. These myofibrils are formed by repetitive 
units called sarcomeres which are approximately 2.5µm to 3µm in length and are the 
functional units of muscle (Hopkins 2006). Sarcomeres are separated by the Z bands and 
consist of smaller contractile filaments (myofilaments), actin which is the thin myofilament 
and myosin which is the thick myofilament as well other support proteins such as troponin 
and tropomyosin. The thick myofilament is anchored to the Z-band by an elastic protein 
called titin, which regulates the spatial relationships between the two myofilaments 
(Dubowitz 2007).  Each muscle fibre is then organised into linearly aligned bundles called a 
fascicle and a bundle of these fascicles then form the muscle.   
There are three layers of connective tissue that enclose and provide structure to skeletal 
muscle and also providing compartmentalization of the muscle fibres. The first is the external 
sheath called the epimysium which envelopes the muscle and allows the muscle to maintain 
its structural integrity during contraction and movement. The middle layer of connective 
tissue is the perimysium which covers the fascicles and acts a way of holding muscle fibres in 
these bundles. This layer also provides the pathway for the capillarity network and the 
innervating motor neurons. The third layer is the endomysium which encases each individual 
muscle fibre within each fascicle (Gillies and Lieber 2011).  
The plasma membrane of the muscle fibre is known as the sarcolemma (also known as the 
plasmalemma), which is found under the endomysium. The sarcolemma is an excitable 
membrane that can activate the contractile machinery in response to signals from the motor 
neuron. When the motor nerve axon innervates the muscle fibre, it forms a synapse which is 
neuromuscular junction. The region at which the sarcolemma makes contact with the 
presynaptic nerve terminal is known as the motor end plate. This is characterised by the deep 
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folding of the sarcolemma. A single motor neuron can innervate a few or numerous muscle 
fibres and this collectively becomes known as the motor unit.     
Skeletal muscle fibres are multinucleated cells. The nuclei accumulate in the periphery of the 




Figure 1.20: A schematic figure of the structure of skeletal muscle and sarcomere. 
A) Skeletal muscle is enclosed by the epimysium and arranged into muscle fascicles which are 
surrounded by the perimysium. Within in each fascicle are muscle fibres which are surrounded by the 
endomysium and each muscle fibre is composed of the myofibril. The sarcolemma is the plasma 
membrane of the muscle fibre. B) Each myofibril is composed of repetitive units called sarcomeres, 
which are separated by Z bands. These Z bands consist of smaller contractile myofilaments – thin 







1.7.2. Mitochondria in skeletal muscle 
There are two subpopulations of mitochondria within skeletal muscle fibres that differ in their 
subcellular localization, morphology, function and biochemical properties. The first 
population is found in small, perinuclear clusters below the sarcolemmal membrane and thus 
are known as the subsarcolemmal (SS) mitochondria. These mitochondria make up for 20% 
of the complete population of skeletal muscle mitochondria and are important in providing 
ATP for membrane transport and gene transcription (Ferreira et al. 2010; Hoppeler 1986). 
Morphologically, SS mitochondria appear punctate. The second population of mitochondria 
(accounting for the remainder of 80% of mitochondrial population) are found in parallel rows 
between the myofibrils adjacent to the Z line of the sarcomere and are called intermyofibrillar 
(IMF) mitochondria. These mitochondria play a prominent role in providing ATP to the 
contractions myofilaments (actin and myosin) to assist contraction (Kirkwood et al. 1986; 
Ogata and Yamasaki 1997). The IMF mitochondria are more elongated in structure as they 
must extend between myofibrils and have a higher oxidative capacity (efficiency in ATP 
production) (Ferreira et al. 2010).  
1.7.3. Skeletal muscle fibre types  
In mammals, skeletal muscle is composed of different types of muscle fibres, grouped 
according to their diverse morphology, functional and metabolic capabilities and contraction 
rates. They are characterised by the expression of specific isoforms of myosin heavy chain 
(MHC) which determine their contractile strengths. These fibre types can be distinguished by 
myofibrillar actomyosin ATPase histochemistry, immunoblot or immunofluorescence 
labelling of MHC isoforms. Motor neurons influence the phenotype of the fibre types and in 
human skeletal muscle, there are three types of motor units; slow, fast fatigable and fast 
fatigue resistant motor unit. This leads to the three different fibre types; Type I (slow twitch 
fatigue resistance), Type IIa (fast twitch fatigue resistance) and Type IIx (fast twitch fatigue 
sensitive) (Burke et al. 1973; Smerdu et al. 2005). Electrical impulses from the nervous 
system influence the growth and differentiation of the different phenotypes of the fibre types. 
Discharge rates at 10 and 100Hz result in changes in gene expression that consequently cause 
the development of the fast and slow fibre types (Schiaffino et al. 1989). Table 1.1 highlights 
the main differences between each of the fibre types. However briefly, Type I fibres are the 
most oxidative and so have a high oxidative capacity, higher mitochondrial content but lower 
ATP consumption due to a longer contraction and relaxation time. Type II fibres are split into 
further two types; Type IIa and Type IIx. Firstly, Type IIa fibres are defined as being fast 
oxidative glycolytic, have a high mitochondrial content and a high ATP consumption due to a 
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quicker contraction rate. Type IIb fibres are known as fast glycolytic with low mitochondrial 
content and higher ATP consumption due to a fast contraction rate (Lieber 2010).  
Most human skeletal muscles have a mosaic of different fibre types, with the ratio of Type I 
and Type II differing within the same muscle and between different muscles. The human 
vastus lateralis muscle (quadriceps) from young healthy adults have approximately equal 
proportions of type II (fast twitch) and Type I (slow twitch). However, sedentary adults over 
the age of ~60 years have been shown to have an increased proportion of hybrid fibres which 
express more than one MHC isoform (St-Jean-Pelletier et al. 2017). Additionally, a study by 
Gehrig et al. (2016), found that in patients with mitochondrial myopathy, there is a shift in the 
fibre type composition from Type I to type II, possibly acting as a compensatory mechanism. 
The decrease in oxidative capacity means a switch from an oxidative to a more glycolytic 
phenotype. This shift will allow for the partial restoration of muscle strength and energy 
production but also a higher lactic acid production, which is characteristic in patients with 
mitochondrial disease (Gehrig et al. 2016). 
Table 1.1: Muscle fibre type, function and characteristics 
 






Fibre diameter  Small Medium Large 
Capillary density  Rich Rich/ medium Sparse 
Mitochondria  Rich Rich Poor 
Oxidative activity  High High Low 
Glycolytic activity  Low High/ intermediate High 
Myoglobin  High High/ Intermediate Low 
Myosin heavy chain  Type I Type IIa Type IIb 
Functional properties 
Recruitment  1 2 4 
Ca2+ 
sequestration(SR)  
Slow Slow/ rapid Rapid 
ATP consumption  Low High High 
Contraction speed  Slow Fast Fast 
Twitch force  Small Intermediate Large 




1.8. Diagnosis of Mitochondrial Diseases 
The diagnosis of mitochondrial diseases requires a multidisciplinary approach, owing to 
factors including mtDNA heteroplasmy, wide genetic and clinical heterogeneity and a clinical 
spectrum which often overlaps with other neurological disorders. With the growing 
knowledge of mitochondrial and nuclear genes responsible for mitochondrial disease, as well 
as a progress in the recognition of phenotype - genotype correlations, the current diagnostic 
procedure has shifted from the “biopsy first approach” to the “genetics first approach” 
because of the advances being made with next generation sequencing (NGS). 
The process of diagnosis first includes a detailed clinical examination from a number of 
specialist clinicians. Despite the vast clinical heterogeneity of mitochondrial disease, the 
identification of certain clinical features alone can lead to targeted mtDNA or nuclear gene 
screening, prior to a muscle biopsy. For example, a child presenting with classic MELAS 
(Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes) phenotypes 
would be tested for the m.3243A>G mutation (usually through sampling blood from the 
patient) whilst a visual failure in a young male adult may prompt targeted sequencing of the 
three common point mutations associated with LHON, as listed previously in section 1.6.1.1 
(Nesbitt et al. 2013; Yu-Wai-Man et al. 2003).  
Despite the impact of NGS in the diagnostic setting for mitochondrial disease, there is still a 
requirement for clinically affected tissue samples that are used for histological, 
immunohistochemical and biochemical investigations. An example for such requirement 
would be the identification of novel pathogenic variants with unknown function that would 
require further investigation of affected tissue through enzymatic activity assays and steady 
state levels of OXPHOS complexes, undertaken with BN-PAGE.  
1.8.1. Muscle biopsy and histochemical investigations 
Skeletal muscle biopsy plays an important role in the diagnostic work up for mitochondrial 
disease, principally because it is commonly clinically affected in patients with pathogenic 
mutations in either mtDNA or nuclear DNA. This is owed to the fact that muscle is a 
mitochondrial rich tissue with a high energy demand, thus is likely to exhibit a respiratory 
chain defect in the presence of a pathogenic variant.  This is also true for the brain and heart 
which are also commonly affected in patients, however muscle is an accessible tissue in 
comparison hence its role in the diagnostic pathway. With the ongoing shift towards the 
“genetics first approach”, the question of when to perform a muscle biopsy arises. It is 
becoming less common to obtain biopsies from young children, however in some adults, the 
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procedure is still undertaken following clinical assessments. For example, this could be due to 
further investigation required for a novel variant with unknown function.  
Many patients manifest distinct histopathological alterations in their skeletal muscle which 
indicate mitochondrial dysfunction. One such hallmark feature observed in muscle histology 
is the presence of Ragged-Red Fibres (RRF) which are detected through the modified Gomori 
trichrome stain (Figure 1.21) (Engel and Cunningham 1963). These fibres present when there 
is an accumulation of mitochondrial aggregates in the subsarcolemmal region of the fibre due 
to mitochondrial proliferation as a result of mitochondrial OXPHOS dysfunction (Moraes et 
al., 1992). Amongst the normal blue stained fibres, RRF are visualised as being red in colour 
with cracking of fibre edges. Whilst it is recognised that RRF is a feature of mitochondrial 
disease, the fibres are also observed in normal ageing muscle (Cao et al. 2001), Duchenne and 
Becker muscular dystrophy and other chronic myopathies (Paizner et al., 1991; Calere et al., 
1994). To distinguish from these disorders, Bernier et al. (2002), suggested that the presence 
of RFF in over 2% of all fibres on the muscle sections of individuals under 50 years of ages 
should be indicative of mitochondrial disease.  
Another canonical pathological feature of mitochondrial disease is the presence of COX- 
deficient fibres. A number of diagnostic protocols have been established in distinguishing 
these fibres in patient muscle biopsies. The most universally used protocol is the sequential 
COX/SDH histochemical assay (Figure 1.21) – often referred to as being the ‘gold standard 
method’. The enzymatic reactions include the loss of oxidized 3,3’ diaminobenzidine (DAB) 
tetrahydrochloride and the electron acceptor nitroblue tetrazolium (NBT). The oxidation of 
DAB results in a brown reaction product whilst NBT forms a blue reaction product known as 
formazan (Old and Johnson 1989; Sciacco and Bonilla 1996) (Ross 2011). Fibres are either 
coloured brown which signifies healthy fibres or blue which identifies the COX-deficient 
fibres. A global loss of COX-activity, indicated by all blue fibres on the skeletal muscle 
section, is observed in cases where the mitochondrial disease is caused by a pathogenic 
variant on a nuclear-encoded gene affecting COX assembly or homoplasmic mt-tRNA 
mutations (Taylor et al. 2003; Tiranti et al. 1998; Zhu et al. 1998). However, in the case of the 
mutation being on the mtDNA, a mosaic pattern is frequently observed on the muscle section 
- COX-deficient fibres appearing blue amongst the brown normal COX-positive fibres. This 
mosaic pattern is due to the differing levels of heteroplasmy (due to mitotic segregation and 
clonal expansion) by which fibres where heteroplasmy has exceeded the threshold for 
deficiency appear as COX-deficient (Bua et al. 2006; Campbell et al. 2014). It is important to 
also consider that clonal expansion leads to healthy aged individuals accumulating a low 
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frequency of COX-deficient fibres (Baines et al. 2014; Bua et al. 2006; Rygiel et al. 2016). A 
suggestive diagnosis of mitochondrial disease is only made when an individual’s (under 50 
years of age) muscle section harbours COX-deficiency fibres at a frequency of >5%.  
More recently, Simard and colleagues (2018), established the nitrotetrazolium blue exclusion 
assay (NBTx assay) as an alternative enzymatic histochemical reaction for the detection of 
COX-deficient fibres. Unlike COX/SDH, the single colour reaction only requires the 
reduction of NBT without the use of DAB and thus the protocol provides a rapid time 
processing during diagnosis. The assay utilises the redox reactions between cytochrome c 
oxidase, NBT and the potent electron carrier phenazine methosulphate (PMS). PMS carries 
electrons from Complex II to NBT which is localised in COX subunits, however PMS only 
favourably transfers electrons when COX activity is intact. Upon accepting the electrons, 
NBT forms formazan. This only occurs in COX-deficient fibres, therefore, the assay allows 
for the direct visualization of deficient cells. Unlike COX/SDH, NBTx is capable of revealing 
low levels of COX-deficiency in single cells. The assay has also the potential for automated 
and quantifiable analysis (Simard et al. 2018).   
Whilst skeletal muscle is commonly used for these investigations, in some cases, cardiac 
muscle, liver and brain (post-mortem) can also be used.  
 
 
Figure 1.21: Histochemical investigations showing hallmarks of mitochondrial dysfunction in 
skeletal muscle 
A) Gomori trichrome stain to detect ragged red fibres which show an accumulation of mitochondrial 
aggregates in the subsarcolemmal region of the fibre due to mitochondrial proliferation, indicated by 
the red in colour (fibre 1). B) Sequential COX/SDH histochemistry showing a mosaic pattern of 
unaffected (COX-positive – fibre 2) and affected (COX-deficient – fibre 3) muscle fibres in transverse 
sections. C) When muscle biopsies are examined longitudinally, COX-deficiency can be seen restricted 
to small segments along the length of the fibre surrounded by COX-positive regions.  
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1.8.2. Biochemical studies  
Spectrophotometric evaluation of individual respiratory chain complex activities is an 
important approach to the biochemical investigation and diagnosis of mitochondrial diseases. 
It can be performed in either fresh or frozen muscle homogenate (~50mg of skeletal muscle 
required), however the latter is more common in diagnostic centres due to cross-continental or 
national referral of patients. Each complex can be analysed in isolation following the 
oxidation/reduction of specific substrates or substrate analogues. The spectrophotometric 
enzyme assays are as follows; NADH:ubiquinone oxidoreductase for complex I, 
succinate:CoQ1 oxidoreductase for complex II, ubiquinol- cytochrome c oxidoreductase for 
complex III, cytochrome c oxidase for complex IV and oligomycin sensitive ATP synthase 
for complex IV. Bernier et al. (2002), recommended a 20-30% of normal complex activities 
as a criterion for the diagnosis of mitochondrial disease.  
Alongside the spectrophotometric assays, another useful assay includes the BN-PAGE assay 
which is used to assess the relative abundance of fully assembled respiratory chain enzyme 
complexes. Similarly, measurements of protein subunits of complexes are assessed through 
western blots and gel electrophoresis. These two techniques are often used to validate 
suspected pathogenic variants (Parikh et al. 2015).  
1.8.3. Molecular genetics studies 
A confirmed defect in the respiratory chain complexes, through both histochemical and 
biochemical testing, can facilitate appropriate molecular genetic testing to elucidate the 
underlying genetic cause. However, as previously discussed, the advent and application of 
NGS has changed the diagnostic approach to a “genetics first approach”.  
Prior to the expansion and application of NGS, first generation sequencing, primarily Sanger 
sequencing (Sanger et al. 1977), was utilised to identify pathogenic variants, however the 
technique was only able to sequence short DNA reads. This led to the development of 
Shotgun de novo sequencing which was able to sequence larger DNA regions such as whole 
chromosomes or genomes. NGS techniques were developed thereafter, classed as second-
generation sequencing techniques. The application of NGS is effective for heterogeneous 
conditions such as mitochondrial diseases as it allow for the interrogation of a large number of 
genes simultaneously. Moreover, it provides a rapid, high throughput sequencing which is 
much more cost effective than Sanger sequencing. Over the past decade, the screening of the 
mitochondrial genome and the high throughput analysis of Mendelian candidate genes has 
been achieved with the following NSG approaches; targeted gene panels for example the 
targeted Complex I panel (Alston et al. 2016), targeted exome sequencing (“MitoExome”) 
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(Calvo et al. 2012) whole exome sequencing (WES) (Haack et al. 2010; Taylor et al. 2014; 
Wortmann et al. 2015), whole genome sequencing (WGS) (Hartmannova et al. 2016) and 
RNA-seq (Kremer et al. 2017). 
If the diagnostic pathway follows the “biopsy first approach” and the evidence from the 
histopathological and biochemical algorithms indicate a defect in a mtDNA gene, the entire 
mitochondrial genome can be analysed. NGS allows for deep coverage across mtDNA and 
thus detection of low levels of heteroplasmy, point mutations and breakpoints of single, large-
scale mtDNA deletions. Alternatively, if evidence is inferring to a defect located in the 
nuclear DNA, either WES, WGS or a targeted multi-gene panel of candidate genes can be 
employed to identify the causative gene.  
In the case of novel variants that have not been previously reported, functional tests must be 
undertaken to confirm the pathogenicity of the defect. These typically include looking at 
pathogenicity predictions based on protein structure and “rescue” experiments where patient 
cells are transfected with a wild type copy of the suspected gene and is shown to rescue the 
disease phenotype. Additionally, protein expression can also be investigated through BN-
PAGE and SDS-PAGE as well as the quadruple immunofluorescence assay (Thompson et al. 
2019). 
1.8.4. Immunofluorescence techniques 
Immunofluorescence techniques using specific monoclonal antibodies targeting the subunit of 
mitochondrial OXPHOS complexes have also been used in investigating biochemical defects 
in skeletal muscle sections. One advantage of this is the direct visualisation of the antigen-
antibody binding sites and therefore a direct protein expression. Another is that 
immunofluorescence techniques allow for the quantification of several subunits of the 
respiratory chain complexes on one muscle section. Rahman et al. (2000) utilised the 
technique to identify specific staining patterns associated with the different subunits of 
Complex IV. The study recognised specific staining patterns/subunit loss associated with 
patients with COX-deficiency secondary to mtDNA mutations whilst most patients did not 
have this particular staining pattern and therefore were thought to harbour nuclear gene 
defects. Another study utilised the technique to determine the expression of the targeted 
proteins in the frontal cortex, cerebellum and medulla on autopsied brain biopsy from a 
MERFF patient and found decreased expression of COX-II in these regions (Sparaco et al. 
1995). Likewise, COX-deficiency was detected using a monoclonal antibody against COX-I 
to show Complex IV deficiency in the small intestine of a patient with MERFF (Tanji et al. 
2001). In addition, De Paepe et al. (2009) developed an immunofluorescence approach to 
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identify all five complexes in skeletal muscle sections of patients with mitochondrial tRNA 
gene defects and was able to stain for Complex I in two tRNA patients who had previously 
been undetected in the routine histochemical diagnostic process.  
As further described in section 1.9 below and also Chapter 2, Rocha et al, developed the 
quadruple immunofluorescence assay and validated the technique using skeletal muscle 
cryosections from patients with various pathogenic variants (Rocha et al. 2015) - Figure 
1.22(B). The technique has since been applied routinely in a diagnostic setting at the 
Newcastle NHS Highly Specialised Service for Rare Mitochondrial Disorders, located within 
the Wellcome Centre for Mitochondrial Research at Newcastle University. 
  
 
Figure 1.22: Comparison of the quadruple immunofluorescence assay to the traditional 
histopathology techniques. 
 (A) The traditional standard histopathology techniques used in serial skeletal muscle sections from a 
patient with a single, large- scale mtDNA deletion (i) H&E used to assess fibre size variation, 
abnormal infiltrations and central nuclei. (ii) Gomori trichrome) (iii) Individual staining of COX 
(fibre marked with asterix (*) indicating loss of Complex IV), (iv) SDH (fibre marked with asterix (*) 
indicating normal Complex II) and (v) sequential COX/SDH staining showing mosaic COX deficiency. 
(B) the application of the quadruple immunofluorescence assay (i) Laminin staining used as a 
myofibre boundary marker (ii) NDUFB8 targeting Complex I (iii) COX-1 targeting complex IV (iv) 
Porin used for mitochondrial mass marker and (v) is the overly of all antibodies used. Fibre marked 
with the * indicate focal accumulation of sub-sarcolemma mitochondria and the down regulated 
immunoreactivity of both NDUFB8 and COX-1, therefore a downregulation in the expression of CI 




1.9. The quadruple immunofluorescence Assay  
The quadruple immunofluorescence assay, as developed by Rocha et al., 2015, targets the two 
most commonly affected complexes in mitochondrial disease; Complex I and Complex IV. 
The assay utilises monoclonal antibodies targeting NDUFB8 (Complex I), COX-1 (Complex 
IV), porin (VDAC- mitochondrial mass) and laminin (myofibre boundary) on a 10µm skeletal 
muscle tissue section. The assay allows for an objective and reliable quantitative method 
which allows for the assessment of Complex I and Complex IV protein abundance relative to 
the mitochondrial mass in each individual muscle fibre within a 10µm transverse skeletal 
muscle tissue sections of patients with different genotypes causing mitochondrial disease 
(Rocha et al. 2015). The analysis of the single muscle fibres is undertaken using an automated 
analysis software (described further in Chapter 2, section 2.5.10.1), where staining intensity 
of NDUFB8, COX-1 and porin is determined.   
A major advantage of the assay is the ability to target Complex I, therefore providing an 
alternative histopathological technique to COX/SDH, for Complex I deficient patients in 
particular. Furthermore, through targeting COX-1, a core catalytic subunit of Complex IV, 
which is essential for the function and assembly of the complex, the assay is targeting a 
subunit which is responsible for the integrity of the complex.  
The assay has been utilised in research, for example the technique has been shown to have 
important implications for the diagnosis of mitochondrial diseases (Ahmed et al. 2017) which 
is expanded upon in Chapter 3. Additionally, the assay has been used to investigate the 
underlying molecular mechanisms of disease, for example gaining a mechanistic insight into 
single large-scale deletions through utilising both the assay and single cell (fibre) approach 
(Rocha et al. 2018). Further muscle related diseases which involve the mitochondria have also 
been investigated using the assay for instance disorders caused by mutations in the DYSF 
gene (dysferlin) (Vincent et al. 2016b) and myofibrillar myopathies caused by mutations in 








1.10.    Overall aims and objectives: 
The aims of this PhD can be divided into two themes; i) improving the diagnosis of 
mitochondrial diseases and ii) improving the understanding of molecular mechanisms 
underlying mitochondrial disease and the expression of a biochemical defect. The principle 
methodology of this work will be the use of patient skeletal muscle sections and the quadruple 
immunofluorescence assay, to achieve the following aims;  
1) Firstly, with regards to the first theme, the aim will be to investigate whether the 
quadruple immunofluorescence assay can be utilised in a diagnostic setting for 
patients with Complex I deficiency. This will be specifically achieved through 
assessing the Complex I expression in the skeletal muscle sections of patients who 
have proven pathogenic mutations in either nuclear encoded subunits or assembly 
factors or mtDNA encoded subunits of Complex I. Given the vast clinical and genetic 
heterogeneity associated with Complex I deficiency, it will be important to assess how 
effectively and accurately this assay is able to detect Complex I deficiency in this 
group of patients (Chapter 3).  
The second theme is specifically exploring the heteroplasmic m.3243A>G pathogenic variant 
located within the MT-TLI gene. This mutation is associated with a vast clinical heterogeneity 
and complexity. This study has the overarching aim of deducing the heteroplasmic threshold 
for individual patients, how this may differ and how this biochemical phenotype may 
correlate with the clinical phenotype. Therefore, the aims for this part of the thesis (Chapters 
4 and 5) are as following;  
1) To characterise the biochemical profile of skeletal muscle sections from patients 
harbouring the m.3243A>G mutation from the MitoCohort. The study will utilise the 
assay in a larger cohort of patients to capture this heterogeneity and to better 
characterise the protein expression of Complex I and Complex IV in single muscle 
fibres.   
2) Taking forward the data attained from the quantitative immunofluorescence assay, the 
next aim will be to assess the relationship between this data and the clinical data 
available for each patient, specifically the homogenate m.3243A>G heteroplasmy 
level and the clinical assessments scoring the phenotypic severity (NMDAS scores).  
This paves way for the final aims of this project which are the following;  
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1) Using a single fibre approach, fibres will be sampled from skeletal muscle sections of 
these patients for downstream molecular genetic testing to determine the heteroplasmy 
level in each individual fibre. The relationship between the biochemical respiratory 
chain defect (Complex I and Complex IV) and heteroplasmy level will be assessed at 
the cellular level.  
2) To determine the threshold level at which Complex I and Complex IV deficiency 
occur in each patient skeletal muscle section. Using the appropriate statistical input, 
the estimated threshold will be determined and to ascertain whether there is a 






























































































2.1. Equipment  
 
Table 2.1:  List of equipment 
Equipment Company  
3510 pH meter Jenway  
 
ABI Step one software v.2  Applied Biosystems 
 
ABI StepOnePlusTM Real-Time PCR system  Applied Biosytems 
 
ABI verti 96 well Thermo Cycler Applied Biosystems 
 
Apoptome Axio Imager Z2 microscope Carl Zeiss 
 
Autoclave Prior Clave 
 
Axio Imager M1 microscope   Carl Zeiss 
 
AxioCam MRc colour digital camera Carl Zeiss  
 
AxioCam MRm monochrome digital camera  Carl Zeiss 
 
AxioVision (release.4.8.2) image capture software Carl Zeiss 
 
Balance VWR  
 
Benchtop Centrifuge, 5417 Eppendorf 
 
Benchtop Centrifuge, 5418 Eppendorf 
 
Benchtop Heat Block – OBD2 Grant  
 
BioRad ChemiDoc MP imaging system  Bio-Rad 
 
Cary WinUV Software (Version 3.00) Agilent Technologies 
 
CCD colour camera  Olympus 
 
Cryostat (Cryo-star) HM 560M  Microm International  
 
Cryostat  Bright – OTF5000 
 
DNA Gel Electrophoresis Tray PeQlab 
 
Excel  Microsoft  
 
Image J – image analysis software Public domain – NIH 
 
Image Lab (version 4.0.1, build 6) Bio-Rad Laboratories  
 
Laminar flow hood Jencons-PLS 
 
Leica Laser Microdissection Microscope System Leica 
 
Microwave, Jet convection and Grill Sharp 
 
NANOpurell Water Purification System Elga Veolia 
 
Olympus BX51 light microscope Olympus 
 
Optima Max – XP Ultracentrifuge Beckman Coulter  
 
Orbital Shaker (SSL1) Stuart  
 
Palm Robo Software (version 4.6) Carl Zeiss 
 
Platform Shaker STRG Stuart Scientific  
 
Power Supply – MP 250 volts Cleaver Scientific  
 
Prism 5 GraphPad Software Inc 
 




PyroMark Q24 Cartridge ε 3, Version 2 Qiagen 
 
PyroMark Q24 System (version 2.0.7) Qiagen  
 
PyroMark Q24 Workstation Qiagen 
 
Quadruple Immunofluorescence Analyser  Dr John Grady (Kinghorn 
Centre for Clinical 
Genomics Garvan Institute 
Sydney NSW Australia) 
 
R (version 3.5.0 (2018-04-23) -- "Joy in Playing") R 
 
R Studio (Version 1.1.447) R Studio 
 
ThermoMixer Comfort Eppendorf 
 
UV hood  Bioair Instruments 
 
UV Visible Spectrophotometer Cary 300 Agilent Technologies  
 
Vortex Genie Scientific Industries  
 
Vortex genie 2 Scientific industries  
 
Vortex Genie 2 Scientific Industries  
 
Zeiss Axioimager  Zeiss  
 




Table 2.2: List of consumables 
Consumable  Company  
0.2ml thin-walled PCR tubes Starlab UK Ltd 
 
10µl Multichannel Pipette  Ergo One 
 
25 well, 1.5mm DNA Gel electrophoresis combs PeQlab 
 
8-Strip PCR Caps, Domed  StarLab 
 
Aerosol resistance pipettes  Starlab UK Ltd 
 
Centrifuge Tubes – 7/1 x 13/8 (11x34mm) Beckman Coulter  
 




Coverslips (22x50mm)  Merck (MSD) 
 
Eppendorf  tubes (1.5ml, 2.0ml) Starlab UK Ltd 
 
Falcon tubes (15ml, 50ml) BD Biosciences 
 
Filtered Pipette Tips (10µl, 20µl, 200µl, 1ml), Tip One StarLab 
 
Gilson pipette (P1, P10, P20, P200, P1000) Gilson Scientific 
 
Gloves  StarLab 
 
Hydrophobic pen Daido Sangyo 
 
MicroAmp®Optical 96- Well reaction plate  Fisher Scientific 
 
Native 4-16% BisTris Gel Life Technologies  
 




Pipette tips (10µl, 20µl, 200µl, 1ml)  Starlab UK Ltd 
 
Polyvinylidene fluoride (PVDF) membrane Immobilon-P, Millipore Co 
 
PyroMark Q24 Plate – 100 Qiagen 
 
Scalpels Swann Morton 
 
StarSeal advanced polyolefin film Starlab UK Ltd 
 
Superfrost Glass slides Merck (MSD) 
 
Teflon Glass Dounce Homogenizer  Thomas Scientific  
 
Weigh boats VWR International Ltd 
 
Whatman filer paper Fisher Scientific 
 
X-Cell SURE Lock apparatus  Thermo Fisher  
 
 
2.3.  Chemicals and Reagents  
Table 2.3: List of chemicals and reagents  
Chemicals  Company  
Ethanol (absolute) Fisher Chemicals 
Methanol (99.9%) Fischer Chemicals  
Liquid Nitrogen Boc 
  
Reagents: Immunofluorescence staining   
Sodium Chloride (NaCl)  Sigma Aldrich Company Ltd 
Trizma Base  Sigma Aldrich Company Ltd 
Tween-20 Sigma Aldrich Company Ltd 
Hydrochloric Acid (HCl) VWR International  
Paraformaldehyde (PFA), 4% Santa Cruz  
Methanol (99.9%) Fisher Chemicals 
Normal Goat Serum (NGS) Sigma Aldrich Company Ltd 
Avidin and Biotin Kit  
Prolong Gold Mounting Media Life Technologies  
  
Reagents: Primary Antibodies   
• Mouse IgG1 NDUFB8 (100µg at 1 mg/ml) Abcam (Ab110242) 
• Mouse IgG1 NDUFS3 (100 µl at 0.5 mg/ml)  Abcam (Ab197971) 
Mouse IgG2a MTCO1 (100µg at 1 mg/ml) Abcam (Ab14705) 
Mouse  IgG2b VDAC (Porin) (100µg at 1 mg/ml) Abcam (Ab14734) 
Polyclonal Rabbit IgG Laminin α-1 (500 µl at 0.5 
mg/ml) 
Sigma Aldrich (L9393) 
Mouse IgG2b Ba-F8-s (26µg/ml) DSHB (3/3/16)  
Mouse SC-71-s IgG1 (26µg/ml) DSHB (3/3/16)  
6H1-s (IgM) = MHC type IIx (64μg/ml) DSHB (4/7/16)  
Polyclonal Rabbit ND1 Gifted by Professor Anne 
Lombés (Institut Cochin, 
France) 
  
Reagents: Secondary Antibodies  
Goat Anti- mouse IgG1 Alexa fluor – 488nm  Life Technologies (A21121) 
Goat Anti-mouse IgG 2a-Alexa fuor - 488nm  Life Technologies (A21141) 
Goat Anti- mouse IgG2b Alexa fluor – 546nm  Life Technologies (A21143)  
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Goat Anti- mouse IgG1-Alexa Fluor - 546nm Life Technologies (A21123) 
Goat Anti-rabbit IgG Alexa fluor - 750nm  Life Technologies (S31556)  
Streptavidin – 647nm  Life Technologies (S32357) 
Anti-mouse IgM Alexa fluor – 647nm Invitrogen (A21238) 
XX Goat Anti-mouse IgG1 Biotin Life Technologies (A10519) 
  
Reagents: DNA extraction   
Nuclease Free Water Promega 
Tween-20 Sigma Aldrich Company Ltd 
Tris- HCl  Sigma Aldrich Company Ltd 
Proteinase K Solution (20mg/ml), RNA grade Thermo Fisher Scientific  
DNA Away Molecular Bio Products  
  
Reagents: Polymerase Chain Reaction (PCR)  
GoTaq® G2 DNA Polymerase (5u/µl) Promega 
5X Colorless GoTaq® Reaction Buffer Promega 
Deoxyribonucleotide Triphosphate (dNTP) A Roche Diagnostics Ltd 
Deoxyribonucleotide Triphosphate (dNTP) C Roche Diagnostics Ltd 
Deoxyribonucleotide Triphosphate (dNTP) G Roche Diagnostics Ltd 
Deoxyribonucleotide Triphosphate (dNTP) T Roche Diagnostics Ltd 
PCR primers  IDT 
Nuclease Free water Promega 
DNA Away Molecular Bio Products  
  
Reagents: Gel Electrophoresis   
Agarose (Molecular Grade)  Bioline Reagents  
Tris Acetate EDTA (TAE), 10x Sigma Aldrich Company Ltd 
Syber Safe DNA Gel Stain, 10,000 Invitrogen  
Bromophenol Blue Sigma Aldrich Company 
Glycerol  Sigma Aldrich Company 
PCR Ranger 100bp Ladder Norgen 
 
Reagents: Pyrosequencing   
 
Streptavidin Sepharose High Performance beads GE Healthcare 
PyroMark Binding Buffer  Qiagen  
PyroMark Annealing Buffer  Qiagen 
PyroMark Wash Buffer, Concentrate Qiagen 
Ethanol Fisher Chemicals 
Sodium Hydroxide Pellets VWR 
PyroMark Enzyme Mixture  Qiagen 
PyroMark Substrate Mixture  Qiagen  
PyroMark dATPaS Qiagen 
PyroMark dCTP Qiagen 
PyroMark dGTP Qiagen 
PyroMark dTTP Qiagen  
Pyrosequencing reverse Primer IDT 
 
Reagents: Real- Time PCR 
 
Taqman PCR Mastermix  Applied Biosystems  
Real-Time PCR probes Eurofins 
Real-Time PCR primers Eurofins 




Reagents: Muscle Homogenisation and Solubilisations  
 
Phosphate Buffer Saline (PBS) OXOID 
Sucrose  BDH 
Imidazole  Sigma Aldrich Company Ltd 
HCl Fisher Scientific  
Native Page 4 x Sample Buffer Invitrogen  
20% n-Dodecyl β-D-Maltoside (DDM)  Sigma Aldrich Company Ltd 
Glycerol  Sigma Aldrich Company Ltd 
Phenylmethylsulphonyl Fluoride (PMSF) Sigma Aldrich Company Ltd 
Isopropanol Sigma Aldrich Company Ltd 
  
Reagents: Blue Native Polyacrylamide Gel (BN-PAGE)  
Pierce BCA Protein Assay Kit Thermo Scientific  
BN-PAGE Marker  
20 x Native Page Running Buffer Novex by Life Technologies  
20 x Native Page Cathode Buffer Novex by Life Technologies 
20 x Native Page Transfer Buffer Novex by Life Technologies 
Marvel Original Dried Skimmed Milk  Marvel 
AmershamTM ECLTM Prime Luminol Enhancer Solution GE Healthcare Life Sciences 




2.4.  Solutions 
1 x PBS (100ml)  1 x PBS tablet 
  100ml deionised water (dH20) 
   
70% Ethanol (500ml)  350ml Ethanol  
  150ml dH20 
   
70% Methanol (400ml)  280ml Methanol 
  120ml dH20 
   
95% Methanol (400ml)  380ml Methanol  
  20ml dH20 
   
50% Glycerol (30ml)  15ml Glycerol 
  15ml dH20 
 
5 x TBST – pH 7.4 (2 litres)  121g Trizma Base 
  90g NaCl  
  2L dH20 
  5ml Tween 20 
  HCl to pH 7.6 
DNA Loading Buffer (50ml)  0.125 (0.25% w/v) Bromophenol Blue (BpB) 
  35ml dH20 
  15ml (30%) Glycerol 
 
Gel pouring buffer/running buffer 
(1 litre)  
  
100ml 10 x TAE 
900ml NANOpure water 
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2% Agarose Gel   2g Agarose  
  100ml 10 x TAE 
   
Single Cell Lysis Buffer  250µl 1% Tween 20 
  50µl 0.5M TrisHCL at pH 8.5 
  5µl Proteinase K 
  190µl dH20 
   
PMSF, 100mM (10ml)  192mg PMSF  
  Dissolve in 10ml Isopropanol  
   
Muscle Homogenisation Buffer 
(30ml) 
 5.13g sucrose (250mM)  
600µl Imidazole/HCl (20mM) 
  30ml dH20 
  300µl PMSF (1mM)   
   
Muscle Solubilisation Buffer 
(50µl)  
 1.75µl Native Page 4x Sample buffer 
20% DDM 
  50% Glycerol 
  26.25µl dH20 
   
1 x Wash Buffer (500ml) 
(Pyrosequencing)  





 4g NaOH 
500ml dH20 
   
1 x Cathode Buffer (200ml)  
(BN-PAGE) 
 10ml 20 x Native Page cathode buffer 
10ml 20 x Native Page running buffer 
  180ml dH20 
   
1 x Anode Buffer (2L)  
(BN-PAGE) 
 50ml 20 x Native Page running buffer 
950ml dH20 
   
10 x Transfer Buffer (1L)  
(BN-PAGE) 
 50ml 20x Native Page Transfer Buffer 
200ml Methanol 
  750ml dH20 
   
Tris- HCl, pH 8.5, 3.75M  45.45g Trisma Base 
  100ml dH20 
  HCl to pH 8.5  







2.5.  Methods 
2.5.1. The Newcastle Mitochondrial Research Biobank  
The Newcastle Mitochondrial Research Biobank is a UK REC approved Research Tissue 
Bank which received ethical approval from the North East – Newcastle and North Tyneside 1 
Research Ethics Committee in 2016. The Biobank is sponsored by the Newcastle Upon Tyne 
Hospitals NHS Foundation Trust and is based within the NHS Highly Specialised Service for 
Rare Mitochondrial Disorders, located within the Wellcome Centre for Mitochondrial 
Research (WCMR) at Newcastle University 
The Biobank consists of tissue samples from mitochondrial patients and their family 
members. Samples are either excess to diagnostic requirements or were collected exclusively 
for research purposes.  
2.5.2. Ethical approval and guidelines 
Skeletal muscle tissue samples used throughout this PhD project were made available for 
access after requesting from the Newcastle Mitochondrial Research Biobank (Research Ethics 
Committee reference: 16/NE/0267). Ethical approval and guidelines for the projects were 
issued under either the Newcastle and North Tyneside Local Research Ethics Committees 
(reference 09/H0906/76) as complied with the declaration of Helsinki (as revised in 2013), or 
by the generic research tissue bank approval for the Newcastle Mitochondrial Research 
Biobank. Any clinical information linked to the samples was also provided under the approval 
of the latter committee with support from the Wellcome Centre for Mitochondrial Research 
Patient Cohort: A natural history study and Patient registry - the MitoCohort, (research ethics 
committee reference: 13/NE/0326). See the below section (2.5.3) for further information on 
the MitoCohort.  
2.5.3. Clinical Data – Mitochondrial Disease Patient Cohort (UK) (MitoCohort) 
The Wellcome Centre for Mitochondrial Research Patient Cohort: A natural history study and 
patient registry (the MitoCohort) received ethical approval from the North East – Newcastle 
and North Tyneside 2 research Ethics Committee in 2013. It replaced the MRC Centre 
Mitochondrial Disorders Patient Cohort (UK) Database (REC Ref 08/H0402/72). The 
MitoCohort is sponsored by The Newcastle Upon Tyne Hospitals NHS Foundation Trust and 
is managed by Newcastle University. The main collaborating centres are Newcastle, 
University College London Hospitals and Oxford University Hospitals. There are a total of 
1675 patients across all these sites. All patients included are clinically, genetically and 
biochemically confirmed as having mitochondrial disease.  
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The clinical data within the MitoCohort is stored in a secure database which can only be 
accessed by authorised individuals. An MDOC (Mitochondrial Disease Oversight Committee) 
application is required to be submitted in order to allow access for research purposes. The 
clinical data attained for patients included in Chapter 4 and 5 was attained via an approved 
MDOC application.  
2.5.4. Patient Cohort 
All patient samples were obtained and used for research purposes with informed consent from 
all participants prior to the start of the projects. All experiments were carried out in 
accordance with the approved guidelines.   
2.5.4.1.  Isolated Complex I patients  
In Chapter 3, 25 skeletal muscle biopsies (quadriceps muscle) of patients were used. 
Measurements of the enzymatic activities of respiratory chain complexes were undertaken 
at one of two approved Mitochondrial Diagnostic laboratories; the NHS Highly Specialised 
Service for Rare Mitochondrial Disorders located within the WMCR at Newcastle 
University or the Neurometabolic Laboratory at University College London Hospitals 
(UCLH). Muscle biopsy referral, enzyme measurements and genetic studies were al l 
undertaken as part of the diagnostic work-up of these patients for suspected mitochondrial 
disease. This study was approved and performed under the ethical guidelines issued by the 
Newcastle and North Tyneside Local Research Ethics Committees (reference 
09/H0906/75) and complied with the Declaration of Helsinki (as revised in 2013).  
2.5.4.2.  m.3243A>G patients 
A cohort of patients (n=17) who harbour the m.3243A>G mutation were selected from the 
MitoCohort UK database for investigation in Chapter 4 (further investigated at in Chapter 
5).  Of the total 1,775 patients (as of October 2019) across all of the sites included in the 
MitoCohort, 455 patients have their genotype recorded as m.3243A>G. Within Newcastle, 
there are 292 patients who are registered as being carriers of m.3243A>G, of which 28 are 
deceased.  For this study, 19 muscle biopsy samples (either quadriceps muscle or tibialis 
anterior (TA)) were requested from the Newcastle Mitochondrial Research Biobank 
(Research Ethics Committee reference: 16/NE/0267). Two further patient biopsies were 
included in this study who were not part of the MitoCohort but were provided by the 




Unless stated, the muscle biopsy referrals, clinical, histochemical, molecular genetics and 
enzymatic investigations were all undertaken as part of the diagnostic work up of these 
patients for suspected mitochondrial disease at the NHS Highly Specialised Service for Rare 
Mitochondrial Disorders (located within the Wellcome, Centre for Mitochondrial Research) 
at Newcastle University.   
2.5.5. Control Muscle Tissue 
The control muscle tissues used throughout these studies were obtained from patients who 
underwent anterior cruciate ligament (ACL) surgery, with prior informed consent and 
approval from the Newcastle biobank (NAHPB reference: 042). Biopsies were obtained from 
the distal part of the hamstring of these individuals. They were made available from the NHS 
Highly Specialised Mitochondrial Diagnostic Service for Rare Mitochondrial Disorders, for 
research purposes and were shown to have normal respiratory activities (both protein 
expression and enzymatic activity). The characteristics of the five controls used in the studies 
are shown in Table 2.4.  
 
Table 2.4: Characteristics of the non-disease control skeletal muscle biopsies (taken from distal 
region of hamstring following ACL surgery) 
Control ID Gender Age (years) at biopsy 
C1 M 17 
C2 M 33 
C3 F 25 
C4 F 23 
C5 M 28 
 
2.5.6. Newcastle Mitochondrial Disease Adult Scale (NMDAS)  
The Newcastle Mitochondrial Disease Adult Scale (NMDAS) was first published in 2006 
(Schaefer et al. 2006) with the aim of standardising assessment of patients both within our 
centre and internationally. The clinically validated method allows for a quantitative measure 
of patients which is important due to the multi-systemic nature of mitochondrial disease and 
the varied severity of clinical symptoms observed by clinicians. The scale also allows for 
assessing patient disease progression.  
An example of the NMDAS assessment is given in the Appendix (Appendix 1). Briefly, the 
assessment is split into three separate sections with 29 questions in total. Section 1 includes 
ten questions completed by the patient or the caregiver, assessing the current function and the 
impact of the disease on a day to day basis. Section 2 entails nine questions which are 
75 
 
completed by the clinician and allows for the assessment of system specific involvements 
over the past 12 months. Section 3 includes ten questions which score the current clinical 
examination performed on the day of the clinic.   
A score is obtained between 0 (normal function) and 5 (poorest form of function) for each of 
the 29 clinical questions, giving a maximum scoring total of 145. The total score for each 
patient is referred to as the ‘Total NMDAS’. These observations are stored in the secure 
MitoCohort database. Further reference to the NMDAS scale will be in Chapter 4.  
2.5.7. Tissue sectioning   
Serial transverse sections were obtained from frozen skeletal muscle blocks using a Cryo-star 
HM 560M cryostat (Microm International), at a temperature of -20°C. The sections were cut 
to either 10µm or 20µm-thickness and two sections were collected per superfrost slides 
(Merck). Sections were dried at room temperature (RT) for approximately 1 hour and then 
stored at -80°C until relevant use.  
2.5.8. Immunofluorescence   
2.5.8.1. Quadruple immunofluorescence 
Tissue sections were removed from -80°C storage and air dried for approximately 1 hour. 
Each section was drawn around with wax pen (to keep liquid on section and to ensure no 
mixing of solutions) and labelled appropriately as either OXPHOS primary or no primary 
control (NPC).  Sections were fixed with cold 4% paraformaldehyde for three minutes 
followed by washes in 1% TBST three times for a period of five minutes each. Sections 
underwent permeabilization in a methanol gradient; 70% methanol for 10 minutes, 95% 
methanol for 10 minutes, 100% methanol for 20 minutes, 95% methanol for ten minutes and 
lastly 70% methanol for ten minutes. Slides were washed again three times for a period five 
minutes each, followed by a 10% normal goat serum (NGS – diluted in 1% TBST) protein 
block for one hour at RT to block non-specific binding. This was followed by a further biotin-
avidin blocking step – avidin for 15 minutes, washed in TBST twice for five minutes each 
time followed by biotin for 15 minutes and again washes in TBST. Approximately 100µl of 
corresponding primary antibodies diluted in 10% NGS (Figure 2.1) were added to each 
section. Primary antibody concentrations can be found in Table 2.5. Sections were then 
incubated in a humidified and dark chamber overnight at 4°C.  
Sections were washed in TBST three times for ten minutes with gentle agitation using the 
Orbital Shaker (SSL1). Following this, sections were incubated with secondary antibodies 
(diluted in 10% NGS) for 2 hours at 4°C. Secondary antibody dilutions can be found in Table 
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2.6. Sections were washed again as previously stated and incubated with 100µl of the 
streptavidin conjugated with Alexa 647 for a further 2 hours at 4°C. The sections were 
washed in TBST three times for 15 minutes and mounted in prolong gold mounting medium 




Figure 2.1: Schematic diagram of the quadruple immunofluorescence assay detecting respiratory 
chain enzymes. 
Two sections of skeletal muscle (OXPHOS and NPC) are on glass slides. OXPHOS section undergoes 
labelling with antibodies targeting Complex I (NDUFB8), Complex IV (COX-1), mitochondrial mass 
(Porin, VDAC1) and laminin for highlighting myofibre boundary. The NPC section is labelled only 
with the laminin.  
 
Table 2.5: Primary antibodies used in the Quadruple immunofluorescence assay 
Antibody Target Supplier Catalogue Dilution 
 
Mouse IgG1 NDUFB8 
 







Mouse IgG2a MTCO1 Subunit of Complex IIV Abcam Ab14705 1:100 
Mouse  IgG2b VDAC 
(Porin) 
Voltage gated anion on 
outer membrane of 
mitochondria 
Abcam Ab14734 1:100 
Polyclonal Rabbit IgG 
Laminin α-1 









Table 2.6: Secondary antibodies used in the Quadruple immunofluorescence assay 
Antibody (Alexa fluor) Wavelength Supplier Catalogue Dilution 
Goat Anti- mouse IgG1  488nm Life Technologies A21121 1:200 
Goat Anti- mouse IgG2b  546nm Life Technologies A21143 1:200 
Goat Anti-rabbit IgG 750nm Life Technologies A21039 1:100 
Streptavidin 647nm Life Technologies S32357 1:100 
XX Goat Anti-mouse IgG1 Biotin n/a Life Technologies A10519 1:200 
 
2.5.8.2.  Fibre type immunofluorescence   
Muscle fibre types were determined using an immunofluorescent protocol targeting the 
different myosin heavy chain isoforms. Transverse 20µm tissue sections were removed from 
80°C storage and air dried for 1 hour. Sections were briefly washed with TBST followed by 
an hour of incubation with 10% NGS at room temperature.  A cocktail of antibodies (Table 
2.7) diluted in 5% NGS were added onto the sections and left to incubate overnight at 4°C 
(Figure 2.2). Following washes in TBST three times for 10 minutes, a cocktail of secondary 
antibodies, listed in Table 2.8, all at a dilution of 1:200 diluted in 5% NGS were added to the 
sections and incubated for 1 and a half hours in the dark at room temperature. Sections were 
then washed in TBST and mounted in prolong gold mounting medium for fluorescence. After 




Figure 2.2: Schematic diagram of the immunofluorescence assay detecting different fibres types in 
skeletal muscle section. 
A 20µm section is labelled with antibodies detecting different myosin chains associated with fibre 




Table 2.7: Primary antibodies used in fibre type immunofluorescence and associated dilutions 
Antibody Target Supplier Catalogue  Dilution 
 
Mouse  
BA-F8-s (IgG2b)  
 
 
Myosin heavy chain 








Mouse SC-71-s (IgG1)   
 
MHC Type IIa DSHB (3/3/16-26μg/ml)  
 
1:200 
6H1-s (IgM)  
 
MHC Type IIx DSHB (4/7/16-64μg/ml)  
 
1:50 
Polyclonal Rabbit IgG 
Laminin α-1 
 
Protein of the 





Table 2.8: Secondary antibodies used in fibre type immunofluorescence and associated dilutions 
Antibody (Alexa fluor) Wavelength  Supplier Catalogue Dilution 
 









Anti-IgG1  546nm Life Technologies  A21123 1:200 
Anti-IgM  647nm Invitrogen  A21238 1:200 
Goat Anti-rabbit IgG  
 
750nm Life Technologies A21039 1:200 
 
2.5.9. Image Acquisition using Zeiss Axio imager MI microscope  
Fluorescent images of the muscle sections were captured at x20 magnification using the Zen 
2011 (blue edition) software and Zeiss Axio imager MI microscope. This microscope was 
equipped with a motorised stage, an AxioCam digital camera and filter cubes which detected 
light at the wavelengths of 488nm, 546nm, 647nm and 750nm. The motorised stage and a 
tiling function on the software allowed for automated scanning of a full muscle section on the 
slide. Exposure times were set for each channel to avoid over saturation and to minimise the 
background fluorescence in the NPC sections. The same exposure times were then maintained 
across all cases (controls and patients) for the experiment. Following this imaging process, 
tiled .zvi files were stitched to generate a .czi file for subsequent image analysis.  Snapped 
images at 20x magnification were also captured for purposes of this thesis, publication and 
PowerPoint presentations.  
2.5.10.  Statistical Analysis of OXHPOS deficiency 
2.5.10.1. Densitometry measurements using the Quadruple Immuno Analyser Software 
Analysis of the single muscle fibres was undertaken using an in-house analysis software 
called the Quadruple Immuno Analyser. The software is coded for by MatLab 2015a and was 
designed by Dr John Grady (Kinghorn Centre for Clinical Genomics Garvan Institute Sydney 
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NSW Australia) in 2016. Fluorescent stitched .czi images were first uploaded into the 
software and the scanning option allowed for the generation of low resolution .jpg images to 
be created per channel (channel 1-4 in accordance to the wavelengths; 488nm (Porin), 546nm 
(COX-1), 647nm (NDUFB8) and 750nm (laminin) respectively), as well as merged images 
for channels 1, 2 and 3 and channels 2, 3 and 4. The laminin immunofluorescence (channel 4) 
was used to detect muscle fibres automatically (setting the parameters which include 
threshold and area for muscle fibre boundary contours to be set) (Figure 2.3). Any contours 
over unwanted muscle fibre and areas including those over background fluorescence, fibres 
with poor morphology or areas of the section which were folded were removed. Any fibres 
which were not detected automatically were drawn around manually. The muscle fibre 
contours were applied to all .jpg images and thus allowed for the measurement of the mean 
intensity/optical density (OD) of 488 (COX-1), 546 (Porin) and 647 (NDUFB8) in each 
individual fibre. The same procedure was repeated for each NPC to determine the levels of 
non-specific binding. Following image analysis, the software created a Microsoft Excel file 
containing the mean OD data for each case. This was then merged into one Excel file and the 
data was saved as a .csv file format using the merged processing on the software. The data 




Figure 2.3: Analysis of single muscle fibres using the Quadruple Immuno Analyser. 
A) A low resolution .jpg image of section is uploaded onto the analysis software and visualised using 
channel 4 (laminin myofibre boundary). B) Surfaces are created based on the detection of fibres using 
channel 4 and C) switching to view the combined .jpg image of Channel 2,3 and 4 allowed for the 
analysis of fibres according to morphology of fibres.  
2.5.10.2. Data analysis 
The Mitochondrial Immunofluorescence Analysis online tool can be found on the following 
link; http://research.ncl.ac.uk/mitoresearch/), uses an R-script written and developed by Dr 
John Grady (2016). Briefly, the script is encoded to correct the background in each channel 
for each myofibre by subtracting the average OD for each channel in the NPC from the values 
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generated from the OXPHOS section.  The background corrected values were then log 
transformed to normalise the data. The VDAC (porin) distribution in the non-disease control 
population of fibres were checked to be plotted as a normal distribution and following this, 
the mean and standard deviation (SD) were obtained. The Z_scores were determined for 
VDAC, Complex I (NDUFB8) and Complex IV based on the predicted level of each based on 
the porin level (as mitochondrial mass marker). Subsequently the Z_scores for all non-disease 
control and patient fibres were determined. Each individual fibres were classified based on 
Z_score boundaries which are based on standard deviation limits. The Z_scores allowed each 
fibre to be classified as positive (Pos), intermediate positive (Int +), intermediate negative (Int 
-) and negative (Neg) for Complex I and Complex IV. The categories of the fibres are 
highlighted in Table 2.9. Fibres were also classified into levels of porin according to Z scores 
(Z-score: "very low" (porin_Z < − 3SD), “low" (porin_Z between − 3SD and − 2SD), 
“normal" (porin_Z between − 2SD and + 2SD), "high" (porin_Z between + 2SD and + 3SD) 
and “very high" (porin_Z above + 3SD)). These boundaries were tested and validated by 
Rocha et al., 2015. 
 
Table 2.9: Fibre classifications based on Z_scores. 
 
The Z scores of COX-1 and NDUFB8 (in conjunction with mitochondrial mass – porin) in 
individual fibres were then plotted against each other to produce a mitochondrial respiratory 
chain profile (also known as a Z-plot), providing a coherent visualisation of the type and 
extent of deficiency (Figure 2.4). 
 






Intermediate positive (Int +) 
 
-3 and - 4.5 
Intermediate negative (Int -) 
 







Figure 2.4: An illustrated representation of the Mitochondrial Respiratory Chain plot. 
The Z-scores of NDUFB8 and COX-1 in conjunction with mitochondrial mass in individual muscle 
fibres, as represented by each individual dot. A) A normal profile where all fibres are above -3 Z score 
for both Complex I (NDUFB8_z on the x-axis) and Complex IV (COX-I_z on the y axis). B) A deficient 
profile where fibres have shifted out of the normal range (fibres are now below -3 Z score). As 
indicated by the arrows, a left shift in fibres denotes Complex I deficiency, downward shift represents 
Complex IV deficiency and a diagonal shift represents a deficiency of both complexes.  
 
2.5.11. Blue-Native Polyacrylamide gel electrophoresis (BN-PAGE)  
2.5.11.1. Muscle homogenisation   
Skeletal muscle biopsies of approximately 20 to 30mg in size (from both patients and 
controls) were cut up and homogenized using a Teflon glass Dounce homogenizer at 4°C (15-
20 gentle strokes) in homogenization buffer (containing 250mM sucrose powder, 20mM 
imidazole/HCl pH 7.4 and 1mM PMSF). The muscle homogenates were centrifuged at 
20,000g for 10 minutes at 4°C. Pellets were re-suspended and washed twice with 1ml of 
homogenization buffer and centrifuged at 20,000g for 5 minutes at 4°C each time. The final 
pellet for each sample was then solubilized in a solubilisation buffer (containing 13.75µl of 
Native page x4 sample buffer, 5.0µl of 20% n-dodecyl β-D maltoside (DDM), 26.25µl of 
dH20 and 5.0µl of 50% glycerol) and were further homogenized on ice for 20 minutes using a 
small glass spatula. Samples were then transferred into Beckman Ultracentrifuge tubes. This 
was followed by centrifugation of the samples at 100,000g (53,000rpm) for 15 minutes at 6°C 
The supernatants were transferred into a fresh 1.5ml Eppendorf tube, snap frozen in liquid 
nitrogen and stored at -80°Cfor BN-PAGE.  
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2.5.11.2. Pierce Assay and BN-PAGE 
The protein concentration of each sample was determined using the Pierce BCA protein assay 
kit, according to the manufacturer’s instructions (Pierce Thermo Scientific) and the UV-Vis-
NIR spectrophotometer (Cary WinUV Software v.3.00). A minimum of 150µg of muscle 
mitochondria extract was required for each sample  
The X-Cell SURE lock apparatus was set up according to the manufacturer’s instructions and 
the native 4-16% BisTris gel (Life technologies) was placed inside. The apparatus was filled 
with both the 1x Cathode buffer (180ml dH2O, 10 ml 20x Native Page running buffer and 
10ml 20x Native Page cathode buffer) and the 1 x Anode buffer (50ml Running buffer and 
950ml dH2O). Subsequently, calculated volumes (containing a minimum of 150µg of muscle 
mitochondria extract) for each sample, mixed with 5µl of 5% coomassie blue, and were 
loaded into the native 4-16% BisTris gel. A volume of 2µl of BN-PAGE marker was also 
added into the first lane of the gel. Samples were electrophoretically separated in first 
dimension according to the NOVEX NativePAGETM Bis-Tris Gel system instructions (2-3 
hours, 250 volts).  
2.5.11.3. Transfer, blocking and application of antibodies 
The proteins from the gel were then transferred onto a PVDF membrane. Firstly, the 
membrane was cut to necessary size, activated in 100% methanol for 30 seconds, placed in 
dH20 for 30 seconds and then in transfer buffer. The proteins were then transferred onto the 
PVDF membrane according to the BIO-RAD manufacturer’s instructions (minimum 1 hour at 
100 volts, 350 mA). Thereafter, the membrane was fixed in 8% acetic acid for 15 minutes at 
room temperature followed by quick washes with dH2O. The membrane was blocked with 5% 
milk (in 1x TBST) for 1 hour at room temperature and then incubated in primary antibody 
diluted to 1:1000 in 5% milk (in 1xTBST), overnight at 4°C (Table 2.5). Following this, the 
membrane was washed 3 times for 10 minutes each with 1x TBST and incubated in secondary 
antibody diluted to 1:2000 in 5% milk for 1 hour at room temperature (Table 2.10). The 








Table 2.10: Antibodies used for BN-PAGE 
Antibody Supplier Catalogue  Dilution 
Primary antibody 
Monoclonal Anti-NDUFB8 IgGI Novex by Life 
Technologies  
459210 (100µg) 1:1000 
 
Monoclonal Anti- SDHA IgGI 
 







Rabbit Anti-mouse IgG   Dako  P02260 1:200 
 
2.5.11.4. Detecting proteins on BN-PAGE  
The membrane was incubated in the Amersham ECL prime detecting reagents for 5 minutes 
in the dark at room temperature.  The proteins were then detected using the BioRad 
ChemiDoc MP imaging system and Image lab software (set to Blots, Colorimetric).  
Complex II was used as a loading control, so the membrane was incubated in primary 
antibody labelling SDHA either overnight at 4°C or 3 hours at room temperature. The steps 
were repeated for the secondary antibody and detection of bands. 
2.5.12. Laser Microdissection  
2.5.12.1. Sample preparation  
The 20µm sections previously stained for fibre typing were left to soak in PBS at 4°C 
overnight which allowed for coverslips to be easily removed. The slides were dehydrated in 
an ethanol gradient – 70% for 10 minutes, 95% for 10 minutes, 100% for 10 minutes and a 
further 10 minutes in 100% ethanol. Sections were stored at -20°C for later use for laser 
microdissection (or at 4°C on ice if being used imminently).  
2.5.12.2. Single fibre laser microdissection   
Sections were left to dry at room temperature for one hour. Laser microdissection was 
undertaken using the PALM microbeam system (Zeiss). An empty membrane slide was used 
for the initial laser setting. Using the PALM RoboSoftware 4.6 (Zeiss), the selected fibres 
were drawn around at x20 magnification (Figure 2.5). Laser microdissected fibres were 
captured into individual 0.2ml PCR tubes containing 15µl single cell lysis buffer (250µl of 
1% Tween20, 50µl of 0.5M TrisHCl at pH8.5, 5µl proteinase K and 195µl dH2O). Samples 
were kept on ice during the procedure and were subsequently centrifuged for approximately 8 
seconds, reaching a speed of approximately 7000rcf (relative centrifugal field), to allow for 





Figure 2.5: Isolation of single muscle fibres by laser capture microdissection. 
A) Muscle section of interest was viewed and located (encircled) using the PALM microbeam system, 
B) Muscle fibre traced around, blue dots represent the cut path of the laser, C) Fibre has been 
removed with the laser into the cap of a 0.2ml PCR tube containing lysis buffer. Scale bars are 
measuring 150µm at x20 magnification.  
 
2.5.12.3. Single cell lysis PCR   
The lysis reaction was as follows: activation of the proteinase K enzyme occurred at 55°C for 
3 hours and the deactivation of proteinase K enzyme was at 95°C for 10 minutes. This was 
undertaken using the ABI Veriti 96-well thermal cycler (Applied Biosystems). Samples were 
stored at -20°C following the lysis, ready for molecular genetic procedures.  
2.5.13. Pyrosequencing 
2.5.13.1. Pre-pyrosequencing PCR 
PCR was used to amplify a fragment of 210bp length of mtDNA, spanning the mutation site. 
The PCR mastermix consisted of: 5µl of 5x GoTaq Buffer, 2.5µl of 10x dNTP mix, 1.25µl of 
10µmol/L m.3243A>G forward primer, 1.25µl of 10µmol/L m.3243A>G reverse primer, 
0.2µl of GoTaq polymerase, all diluted in 13.8µl autoclaved dH2O. Primer details are as listed 
in Table 2.11. 1µl of template DNA was added to the 24µl master mix per well of a 24-well 
PCR plate.  
With each experiment, one blank control containing no template DNA (master mix with no 
DNA) and three positive controls (with known heteroplasmy levels of 18%, 48% and 78% 
respectively) were included alongside the single fibres, to provide internal quality control 
procedures. The PCR was undertaken with the ABI Veriti 96-well thermal cycler (Applied 




Table 2.11: Primers used for pre-pyrosequencing PCR 














5' GCG ATT AGA ATG GGT ACA ATG AG 3' 23 53.5 
 
Table 2.12: Pre-pyrosequencing PCR and conditions 









Denaturation 95°C 30 seconds  
35-38 cycles 
 
Primer annealing 63°C 30 seconds 
Extension 72°C 30 seconds 
Final extension 72°C 10 minutes 1 
Hold 4°C ∞ - 
 
2.5.13.2. DNA Gel electrophoresis 
To verify the amplification of the target DNA sequence, the PCR products were visualised 
using a 2% agarose gel. Gels were prepared by dissolving 2.0g of agarose in 100ml of 1x 
TAE buffer by heating in a microwave until boiling. After cooling the conical flask, 4.0µl of 
SYBR Safe DNA Gel stain were added and gently mixed into the agarose/TAE buffer mix. 
The gel mix was then poured into a cassette containing a comb for 25 x 1.5mm wells and left 
to set for 30 minutes at room temperature. The gel was then placed into an electrophoresis 
tank filled with 1x TAE running buffer, immersing the gel completely. Following this, 5µl of 
each PCR product was mixed with 1µl of bromophenol blue (BpB) DNA loading dye and 
added into the wells of the agarose gel subsequently. A 100bp DNA ladder and the negative 
control were also loaded into the gel. The gel was electrophoresed for 50 minutes using a 
benchtop power supply set at 120 volts (V). The bands were detected using the BioRad 
ChemiDoc MP imaging system and the SYBR safe protocol, according to the manufacturer’s 




2.5.13.3. Pyrosequencing reaction 
Following detection of amplicons showing positive amplification of the target DNA sequence 
in each PCR, quantitative pyrosequencing was undertaken using the PyroMark Q24 system 
from Qiagen (UK), to determine the heteroplasmy levels of the m.3243A>G mutation. Prior 
to the pyrosequencing reaction, a pyrosequencing run file was produced containing the plate 
layout information using the PyroMark software (Version 2.0.7, Build 3). The instrument 
used for the reactions was the “PyroMark Q24 Method 0015”.  
2.5.13.4. Pre-pyrosequencing PCR – binding of amplicons to the sepharose beads 
For each sample, 10µl of the PCR products (referred to as amplicons) were added into a 24 
well PCR plate with 70µl of binding buffer mixture (40µl of binding buffer, 2µl of 
streptavidin sepharose beads and 28µl of dH2O per sample), giving a final volume of 80µl. 
Domed caps were used to seal the 24 well plate before being placed on a shaking platform for 
10 minutes which allowed the binding of the streptavidin sepharose beads to the amplicons.  
2.5.13.5. Sample clean-up and annealing reaction 
Once samples had been agitated for 10 minutes, a handheld vacuum pump tool (VPT) with 
filter probes attached was used to capture the beads from the 24 well plate (held in wells for 
approximately 15 seconds) and was moved through a series of sequential steps: 5 seconds in 
70% ethanol, 5 seconds in denaturation buffer and 10 seconds in wash buffer. The handheld 
VPT was deactivated and then placed into a 24-shallow well plate containing 25µl of 
annealing buffer in each well (24.25µl of annealing buffer and 0.75µl of 10µmol/L 
sequencing primer), releasing the beads. Table 2.13 highlights the detail for sequencing 
primer. The plate was heated at 80°C for 2 minutes to denature the templates, before placing 
into the PyroMark Q24 system and left to stand at room temperature for a minimum of 5 
minutes to allow for the annealing of the pyrosequencing primer to the amplicon strand.  
 
Table 2.13: Primers used for Pyrosequencing annealing reaction 















2.5.13.6. Preparation of cartridge and pyrosequencing reaction  
The PyroMark 24 cartridge was first rinsed with dH20 and then loaded with the appropriate 
volumes of the enzyme, substrate and dNTPs, as illustrated in the Figure 2.6. Volumes were 
determined via the ‘Pre-run information’ on the PyroMark software, according to the 
pyrosequencing run file,  
 
Figure 2.6: A schematic diagram showing the layout of cartridge during experimental preparation 
for the pyrosequencing reaction. 
Individual reagents, as indicated by the annotations, are placed into the designated wells in the 
cartridge. Volumes of each was determined via the PyroMark Software. 
 
2.5.13.7. Analysis of Pyrosequencing data 
On completion of the pyrosequencing reaction, the PyroMark software was used to 
automatically calculate the m.3243A>G heteroplasmy level in each sample. Wells marked as 
blue showed a pass, yellow indicated uncertainty in the calculations thus indicating a repeat of 
the sample was required and red indicated a failed calculation of the sample. Negative 
controls were seen to be red as no DNA was added.    
The interpretation of the pyro-gram data is demonstrated by Figure 2.7. Firstly, because a 
biotinylated forward primer was used, the pyrosequencing reaction was undertaken on a 
reverse strand and so the wild-type allele will be a T (due to the pairing with wild-type allele 
A) and the mutant allele will be a C (paring with mutant allele G). Therefore, the sequence to 
analyse was; T/CCTGCCATCTT as shown at the x-axis of the pyro-gram. Fibres which are 
wild-type showed the peak at the C allele (underlined and corresponding to the wild-type 
allele) at the same height as the T allele – thus the same ratio. But fibres with the m.3243A>G 
mtDNA mutation showed a clear skewing of the C: T allele ratio on the pyro-gram, due to the 
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mutant allele C. The amount of dTTP and dCTP incorporated at position 3243 during the 
pyrosequencing reaction was determined and from this the percentage of heteroplasmy was 
calculated. A heteroplasmy below 3% would be considered a wild-type. When peaks are 
below 50 on the y-axis, the read-out is considered not a pass. The blank control should have 
a peak below 10.  
 
 
Figure 2.7: Pyro-gram outputs from the PyroMark software. 
A) Fibre with 2% heteroplasmy and C: T nucleotide ratio very similar B) sample showing 61% C) 
96% m.3243A>G heteroplasmy level.  
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2.5.14. Statistics analyses  
Statistical analysis was performed using R v3.3.0 and Mini tab 17. Graphs were produced in 
GraphPad Prism v7.0 (GraphPad Software Inc.) or R, using ggplot. A p value of <0.05 was 
used to consider a result as being statistically significant. Specific tests are specified in the 































































Chapter 3:  Using a quantitative quadruple immunofluorescence 































This chapter is based on the first theme of this thesis; the diagnosis of mitochondrial disease. 
It is specifically based on the diagnosis of Complex I deficiency in isolated Complex I 
deficient cases. Thereby, this section will first introduce Complex I structure and assembly, 
followed by the discussion of isolated Complex I deficiency in a clinical setting. Finally, the 
current limitations in the diagnostic work-up for the identification of Complex I deficiency 
will also be highlighted in the context of the aim of this study.  
3.1.1. Complex I structure  
The function of Complex I is detailed in section 1.3.1.3, Chapter 1. In terms of structure, the 
complex constitutes of 45 structural subunits. Of these subunits, 14 are known as the ‘core 
subunits’ which are highly conserved between both human and bacterial Complex I. Seven of 
the 14 core subunits are encoded by the nDNA (nuclear core subunits) whilst the remainder 
are mtDNA encoded (ND1-ND6 and ND4-L). Overall, these core subunits have a critical role 
in the biogenetic functions of Complex I; containing co-factors (FMN and Fe-S clusters) and 
proton pumping (Baradaran et al. 2013; Berrisford and Sazanov 2009; Sazanov and Hinchliffe 
2006; Vinothkumar et al. 2014; Zickermann et al. 2015). The remaining 30 mammalian 
subunits are known as the “supernumerary” or “accessory” subunits. These accessory subunits 
have now been localised according to the architecture of the bovine Complex I through the 
use of electron cryomicroscopy (Cryo-EM) (Zhu et al. 2016). This study revealed that these 
accessory subunits bind peripherally around the core subunits. Whilst the roles of these 
subunits have not yet been entirely determined, they are believed to be critical for OXPHOS 
function through the following roles; assisting in the assembly of Complex I, allowing for 
structural stability, regulation of biogenesis and importantly, the protection of core subunits 
against oxidative stress through forming a cage-like structure around them (Fiedorczuk et al. 
2016; Sazanov 2015; Stroud et al. 2016; Vinothkumar et al. 2014; Zhu et al. 2016; 
Zickermann et al. 2015). There are at least 15 known assembly factors which are necessary 
for the assembly of Complex I. These assembly factors are only temporarily associated with 
either a single Complex I subunit or with a larger number of subunits during the formation of 
different modules. The assembly factors are dissociated once the final holoenzyme is 
assembled (Sanchez-Caballero et al. 2016; Wirth et al. 2016). Additionally, assembly factors 
have also been linked to the biogenesis of co-factors including Fe-S clusters (Guerrero-
Castillo et al. 2017; Sanchez-Caballero et al. 2016). 
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3.1.1.1. Determining the structure of Complex I 
In recent years, much progress has been made in elucidating the complete structure and 
allocation of each of the subunits of Complex I. The L shaped structure of the complex was 
first determined in bacteria using EM (Friedrich and Bottcher 2004). Following this, X-ray 
crystallography studies allowed for further structural details to be revealed using the enzymes 
from the bacterium Thermus thermophilus (Baradaran et al. 2013; Efremov et al. 2010; 
Sazanov and Hinchliffe 2006) and the fungus Yarrowia lipolytica (Hunte et al. 2010; 
Zickermann et al. 2015). More recently, a number of studies have used the advancements 
made in single particle Cryo-EM with direct electron detectors, to identify higher resolution 
atomic structures of the entire mammalian Complex I. The study by Vinothkumar et al. 
(2014), produced a 5 Å resolution structure of the enzyme from bovine (Bos taurus) heart, 
which resolved the structures of the core subunits containing Fe-S clusters and 60 
transmembrane helices, as well as identifying 18 supernumerary transmembrane helices. This 
study also modelled 14 of the 30 supernumerary subunits. This was followed by the near 
completed atomic structure of Complex I derived from Ovis aries (Ovine) at a 3.9 Å 
resolution (Fiedorczuk et al. 2016). Through combining Cryo-EM with cross-linking and 
mass spectrometry experiments, the study was able to resolve all 14 core and 30 
supernumerary mitochondrial subunits. In unison, Zhu et al. (2016) published a 4.2 Å 
resolution Cryo-EM model for bovine Complex I where the study located and modelled all 45 
subunits, thus providing the first structure of the entire mammalian complex. However, in 
addition to this, a 3.3 Å resolution structure of Complex I from mouse heart mitochondria was 
resolved in the active state (Agip et al. 2018) – as shown in Figure 3.1.  
3.1.1.2. Functional modules of Complex I 
The L-shaped structure of Complex I consists of two fragments; a hydrophilic peripheral arm 
which extends into the matrix of the mitochondria and a hydrophobic arm which is embedded 
in the IMM (Grigorieff 1998; Vinothkumar et al. 2014; Zickermann et al. 2015). This 
structure can be further divided into three functional modules. There are two modules within 
the peripheral arm. The first is the N module at the tip of the peripheral arm which binds and 
oxidizes NADH and therefore provides electrons to the Fe-S clusters. Within this module, the 
core subunits NDUFV1, NDUFV2 and NDUFS1 alongside FMN are responsible for the 
oxidation of NADH. The second is the Q module which acts as a connector of both the 
peripheral and membrane arm and the site at which the electrons are transferred to 
ubiquinone, leading to the subsequent reduction to ubiquinol. The core subunits NDUFS2, 
NDUSF3, NDUFS7 and NDUFS8 are located within the Q module. A pocket between 
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NDUFS7 and NDUFS8 is the proposed site for ubiquinone binding and reduction – referred 
to as the Q site (Angerer et al. 2012). Collectively, the peripheral arm contains all the of the 
redox factors necessary for the movement of electrons through the complex.  
The membrane arm contains the third module known as the P module which catalyses proton 
transfer from the matrix to the IMS. This module is often referred to as two parts; the 
proximal P module (PP) or distal P module (PD) (Brandt 2006; Hunte et al. 2010). The seven 
mtDNA encoded core subunits are found in the P module. A long lateral helix identified in 
the ND5 subunit bridges the PP and PD
 together. ND1 contains a quinone binding site 
(Lazarou et al. 2009) and ND2, ND4 and ND5 are known as anti-porter like subunits with 
discontinuous helices (Zhu et al. 2016; Zickermann et al. 2015). The P module harbours 78 
transmembrane helices with a central axis of polar residues that propagates from the Q site to 
the anti-porter like subunits and is proposed to be important for the translocation of protons 
across from the matrix, through the channels within ND2, ND4 and ND5 and into the IMS 
(Baradaran et al. 2013; Fiedorczuk et al. 2016). The proton translocation events in the 
membrane arm is believed to be due to conformational changes linked to the redox reaction of 
ubiquinone (Brandt 2006; Fiedorczuk et al. 2016; Sazanov 2015).   
Figure 3.1 highlights the functional subunits of Complex I and Figure 3.2 shows the subunits 







Figure 3.1: A 3.3 Å resolution modular structure of mouse heart Complex I.   
The peripheral matrix arm and membrane arm of Complex I forms an L-shape. The complex is composed 
of three functional regions containing all 14 core subunits – located on the matrix peripheral arm is the 
(A) N module which has a role of binding and oxidising NADH and contains the three nuclear encoded 
core subunits – NDUFVI, NDUFV2 and NDUFS1 and (B) Q module which modulates electron transport 
to ubiquinone and contains four nuclear encoded core subunits – NDUFS3, NDUFS2, NDUFS7 and 
NDUFS8. Located on the membrane arm is the (C) The P module which translocate protons into the 
intermembrane space and contains all the mitochondrial DNA encoded subunits of complex I -ND1 – 






Figure 3.2: Subunit 
composition of Complex I. 
Bovine structure of Complex I 
highlighting all Complex I 
core and accessory subunits. 
Figure has been adapted from 
(Formosa et al. 2018). 
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3.1.2. Complex I assembly 
An exhaustive amount of research has been completed in order to progress the understanding 
of the Complex I assembly process. Studies have employed several model systems to study 
the assembly process in various organisms including cultured fibroblasts from patients who 
have pathogenic mutations on Complex I subunits or assembly factors to identify assembly 
intermediates (Cardol et al. 2004; Lazarou et al. 2009; McKenzie and Ryan 2010; Vogel et al. 
2007; Weidner et al. 1993). However, the use of patient cell lines in experiments are 
sometimes hindered by the fact that the mutated cells lines may lead to improper 
subassemblies to be formed which are often then degraded (Sanchez-Caballero et al. 2016). 
More recent experimental approaches include the addition and release of mitochondrial 
translational inhibitor chloramphenicol and complexome profiling (Guerrero-Castillo et al. 
2017), as well as gene editing tools such as TALENS and CRISPR/Cas9 gene (Stroud et al. 
2016). 
The assembly of Complex I has been shown to be a complicated multistep process. All 
proposed models follow the same sequence of steps leading to the formation of the complete 
holoenzyme (Antonicka et al. 2003; Lazarou et al. 2007; McKenzie and Ryan 2010; Vogel et 
al. 2007). The latest model is described as a “modular assembly model”, whereby five main 
subassembly intermediates are formed separately, forming higher molecular mass 
intermediates which assemble together to create the final holoenzyme (Guerrero-Castillo et al, 
2016). These intermediates are termed; Q/PP-a (Q module and the proximal end of the P 
module, a = first part of this assembly process), PP-b (proximal end of P module, b = second 
part of this assembly process), PD-a (distal part of P module, a= first part of this assembly 
process), PD-b (distal part of P module, b = second part of this assembly process) and N. Each 
of these intermediates have been labelled in Figure 3.3 (adapted from (Guerrero-Castillo et al. 
2017).  
Formation of the Q Module: the Q module is first to be assembled (Zhu et al., 2016; 
Guerro-Castillo et al., 2017) and is composed of; NDUFS2 and NDUFS3 (core subunits), 
NDUFA5 and NDUFS7 and NDUFS8 (contain Fe-S subunits). This assembly process is 
undertaken with the cooperation of the assembly factors NDUFAF3 and NDUFAF4.  
Formation of the P Module: the next assembly process is the formation of the Q/Pp-a 
intermediate which starts with the insertion of ND1 into the Pp-a module with the cooperation 
from the assembly factor TIMMDC1. The Q/Pp-a intermediate is completed with the 
insertions of NDUFA3, NDUFA8 and NDUFA13 subunits followed by NDUFA1 and 
NDUFA9 with assistance of the assembly factor NDUFAF2. Following this process, the 
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formation of the Pp-b/PD-a intermediate is formed as two separate modules. The first module 
is the Pp-b in which ND2, NDUFC1 and NDUFC2 are assembled with the association of the 
NDUFAF1, ECSIT, ACAD9 and NDUCOA1 assembly factors. ND3 chaperoned by the 
assembly factor TMEM126B is inserted into the module followed by ND6 and ND4-L, 
completing the formation of this module. The assembly of the PD-a module starts with the 
insertion of subunits NDFUB5, NDUFB6, NDUFB10 and NDUFB11. The assembly factor 
FOXRED1 then modulates the insertion of ND4 and NDUFB1. This is followed by 
NDUFB4, NDUFA10 and NDUFS5 which completes the formation of the Pp-b/PD-a higher 
intermediate. The PD-b module is the next to be formed which is the combined assembly of 
ND5 alongside the subunits NDUFB8, NDUFB7, NDUFB9, NDUFB2, NDUFB3 and 
NDUFAB1. This module then combines with the previous assembled modules to form the 
1.5MDa Q/P intermediate (Guerrero-Castillo et al. 2017; Leman et al. 2015; McKenzie and 
Ryan 2010). 
Formation of the N Module: the final stage of this process is the assembly of the N module 
which includes the joining of NDUFV1 and NDUFV2 (both of which are core subunits and 
flavoproteins) with NDUFS1 (a Fe-S containing subunit) and NDUFA2 (Guerrero-Castillo et 
al. 2017; Leman et al. 2015; McKenzie and Ryan 2010). 
Formation of fully assembled Complex I: the completed N module, alongside the following 
last subunits which include NDUFA11, NDUFV3, NDUFA12, NDUFS4, NDUFS6, 
NDUFA6, NDUFB1 and NDUFA7, attach to Q/P intermediate. All remaining assembly 
factors dissociate from the structure leading to the formation of the mature 1MDa Complex I 











Figure 3.3: A comprehensive model of Complex I assembly. 
Individual assembly intermediates have been outlined with the names of the intermediates within a red 
dashed box; Q/PP-a, PP-b, PD-a, PD-b and N. Figure is adapted from (Guerrero-Castillo et al. 2017).  
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3.1.3. Isolated Complex I deficiency in the clinical setting  
Isolated Complex I deficiency (OMIM #252010) is the most commonly observed biochemical 
phenotype in mitochondrial disease patients (Kirby et al. 2004a; McFarland et al. 2004), 
particularly within paediatric cases (Lazarou et al. 2009; Swalwell et al. 2011). It is 
characterised by the sole impairment of Complex I and exhibits considerable genetic 
heterogeneity; mutations can potentially affect one of the 38 nuclear-encoded subunits, 7 
mtDNA-encoded subunits or at least 15 Complex I assembly factors (Formosa et al. 2018; 
Guerrero-Castillo et al. 2017). 
3.1.3.1. Pathogenic mutations associated with Complex I deficiency  
The first reports of pathogenic mutations causing isolated Complex I deficiency were 
identified within mtDNA-encoded genes in 1988, specifically in Mt-ND4 (m.11778G>A point 
mutation causing an arginine 340 to histidine (R340H) substitution) and large deletions of the 
mtDNA (Holt et al. 1988; Wallace et al. 1988). To date, pathogenic variants have been 
reported in all 7 mtDNA- encoded core structural subunits (ND1- 6 and ND4L), 21 of the 
nuclear-encoded subunits and 12 assembly factors (reviewed in references (Alston et al. 2017; 
Craven et al. 2017; Ghezzi and Zeviani 2018)). Table 3.1 highlights the first reported 
pathogenic mutation associated with each of the subunits and assembly factors. The majority 
of these mutations are associated with a reduction in Complex I assembly and/or Complex I 
activity. However there are reports of mutations where only the catalytic activity of the 
complex has been affected, for example p.Asp446Asn NDUFS2 (Ngu et al. 2012) and MT-
ND5 m.13514A>G (p.Asp393Asn) (Bugiani et al. 2004; Lebon et al. 2003). 
Swalwell et al. (2011), indicated that 25-30% of patient’s harbour defects involving mtDNA 
genes and therefore the remaining 70% of cases are caused by nuclear gene variants (Haack et 
al. 2012). As expected, Complex I deficiency resulting from defects on nuclear-encoded 
subunits have an autosomal recessive inheritance pattern whereas defects on any of the seven 
mtDNA-encoded subunits result in maternal inheritance. However, X-linked inheritance has 
been observed in patients harbouring mutations in the nuclear encoded genes NDUFA1 
(Fernandez-Moreira et al. 2007) and NDUFB11 (van Rahden et al. 2015). Additionally, 
sporadic cases of Complex I deficiency have been reported in cases affected by mtDNA 






Table 3.1: List of Complex I subunits and assembly factors and first report of pathogenic mutations 
associated with each 
Subunit Core/Assembly Report of first pathogenic mutation 
 
Mitochondrial-encoded subunits  
MTND1 Core (Kirby et al. 2004a) 
MTND2 Core (Ugalde et al. 2007) 
MTND3 Core (Crimi et al. 2004) (McFarland et al. 
2004) 
MTND4 Core (Singh et al. 1989) 
MTND4-L Core Brown et al., 1995 
MTND5 Core (Santorelli et al. 1997) 
MTND6 Core (Jun et al. 1994) 
Nuclear-encoded subunits  
 
NDUFS1 Core (Bénit et al. 2001) 
NDUFS2 Accessory (Loeffen et al. 2001) 
NDUFS3 Core (Benit et al. 2004) 
NDUFS4 Accessory (Budde et al. 2000) 
NDUFS5 Accessory n/a 
NDUFS6 Accessory (Kirby et al. 2004b) 
NDUFS7 Core (Triepels et al. 1999) 
NDUFS8 Core (Loeffen et al. 1998) 
NDUFA1 Accessory (Fernandez-Moreira et al. 2007) 
NDUFA2 Accessory (Hoefs et al. 2008) 
NDUFA3 Accessory n/a 
NDUFA5 Accessory n/a 
NDUFA6 Accessory (Alston et al. 2018) 
NDUFA7 Accessory n/a 
NDUFA8 Accessory (Triepels et al. 1998) 
NDUFA9 Accessory (van den Bosch et al. 2012) 
NDUFA10 Accessory (Hoefs et al. 2011) 
NDUFA11 Accessory (Berger et al. 2008) 
NDUFA12 Accessory (Ostergaard et al. 2011) 
NDUFA13 Accessory (Angebault et al. 2015) 
NDUFAB1 Accessory n/a 
NDUFV1 Core (Schuelke et al. 1999) 
NDUFV2 Core (Benit et al. 2003) 
NDUFV3 Accessory n/a 
NDUFB1 Accessory n/a 
NDUFB2 Accessory n/a 
NDUFB3 Accessory (Calvo et al. 2012; Haack et al. 2012) 
NDUFB4 Accessory n/a 
NDUFB5 Accessory n/a 
NDUFB6 Accessory n/a 
NDUFB7 Accessory n/a 
NDUFB8 Accessory (Piekutowska-Abramczuk et al. 2018) 
NDUFB9 Accessory (Haack et al. 2012) 
NDUFB10 Accessory n/a 
NDUFB11 Accessory (van Rahden et al. 2015) 
NDUFC1 Accessory n/a 
NDUFC2 Accessory n/a 
Nuclear-encoded assembly factors  
 
NDUFAF1 n/a (Dunning et al. 2007) 










3.1.3.2. Clinical symptoms associated with Complex I deficiency  
Further to this wide genetic heterogeneity, Complex I deficiency exhibits a considerable 
clinical heterogeneity. The spectrum of symptoms ranges from severe presentations including 
Leigh Syndrome (LS) and fatal infantile lactic acidosis (FILA) in early childhood through to 
LHON and exercise-induced muscle weakness, which develop during young adult life.  
LS is the most common clinical presentation among children associated with isolated 
Complex I deficiency (Fassone and Rahman 2012; Koene et al. 2012). Presenting as an early 
onset disorder, the mean age of onset is between 3 to 12 months of age with the median age of 
death shown to be 2.4 years of age (Sofou et al. 2014). LS is defined as being a severe 
progressive neurodegenerative disorder in which the most common neuro-radiological 
features of these infants is bilateral symmetrical lesions in the striatum and brainstem. Thus, 
affected infants usually show a global developmental delay and failure to thrive (Loeffen et al. 
2000). Other symptoms include optic atrophy, dysphagia, cranial nerve palsies and muscle 
weakness. LS is associated with more than 75 genes encoded by either the nuclear DNA or 
the mtDNA (Lake et al. 2016; Sofou et al. 2018). Of this number of genes, at least 23 encode 
for Complex I proteins; MTND1, MTND2, MTND3, MTND4, MTND5, MTND6, NSUFS4, 
NDUFS8, NDUFS7, NDUFV1, NDUFV2, NDUFS1, NDUFS3, NDUFS2, NDUFA1, 
NDUFA2, NDUFA9, NDUFA10, NDUFA12, NDUFAF2, NDUFAF5, NDUFAF6 and 
FOXRED1 (Lake et al. 2016). 
LHON, an adult onset disorder, is defined by the degeneration of the retinal ganglion cells 
resulting in acute loss of vision. The age of onset ranges from 15 to 30 years of age, with 
males being affected five times more than females (Yu-Wai-Man et al. 2009). The cause of 
LHON in the European population is generally associated with mutations on mtDNA-encoded 
core subunits of Complex I. The most common mutations, associated with more than 95% of 
LHON cases, are; m.3460G>A within the MTND1 gene (Howell et al. 1991), m.11778G>A 
NDUFAF3 n/a (Saada et al. 2009) 
NDUFAF4 n/a (Saada et al. 2009) 
NDUFAF5 n/a (Sugiana et al. 2008) 
NDUFAF6 n/a (Pagliarini et al. 2008) 
NDUFAF7 n/a (Wang et al. 2017) 
ACAD9 n/a (Haack et al. 2010) 
FOXRED1 n/a (Calvo et al. 2010) 
TIMMDC1 n/a (Kremer et al. 2017) 
TMEM126B n/a (Alston et al. 2016) 
NUBPL  n/a (Calvo et al. 2010) 
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within the MTND4 gene (Wallace et al. 1988) and m.14484T>C within the MTND6 gene 
(Mackey and Howell 1992). 
Other phenotypes associated with Complex I deficiency are leukoencephalopathy (Bjorkman 
et al. 2015) and neonatal cardiomyopathy and encephalopathy (Bugiani et al. 2004; Collet et 
al. 2016a). The latter phenotype has been found to be associated with mutations in NDUFS2 
(Loeffen et al. 2001), NDUSF4 (Petruzzella et al. 2001), NDUFA2 (Hoefs et al. 2008), 
NDUFAF1 (Fassone et al. 2011) and ACAD9 (Collet et al. 2016b; Dewulf et al. 2016). Lactic 
acidosis is also common in paediatric Complex I deficient patients and examples of reported 
associations include NDUFS6 (Spiegel et al. 2009), NDUFAF5 (Sugiana et al. 2008), 
NDUFB3 (Calvo et al. 2012; Haack et al. 2012) and NDUFAF3 (Saada et al. 2009).   
There are currently a total of 15 known Complex I assembly factors of which 12 have known 
pathogenic mutations associated with them (reviewed in Ghezzi and Zeviani (2018). These 
known mutations are listed in Table 3.1.  
3.1.4. Limitations in the current diagnostic setting for Complex I deficiency 
The diagnosis of mitochondrial diseases requires a multidisciplinary approach, owing to 
factors such as the wide genetic heterogeneity, vast clinical spectrum which often overlaps 
with other neurological disorders and heteroplasmy in cases where mtDNA is affected. The 
process of diagnosis starts with a detailed clinical examination from specialist clinician(s) and 
often followed by histological and immunohistochemical studies, enzymatic analysis of the 
OXPHOS complexes and the genetic analysis of either, or both, the nDNA and mtDNA. The 
order in which the diagnosis workup is undertaken is dependent on a number of aspects 
including how well the phenotype- genotype correlates during clinical examination and 
whether this simplifies the molecular genetic analysis through targeted candidate genes and 
also the availability of tissue from the patient.  
This section of the chapter will focus upon the diagnosis process for isolated Complex I 
deficiency, which is the most frequently observed biochemical manifestation of an OXPHOS 
defect within a paediatric setting (Swalwell et al. 2011). While the current diagnosis process 
is highly efficient, particularly with the development of molecular studies, there are clear 
limitations in the algorithms for the detection of Complex I deficiency – these aspects will be 
described below when compared to the advantages of the quadruple immunofluorescence 




3.1.4.1. The Molecular Genetics first approach  
With the growing knowledge of mitochondrial and nuclear genes responsible for Complex I 
deficiency, as well as a progress in the recognition of phenotype - genotype correlations, the 
current diagnostic procedure has shifted towards the “genetic first approach” because of the 
advances being made with NGS. The targeted gene panels including a custom Ampliseq 
capture array targeting 49 Complex I genes, WES or WGS are now being commonly used to 
search for potential genetic diagnoses, with new disease genes constantly being identified 
(Alston et al. 2016; Haack et al. 2010; Hartmannova et al. 2016; Lieber et al. 2013; Plutino et 
al. 2018). Clinical features as detailed by the physician can guide the molecular genetic 
testing for example, a young adult man presenting with visual decline will prompt screening 
of the mtDNA for the three commonly associated LHON mutations as previously detailed. 
Furthermore, patients showing symptoms typified of LS would prompt analysis of the 
following genes; MTND1, MTND2, MTND3, MTND4, MTND5, MTND6, NSUFS4, NDUFS8, 
NDUFS7, NDUFV1, NDUFV2, NDUFS1, NDUFS3, NDUFS2, NDUFA1, NDUFA2, 
NDUFA9, NDUFA10, NDUFA12, NDUFAF2, NDUFAF5, NDUFAF6 and FOXRED1 (Lake 
et al. 2016). 
3.1.4.2. The use of muscle biopsy for histopathological and biochemical analyses 
Despite the advances in the molecular genetic testing associated with isolated Complex I 
deficiency, skeletal muscle biopsy still plays an essential role in the diagnostic algorithm. 
Biopsies are most often taken from patients in order to facilitate an appropriate molecular 
genetic testing to elucidate the underlying genetic cause or to gain an understanding into the 
effect of the genetic mutation on the respiratory chain complexes in the tissue.  
The investigation of the muscle section includes both histopathological and biochemical 
algorithms, as previously detailed in section 1.8.1, Chapter 1. Histopathological analyses 
include modified Gomori Trichrome (assessing RRF), COX/SDH and more recently, the NBTx 
assay (Engel and Cunningham 1963; Old and Johnson 1989; Ross 2011; Sciacco et al. 1994; 
Simard et al. 2018). Although these histochemical investigations are successful in determining 
RRF and COX-deficient fibres in other mitochondrial diseases, one major limitation when 
considering patients with isolated Complex I deficiency is that there is no determination of 
Complex I status in the tissue. Consequently, in such patients, fibres will appear as normal as 
both Complex II and Complex IV activities will be intact.   
In vitro spectrophotometric biochemical assays measuring the enzyme activity of each 
respiratory chain complex in muscle is also commonly undertaken in the diagnosis process. The 
use of muscle is preferred in comparison to fibroblasts which often show normal findings 
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despite a respiratory chain defect being present (Horvath et al. 2006; Spinazzola et al. 2006). 
However most diagnostic laboratories request at least 50mg of muscle tissue in order to reliably 
measure enzyme activities, which represents a considerable proportion of the total amount of 
patient material available, particularly in children. Importantly, the drawbacks concerning the 
diagnosis of Complex I deficiency using the biochemical assay include the fact that the assays 
for Complex I are known to have both low sensitivity and low specificity. This is believed to 
be due to the poor solubility of co-enzyme-Q analogues and reaction mixture turbidity. A study 
by Janssen et al. (2007a), developed an assay to measure Complex I activity in muscle and 
fibroblast samples which was designed to avoid non-specific NADH oxidation as the electrons 
produced in these reactions are not accepted by decylubiquinone, resulting in high rotenone 
sensitivity. Another limitation concerning Complex I deficiency is that the biochemical assay 
is known to only measure the redox activity of the peripheral arm of Complex I (containing the 
N-module and Q- module). Therefore, patients with mutations residing in the membrane arm 
(P-module) - where only the proton pumping ability is affected rather than electron transport - 
may show a ‘normal’ enzyme profile following biochemical assessment despite an underlying 
Complex I defect, although this may reflect the level of mtDNA heteroplasmy in muscle tissue 
(threshold for biochemical deficiency not reached) (Fassone and Rahman 2012). An example 
of this would be patients with defects in the MTND5 gene, particularly those with the MT-ND5 
m.13514A>G (p.Asp393Asn) variant (Bugiani et al. 2004; Corona et al. 2001; Lebon et al. 
2003). One last limitation to consider is that the assay may fail to detect subtle deficiencies as 
a small percentage of respiratory chain deficient cells may not be detectable by enzyme 
measurements on tissue homogenates.  
However, alternative functional biochemical assays such as the assessment of Complex I 
assembly in muscle homogenates using BN-PAGE are helpful in determining the effects of 
known or unknown genetic variants on the assembly. Additionally, western blots help with 
assessing the steady state levels of subunits of Complex I, clarifying the impact the genetic 
mutation may have on the subunit.  
3.1.4.3. The Quadruple immunofluorescence assay and Complex I deficiency  
As described in Chapter 1 and Chapter 2, Rocha and colleagues developed the quadruple 
immunofluorescence assay and validated the technique using skeletal muscle cryosections 
from patients with various pathogenic variants (Rocha et al. 2015). 
Taking into account the limitations described in the current diagnostic tools, predominantly 
with the histological algorithms, this assay can help overcome the issues regarding isolated 
Complex I deficient cases. The key advantage of the assay is the direct assessment of 
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Complex I through the immunodetection of NDUFB8, alongside the assessment of Complex 
IV (monoclonal antibody labelling COX-1) and mitochondrial mass (porin). Additionally, the 
assay requires a substantially smaller amount of skeletal muscle tissue - the use of a single 
10µm transversely-orientated muscle section is sufficient enough to provide an objective and 
reliable quantitative method for the assessment of Complex I and Complex IV protein 
abundance relative to the mitochondrial mass in individual muscle fibres. This is particularly 
beneficial when material received for the patient is too small of an amount to undergo 
conventional biochemical assay assessment. Lastly, unlike COX/SDH, an automated 






















3.2. Aims  
The quadruple immunofluorescence technique has since been applied routinely in a diagnostic 
setting at the Wellcome Centre for Mitochondrial Research at Newcastle University. 
However, given the vast clinical and genetic heterogeneity associated with Complex I 
deficiency, there has been no study undertaken on how effectively and accurately this assay is 
able to detect Complex I deficiency in this group of patients.  Moreover, accessing how well 
the findings from applying the assay correlates to the known literature will also be important 
to identify.    
Therefore, this study aims to assess and validate the use of the quadruple immunofluorescence 
assay in detecting Complex I deficiency in a diagnostic setting. The study will aim to assess 
Complex I status in skeletal muscle biopsies from 25 patients with proven pathogenic variants 
in proteins leading to a biochemical defect of isolated Complex I activity, including nuclear-
encoded Complex I structural subunits, Complex I assembly factors, or one of the 7 mtDNA-






















3.3.1. Tissue samples and patient cohort 
Twenty-five skeletal muscle biopsies (quadriceps muscle) of patients -both paediatric (<16 
years of age) and adult (≥16 years of age), who have been investigated for mitochondrial 
disease and shown to have genetically-confirmed pathogenic variants attributed to isolated 
Complex I deficiency were included in this study (see Table 3.2 for detailed information). 
Moreover, Table 3.3 highlights the genes affected in the cohort and their associated function 
and insertion into the assembly of the complex.  
Measurements of the enzymatic activities of respiratory chain complexes were undertaken at 
one of two accredited Mitochondrial Diagnostic laboratories, the NHS Highly Specialised 
Services located within the Wellcome Centre for Mitochondrial Research at Newcastle 
University or the Neurometabolic Laboratory at University College London Hospitals 
(UCLH). Muscle biopsy referral, enzyme measurements and genetic studies were all 
undertaken as part of the diagnostic work-up of these patients for suspected mitochondrial 
disease.  
All samples were obtained and used with informed consent. This study was approved and 
performed under the ethical guidelines issued by the Newcastle and North Tyneside Local 
Research Ethics Committees (reference 09/H0906/75) and complied with the Declaration of 
Helsinki. Control muscle was obtained from patients who were undergoing anterior cruciate 


















Nuclear- encoded Complex I subunits 
 
 




NDUFB3 Homozygous c.64T>C, pTrp22Arg 33% n.a. 
P2b F Paediatric IUGR. Acute life-threatening event, age 20 
days, required intubation. Hypertrophic 
cardiomyopathy 
 
NDUFB3 Homozygous c.64T>C, pTrp22Arg 
 
32% n.a. 
P3c F Paediatric Oligohydramnios. IUGR. Poor feeding at birth. 
MRI brain and echocardiogram normal. Age-





Homozygous c.64T>C, pTrp22Arg 
 
35% n.a. 





P5 F Paediatric Consanguineous, first cousin parents; Leigh-
like syndrome; elevated lactates 


































P9 F Paediatric Leigh-like syndrome; elevated lactates 
 
NDUFAF6 Compound heterozygous c.805C>T, 
p.(His269Tyr) and c.581-7A>G 
 
26% n.a. 
P10 F Paediatric Lethal infantile mitochondrial disease 
presentation; presented day 1 with persistent 







P11 F Paediatric Presented at 8 months; developmental 
regression, rotatory nystagmus bilaterally; 
elevated blood and CSF lactate; extensive basal 





Compound heterozygous c.826C>T, 
p.(Arg276*) and c.848C>T, 
p.(Ala283Val) 
44% n.a. 
P12 M Paediatric Myoclonic seizures, developmental delay FOXRED1 Compound heterozygous 
c.612_615dup, p.(Ala206Serfs*15) 
and c.1261G>A, p.Val421Met 
 
31% n.a. 
P13 M Paediatric Hypertrophic cardiomyopathy at birth; severe 
metabolic acidosis (18-30 mmol/L); died at 2 
days of age 
ACAD9 
 
Compound heterozygous c.868G>A, 








Compound heterozygous c.1150G>A, 




P15d M Adult Exercise intolerance, unable to perform 
sustained aerobic exercise; normal strength; 
normal ECG and echocardiogram; normal 
resting lactate, normal CK 
 









F Adult Exercise intolerance, persistent lactic acidaemia MTND1 m.3356T>C, p.(Met17Thr) 3% 92% 
P17 
 
M Paediatric LS MTND3 m.10158T>C, p.(Ser34Pro) 44% 90% 
P18 
 
M Paediatric LS MTND3 m.10197G>A, p.(Ala47Thr) n.d. 93% 
P19 
 
M Paediatric LS MTND5 m.13514A>G, p.(Asp393Gly) 27% 66% 
P20f 
 
F Paediatric Chronic renal failure, myopathy and persistent 
lactic acidosis 






F Paediatric Bilateral ptosis, ophthalmoplegia, pyramidal 
tract signs, elevated blood and CSF lactates 
 
MTND5 m.13094T>C, p.(Val253Ala) 59% 58% 
P22 
 
M Adult Mitochondrial myopathy, elevated lactates MTND5 m.13513G>A, p.(Asp393Asn) 39% 60% 
P23 
 
M Paediatric LS  MTND5 m.13513G>A, p.(Asp393Asn) 38% 77% 
P24 
 
F Adult Elevated CK, muscle pain and fatigue, 
myopathy 








Failure to strive, myopathy, increased brainstem 










*Residual Complex I activities, normalised to the activity of the matrix marker enzyme citrate synthase, are expresses as a percentage of mean control values. 
Residual Complex I activity and homogenate heteroplasmy level measured in muscle unless stated otherwise.  
Key: Hom het, homogenate heteroplasmy; IUGR, intrauterine growth restriction; FTT, failure to thrive; ECG, electrocardiogram; CK, creatinine kinase; LS, Leigh 
syndrome; a,b,c,d,e published patients: aP1 = Patient 3 in  Alston et al (2016) JMG, b P2 = Patient 2 in  Alston et al (2016) JMG, c P3 = Patient 6 in  Alston et al (2016) JMG, d 
P15 = Patient S1 in  Alston et al (2016) AJHG, eP16 = Patient 1 in Gorman et al (2015) Clinical Science, f P20 = Patient published in Alston et al (2010) Neuromuscular 
disorders, F; Female, M; Male,  n.a.; not applicable, n.d.; not determined  
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Table 3.3: Genes affected in the cohort of confirmed Isolated Complex I deficiency patients; their 
known/postulated function and assembly intermediate 






Accessory subunit with no  role in 




NDUFS4 Nuclear Accessory subunit with no  role in 
catalytic function of CI 
 
N module  
NDUFS6 Nuclear Accessory subunit with no  role in 
catalytic function of CI 
 
N module  
NDUFS2 Nuclear Core subunit involved with catalytic 
function of CI 
 
Q module  
NDUFS3 Nuclear Core subunit of CI involved with 
catalytic function of CI 
 
Q module 
NDUFAF6 Nuclear Assembly factor involved in the 
assembly of CI at early stages 
 
Q/Pp-a intermediate 
NDUFAF5 Nuclear Assembly factor involved in the 
assembly of CI at early stages 
 
Q/Pp-a intermediate 
FOXRED1 Nuclear Assembly factor involved in the 
assembly of CI at mid-late stage  
 
PD-a intermediate  
ACAD9 Nuclear Assembly factor involved in the 
assembly of CI at early -mid stage 
 
Pp-b intermediate 
TMEM126B Nuclear Assembly factor involved in the 
assembly of CI at mid-late stage 
 
PD-a intermediate 
MT-ND1 mtDNA Core subunit involved in electron 
transfer to ubiquinone  
 
Q/Pp-a intermediate 
MT-ND3 mtDNA Core subunit involved in electron 




MT-ND5 mtDNA Core subunit involved in electron 










3.3.2. Quadruple Immunofluorescence 
The quadruple immunofluorescence assay was undertaken on 10µm sections of each patient 
(n=25) and control (n=5), as described in section 2.5.8.1 in Chapter 2. Briefly, sections were 
incubated with the primary antibodies (Table 3.4) overnight at 4°C followed by three wash 
steps for 10 minutes each. This was followed by incubation with secondary antibodies for 2 
hours in 4°C and a further incubation step with streptavidin conjugated with Alexa 647 for 2 
hours at 4°C (Table 3.4). Sections were then mounted using ProLong gold antifade reagent. 
NPC sections were processed alongside the OXHPOS sections (Figure 3.4). Where stated, 





Figure 3.4: A schematic diagram highlighting the study design and the quadruple 
immunofluorescence protocol. 
A total of 25 patients were assessed using the assay which detects the immunoreactivity of complex I, 






Table 3.4: Primary and secondary antibodies used for immunofluorescence 
Antibody Target Supplier Catalogue  Dilution 
 
Primary Antibodies  
Mouse IgG1 NDUFB8 Subunit of Complex I Abcam Ab110242 1:100 
 
Mouse IgG2a MTCO1 Subunit of Complex IIV Abcam Ab14705 1:100 
 
Mouse  IgG2b VDAC 
(Porin) 
Voltage gated anion on outer 
membrane of mitochondria 




Polyclonal Rabbit IgG 
Laminin α-1 
Protein of the extracellular 
matrix  
Sigma Aldrich L9393 1:50 
     
Secondary Antibodies     





























Antibodies tested  
Mouse IgG1 NDUFS3 Subunit of Complex I Abcam Ab110240 1:100 
 
Polyclonal Rabbit ND1 Subunit of Complex I Gifted by Prof. 















3.3.3. Image Acquisition 
As outlined in section 2.5.9 in Chapter 2, tiled fluorescent images were captured at x20 
magnification using the Zen 2011 (blue edition) software and Zeiss Axio imager MI 
microscope, equipped with a motorised stage, an AxioCam digital camera and filter cubes 
detecting wavelengths at 488nm, 546nm, 647nm and 750nm. Exposure times were set for 
each channel to avoid over saturation – the same exposure times were then maintained across 
all cases and controls.  
3.3.4. Statistical Analysis    
3.3.4.1. Densitometry measurements 
Fluorescent images were analysed using the Quadruple Immuno Analyser analysis software 
(coded for by MatLab 2015a), as described in detail in section 2.5.10.1 in Chapter 2. The 
laminin immunofluorescence (750 channel) was used to detect fibres automatically. Any 
unwanted surfaces including those over background, fibres with poor morphology or folded 
regions of the section were removed.  The surfaces allowed for the measurement of mean 
intensity/optical density (OD) of 488 (COX-1), 546 (Porin) and 647 (NDUFB8) in each 
individual fibre. The same procedure was repeated for each NPC in order to determine the 
levels of non-specific binding.  
3.3.4.2. Data Analysis 
The Microsoft Excel fibres containing the mean ODs for each case, were merged and 
uploaded onto the Mitochondrial Immunofluorescence Analysis online tool 
(http://research.ncl.ac.uk/mitoresearch/), as fully described in Chapter 2, section 2.5.10.2. 
The analysis determined the Z scores for porin, COX-1 and NDUFB8 for each fibre analysed 
based on their expected levels, which were derived using data obtained from control muscle 
sections. Fibres were classified, based on the SD limits, into groups of NDUFB8 and COX-1 
levels; >-3 = normal, -3 to -4.5 = intermediate positive, -4.5 to -6 = intermediate negative and 
<-6 = deficient/negative. Fibres were also classified into levels of porin according to Z scores 
(Z-score: "very low" (porin_Z < − 3SD), “low" (porin_Z between − 3SD and − 2SD), 
“normal" (porin_Z between − 2SD and + 2SD), "high" (porin_Z between + 2SD and + 3SD) 
and “very high" (porin_Z above + 3SD)) (Rocha et al., 2015).  
The mitochondrial respiratory chain profiles were produced using Prism 5 (GraphPad 





3.3.5. Blue Native–Polyacrylamide Gel Electrophoresis (BN-PAGE)  
Mitochondrial fractions from both controls and patient muscle were prepared for BN-PAGE 
as previously described in detail in Chapter 2, section 2.5.11. The protein concentration of 
samples was determined using the Pierce BCA protein assay kit and absorption 
spectrophotometry measured at 562nm. A minimum of 150ug of muscle mitochondria 
extracts were loaded on a native 4-16% BisTris gel (Life technologies) and electrophoretically 
separated in first dimension according to the NOVEX NativePAGETM Bis-Tris Gel system 
instructions (2 hours, 250 volts). Proteins were transferred onto a polyvinylidene fluoride 
(PVDF) membrane (Immobilon-P, Millipore Corporation) through wet transfer. Thereafter, 
the membrane was fixed in 8% acetic acid, washed and blocked with 5% milk for 1 hour at 
room temperature.  Membrane was then subjected to standard immunoblotting analysis of 
OXPHOS complexes using primary and horseradish peroxidise conjugated secondary 



















3.4. Results  
A total of 25 skeletal muscle biopsies taken from patients with genetically confirmed 
pathogenic variants either shown or predicted to cause isolated Complex I deficiency (P1-
P25), were used to validate a recently-developed quadruple immunofluorescence assay within 
a diagnostic setting. The clinical, biochemical and molecular genetic characteristics of this 
patient cohort are shown in Table 3.2. The fibres in all muscle sections were classified 
according to Z scores – where any fibres with a Z score under -3SD were classified as 
deficient (Rocha et al., 2015). The quadruple immunofluorescence assay results in this chapter 
(particularly the NDUFB8 immunoreactivity) are presented as a percentage of fibres deficient 
in Complex I – calculated by totalling the percentage of fibres classified as negative, 
intermediate negative and intermediate positive fibres (Table 3.5). These findings were then 
subsequently correlated with the diagnostic biochemical findings which are presented as 
residual Complex I activity (Table 3.2).  
3.4.1. Group 1- Nuclear-encoded Complex I structural subunits 
All eight patients in Group 1 (P1-P8) harbouring pathogenic variants in a nuclear-encoded 
Complex I structural subunits (core or accessory), showed varying levels of decreased 
NDUFB8 immunoreactivity (representing a decrease in NDUFB8 protein 
abundance/expression) when compared to non-disease control muscle (Figure 3.5). Further 
analysis revealed that the proportion of Complex I-deficient fibres ranged between 39% and 
99% across this group of patients whilst 0% for all patients for Complex IV.  
The mitochondrial respiratory chain profiles (Figure 3.6), show the NDUFB8 and COX-1 
protein abundance in conjunction with mitochondrial mass (porin) in individual muscle fibres 
as represented by each individual point. The graphs highlight that most of the fibres analysed 
were outside of the normal range for NDUFB8 (Z-score between -3SD to 3SD) – causing a 
shift in their distribution on the plot to the left of the graph - despite the normal levels of 
Complex IV in virtually all fibres assessed (n=131 to 13422 fibres analysed in total in cases; 
this number is dependent on the size of muscle section). These findings were in agreement 
with the respiratory chain biochemical findings, where a decrease in residual Complex I 
activity was observed (Table 3.2).
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Table 3.5: Percentage of Complex I- deficient fibres detected with the quadruple immunofluorescence assay 








Complex IV (COX-1) Levels (%) 
 
Total n = 
Pos Int (+) Int (-) Neg % Deficiency Pos Int (+) Int (-) Neg % Deficiency 
Nuclear-encoded Complex I  
structural subunits 
P1 20.20 39.68 31.22 8.90 79% 100 0 0 0 0% 4372 
P2 7.16 7.51 9.12 76.21 93% 100 0 0 0 0% 559 
P3 61.29 31.33 6.96 0.42 39% 100 0 0 0 0% 13422 
P4 19.3 10.95 26.04 61.08 98% 100 0 0 0 0% 5964 
P5 11.06 33.78 40.81 14.65 89% 100 0 0 0 0% 4683 
P6 21.25 48.86 27.27 2.61 79% 100 0 0 0 0% 880 
P7 1.33 11.62 31.68 55.37 99% 100 0 0 0 0% 5337 
P8 4.54 17.04 33.06 45.36 96% 100 0 0 0 0% 7175 
Nuclear-encoded Complex I 
assembly factors 
P9 1.5 5.18 12.25 81.23 99% 100 0 0 0 0% 9504 
P10 3.68 13.95 32.27 50.10 96% 100 0 0 0 0% 5355 
P11 73.9 19.23 6.50 0.37 26% 100 0 0 0 0% 7352 
P12 3.57 8.26 11.42 76.76 96% 100 0 0 0 0% 1708 
P13 0 0 0 100 100% 100 0 0 0 0% 2684 
P14 0 0 0 100 100% 100 0 0 0 0% 239 
P15 0 0 0 100 100% 100 0 0 0 0% 131 
mtDNA-encoded Complex I  
structural subunits 
P16 8.48 0.86 0.72 89.94 92% 100 0 0 0 0% 696 
P17 9.74 41.66 37.28 11.31 90% 100 0 0 0 0% 5842 
P18 100 0 0 0 0% 100 0 0 0 0% 7302 
P19 100 0 0 0 0% 100 0 0 0 0% 2427 
P20 0 0 0 100 100% 100 0 0 0 0% 3795 
P21 100 0 0 0 0% 100 0 0 0 0% 1311 
P22 100 0 0 0 0% 100 0 0 0 0% 3341 
P23 100 0 0 0 0% 100 0 0 0 0% 2730 
P24 100 0 0 0 0% 100 0 0 0 0% 675 




Figure 3.5: Images of Complex I, IV and porin expression in skeletal muscle sections from patients 
with isolated Complex I deficiency caused by defects on nuclear-encoded Complex I subunits using 
the immunofluorescence assay. 
Fluorescent detection was used to visualise NDUFB8—purple (Complex I), COX –1—green (Complex 
IV), porin—red (mitochondrial mass) and laminin—white (fibre boundary marker). Control muscle 
(highlighted by the red box) shows normal signals for NDUFB8, COX-1 and porin. However, a 
marked decreased in NDUFB8 signal is seen in all patients (P1-P8) compared to the COX-1 and 
porin staining. Exposure times were maintained throughout all cases. Images taken at x20 




Figure 3.6: Mitochondrial respiratory chain expression profile linking Complex I, Complex IV and 
porin levels in patients with isolated Complex I deficiency caused by defects in nuclear-encoded 
Complex I subunits. 
Graphs show complex I and complex IV expression profile from (A) Normal adult control and patients 
with (B – D) homozygous c.64T>C, p.Trp22Arg NDUFB3 variant, P1 - n= 4372 fibres analysed, P2 – 
n= 559, P3 – n= 13422 (E) compound heterozygous NDUFS4  variant, P4, n = 5964 (F) Homozygous 
exon 3 and 4 deletion in NDUFS4, P5, n = 4683 (G) homozygous NDUFS6 variant , P6, n = 880 (H) 
Homozygous NDUFS2 variant , P7, n = 5337 (I) Homozygous NDUFS3 variant , P8, n =7154. Each 
dot represents a single muscle fibre, colour co-ordinated according to its mitochondrial mass: very 
low – blue, Low - light blue, Normal – beige, High – orange, Very high -red. Black dashed lines 
represent the SD limits for the classification of the fibres. Lines adjacent to X and Y axis represent the 
levels of NDUFB8 and COX-1: beige: normal (<-3), light beige: intermediate (+) (-3 to -4.5), light 
blue: intermediate (-) (-4.5 to -6) and blue: deficient (> -6). Bold dashed lines indicate the mean 
expression level of normal fibres. 
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3.4.2. Group 2- Nuclear-encoded Complex I assembly factors 
Similar to patients in Group 1, all seven patients in Group 2 (P9 to P15) who harbour 
pathogenic variants in nuclear-encoded assembly factors, displayed a severe loss of NDUFB8 
immunoreactivity (Figure 3.7). With the exception of P11, further quantification showed that 
the percentage of Complex I- deficient fibres was >96%, highlighting the severe loss of 
NDUFB8. Specifically, the assay detected a complete loss of NDUFB8 immunoreactivity 
(100% Complex I -deficient fibres) in patients P13, P14 and P15, all of whom had pathogenic 
variants in either the ACAD9 or TMEM126B genes; these encode Complex I assembly factors 
involved in the biogenesis of the proximal part of the P module (PP). Only P11, who has 
compound heterozygous pathogenic variants in the NDUFAF5 gene, encoding a Complex I 
assembly factor involved in the early step of the biogenesis of the holoenzyme, maintained a 
relatively mild level of NDUFB8 (26% Complex I -deficient fibres). As previously observed 
in patients from Group 1, the mitochondrial respiratory chain profiles from patients in Group 
2 (Figure 3.8) showed a “shifting to the left”, but to a greater extent. Again, the findings 
determined from quadruple immunofluorescence assay correlated with the available 
biochemical results which show a more severe decrease in residual Complex I activity in 





Figure 3.7: Images of Complex I, IV and porin expression in skeletal muscle sections from patients 
with isolated Complex I deficiency caused by defects on nuclear-encoded Complex I assembly 
factors using the immunofluorescence assay. 
Fluorescent detection was used to visualise NDUFB8—purple (Complex I), COX –1—green (Complex 
IV), porin—red (mitochondrial mass) and laminin—white (fibre boundary marker). A marked 
decreased in NDUFB8 signal is seen in all patients (P9-P15) compared to the COX-1 and porin 
staining. Exposure times were maintained throughout all cases. Images taken at x20 magnification. 





Figure 3.8: Mitochondrial respiratory chain expression profile linking Complex I, Complex IV and 
porin levels in patients with isolated Complex I deficiency caused by defects in nuclear-encoded 
Complex I assembly factors. 
Graphs show complex I and complex IV expression profile from patients with (A)  Compound 
heterozygous NDUFAF6 variant , P9, n = 9501 (B) Homozygous NDUFAF6 variant , P10, n = 5355 
(C) Compound heterozygous NDUFAF5variant , P11, n = 7352 (D) Compound heterozygous 
FOXRED1 variant , P12, n = 1702 (E-F) Compound heterozygous ACAD9 variant , (E = P13, n = 
2684 , F = P14, n = 239 ) (G) Homozygous TMEM126B variant , P15, n = 131. Each dot represents a 
single muscle fibre, colour co-ordinated according to its mitochondrial mass: very low – blue, Low - 
light blue, Normal – beige, High – orange, Very high -red. Black dashed lines represent the SD limits 
for the classification of the fibres. Lines adjacent to X and Y axis represent the levels of NDUFB8 and 
COX-1: beige: normal (<-3), light beige: intermediate (+) (-3 to -4.5), light blue: intermediate (-) (-




3.4.3. Assay showed variable results in patients with mutations in mtDNA-encoded 
Complex I subunits (Group 3) 
The ten patients in Group 3 (P16-P25) who harbour mutations in mtDNA genes encoding core 
structural subunits of Complex I, showed more heterogeneous results in contrast to both 
Group 1 and Group 2 patients. The quadruple immunofluorescence assay detected 100% 
Complex I-deficient fibres, representing a complete loss of NDUFB8 immunoreactivity, in 
three previously-reported patients with high levels of pathogenic mtDNA variants in muscle; 
P16 who has a m.3356T>C, p.(Met17Thr) MTND1 variant, P17 who harbours a m.10158T>C, 
p.(Ser34Pro) MTND3 variant and P20 who harbours a m.12425delA MTND5 frameshift 
mutation (Figure 3.9). As expected, the mitochondrial respiratory chain profiles for these 
three patients were all shifted to the left, consistent with the loss of NDUFB8 
immunoreactivity associated with preserved COX-I immunoreactivity (Figure 3.11).  
The remaining seven patients (P18, P19, P21, P22, P23, P24 and P25) showed NDUFB8 
immunoreactivity similar to control muscle (Figure 3.10). The mitochondrial respiratory 
chain profiles demonstrated normal respiratory chain expression as all fibres fell within the 
normal range (with Z_scores between -3SD and 3SD) (Figure 3.11). Of these 7 patients, P22 
to P25 all harbour a common pathogenic m.13513G>A, p.(Asp393Asn) MTND5 variant, P19 
harbours a m.13514A>G, p.(Asp393Gly) variant, P21 harbours a m.13094T>C, 
p.(Val253Ala) variant whilst P18 has high levels of a m.10197G>A, p. Ala393Thr MTND3 
variant. Detection of normal levels of immunoreactive NDUFB8 subunit in these patients 







Figure 3.9: Images of Complex I, IV and porin expression in skeletal muscle sections from patients 
with isolated Complex I deficiency caused by defects on mtDNA-encoded CI subunits using the 
immunofluorescence assay. 
Fluorescent detection was used to visualise NDUFB8—purple (Complex I), COX –1—green (Complex 
IV), porin—red (mitochondrial mass) and laminin—white (fibre boundary marker). A marked 
decreased in NDUFB8 immunoreactivity is seen in 3 of the 10 assessed patients in group 3; patients 
P16, P17 and P20 compared to the COX-1 and porin staining. Exposure times were maintained 




Figure 3.10: Images of Complex I, IV and porin expression in skeletal muscle sections from 
patients with isolated Complex I deficiency caused by defects on mtDNA-encoded Complex I 
subunits using the immunofluorescence assay. 
Fluorescent detection was used to visualise NDUFB8—purple (Complex I), COX –1—green (Complex 
IV), porin—red (mitochondrial mass) and laminin—white (fibre boundary marker). In all patients, 
normal levels of NDUFB8 immunoreactivity is seen. Exposure times were maintained throughout all 








Figure 3.11: Mitochondrial respiratory chain expression profile linking complex I (NDUFB8), 
complex IV and porin levels in patients with isolated Complex I deficiency caused by defects in 
mtDNA-encoded Complex I subunits. 
Graphs show Complex I and Complex IV expression profile from patients with (A) m.3356T>C 
MTND1 variant , P16, n=696 (B) m.10158T>C MTND3 variant , P17, n = 5842 (C) m.10197G>A 
MTND3 variant , P18, n=3341 (D) m.13514A>G MTND5 variant , P19, n = 2427 (E) m.12425delA 
MTND5 variant , P20, n = 3795 (F) m.13094T>C MTND5 variant , P21, n=1311 (G)  m.13513G>A 
MTND5 variant , P22, n = 3341 (H) m.13513G>A MTND5 variant , P23, n=2730 (I) m.13513G>A 
MTND5 variant , P24, n =675 (J) m.13513G>A MTND5 variant , P25, n = 785. Each dot represents 
a single muscle fibre, colour co-ordinated according to its mitochondrial mass: very low – blue, Low - 
light blue, Normal – beige, High – orange, very high -red. Black dashed lines represent the SD limits 
for the classification of the fibres. Lines adjacent to X and Y axis represent the levels of NDUFB8 and 
COX-1: beige: normal (<-3), light beige: intermediate (+) (-3 to -4.5), light blue: intermediate (-) (-
4.5 to -6) and blue: deficient (> -6). Bold dashed lines indicate the mean expression level of normal 
fibres. 
 
3.4.4. Patients with mutations in mtDNA-encoded CI subunits and normal NDUFB8 
profile also display normal NDUFS3 levels 
Most interestingly, since the interrogation of NDUFB8 immunoreactivity failed to detect 
Complex I deficiency in 7 of the 10 patients in Group 3, it was further investigated whether 
any deficiency could be detected using alternative antibodies against Complex I. The two 
antibodies tested were targeting the nuclear-encoded core subunit NDUFS3 (a commercially 
available antibody – Abcam: Ab110240) and the mtDNA encoded core subunit ND1 – both of 
which are integrated during the early stages of the Complex I assembly. The primary rabbit 
polyclonal antibody labelling ND1 was gifted by Professor Anne Lombes (as reported in 
Barthélémy et al., 2001). 
To optimise the two antibodies, the quadruple immunofluorescence assay (though not 
including antibody to label COX-1), was performed on 10μm skeletal muscle sections from a 
control and P6 (NDUFS6, Homozygous c.316_319delGAAA, p.(Glu106Glnfs*41) (a 
representative case of isolated Complex I deficiency). The staining was performed using ND1 
alongside NDUFB8 and porin. The application of the antibody at a dilution of 1:100 (the 
same dilution as other mitochondrial antibodies) showed non-specific binding to fibres in the 
control muscle in comparison to both NDUFB8 and porin levels. The observation of muscle 
sections needs to take into account the different muscle fibre types and so different staining 
patterns will be seen indicatively. In fibres where porin staining intensity is low, it signifies a 
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Type II fibre whilst higher staining intensity will be signifying a Type I fibre  (as highlighted 
on the control tissue with an asterisk (*) in Figure 3.12(A)). The staining intensity of 
NDUFB8 was comparable in both fibre types to the porin, but there is no correlation of ND1 
intensity to either hence the inference that there is non-specific binding. In the patient muscle 
section, ND1 failed to detect Complex I deficiency in fibres that showed loss of NDUFB8 
immunoreactivity and intact porin (indicated with asterisk (*) in Figure 3.12(B)). This lack of 
detection alongside the non-specific binding rendered ND1 as an impractical choice of 
antibody to include into the quadruple immunofluorescence assay as a way of detecting 






Figure 3.12: Immunofluorescent images of Complex I targeted with ND1 and NDUFB8 alongside 
porin expression in skeletal muscle sections from A) control case and B) an isolated Complex I 
deficiency case – P6 (NDUFS6, Homozygous c.316_319delGAAA, p.(Glu106Glnfs*41). 
Fluorescent detection was used to visualise ND1— green (Complex I), NDUFB8 – Complex I (purple) 
and porin—red (mitochondrial mass) and laminin—white (fibre boundary marker). In control case 
(A), ND1 immunoreactivity is seen to non-specifically bind to the tissue section. No correlation with 
porin is seen whilst NDUFB8 correlates with porin. In patient case (B), the antibody labelling ND1 
failed to detect deficient fibres where NDUFB8 immunoreactivity is decreased compared to porin. 
Asterisks * = mark fibres given as examples of this. Images taken at x20 magnification.  Scale bars 
measure 50µm.  
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The antibody targeting NDUFS3 was also investigated in the same patient case and control, 
alongside porin and laminin. The isotype of NDUFS3 was the same as NDUFB8 (IgG1) 
hence why it could not be included in this experiment. The control muscle section showed 
correlation of NDUFS3 with porin levels indicating that the antibody was specifically binding 
to the muscle fibres (as indicated with an asterisks (*) in Figure 3.13(A)). In the patient case, 
NDUFS3 immunoreactivity was decreased in fibres in comparison to the porin levels (Figure 
3.13b), showing that the commercially available antibody was able to detect Complex I 
deficiency in muscle fibres. 
 
 
Figure 3.13: Immunofluorescent 
images of Complex I targeted 
with NDUFS3 and porin 
expression in skeletal muscle 
sections from A) control case 
and B) an isolated Complex I 
deficiency case. 
Fluorescent detection was used to 
visualise NDUFS3— green 
(Complex I), porin—red 
(mitochondrial mass) and 
laminin—white (fibre boundary 
marker). In control case (A), 
NDUFS3 immunoreactivity is 
seen to be equivalent to porin 
expression. In patient case (B), 
NDUFS3 immunoreactivity is 
decreased in fibres compared to 
porin. * = Asterisks mark fibres 
given as examples of this. Images 
taken at x20 magnification.  Scale 





To investigate this finding further, the complete quadruple immunofluorescence assay was 
performed on sections from P18, P19, P20, P21, P23, P4 and P25 using antibodies against 
NDUFS3, porin, COX-I and laminin (Figure 3.14). As shown in Figure 3.15, the 
mitochondrial respiratory chain profile for P20 shows a shift of fibres to the left whilst for all 
the remaining patients, fibres were shown to be in the normal range – in line with findings 
from the assessment with the NDUFB8 antibody. This provides further clarification that 
NDUFS3 was capable of reproducing the same findings, but also that the initial results with 










Figure 3.14: Images of Complex I, IV and porin expression in skeletal muscle sections from 
patients with isolated Complex I deficiency caused by defects on mtDNA-encoded Complex I 
subunits using the immunofluorescence assay. 
Fluorescent detection was used to visualise NDUFS3—purple (Complex I), COX –1—green (Complex 
IV), porin—red (mitochondrial mass) and laminin—white (fibre boundary marker). Patient P20 was 
used a positive control and a marked decrease in NDUFS3 immunoreactivity is seen. Whilst in the 
remaining patients, normal levels of NDUFS3 signal is expressed. Exposure times were maintained 




Figure 3.15: Mitochondrial respiratory chain expression profile linking complex I (NDUFS3), 
complex IV and porin levels in patients with Isolated complex I deficiency caused by defects in 
mtDNA-encoded Complex I subunits. 
Graphs show complex I and complex IV expression profile from patients with (A) m.12425delA 
MTND5 variant , P20, n = 5536 (B) m.10197G>A MTND3 variant , P18, n=6645 (C) m.13514A>G 
MTND5 variant , P19, n = 2730 (D) m.13094T>C MTND5 variant , P21, n=3979 (E) m.13513G>A 
MTND5 variant , P23, n=10009 (F) m.13513G>A MTND5 variant , P24, n =575 (G) m.13513G>A 
MTND5 variant , P25, n = 1168. Each dot represents a single muscle fibre, colour co-ordinated 
according to its mitochondrial mass: very low – blue, Low - light blue, Normal – beige, High – 
orange, very high -red. Black dashed lines represent the SD limits for the classification of the fibres. 
Lines adjacent to X and Y axis represent the levels of NDUFB8 and COX-1: beige: normal (<-3), light 
beige: intermediate (+) (-3 to -4.5), light blue: intermediate (-) (-4.5 to -6) and blue: deficient (> -6). 
Bold dashed lines indicate the mean expression level of normal fibres. 
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3.4.5. BN-PAGE assessing the steady-state levels of assembled Complex I 
To further interrogate the quadruple immunofluorescent assay results observed in the subset 
of patients displaying normal NDUFB8 and NDUFS3 immunoreactivity, BN-PAGE analysis 
was performed  to assess the steady-state levels of fully assembled Complex I (980 kDa) 
where muscle was available for patients (P18, P19, P21, P22, P23 and P25). P17 was also 
included as a positive control in this analysis given that the assay had shown decreased levels 
of NDUFB8 immunoreactivity. The samples prepared for BN-PAGE analysis retain 
OXPHOS complexes in their structural and active form, permitting the investigation of any 
effects on the assembly of the holoenzyme or catalytic activity. However, as the measured 
residual Complex I activity had previously been undertaken spectrophotometrically, only the 
levels of fully assembled Complex I were assessed.  
The analysis of muscle mitochondrial fractions by BN-PAGE revealed a decrease in steady-
state levels of fully-assembled Complex I in P17, P18, P23 and, P24 (Figure 3.16) when 
compared to controls, indicating that the mutations harboured by these patients affect levels of 
fully assembled Complex I. As Complex II activity is normal in these patients, the SDHA 
subunit was labelled (detected by immunoreactivity against the SDHA subunit) and the 
steady-state levels of assembled Complex II was used as a loading control. By contrast, 
patients P19, P21 and P22 showed normal levels of fully assembled Complex I, which falls in 
line with the findings from the assay, therefore likely indicating that these mutations affect the 
activity of the complex rather than the assembly.  
The level of Complex I was also normal in P25, correlating with the findings from the 
quadruple immunofluorescence assay (Figure 3.16). Furthermore, the residual, biochemical 
Complex I activity measured spectrophotometrically was also 100%, indicating that the 
m.13513G>A, p.(Asp393Asn) variant in this case has no major effect on the activity or 
assembly of Complex I, despite the relatively high level of mtDNA heteroplasmy and severe 




Figure 3.16: Analysis of Complex I assembly by BN-PAGE. 
Complex I assembly profiles were analysed using one BN-PAGE (4-16% gradient). Analysis showed a 
decrease in fully assembled Complex I in patients P17, P18, P23 and P24, whilst normal assembly is 
seen in patients P19, P21, P22 and P25. Complex II was used a loading control. Both OXPHOS 
complexes were detected by immunoblotting using subunit specific antibodies – NDUFB8 (Complex I) 
and SDHA (Complex II). No assembly intermediates were visualised in these patient samples however 
an additional band was observed for P24, above 980kDa which is indicative of supercomplex as mass 












Considering these findings from the BN-PAGE assessment, Table 3.6 summarises all the 
experimental data collected for these patients which will then be discussed in the following 
section. 



























Nuclear-encoded Complex I structural subunits 
 
P01a 79 0 Decreased 33 n.d 
P02b 93 0 Decreased 32 n.d 
P03c 39 0 Decreased 35 n.d 
P04 98 0 n.d 39 n.d 
P05 89 0 n.d 37 n.d 
P06 79 0 n.d 5 n.d 
P07 99 0 n.d 42 n.d 
P08 96 0 n.d 26 n.d 
Nuclear-encoded Complex I assembly factors  
 
 
P09 99 0 n.d 26 n.d 
P10 96 0 n.d 45 n.d 
P11 26 0 n.d 44 n.d 
P12 96 0 n.d 31 n.d 
P13 100 0 n.d 13 n.d 
P14 100 0 n.d 13 n.d 
P15d 100 0 Complete 
absence  
36 n.d 
mtDNA-encoded Complex I structural subunits 
 
 
P16e 92 0 Decreased 3 92 
P17 90 0 Decreased 44 90 




P19 0 0 Normal 27 66 
P20f 100 0 n.d 16 85 
P21 0 0 Normal 59 58 
P22 0 0 Normal 39 60 
P23 0 0 Decreased 38 77 
P24 0 0 Decreased 100 45 
P25 0 0 Normal 100 63 
 
*All homogenate heteroplamsy as measured in skeletal muscle section and the biochemical data relating 
to Complex I enzymatic activity in muscle was provided by the NHS Highly Specialised Service for 
Rare Mitochondrial Disorders laboratory team 
P1a = Patient 3 in Alston et al. (2016), JMG; P2b = Patient 2 in Alston et al. (2016), JMG; P3c = Patient 6 
in Alston et al. (2016), JMG; P15d = patient S1 in Alston et al (2016), AJHG; P16e = Patient 1 in 
Gorman et al (2015), Clinical Science; P20f = Patient published in Alston et al (2010) Neuromuscular 
disorders 




3.5. Discussion  
This study aimed to assess and validate the application of the quadruple immunofluorescent 
OXPHOS assay to the diagnosis of patients with isolated mitochondrial Complex I 
deficiency. The quadruple immunofluorescence assay, which detects NDUFB8 as a marker of 
Complex I integrity, was successful in detecting Complex I deficiency in 18 of the 25 patients 
tested, including all patients with pathogenic variants in nuclear genes encoding Complex I 
structural subunits and assembly factors (Groups 1 and 2). However, only three of the ten 
patients harbouring pathogenic mtDNA variants (Group 3) showed a consistent decrease in 
NDUFB8 immunoreactivity and thus protein abundance/expression, later confirmed using a 
further commercially available antibody against NDUFS3, another key component of 
Complex I. The assay was optimised using a commercially available and widely-used 
antibody against NDUFB8, a subunit which is assembled at the mid/late stage of assembly, 
alongside the mtDNA-encoded core structural subunit, ND5. Although, it would have been 
preferable to use an antibody targeting a mtDNA-encoded subunit, such as ND1 (interrogating 
the early stage of Complex I assembly), there are currently no robust, commercially-available 
antibodies raised against this or other mtDNA subunits which is important to consider if the 
assay is to be adopted across diagnostic centres.   
Using this assay, Complex I deficiency was successfully detected in patients that harboured 
mutations in nuclear genes encoding either the accessory, (P1, P2, P3 = NDUFB3 subunit of 
the P-D region of the P-module, P4 and P5 = NDUFS4 subunit of the N-module, P6 = 
NDUFS6 subunit of the N-Module, P7 = NDUFS2 subunit of the Q-module) or the core 
subunits (P8 = NDUFS3 subunit of the Q-module) of Complex I, in line with the biochemical 
findings which were obtained spectrophotometrically during the diagnosis of patients. Of 
interest, it was noted that despite patients P1, P2 and P3 harbouring the same genetic variant 
(p.Trp22Arg in NDUFB3) and similar residual Complex I activities, the quadruple 
immunofluorescence assay findings showed variable levels of NDUBF8 immunoreactivity 
(P1= 79%, P2 =93% P3 = 39%). However, these findings are consistent with the steady state 
levels of the NDUFB8 subunit of Complex I on both a western and BN-PAGE originally 
reported by Alston and colleagues (2016), where it was shown that P1 and P2 (P3 and P2 
respectively) had decreased protein levels when compared to P3 (P6 in Alston et al. (2016)). 
Taken together, the collective data highlights the potential of the assay to be a diagnostic tool 
for such cases and shows that all mutations in Group 1 exerted a similar effect on steady-state 
levels of fully assembled Complex I as previously documented (Alston et al. 2016; Kirby et 
al. 2004a; Petruzzella et al. 2001). 
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Similarly, the assay was able to diagnose all patients with genetic variants in Complex I 
assembly factors. As expected, mutation of these genes led to a decrease in Complex I 
assembly and accordingly the assay recorded a marked loss of Complex I  immunoreactivity 
in many of the fibres analysed; a complete loss of NDUFB8 immunoreactivity (100% CI 
deficient fibres) was noted in P13, P14 (ACAD9 variants) and P15 (TMEM126B variant), 
consistent with previous reports of severe Complex I deficiency in ACAD9 and TMEM126B 
mutations (Alston et al. 2016; Haack et al. 2010; Nouws et al. 2010; Nouws et al. 2014). 
These two assembly factors, alongside with NDUFAF1, ECSIT and TIMMDC1 (illustrated in 
the assembly process of Complex I in Figure 3.17), form the ‘Mitochondrial Complex I 
assembly’ (MCIA) complex (Heide et al. 2012), which is associated with the assembly of the 
PP submodule (that contains the ND2, ND3, ND4-L and ND6 mitochondrial- encoded 
subunits). Since depletion of TMEM126B leads to the accumulation of the Q/PP-a (Q module-
ND1) intermediate, it seems that NDUFB8 is unstable and as such degraded before the 
complete assembly of the holoenzyme, explaining why a complete loss of NDUFB8 protein is 
observed in all fibres (Guarani et al. 2015; Heide et al. 2012). 
For patients in Group 3 (pathogenic variants in mtDNA-encoded Complex I structural 
subunits), the assay was able to detect Complex I deficiency in three patients (P16, P17 and 
P20). The m.12425delA MTND5 mutation in P20 leads to a truncated form of the ND5 
subunit to be translated, which has previously been shown to have a severe impact on 
Complex I assembly (Alston et al. 2010). This was supported by the quadruple 
immunofluorescence assay results, where a complete loss of NDUFB8 immunoreactivity 
(100% Complex I-deficient fibres) was observed. Similarly, P16 harbours a m.3356T>C, 
p.(Met17Thr) MTND1 variant at high levels in muscle, which is associated with a severe 
defect in Complex I assembly (Gorman et al. 2015b), validating the results from the assay 
(>90% Complex I-deficient fibres). Finally, P17 harbours a m.10158T>C, p. (Ser34Pro) 
MTND3 variant, leading to a marked decrease in NDUFB8 immunoreactivity and steady-state 
levels of fully-assembled Complex I; together these results show that the quadruple 
immunofluorescence assay confidently detected the deficiency associated with mtDNA 





Figure 3.17: The assembly of Complex I with indication of where the subunits affected in the cohort of patients enter the complex. 





The remaining seven patients, where normal NDUFB8 (and, where tested, NDUFS3) 
immunoreactivity was detected, harbour well-characterised pathogenic variants in either the 
MTND5 (P19, P21, P22, P23, P24 and P25) or MTND3 genes (P18).  It has been shown that 
missense variants in these proteins predominantly affect Complex I redox activity whereas 
mutations in the MTND1, MTND2 and MTND6 genes have a more severe impact on complex 
assembly (Andrews et al. 2013; Kirby et al. 2004a; Lazarou et al. 2009; McFarland et al. 
2004; Perales-Clemente et al. 2010; Ugalde et al. 2003). Therefore it can be suspected that in 
the patients where normal levels of Complex I was detected based on both the assay and BN-
PAGE analysis (P19: MTND5, m.13514A>G, p.(Asp393Gly); P21: MTND5, m.13094T>C, 
p.(Val253Thr); P22: MTND5, m.13513G>A, p.(Asp393Asn)), the mutations are likely to be 
only affecting the catalytic site of the holoenzyme without disturbing Complex I stability and 
assembly. In line with this, the m.13514A>G MTND5 mutation (P19) has been shown to 
affect the redox activity of Complex I (Bugiani et al. 2004; Corona et al. 2001; Lebon et al. 
2003). The change of amino acid at position 393 (which is part of a putative quinone-reactive 
site of the enzyme), causes a loss of the putative quinone-reactive site, thereby leading to a 
decline in Complex I activity (Blok et al. 2007; Fisher and Rich 2000), thus validating the 
findings from the quadruple immunofluorescence assay . Therefore, patients who harbour 
mtDNA variants which only affect Complex I catalytic activity are likely to show normal 
mitochondrial respiratory chain profiles as determined by the assay.  
Furthermore, many studies have also shown that defects in the MTND3 and MTND5 genes 
display variable biochemical phenotypes; either decreased redox activities as determined by 
biochemical spectrophotometric assays, decreased levels of fully assembled Complex I or 
both (Bugiani et al. 2004; Chae et al. 2007; Chol et al. 2003; Corona et al. 2001; Hanna et al. 
1998; Kirby et al. 2003; Kirby et al. 2004a; Lebon et al. 2003; Petruzzella et al. 2001; 
Santorelli et al. 1997; Sarzi et al. 2007; Shanske et al. 2008). This supports the variability 
found in the results determined by the assay, as the m.13513G>A, p.(Asp393Asn) variant, the 
most frequently occurring mutation in the MTND5 gene (Shanske et al. 2008), can manifest 
differing effects: either a decrease in fully assembled Complex I (P23 and P24) or normal 
levels of assembled Complex I  (P25) (Blok et al. 2007; Bugiani et al. 2004; Chol et al. 2003; 
Corona et al. 2001; Hanna et al. 1998; Kirby et al. 2003; Petruzzella et al. 2001; Santorelli et 
al. 1997; Shanske et al. 2008). Somewhat surprisingly, P25 (homogenate m.13513G>A 
heteroplasmy level of 63% in muscle) also presented with normal redox catalytic activity and 
Complex I assembly profile, which could likely be due to the confounding factor of 




biochemical defect only when the levels of mutated mtDNA exceeds 80-90% (Mariotti et al. 
1994), lower thresholds are reported in patients with Complex I deficiency due to structural 
subunit mutation (Corona et al. 2001; Kirby et al. 2004a). In the case of P25, it could be 
possible that the pathogenic threshold in this patient is higher, thereby explaining the absence 
of a biochemical defect despite the presence of relatively high mutation levels and an 
associated clinical phenotype. Additionally, it would important to factor in the age of this 
patient (a paediatric case), as well the severity of the clinical phenotype. It could also be 
suspected that there is a compensatory mechanism which is allowing for the normal assembly 
and activity of Complex I in this patient. 
Finally, normal NDUFB8 immunoreactivity but decreased levels of fully- assembled 
Complex I was detected in patient P18 harbouring a pathogenic m.10197G>A, p.(Ala47Thr) 
MTND3 variant. This has previously been associated with decreased redox catalytic activity 
and diminished levels of fully assembled Complex I (Chae et al. 2007; Kirby et al. 2004a; 
Sarzi et al. 2007); although unfortunately due to inadequate amounts of skeletal muscle tissue 
from this patient, it was not possible to verify if an effect on the activity was also present. The 
quadruple immunofluorescence data indicates, however, that the subunit must be present as 
the NDUFB8 level was normal. Interrogating NDUFS3 levels also showed normal results, 
suggesting that the assay is less likely to identify Complex I defects associated with 
pathogenic variants causing milder defects in Complex I assembly. 
Overall, the assay has been shown to be a beneficial tool for assessing Complex I deficiency, 
however this is predominantly based on the successful detection of decreased Complex I 
protein expression in the skeletal muscle sections of patients harbouring pathogenic variants 
affecting nuclear-encoded subunits and assembly factors. Therefore, the question of “what is 
the exact role of the quadruple immunofluorescence assay in the diagnostic setting?” arises. 
As previously emphasised, one of the major advantages of the assay is that the biochemical 
status of Complex I and Complex IV expression can be deduced from a single 10µm section, 
which is pertinent in cases where there is a shortage of skeletal muscle tissue from a patient or 
for paediatric cases where biopsy samples are small in size. However, at a time when the 
diagnostic process is moving towards the “Genetics first” approach, where and when does this 
assay fit into this diagnostic approach? 
Figure 3.18 highlights a flowchart designating the role of the assay in this current diagnostic 
pathway. Firstly, in cases where a diagnosis is achieved following the sequencing of either the 
mtDNA or nuclear DNA-encoded genes (WGS, WES, targeted-panels) after clinical 




the assay. However, the assay can be used as a way of validating a novel genetic variant to 
investigate the impact on OXPHOS (determine a biochemical defect). In cases where a 
diagnosis is not reached via the “Genetic first approach”, this assay can then be used as a 
diagnostic tool using patient skeletal muscle section to determine a biochemical defect. These 
findings, potentially alongside other functional assays (spectrophotometric enzymatic assays, 
BN-PAGE), can then re-direct the screening of the mitochondrial genome or candidate 
nuclear-encoded genes. As previously stated, in cases where the assay fails to detect 
deficiency, results from this study would suggest that a direct investigation of the mtDNA 
needs to be undertaken through NGS, for example patients with point mutations on mtDNA-
encoded subunits (particularly MTND5) displayed normal expression of Complex I in their 
skeletal muscle sections. However, time constraints and expense must also be considered 
which leads to the next question of how necessary and helpful would it be to have all this 
information for patients? It can be argued that it is helpful given that this study has shown that 
in some cases, the different algorithms confirm differing impacts of mutations on Complex I, 
for example, it can be used to identify patients who have Complex I deficiency due to 
decreased expression or assembly of Complex I as opposed to those who have purely reduced 
enzymatic activity. Therefore, it can be helpful to have all information, particularly during the 






Figure 3.18: A schematic flowchart designating the role of the quadruple immunofluorescence assay in the 
current diagnostic process for Mitochondrial disease.  
The diagnosis of Mitochondrial Disease is being led by the “Genetic first approach” which will lead 
to either a confirmation of the diagnosis and so no skeletal muscle biopsy will be required. But if the 
genetic variant is novel or further validation is required, then a biopsy and the quadruple 
immunofluorescence assay (highlighted by yellow box) on a 10µm section will be helpful to give 
clarification of an OXPHOS (oxidative phosphorylation) defect, alongside other functional tests 
(spectrophotometric respiratory chain enzyme assay and BN-PAGE and SDS-PAGE to assess protein 
steady-state levels and assembled complexes). However, if no diagnosis is reached via the pathway, 
then the assay can be used a diagnostic tool to investigate the 10µm patient skeletal muscle section 
further for OXPHOS assessment. Findings from the assay alongside the other functional assays, can 




3.6. Limitations of this study   
Although this study has been able to show the diagnostic properties of the quadruple 
immunofluorescence assay, a few limitations to this study must be considered.  
Firstly, whilst NDUFB8 is commercially available and widely used in both research and in 
the diagnostic setting, a limitation for this study is the absence of antibodies which target 
mtDNA-encoded subunits of Complex I. Whilst ND1 was tested and seen to have failed in the 
use of the assay, a commercially available antibody could have provided a helpful tool to 
interrogate an mtDNA-encoded subunit which is involved at the initial stage of Complex I 
assembly, similar to NDUFS3. A comparison between the two antibodies (NDUFB8 and 
ND1) could have been undertaken to highlight the extent at which the assay is able to detect 
Complex I deficiency in these cases, particularly within the patients that showed normal 
levels of both NDUFB8 and NDUFS3.   
Secondly, another limitation to the assay is that it is not cost or time effective and thus could 
potentially hinder the approach to a certain extent in a diagnostic setting.    
Thirdly, another limitation to this study is the use of the adult-derived control tissues to 
analyse paediatric cases. Ideally, non-disease controls and cases should have been aged-
matched in order to ensure that analysis of paediatric cases were based on the expected levels 
of porin in very small fibres compared to the adult fibres, which are much larger in size. In 
addition, muscle biopsies taken from these individuals who underwent ACL surgery may not 
be representative of the area from which biopsies of patients are attained from for diagnostic 
purposes (quadriceps and TA). However, these limitations could not be accounted for as 
biopsies attained from non-disease participants who are entirely healthy with no physical 
injury, is difficult to obtain. Thus, these ACL biopsies were sufficient for these studies 
(including Chapter 4), further justified by the fact that both histochemical investigations 
(undertaken by the NHS Highly Specialised Service for Rare Mitochondrial Disorders, 
located within the Wellcome Centre for Mitochondrial Research at Newcastle University) and 
immunofluorescent investigations showed normal protein expression of both Complex I and 
Complex IV, prior to use in studies. 
3.7. Conclusion  
In conclusion, this study has accessed and validated the use of a quadruple 
immunofluorescence assay in a diagnostic setting for identifying patients with suspected 
Complex I deficiency, using a single 10µm transverse skeletal muscle section. Through the 




protein abundance at a single cell level, a key advantage of the assay in comparison to current 
histochemical and histological methodologies. Given the findings attained, this study can 
provide evidence that this assay has clear diagnostic potential for patients with Complex I 
deficiency, particularly for those with mutations affecting nuclear-encoded genes, which 
account for ~75-80% of genetic causes of Complex I deficiency. Whilst the assay is not 
sufficiently sensitive to identify a biochemical defect associated with some very well-
characterised mtDNA variants – or rare catalytic defects affecting either mtDNA-encoded or 
nuclear-encoded Complex I subunits, it can be emphasised that a combination of the 
quadruple immunofluorescence assay, in tandem with full mitochondrial genome sequencing 
and standard biochemical assays, the assay can be used to investigate likely genetic causes of 
Complex I deficiency in patients with mitochondrial disease (principally pathogenic variants 
associated with clinical symptoms that may result from mutation of mtDNA-encoded 
structural Complex I subunits), especially when muscle biopsy sample sizes are small, 
necessitating the analysis of cryosectioned material.  
Therefore, it can be concluded that the assay can contribute to the current available diagnostic 
tools for studying mitochondrial disease, which are typified by extensive biochemical, genetic 




















































Chapter 4: Using the quadruple immunofluorescence assay to 
determine the OXPHOS biochemical profile of individual skeletal 
































This chapter will be describing the findings from the second theme of this thesis; 
understanding the mechanism underlying mitochondrial disease. This section will introduce 
the background, current proposed pathological mechanisms and clinical features associated 
with the m.3243A>G pathogenic variant, to underpin the understanding of the aims of this 
chapter and Chapter 5.   
4.1.1. The m.3243A>G pathogenic variant 
The m.3243A>G variant is the most prevalent pathogenic heteroplasmic point mutation of the 
mtDNA (Elliott et al. 2008; Gorman et al. 2016; Nesbitt et al. 2013). The mutation is located 
within the MT-TLI gene which encodes mitochondrial tRNALeu (UUR) (Anderson et al. 1981). A 
single nucleotide substitution of adenine (A) to guanine (G) occurs at position 3243 within the 
dihydrouridine loop (D-loop, also known as the DHU loop) of the tRNALeu (UUR) (Figure 4.1) 
(Goto et al. 1990). The normal function of the tRNALeu (UUR) gene is the translation of the 
UUR (R = A or G) leucine codons (UUA or UUG), hence the nomenclature tRNALeu(UUR) 
(Kobayashi et al. 1990). 
The structure of the mt-tRNALeu (UUR) is shown in Figure 4.1. The tertiary structure of the mt-
tRNA consists of four domains; acceptor stem, dihydrouridine (DHU/D loop), anticodon loop 
and the TΨC (T) loop. These four domains primarily exist as Watson-Crick base pairs which 
allows for the cloverleaf structure. Mitochondrial tRNAs undergo extensive post-
transcriptional maturation and modifications which are essential for the stability and function 
of their strictures. One such modification includes the addition of the CCA sequence (by the 
CCA-adding enzymes) at the 3’ end of the mt-tRNA that represents the site of 
aminoacylation. This sequence is also important for tRNA positioning in the ribosome and 
translation termination. The “wobble” base at position U34 is one of the key tRNA positions 
for modification to occur, particularly the taurinomethylurdine (τm5U) modification (further 
described in section 4.1.3). Other modifications of mt-tRNALeu (UUR) are also depicted in 
Figure 4.1 which include; 1-methyladenosine (m1A), 1-methylguanosine (m1G), 2-
methylguanosine (m2G), pseudouridine (Ψ), ribothymidine (T), dihydrouridine (D), and 5-
methylcytidine (m5C). These post-transcriptionally modified nucleotides ensure proper 
stability and function which include base stacking, modulate codon-anticodon binding, 
allowing rigidity or flexibility in the structure of the mt-tRNA, enhance or restrict codon 
recognition or to facilitate translocation (D'Souza and Minczuk 2018; Kamble et al. 2017; 





Figure 4.1: A schematic diagram of the cloverleaf secondary structure of mitochondrial tRNALeu 
(UUR). 
Mitochondrial (mt) tRNA consist of four domains; acceptor stem, dihydrouridine (DHU/D) loop, 
anticodon loop and the TΨC (T) loop. The A14 nucleotide (encircled in red) of the D-loop/DHU loop 
is substituted by a guanine residue in the m.3243A>G mutation, as indicated by the arrow. 
Mitochondrial tRNAs undergo multiple post-transcriptional modifications; the uridine (U in blue) at 
position 34 (the “wobble” base) is subjected to post-translational modification to become 5-
taurinomethylurdine (τm5U). Symbol for other modifications; 1-methyladenosine (m1A), 1-
methylguanosine (m1G), 2-methylguanosine (m2G), pseudouridine (Ψ), ribothymidine (T), 
dihydrouridine (D), and 5-methylcytidine (m5C). The CCA sequence above the discriminator codon (A 
encircled in green) is the site of aminoacylation and is also added on post-transcriptionally. Adapted 




4.1.2. Epidemiology of the mutation  
Epidemiological studies have estimated the m.3243A>G mutation prevalence as 7.59-
7.8/100,000 in the population of North-East England (Chinnery et al. 2000; Gorman et al. 
2015a) and 16.3/100,000 in the population of Northern Finland (Majamaa et al. 1998). The 
carrier estimate in the population of an Australia cohort was determined to be 236/100,000 
in a study undertaken by Manwaring et al. (2007).  In the United Kingdom, the MitoCohort 
consists of 1775 patients (as of October 2019) with mitochondrial disease across all of the 
sites (Newcastle University, University College London Hospitals and Oxford University 
Hospitals), of which 455 patients have their genotype recorded as m.3243A>G. More 
specifically, 292 patients harbouring the mutation are registered with the Newcastle upon 
Tyne mitochondrial disease clinic.   
4.1.3. Mechanisms leading to pathogenicity of the mutation  
A plethora of studies have been undertaken to determine the mechanism by which the 
m.3243A>G mutation causes pathogenicity. These studies have predominantly used 
transmitochondrial cybrid cellular systems; models which are used to study the 
pathophysiological consequences of a specific mtDNA variant in a control nuclear 
background. These cell lines are generated by fusing the patient’s cytoplasts (enucleated cells 
that contain mtDNA) with a cell line that lacks mtDNA (rho zero), to produce clones with 
mixed mitochondrial populations. The use of these cells to study the m.3243A>G mutation 
allowed for the characterisation of the biochemical phenotypes across different levels of 
heteroplasmy, as well as investigating the mechanisms. An advantage of this approach is that 
it provides a uniform nuclear background for studies using cytoplasts made from different 
individuals, thereby eliminating confounding nuclear variables. However, this is not the case 
for studies investigating the m.3243A>G mutation (particularly in MELAS) which have used 
either transmitochondrial cybrid cells made from human osteosarcoma derived rho zero cell 
lines (143B-206) (Chomyn et al. 1992; Chomyn et al. 2000; Janssen et al. 1999; Janssen et al. 
2007b; King et al. 1992) or lung carcinoma (A549) (Dunbar et al. 1995). Another is the 
WS227.546 cell line (Park et al. 2003). Using these different cell lines re-introduces the 
confounding effects of different nuclear genetic backgrounds, which have been shown to 
influence the segregation of mutant and wild-type mtDNA, therefore influencing the 
genotype-phenotype relationship being investigated in these studies. For example, the 143B-
206 cell line showed an increase/shift towards higher proportions of mutant mtDNA whilst 
the A549 cell line showed an increase/shift towards higher proportions of wild-type mtDNA 




patient cells (such as myoblasts or lymphoblastoid) and tissue (muscle biopsies) (Borner et al. 
2000; Sasarman et al. 2008) but also have the issue of confounding effects of different nuclear 
genomes.  
Whilst the precise mechanism is still under debate, some proposed mechanisms at the 
molecular level of the mutation have been suggested by these studies and are listed below in 
Table 4.1. Any of the mechanisms described can be debated to be the correct mechanism but 
it is evident that current findings are either overlapping or conflicting with one another, thus 
indicating the need for further research. A number of the studies have suggested that the 
mechanism involves impaired translation of all mitochondrial respiratory chain subunits 
which consequently results in the decrease in ATP synthesis (Chomyn et al. 1992; Goto et al. 
1990; Janssen et al. 1999; King et al. 1992; Koga et al. 1993). This would be an acceptable 
mechanism as the role of mt-tRNA is to transport amino acids to the ribosomes leading to 
translation and eventual protein synthesis. However, emphasis has been placed on the taurine 
modification of the anticodon wobble base theory, particularly within MELAS patients. In 
normal mt-tRNALeu(UUR), uridine at the anticodon wobble position undergoes post 
translational modification, known as the taurine modification of uridine (5-
taurinomethyluridine (τm5U)). This modification at the wobble position allows for the precise 
and efficient codon recognition by the tRNA (Yokoyama et al. 1985). However, in the case of 
the m.3243A>G mutation within transmitochondiral cybrid cell lines, this modification does 
not occur therefore the mutant mt-tRNALeu(UUR) is deficient of the normal τm5U (Suzuki et al. 
2002; Yasukawa et al. 2000). This results in impaired protein synthesis either through 
misreading according to the mitochondrial wobble rule (Watanabe 2010) or a decoding 
deficiency (Hanada et al. 2001; Takemoto et al. 1995). The study by Kirino et al. (2005) 
demonstrated that there was a specific correlation between this lack of modification and the 
clinical features of MELAS, whilst normal modification was described in patient tissue or 
transmitochondrial cell lines harbouring other MT-TL1 mutations associated with non-
MELAS phenotypes (m.3242A>G, m.3250T>C and m.3245C>T). This interest in the 
mechanism had led to investigation into taurine therapy as potential treatment for MELAS 
patients, however the study concluded that ongoing research will confirm whether or not oral 
administration of taurine may be an effective therapy (Rikimaru et al. 2012). 
However, the change in the L-shaped tertiary structure of the tRNALeu(UUR) is a likely starting 
point at which further mechanisms that lead to the pathogenicity of the mutation occur. This is 
in agreement with Chomyn et al. (2000) who proposed the following; the m.3243A>G 




modification at the wobble position. This results in an unstable molecule (metabolically) and 
reduction in aminoacylation, causing a decrease in protein synthesis due to reduced 
association of the mRNA with the ribosomes, which is thought to have an effect on 
mitochondrial translation factor, such as IF-2mt (Ma and Spremulli 1995). Therefore, after the 
alteration of the structure, it could be suggested that these mechanisms are all in interplay 
with one another.  
Table 4.1: Proposed mechanisms for the pathogenicity of the m.3243A>G mutations and key findings 
from the studies undertaken 
Mechanism and reference  
 
Study findings  
 
 
Impairment of transcription termination 
 
Hess et al. (1991) - Mutation caused a decrease in the affinity of mt-TERM (also 
known as MTERF) to its binding site on the mtDNA which spans 
between the nucleotides 3229 and 3256 on the region of the MT-
TL1 gene 
- Leads to the impairment of transcription termination at the end of 
the 16S rRNA gene which causes interference in the efficiency 
and proper synthesis of 16S rRNA  
Chomyn et al. (1992) - Mutation causes no change in the rRNA levels in relation to the 
transcripts from upstream and downstream of the termination site  
- The mitochondrial protein synthesis rate was decreased 
King et al. (1992) - Determined a small but consistent accumulation in the steady 
state levels of the unprocessed intermediate RNA transcript 
RNA19 (an intermediate transcript contains the transcripts for 
16S rRNA + tRNALeu(URR) + ND1 genes), in cells with very high 
levels of the mutation 
- The mitochondrial protein synthesis rate was decreased  
- ND1 subunit of Complex I was shown to be slightly altered in 
mobility on polyacrylamide gel electrophoresis  
- No significant difference was found in steady state levels of RNA 
species between controls and mutant cells  
Schon et al., 1992 - Incorporation of the unprocessed RNA19 into the mitochondrial 
ribosome renders it functionally defective 
- Causes eventual protein synthesis defects, likely due to the 
stalling of translation by the ribosomes 
 
Alterations to the L-shaped tertiary structure 
 
Wittenhagen and Kelley 
(2002) 
- Mutation affects the tertiary structure of tRNALeu (URR) by 
inducing abnormal tRNA dimerization of the molecule at the D-
stem (self-complementary hexanucleotide (5’GGGCCC;G 
mutation site) 
- This attenuates the aminoacylation of the tRNALeu (URR) thereby 
leading to a decrease in the biological activity of the tRNA 
 
Taurine modification of the anticodon wobble base  
 
Yasukawa et al. (2000) 
Suzuki et al. (2002) 
- Uridine modification does not occur in transmitochondrial cybrid 




Watanabe (2010) - Lack of modification results in impaired protein synthesis 
through misreading according to the mitochondrial wobble rule 
Takemoto et al. (1995) 
Hanada et al. (2001) 
- Lack of modification results in decoding deficiency 
Kirino et al. (2004) - Transmitochondrial cells containing constructs of the mt-
tRNALeu(UUR) molecule lacking the taurine modification (τm5U 
deficiency) showed severe and specific reduction in the UUG 
decoding, as well as UUA decoding  
 
Decreased steady-levels of tRNA Leu(UUR) 
 
Janssen et al. (1999) - Mutation caused a decrease in the steady-state levels of the mt-
tRNALeu(UUR) molecule which consequently caused a decrease in 
mitochondrial translation 
Chomyn et al. (2000) - Mutation affected both the steady state levels and aminoacylation 
efficiency of the molecule, affecting the rate of translation. 
 
Misincorporation of amino acids 
 
Janssen et al. (2007b) - Transmitochondrial cells (143B) showed that COX-I and COX-II 
existed exclusively with the correct amino acid sequence, thus no 
evidence of misincorporation 
- Evidence of correct incorporation of leucine occurring at the 
UUR codons 
Sasarman et al. (2008) - Mutation was found to cause severe combined respiratory chain 
deficiency in near homoplasmic myoblasts (complete lack of 
assembly of complexes I, IV and V was observed) 
- Indicated that amino acids were being misincorporated during 
protein synthesis in the presence of the mutation 
- Overall protein synthesis remained close to normal 
- A loss and gain of function of the tRNALeu(UUR) occurring in the 
presence of the mutation to cause the severe respiratory chain 
deficiency. 
 
Defects in aminoacylation 
 
Borner et al. (2000) - Eight patient samples (seven muscle biopsies and one 
lymphoblastoid cell line) of which four samples had a decrease in 
the mutated tRNALeu(UUR) in the total tRNALeu(UUR) population, 
indicating that there was a reduction in the expression of the 
mutated molecule  
- Reduction in the levels of functional tRNALeu(UUR) 
- Six patients samples showed a reduction in the amount of 
aminoacylated tRNALeu(UUR)  
- Variability founded in patient samples alluded to involvement of 
additional factors that are contributing towards the pathogenicity 
of the mutation 
Yasukawa et al. (2000) - Proposed that the decrease in aminoacylated tRNALeu(UUR) was a 
mechanism by which pathogenicity occurred 
- A substantial decrease in the steady state levels of the mutated 
tRNALeu(UUR), likely due to the decreased stability of molecule 
Park et al. (2003) - Mutation caused a 25-fold decrease in the aminoacylation 
efficiency of tRNALeu(UUR) and this combined with the reduction 
in steady state levels of tRNALeu(UUR) -led to the reduction in the 
rates of protein translation in mutant cells 
- No detection of difference in aminoacylated efficiencies between 





4.1.4. Clinical phenotypes  
The pathogenic m.3243A>G variant is associated with a vast clinical presentation and 
importantly, with multi-systemic disorders. The mutation was first reported in patients with 
MELAS and in one patient presenting with CPEO (Goto et al. 1990). MELAS is a severe and 
progressive multisystem disorder of either child or adult onset, with the vast majority of 
patients presenting between the ages of two and 40 (El-Hattab et al, 2001). This disorder is 
defined and diagnosed by the following criteria; stroke like episodes (SLE) before the age of 
40, encephalopathy characterised by seizures, dementia or both and finally lactic acidosis with 
or without the presence of RRFs in skeletal muscle (Hirano et al. 1992). A second clinical 
diagnostic criteria has also been clarified by Yatsuga and colleagues (2012), whereby the 
individual can present with at least two symptoms from each of the categories distinguished; 
Category A (headaches and vomiting, seizures, hemiplegia, cortical blindness, acute focal 
lesions on neuroimaging) and Category B (high plasma or cerebral spinal fluid (CSF), 
mitochondrial abnormalities on muscle biopsy, a MELAS-related pathogenic variant) 
(Yatsuga et al. 2012). The mutation is commonly associated with MELAS, with 
approximately 80% of affected individuals being m.3243A>G carriers (Goto et al. 1990; 
Kobayashi et al. 1990). However, this syndrome only accounts for approximately 15% of 
patients who harbour the m.3243A>G mutation (Nesbitt et al. 2013).  
The most common disorder which is associated with the mutation is MIDD (maternally 
inherited diabetes and deafness) (de Laat et al. 2013; Mancuso et al. 2014; Nesbitt et al. 
2013), which was first reported by van den Ouweland et al. (1992). However, both MELAS 
and MIDD have been shown to have an overlap in clinical phenotypes: it has been reported 
that 13% of 199 affected members carrying the mutation had a combination of both MIDD 
and MELAS features (clinically known as MELAS/MIDD) (Gerbitz et al. 1995). Other 
phenotypes include; MERRF (myoclonus epilepsy with ragged red fibres) (Fabrizi et al. 
1996), MELAS/MERRF (Campos et al. 1996), CPEO (Goto et al. 1990; Koga et al. 2000; 
Mariotti et al. 1995; Moraes et al. 1993b) and Leigh Syndrome (LS) (Koga et al. 2000; 
Vilarinho et al. 1997).  
Many patients present with various other phenotypes that do not fit the criteria of the 
recognised clinical syndromes. These have been reported as; myopathy (Kärppä et al. 2005), 
cardiac abnormalities including cardiomyopathy (Anan et al. 1995; Bates et al. 2013; 
Hollingsworth et al. 2012; Majamaa-Voltti et al. 2002a; Nesbitt et al. 2013), dysphagia (de 
Laat et al. 2015), gastro intestinal (GI) dysmotility (Kaufmann et al. 2011; Nesbitt et al. 




1992; Nesbitt et al. 2013), diabetes mellitus (Kadowaki et al. 1994), renal failure (Damian et 
al. 1995; Iwasaki et al. 2001; Suzuki et al. 2003), short stature (Moraes et al. 1993a), ataxia 
(Petruzzella et al. 2004), cognitive impairment (El-Hattab et al. 2015), and 
depression/psychiatric involvement (Pickett et al. 2018; Verhaak et al. 2016). 
A study by Pickett and colleagues (2018) determined the correlation between phenotypes and 
found that seizures, encephalopathy and SLE (MELAS phenotypes) were all statistically 
correlated with one another, as well as showing a correlation between hearing impairment and 
diabetes (MIDD phenotypes). The latter was also found to be statistically significant in the 
study by Mancuso et al. (2014).  Asymptomatic carriers of m.3243A>G mutation have also 
been reported (Nesbitt et al. 2013).  
In terms of mortality in patients harbouring the m.3243A>G mutation, both cardiac and 
neurological problems have been reported as the most common causes of early death in 
patients (Nesbitt et al. 2013). Sudden adult death syndrome has also been reported in both 
symptomatic and asymptomatic patients (Bates et al. 2013; Majamaa-Voltti et al. 2002b; Ng 
et al. 2016).  
4.1.5. Muscle involvement in m.3243A>G patients 
As shown above, muscle involvement is common in patients carrying the m.3243A>G 
variant. Individuals typically present with proximal limb weakness, ptosis and CPEO (Moraes 
et al. 1993a). Studies have shown the frequency of myopathy in patients to range between 
25% (4 of 16 patients) to 61% (22 of 36 patients) (Deschauer et al. 2001; Hammans et al. 
1995; Yatsuga et al. 2012). Nesbitt et al. (2013) showed that in the 36 patients who showed a 
spectrum of phenotypes different to the classical MELAS and MIDD disorders, muscle 
involvement and CNS were the most common phenotypes observed. Of these patients, 27% 
presented with proximal myopathy. A population based study undertaken by Kärppä et al. 
(2005) assessed the spectrum of myopathy in 50 patients harbouring the mutation. Half of the 
patients were clinically defined as myopathic, presenting as mild or moderate limb weakness 
defined by clinical observations comprising of patients possessing a waddling gate and 
symmetrical proximal myopathy. It was previously found that mild limb weakness was 
commonly observed in affected patients (Hammans et al. 1995). Other myopathic features 
found in patients included ptosis and CPEO (weakness of the levator muscle and the 
limitation of eye movements). Further to this study, patients have been found to show a 
reduction in muscle strength, for example de Laat et al. (2012) reported that 49.9% of patients 
displayed decreased muscle strength as well 29% of patients manifesting muscle weakness in 




mild or moderate proximal muscle weakness. Lastly, exercise intolerance was indicated to be 
an important subtle sign of m.3243A>G related disease after patients were assessed with 
either the NMDAS (de Laat et al. 2012) or questionnaires (Kaufmann et al. 2011).  
In terms of morphological analysis of muscle biopsies, the presence of RRFs (either COX-
positive or deficient as detected by SDH staining) and/or COX-deficient fibres are found in 
the skeletal muscle sections of patients (Goto et al. 1990; Greaves et al. 2010; Jeppesen et al. 
2006; Kärppä et al. 2005; Mimaki et al. 2009). However, in some patients, skeletal muscle 
may appear normal, particularly in MELAS patients (de Laat et al. 2016; Moraes et al. 1992), 
even when the Complex I and Complex IV activities were decreased (de Laat et al. 2016). 
Studies have quantified the proportion of COX-deficient fibres and RRFs in patients and it 
was shown that the RRFs found in MELAS patients were mostly COX-positive whereas 
patients with CPEO displayed RRFs that were predominantly COX-deficient (Moraes et al. 
1993b; Petruzzella et al. 1994). Additionally, Jeppesen et al. (2006) investigated 51 biopsies 
of m.3243A>G patients and determined the frequency of abnormal fibres; 25 of 51 had more 
than 2% RRF and/or COX-deficient fibres, 10 had RRF fibres and COX-deficient fibres, 11 
had only RRF fibres and 4 only had COX-deficient fibres. There is currently no literature 
about the protein expression of Complex I or III in skeletal muscle fibres of patients with 
m.3243A>G pathogenic variant.   
4.1.6. Causes of phenotypic variation  
This wide spectrum of clinical phenotypes observed in patients harbouring the m.3243A>G 
mutation is currently poorly understood. This leads to a complication in the clinical setting 
when considering the disease burden, with the long term prognosis being very difficult to 
predict in such patients (Chinnery and Turnbull 1997; Kaufmann et al. 2011; Mancuso et al. 
2014). It is generally accepted that the severity of phenotype is correlated to high levels of 
heteroplasmy (Chinnery and Turnbull 1997; Hammans et al. 1995; Shoffner et al. 1990; 
Wallace et al. 1988). Although, this relationship is complicated by the variation in 
heteroplasmy between tissues, for example, muscle is known to harbour high levels of 
heteroplasmy whilst blood is shown to have less. In addition to this, ongoing research is 
showing that the phenotypically variability could be explained further by a number of factors, 
as listed below. The factors which are of interest to this thesis are only listed below but other 







Heteroplasmy has been suggested to be a critical factor contributing to the phenotypic 
variation observed within patients. The relationship between heteroplasmy level and clinical 
phenotypes has been extensively studied. Previous studies suggested that patients with high 
heteroplasmy levels in skeletal muscle presented at an early age with MELAS-like syndrome 
whilst those with lower heteroplasmy levels presented with less severe phenotypes such as 
CPEO, myopathy and deafness (Chinnery and Turnbull 1997; Hammans et al. 1995; Kandel 
et al. 2017; Moraes et al. 1993a; Petruzzella et al. 1994). This correlation between disease 
severity and phenotypic presentation was further exemplified by Koga et al. (2000) who 
showed that unrelated patients (n=5) with LS or MELAS had heteroplasmy levels of 92%, 
87% and 74% respectively whilst those with CPEO or MIDD had levels of 33% and 5% 
respectively. In addition, the correlation between heteroplasmy level and specific phenotypic 
presentation was demonstrated by Jeppesen et al. (2006) where heteroplasmy levels of over 
65% in skeletal muscle was correlated to both hearing impairment and diabetes (in 14 of the 
51 patients). Furthermore, findings from the study by Pickett et al. (2018) who investigated 
238 patients from the MitoCohort, showed that the following phenotypes were significantly 
associated with higher levels of heteroplasmy; hearing impairment, dystonia-dysarthria, 
diabetes, SLE, cerebellar ataxia, myopathy, cardiovascular involvement and encephalopathy.  
However, the role of heteroplasmy in the phenotypic variation is further complicated by 
patients who harbour low m.3243A>G heteroplasmy levels but have severe phenotype 
expressions. For example, a study by Hollingsworth et al. (2012), reported two patients who 
presented with low m.3243A>G heteroplasmy levels in muscle, yet one patient was 
asymptomatic (aged 31 and heteroplasmy level of 24%) whilst the second patient presented 
with a severe MELAS phenotype (aged 46, heteroplasmy level of 26%), highlighting that 
heteroplasmy levels are a contributing factor towards the phenotypic variation, but does not 
fully explain it. This is further emphasised by the study undertaken by Grady et al. (2018),  
where it was shown that age, muscle heteroplasmy level and muscle mtDNA copy number 
explains only 40% of the variance in disease burden in m.3243A>G‐related disease. The main 
aspect of heteroplasmy and threshold effect will be further discussed in Chapter 5. 
Mitochondrial DNA copy number 
Similarly, to heteroplasmy, mtDNA copy number also impacts the m.3243A>G mutation and 
therefore the clinical phenotype. Low mtDNA copy number in skeletal muscle of m.3243A>G 




combining with both homogenate heteroplasmy and age, it was shown that mtDNA copy 
number accounted for 40% of the phenotypic variation.  
The mtDNA copy number differs between cells, particularly in skeletal muscle due to the 
different fibre types. In patients with mitochondrial disease, a high proportion of wild-type 
mtDNA can have a compensatory effect against low levels of mutated mtDNA. Therefore, the 
fact that low mtDNA copy number leads to more severe disease is expected as there is no 
compensation from the wild-type copy number population. However studies have shown the 
existence of high levels of wild-type mtDNA copy number in deficient fibres, indicating that 
this compensatory mechanism was not capable of rescuing the cell phenotype and that high 
mtDNA copy number does not influence heteroplasmy level (Durham et al. 2007; Moraes et 
al. 1992; Tokunaga et al. 1994). Additionally, mtDNA copy number in individuals is likely to 
be influenced by the physical activity, for example a patient who is physically inactive will 
have low mtDNA copy number in comparison to a patient who is capable of physical activity 
(Grady et al. 2018).  
Biological sex  
The first report to show sex as a risk factor for SLE was by Mancuso et al. (2014) who 
demonstrated a significant prevalence of males in the MELAS phenotype group (33 males out 
of 51 participants – 67.4%) in comparison to the non-MELAS phenotype group (32 males out 
of 75 participants – 42.7%). There was no difference seen between the two groups of patients 
in terms of age of onset, disease duration and levels of m.3243A>G heteroplasmy levels in the 
three tissues examined (urine, blood and muscle). In addition to this, Pickett et al. (2018) also 
showed phenotypes in which the effect of sex was significant; males were seen to be a risk 
factor for ptosis and females for myopathy (P=2.6 x 10-3 and P=7.9x10-3 respectively, odds 
ratio less than 1). Consistent with the findings by Mancuso et al. (2014), this study also 
observed that males were more affected than females by SLE, however this did not reach 
significance, possibly due to different ascertainment strategies in the two studies.  
Age  
Disease caused by the m.3243A>G mutation is progressive, therefore, it is important to 
consider the age of patients in a clinical setting. It has been shown that higher severity of 
diabetes, hearing impairment, cerebellar ataxia and neuropathy are strongly associated with 






The variation of phenotypes in patients could be due to the role of additive nuclear factors. 
This is supported by a study describing two pairs of monozygotic twins who showed 
extremely similar clinical courses within each pair; alongside this, the heteroplasmic ratios 
were also similar between the twins indicating that this may be regulated by nuclear genes 
(Maeda et al. 2016). The role of nuclear factors was also investigated by Pickett et al. (2018) 
who demonstrated high to moderate heritability estimates for hearing impairment, psychiatric 
involvement, cognition, migraine and cerebellar ataxia, thus highlighting a strong indication 
that the presence of nuclear effects influencing disease phenotype.  
4.1.7. Biochemical features associated with the m.3243A>G variant  
Mutations in mt-tRNA most likely lead to defects in mitochondrial translation, therefore all 
mtDNA-encoded OXPHOS complexes (Complex I, III, IV and V) would be affected. 
However, it is now evident that variable forms of mitochondrial respiratory chain deficiencies 
have been associated with the m.3243A>G mutation. Both patient skeletal muscles and 
transmitochondrial cybrid cells (either 143B-206 or A549) have shown either combined or 
isolated deficiencies of Complex I, II and IV (Chomyn et al. 2000; Ciafaloni et al. 1992; 
Dunbar et al. 1996; Flierl et al. 1997; Janssen et al. 2007a; Jeppesen et al. 2006; Mariotti et al. 
1995). However, the dysfunction of Complex I (either loss of enzymatic activity or loss of 
protein) predominates in m.3243A>G carriers, particularly in MELAS patients (Fornuskova et 
al. 2008; Goto et al. 1992; Morgan-Hughes et al. 1995). Studies have also shown evidence for 
this predominance in patient muscle biopsies. Goto and colleagues (1992) showed that 13 of 
40 MELAS patients had Complex I deficiency. Further to this, a study by Mariotti et al. 
(1995) investigated 19 patients of which nine showed decreased Complex I activity. Similar 
observations were also made by Jeppesen and colleagues (2006) and Morgan-Hughes and 
colleagues (1995). Additionally, using the quadruple immunofluorescence assay to directly 
interrogate the NDUFB8 subunit of Complex I, Rocha et al. (2015) also highlighted the 
predominance of Complex I deficiency in five patients through the mitochondrial respiratory 
chain profile expression plots, indicated by the “left-shift” of individual single fibres as 
previously shown in Chapter 3. 
The predominance of Complex I deficiency has been linked to the mechanism/s by which the 
mutation causes pathogenicity. A severe decrease in the rate of synthesis of both ND6 and 
ND5 subunits has been observed in transmitochondrial cell lines and patient-derived cells 
(Chomyn et al. 2000; Dunbar et al. 1996; Kirino et al. 2004; Sasarman et al. 2008). This has 




result of taurine modification deficiency which reduces the expression of UUG-dependent 
proteins (Kirino et al. 2005).   
Some of these studies also showed that patients had Complex IV deficiency, mostly in 
combination with Complex I deficiency (Goto et al. 1992; Mariotti et al. 1995). Again, Rocha 
et al. (2015) showed Complex IV deficiency in the same four patients. The presence of COX-
deficient fibres has been shown to be far less frequent in m.3243A>G carriers than both 



























The aims of the work presented in this chapter are two-fold. First, the aim was to characterise 
the biochemical profile of skeletal muscle sections from patients harbouring the m.3243A>G 
mutation from the MitoCohort. The study by Rocha et al., (2015) utilised the quadruple 
immunofluorescence assay to assess only a limited number of patients (n=5). However, it is 
evident that m.3243A>G patients are heterogeneous in their biochemical profile, therefore 
this current study utilised the assay in a larger and more comprehensive cohort of patients to 
capture this heterogeneity and to better characterise the protein expression of Complex I and 
Complex IV in single muscle fibres.   
The second aim was to assess the relationship between the quantitative data from the 





















4.3. Methods  
4.3.1. Tissue samples and ethics 
Skeletal muscle biopsies (either Tibialis Anterior muscle (TA) or Quadriceps (quads)) from 
19 patients who harbour the m.3243A>G mutation were used for this study. The samples were 
requested from the Newcastle Mitochondrial Research Biobank (Research Ethics Committee 
reference: 16/NE/0267). Ethical approval and guidelines for the projects were granted by the 
generic research tissue bank approval for the Newcastle Mitochondrial Research Biobank.  
Unless stated in this thesis, the muscle biopsy referrals, clinical, histochemical, molecular 
genetics and enzymatic investigations were all undertaken as part of the diagnostic work up of 
these patients for suspected mitochondrial disease at the NHS Highly Specialised Service for 
Rare Mitochondrial Disorders for adults and children located within the Wellcome Centre for 
Mitochondrial Research, at Newcastle University.   
4.3.2. Clinical information for cohort 
Clinical information for the 19 patients included in this study cohort is presented in Table 4.3. 
All clinical information including age (closest to the date at which muscle biopsy taken), 
clinical presentations, NMDAS scores (closest to the biopsy) and skeletal muscle homogenate 
m.3243A>G heteroplasmy levels were acquired from the MitoCohort (research ethics 
committee reference: 13/NE/0326) (section 2.5.3, Chapter 2). Both P11 and P19 were not 
part of the MitoCohort (provided by the Neuromuscular Centre, Institute for exercise and 
Environmental medicine at the University of Texas, Dallas), therefore there was no NMDAS 
scores for these patients. 
The 17 patients from the MitoCohort were selected from a larger group of patients (58 
patients) who had consented for the use of their skeletal muscle tissue in research. The 
selection of the patients (n=17) were based on homogenate heteroplasmy (high), muscle 
phenotype (myopathy scored over 2 on NMDAS) and total NMDAS scores (high therefore 
severe phenotype). This selection process was undertaken to allow for the best chance in 
capturing deficiencies with the quadruple immunofluorescence assay.  
Patient clinical phenotypes, determined using NMDAS scores for individual questions and the 
thresholds presented by Pickett et al. (2018), are shown in Table 4.2. To account for the 
stochastic nature of traits, such as SLE, the maximum NMDAS score attained by a patient for 
each phenotype was used.  
Patients ranged in age between 25 and 59 years at the time of skeletal muscle biopsy – the 




Table 4.2: Clinical and molecular genetic characteristics of the patient cohort harbouring the 

























dysmotility, severe migraine, 









P2 F 55 Asymptomatic cardiac 
involvement, severe diabetes, 
end-stage deafness 
 
84 20.7 n.d 
P3 M 49 Mild-ataxia, severe 
migraines, myopathy 
 
80 20.4 n.d 
P4 F 34 Deafness, myopathy, fatigue, 
mild ataxia, chronic 
constipation 
 
78 23.2 25% 
P5 F 44 Mild-ataxia, symptomatic 
cardiac involvement, severe 
diabetes, mild 
encephalopathy, severe 
deafness, severe migraine, 
myopathy, seizures, SLE 
  
78 27.9 n.d 
P6 F 25 Mild ataxia, symptomatic 
cardiac involvement, 
severely affected cognition, 
CPEO, moderate 
encephalopathy, moderate 
deafness, myopathy, bilateral 
ptosis, seizures, SLE 
 
77 33.5 n.d 
P7 F 48 Mild-ataxia, CPEO, severe 
migraine, myopathy, bilateral 
ptosis 
 
74 21.8 n.d 
P8 F 57 Mild-ataxia, asymptomatic 
cardiac involvement,  severe 
diabetes, severe deafness, 
myopathy  
 
70 26.9 n.d 
P9 M 51 Ataxia, symptomatic cardiac 
involvement, severely 
affected cognition, severe 
diabetes, mild 
encephalopathy, GI 
dysmotility, severe deafness, 
myopathy, sensory 
impairment, bilateral ptosis, 
seizures 





P10 F 18 Severe migraine, myopathy 
 
66 21.5 n.d 
P11 F 25 Modest exercise intolerance  
 
64 n/a n.d 
P12 M 32 Mild GI symptoms  
 
63 4.1 n.d 
P13 F 59 Moderate deafness  
 









Mild-ataxia, severe cardiac 
involvement, severe 
cognitive impairment, severe 
CPEO, severe diabetes, 
myopathy, sensory 








P15 F 56 Mild-ataxia, asymptomatic 
cardiac involvement, 
impaired glucose intolerance, 
GI dysmotility, moderate 
deafness, severe migraine, 
myopathy 
 
55 22.8 n.d 
P16 M 52 Mild-ataxia, symptomatic 
cardiac involvement, CPEO, 
severe diabetes, moderate 
deafness, myopathy, motor 
impairment, ptosis 
 
50 49.7 n.d 
P17 M 43 Mild encephalopathy, end-
stage deafness, severe 
migraine  
 
46 14 93% 
P18 F 55 Severe ataxia, severe 
cognitive impairment CPEO, 
moderate encephalopathy, GI 
dysmotility, severe deafness, 
myopathy, seizures 
 
39 49.7 100% 
P19 F 47 Exercise intolerance, ptosis  
 
34 n/a n.d 
Age = closest to the biopsy; Total NMDAS = closest to the biopsy; GI = 
Gastrointestinal; SLE = Stroke-like episodes; CPEO = Chronic progressive 
external ophthalmoplegia; n/a = not applicable  
*All biochemical data relating to Complex I enzymatic activity in muscle was 
provided by the NHS Highly Specialised Service for Rare Mitochondrial Disorders 
laboratory team 








4.3.3. Tissue sectioning, quadruple immunofluorescence and image acquisition 
10µm serial transverse skeletal muscle cryosections were collected onto glass slides. Sections 
were dried at RT for approximately 1 hour and then stored at -80°C. Before undertaking the 
staining process, slides were taken out of storage and air dried for approximately 1 hour at 
RT.  The quadruple immunofluorescence assay was undertaken on these patient (n=19) and 
non-disease control (n=5) skeletal muscle cryosections, as outlined in section 2.5.8.1 in 
Chapter 2 and Figure 4.2. The acquisition of images of the section and the subsequent 




Figure 4.2: A schematic diagram highlighting the study design and quadruple immunofluorescent 
protocol. 
Nineteen patients were assessed using the assay which detects the immunoreactivity of Complex I, 







4.3.4. Data and statistical analysis 
 NMDAS scores obtained closest to the date of the biopsy were used in the overall analysis of 
the data attained in this chapter. The score for selected phenotypes is listed in Table 7.1 in 
Appendix 2 (Chapter 7). As this study is using skeletal muscle, it was important to assess the 
muscle-related phenotypes myopathy, exercise intolerance, cardiovascular, CPEO and ptosis. 
Stroke-like-episodes was also included in the analysis, as it is a measure of the severity of the 
disease. NMDAS thresholds scores as defined by Pickett et al. (2018) were used to determine 
affection status for binary trait analysis – phenotypes were then expressed as being present or 
absent.  
The statistical analysis in this study was conducted with Microsoft Excel for the quadruple 
immunofluorescence assay data. Prism 5 (GraphPad Software Inc) was used to generate the 
mitochondrial respiratory chain profiles. R (version 3.5.2 (2018-12-20)) was used for linear 
and logistic regression models. The graphs were generated using the ggplot2 (Wickham 2016) 
package in R.  



















Nineteen skeletal muscle biopsies taken from patients with the genetically confirmed 
pathogenic variant of m.3243A>G in the MT-TL1 gene were assessed using the quadruple 
immunofluorescence assay. This generated a biochemical profile for each patient by 
measuring the levels of NDUFB8 (Complex I) and COX-1 (Complex IV) protein abundance 
in individual muscle fibres of a 10µm skeletal muscle section. The number of muscle fibres 
analysed per patient ranged from 104 (P09) to 1464 (P11) (see Table 4.3).  
4.4.1. Immunoreactivity of NDUFB8 and COX-1 in m.3243A>G patients  
The fluorescent images obtained from the quadruple immunofluorescence assay showed 
variable levels of immunoreactivity (therefore protein expression) of NDUFB8 and COX-1 in 
all patients assessed (Figure 4.3). Visual inspection of the x20 images of the muscle sections 
(a representative area of the whole section), showed decreased expression of NDUFB8 in 
individual fibres in a number of patients, when compared to the representative non-disease 
control muscle section. This decrease in Complex I is particularly evident in the tissue 
sections of patients P01, P04, P05, P06 and P07. The remainder of patients show a decrease in 
NDUFB8 immunoreactivity in fewer number of fibres, or more of a subtle loss which would 
require validation through quantification.  
In contrast, the immunoreactivity of COX-1 is less apparent visually, although patients P02, 
P06 and P18 show decreased staining intensity when compared to the control and the other 
patients. Additionally, in the merged images, patients P03, P06, P07, P11, P16 and P19 
display fibres which are visibly red in colour highlighting the immunoreactivity of porin– thus 

















Figure 4.3: Images of Complex I, IV and porin expression in skeletal muscle sections of 
m.3243A>G patients. 
Fluorescent detection was used to visualise NDUFB8 (Complex I), —purple COX –1 (Complex IV)—
green, porin (mitochondrial mass)—red and laminin (fibre boundary marker)—white. A representative 
non-diseased control muscle (highlighted by the red box) shows normal immunoreactivity for 
NDUFB8, COX-1 and porin. Varying immunoreactivity of Complex I and Complex IV was detected in 
patients (01-P19). Patients marked with red asterisks (*) are those that showed normal 
immunoreactivity of both Complex I and Complex IV. RRF in merged images show fibres that have no 




4.4.2. Quantifying the quadruple immunofluorescence assay biochemical findings  
The staining intensities of the fluorescent images were analysed, allowing for the 
quantification of NDUFB8 and COX-1 in single muscle fibres. The quadruple 
immunofluorescence assay biochemical data are presented as a total percentage of deficient 
fibres (consistent with Chapter 3); fibres which are categorised as intermediate positive, 
intermediate negative and negative in NDUFB8 and COX-1 protein abundance, based on Z 
scores (as descried in Chapter 2, section 2.5.10.2). Table 4.3 shows the percentage 
distribution of fibres across each category for NDUFB8 and COX-1.  
4.4.2.1. Biochemical findings for control group;  
The five non-disease controls (C01, C02, C03, C04 and C05) were analysed; the total 
percentage of deficiency observed in this group ranged from 0% to 1.35% for Complex I and 
0% to 0.62% for Complex IV, across three different experimental batches (see Table 7.2 in 
Appendix 3, Chapter 7). This demonstrates that there was very little variation between all of 
the batches which highlights the reproducibility of this assay. 
4.4.2.2. Biochemical findings in m.3243A>G patient muscle;  
In comparison, the findings from the 19 patients showed a greater variation in the percentage 
of deficient fibres detected. Evaluating the levels of Complex IV (COX-1), it can be seen 
from Table 4.3 that the total percentage of Complex IV-deficient fibres ranged from 0% (P10 
and P12) to 29.95% (P06). Patients P06 and P18 (11.69%) displayed the greatest proportion 
of Complex IV-deficient fibres in their skeletal muscle section compared to the other patients. 
Patients P11 (6.97%) and P13 (4.28%) displayed milder Complex IV deficiency whilst 
Patients P10 and P12 showed no deficiency. The latter two patients displayed levels that are 
equivalent to the non-diseased controls. The remainder of the patients showed less than 4% of 
Complex IV-deficient fibres.  
In contrast, Complex I (NDUFB8) levels were more affected in this cohort of patients – the 
skeletal muscle section of 13 patients displayed Complex I deficiency; P01, P04, P05, P06, 
P07, P08, P09, P11, P13, P14, P16, P18 and P19. The total percentage of Complex I-deficient 
fibres ranged from 0% (P10) to 79.45% (P01) (Table 4.3).  
The skeletal muscle sections of the remaining six patients (P02, P03, P10, P12, P15 and P17), 
presented with Complex I-deficient fibres ranging from 0% (P10) to 2.20% (P02) – similar to 
the non-disease control group. Furthermore, in these six muscle sections, the proportion of 




these patients showed an absent or a very mild Complex I and Complex IV deficiency in the 
single muscle fibres analysed – levels similar to the non-disease cases.  
 
Table 4.3: Quantification of Complex I (NDUFB8) and Complex IV (COX-I) deficiency in skeletal 



























P01 20.55 8.38 12.28 58.78 79.45 97.93 1.84 0.23 0.00 2.07 871 
P04 36.39 3.56 7.21 52.84 63.61 96.27 2.88 0.68 0.17 3.73 1179 
P05 41.29 39.53 14.15 5.03 58.71 99.30 0.58 0.12 0.00 0.70 855 
P06 30.55 15.04 19.21 35.20 69.45 70.05 18.26 9.43 2.27 29.95 838 
P07 60.81 9.52 11.36 18.32 39.19 98.72 0.92 0.37 0.00 1.28 546 
P08 87.42 4.72 2.52 5.35 12.50 97.80 0.63 1.26 0.31 2.20 318 
P09 80.77 3.85 2.88 12.50 19.23 99.04 0.96 0.00 0.00 0.96 104 
P11 78.07 2.80 5.19 13.93 21.93 93.03 4.10 2.25 0.61 6.97 1464 
P13 91.59 2.70 2.54 3.17 8.41 95.72 2.06 1.51 0.71 4.28 1261 
P14 91.00 0.71 1.66 6.64 9.00 98.82 0.47 0.24 0.47 1.18 422 
P16 83.62 4.52 3.11 8.76 16.38 96.33 2.54 0.56 0.56 3.67 354 
P18 80.13 5.64 5.17 9.06 19.87 88.31 5.56 4.21 1.91 11.69 1258 
P19 88.50 2.54 2.30 6.66 11.50 97.58 1.33 0.61 0.48 2.42 826 
Group B 
P02 97.80 1.34 0.19 0.67 2.20 99.52 0.29 0.10 0.10 0.48 1047 
P03 98.22 0.20 0.99 0.59 1.78 97.23 2.37 0.20 0.20 2.77 506 
P10 100.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 0.00 501 
P12 99.54 0.00 0.00 0.46 0.46 100.00 0.00 0.00 0.00 0.00 431 
P15 99.09 0.50 0.30 0.10 0.91 99.80 0.20 0.00 0.00 0.20 991 




4.4.3. Two distinct groups of patient muscle biopsies   
This difference in the quadruple immunofluorescence data has shown that the patients in this 
cohort appear to fall into two main groups. Patients were defined as falling into Group A if 
their muscle biopsies showed decreased levels of Complex I and near normal levels of COX-1 
when compared to non-disease controls (except for P06 and P18 who showed larger decrease 
in COX-1 expression). Patient were then defined as being in Group B if their skeletal muscle 
section showed none or very low levels of Complex I and Complex IV, similar to the non-
disease controls.  
Considering the residual Complex I activity (homogenate skeletal muscle), P01, P04 and P09 
(Group A) also showed a decrease in enzymatic activity (13%, 25% and 50% respectively). 
However, P13 and P18 who are also in Group A have normal enzymatic activities (82% and 
100%) – indicating that the mutation is affecting the assembly of Complex I and/or Complex 
IV only. P17 (Group B) also showed normal enzymatic activity (93%).  
4.4.4. The mitochondrial respiratory chain expression profiles of m.3243A>G patient 
skeletal muscle section  
As already described in both Chapters 2 and 3, a graphical representation of the quadruple 
immunofluorescence assay biochemical data is given through the mitochondrial respiratory 
chain expression profiles. Figure 4.4 shows a representative non-disease control in which all 
fibres assessed in the muscle section (represented by individual dots) fall within the normal 
range – all fibres having a Z_score above -3 for both Complex I (NDUFB8_z) and Complex 
IV (COX_z). Reiterating the findings above, the expression profiles for the skeletal muscle 
sections of the 13 Group A patients (Patients P01, P04, P05, P06, P07, P08, P09, P11, P13, 
P14, P16, P18 and P19) show a “left shift” in a group of fibres – indicative of the Complex I-
deficient fibres ((Z_scores fall below -3 for NDUFB8_z). In all of these patient sections 
excluding P09, a “downward shift” is then seen in a small proportion of fibres, highlighting 
that these fibres fall below -3 Z_score for COX-1_Z and therefore are Complex IV-deficient. 
The six Group B patient muscle sections (P02, P03, P10, P12, P15 and P17) show profiles 
that are similar to the non-disease control, in which the vast majority of fibres are within the 
normal range – as expected following the analysis. Patients P02, P03, P15 and P17 have very 
few fibres that are deficient for Complex I and Complex IV, however as stated in Table 4.3, 
the proportion of these fibres range between 0.% to 2.20% of total fibres for Complex I and 
0% to 2.77% of total fibres for Complex IV. Thus, for example in P15, a total number of 991 
fibres were analysed of which nine fibres are deficient for Complex I and two fibres are both 





Figure 4.4: Mitochondrial respiratory chain (MRC) expression profile linking Complex I 
(NDUFB8), Complex IV (COX-1) and porin levels in m.3243A>G muscle sections. 
Complex I and Complex IV expression profiles from all patients (n=19) and one representative non-
disease control (control muscle). Fibres within black box (top left) are normal fibres. Fibres that show 
a “left shift” are Complex I-deficient. A “downward shift” shows Complex IV deficiency. Patients 
marked with red asterisk (*) are those in Group B. Porin level colours = Red fibres = very high levels, 
Orange = high, Beige = normal, Blue = low, Dark blue = very low.  Het = skeletal muscle 




4.4.5. Correlating the quadruple immunofluorescence data with the clinical data 
Using the data generated from the quantitative quadruple immunofluorescence assay (the 
Z_scores for individual fibres and the total percentage of deficient fibres for Complex I and 
IV), it was investigated whether the clinical data are associated with the biochemical status. 
Table 4.4 highlights the total deficiency for Complex I and IV, alongside the level of 
m.3243A>G heteroplasmy in muscle homogenate and age (closest to the date of biopsy).  
 
Table 4.4: Age, homogenate heteroplasmy and total Complex I and Complex IV deficiency in skeletal 
muscle sections 
 
4.4.5.1.  Biochemical data (Z_scores) vs homogenate m.3243A>G heteroplasmy levels 
The relationships between the Z_scores for Complex I and Complex IV in individual fibres of 
each patient and their homogenate heteroplasmy were investigated using linear mixed effects 
models (Figure 4.5). Complex I Z_scores were significantly positively correlated with the 
homogenate heteroplasmy of patients (P=0.0260, gradient of slope = -0.0597, SE = 0.0245 
and y intercept = 2.1793, SE = 1.6251) – Figure 4.5(A). This shows that as the homogenate 
heteroplasmy increased, the Z_score value for Complex I decreased. In contrast, the Z_scores 
for Complex IV were not significantly correlated to the homogenate heteroplasmy (P = 
0.3423, gradient of slope = -0.0147, SE = 0.0150, y intercept = 1.0004, SE = 0.9971) – 



















P01 26 89 13 (decreased) 79.45 2.07 871 
P04 34 78 25 (decreased) 63.61 3.73 1179 
P05 44 78 n.d 58.71 0.70 855 
P06 25 77 n.d 69.45 29.95 838 
P07 48 74 n.d 39.19 1.28 546 
P08 57 70 n.d 12.50 2.20 318 
P09 51 67 50 (decreased) 19.23 0.96 104 
P11 25 64 n.d 21.93 6.97 1464 
P13 59 62 82 (normal) 8.41 4.28 1261 
P14 40 57 n.d 9.00 1.18 422 
P16 52 50 n.d 16.38 3.67 354 
P18 55 39 100 (normal) 19.87 11.69 1258 
P19 47 34 n.d 11.50 2.42 826 
Group B 
P02 55 84 n.d 2.20 0.48 1047 
P03 49 80 n.d 1.78 2.77 506 
P10 18 66 n.d 0.00 0.00 501 
P12 32 63 n.d 0.46 0.00 431 
P15 56 55 n.d 0.91 0.20 991 
P17 43 46 93 (normal) 2.07 1.72 290 




cohort of patients. Age (closest to biopsy) was not associated with either Complex I or 





Figure 4.5: Relationship between homogenate heteroplasmy and the Z-scores determined for a) 
Complex I and b) Complex IV deficiency in individual muscle fibres. 
Complex I Z_scores are significantly correlated to homogenate heteroplasmy (P=0.0260, gradient of 
slope = --0.0597, SE = 0.0245 and y intercept = 2.1793, SE = 1.6251), but Complex IV is not (P = 
0.3423, gradient of slope = -0.0147, SE = 0.0150, y intercept = 1.0004, SE = 0.9971). Patients are 
represented with different colours and each individual point represents a single fibre. Red dashed line 
at y=-3 is the Z_score deficiency. Solid black lines are the regression lines representing the slope and 




4.4.5.2. Biochemical deficiency vs homogenate m.3243A>G heteroplasmy levels 
Although a significant relationship was detected for Complex I Z_scores and homogenate 
heteroplasmy, this analysis took into account all fibres; both normal and deficient. So, to 
explore this further, the relationships between the proportion of Complex I and Complex IV- 
deficient fibres and homogenate m.3243A>G heteroplasmy were investigated (Figure 4.6).  
Homogenate heteroplasmy was significantly positively correlated with the proportion of 
Complex I-deficient fibres (R2 = 0.216, P = 0.026, β = 0.869, SE=0.356). However, it is 
apparent in Figure 4.6(A), that despite the high heteroplasmy levels, a number of patients 
(P02, P03, P10, P12, P15 and P17) still presented with low proportions of Complex I-
deficient fibres (Table 4.4). In contrast, homogenate heteroplasmy and the proportion of 
Complex IV deficiency levels was not significantly correlated (R2 = -0.058, P = 0.909, β = 
0.012, SE=0.109) – Figure 4.6(B). This was as expected as all patients but P06 and P18 
presented with no deficiency or very low levels similar to controls. This is consistent with the 
findings above with the Z_score data. Furthermore, age (closest to the biopsy) was also not 
associated with either Complex I or Complex IV deficiency (P = 0.080 and P = 0.266 








Figure 4.6: Relationship between homogenate heteroplasmy and the percentage of A) Complex I 
and B) Complex IV deficiency.  
A) Homogenate heteroplasmy was significantly positively correlated with the proportion of Complex 
I-deficient fibres (R2 = 0.216, P = 0.026, β = 0.869, SE=0.356) B) Homogenate heteroplasmy was not 
significantly correlated with the proportion of Complex IV- deficient fibres ((R2 = -0.058, P = 0.909, β 
= 0.012, SE=0.109) Blue line = linear regression, Grey shading = 95% confidence interval. Each 





4.4.5.3. Correlating the biochemical findings with clinical phenotypes  
Next, the relationship between the quadruple immunofluorescence assay data and the 
phenotypes scored on the NMDAS (closest to the biopsy) for each patient was  investigated to 
determine which category of patients (present or absent for the phenotype according to Pickett 
et al., 2018) had the highest proportion of Complex I-deficient and Complex IV-deficient 
fibres. However, it must be noted that due to the small number of patients (n=19), statistical 
tests could not be undertaken in certain phenotypes (SLE, cardiovascular and exercise 
intolerance), as a meaningful number of patients did not fall into both “present” and 
“absence” categories, thus hindering the statistical comparisons.  
It was found that patients who presented with myopathy had the highest proportion of 
Complex I-deficient fibres (Figure 4.7(A)). However, statistical significance was not reached 
(Mann-Whitney U test; P= 0.497). Figure 4.7(B) shows no difference in the patients between 
the two categories for Complex IV-deficiency (P = 1.00). Again, this is as expected as all but 
two patients showed low or no levels of Complex IV-deficiency in the cohort. The analysis of 
the CPEO NMDAS scores with the biochemical deficiency were also analysed and Figure 
4.7(C) shows that patients who were absent from the phenotype had the highest proportion of 
Complex I-deficient fibres but this difference was not statistically significant (Mann-Whitney 
U test; P= 0.6868). Likewise, whilst patients who were absent for ptosis had the highest 
proportion of Complex I-deficient fibres, no significance was reached in this difference 
between the two categories of patients (Mann-Whitney U test; P= 0.597). However, the 
number of patients per group is likely to be influencing these statistical outcomes as it limits 
the statistical power to detect an effect. As with myopathy, CPEO and ptosis did not show a 

















Figure 4.7: Boxplots showing the proportion of Complex I-deficient and Complex IV-deficient 
fibres (%) within patients who fall below (absent) and above thresholds (present) scores: 
For a – b) Myopathy, c-d) CPEO and e – f) Ptosis. Proportion of Complex I-deficient fibres are higher 
in those with myopathy and lower for those with CPEO and Ptosis. No significance was reached for 
these differences. The proportion of Complex IV-deficient fibres are similar for both categories of 
patients. Each individual patient is coloured according to their groups; red = Group A patients; blue 





This study aimed to characterise the biochemical status of skeletal muscle sections of patients 
harbouring the m.3243A>G mutation, using the quadruple immunofluorescence assay to 
determine the abundance of Complex I and Complex IV in fibres within a 10µm section.  The 
relationship between the quantitative data (Z_scores for all individual fibres on muscle 
sections and the proportion of Complex I and Complex IV-deficient fibres) and the clinical 
data (level of m.3243A>G heteroplasmy level in muscle homogenate, clinical phenotypes and 
age (both closest to the biopsy) of patient) was also investigated. A total number of 19 
patients were included in this study. 
4.5.1. The biochemical status of m.3243A>G patients is heterogeneous based on 
Complex I interrogation  
The study by Rocha et al. (2015) first determined the profiles of skeletal muscle sections of 
four m.3243A>G patients through quantifying the protein abundance of Complex I and 
Complex IV in single muscle fibres within a 10µm section, using an antibodies labelling the 
subunits NDUFB8 and MTCO1. However, this current study has characterised the 
biochemical profile of these patients in a larger, more comprehensive cohort. The application 
of the immunofluorescence assay in this cohort has identified that the biochemical status of 
m.3243A>G patient skeletal muscle sections can be divided into two groups; those with a 
biochemical deficiency (Group A) and those with normal biochemical status (Group B). 
The assay detected both Complex I and Complex IV deficiency in 13 of the 19 patient skeletal 
muscle sections, however Complex I deficiency predominated. The skeletal muscles from 
Group A patients displayed Complex I deficiency ranging from 8.41% to 79.45%. Four of 
these 13 patients also displayed a combined Complex IV deficiency alongside the Complex I 
deficiency – ranging from 4.28% and 29.95%. These findings add to the existing literature in 
that Complex I is primarily affected in patients with m.3243A>G (Fornuskova et al. 2008; 
Goto et al. 1992; Mariotti et al. 1995; Morgan-Hughes et al. 1995). As previously discussed, 
the predominance of Complex I deficiency is hypothesised to be due to the impact the 
m.3243A>G mutation has on the synthesis of ND6 and ND5 subunits as a result of the high 
UUG codon content in the polypeptides (Chomyn et al. 2000; Dunbar et al. 1996; Kirino et al. 
2004; Sasarman et al. 2008). 
The skeletal muscle section of the remaining six Group B patients displayed profiles showing 
no biochemical deficiency of Complex I and Complex IV, comparable to the non-disease 
control group. Again, this is in line with the existing literature; of the 19 patients assessed by 




activity as measured by spectrophotometric assays and normalised to citrate synthase. 
However, this study used homogenate muscle sample and therefore any potential biochemical 
defect could be lost when globally assessed.  For that reason, the use of the quadruple 
immunofluorescence assay has confirmed the findings of normal skeletal muscle sections at a 
single cell level, for these patients. Although, investigating a number of serial sections from 
the remainder of the biopsy of these patients will confirm the current findings.    
4.5.2. Complex I deficiency correlates with homogenate heteroplasmy levels 
As this assay has generated unique quantitative data, it enabled the exploration of the 
relationships between the biochemical deficiency of Complex I and Complex IV to the 
homogenate heteroplasmy recorded for these patients. Previous studies have attempted to 
correlate the biochemical deficiency observed in m.3243A>G patients to the heteroplasmy 
levels, but no clear correlations were reported – studies either described a strong inverse 
correlation between Complex I enzymatic activity and heteroplasmy level in homogenate 
muscle biopsy (Hollingsworth et al. 2012; Mariotti et al. 1995) or no association of Complex I 
or Complex IV with heteroplasmy level (Ciafaloni et al. 1992; Jeppesen et al. 2006; Morgan-
Hughes et al. 1995). However, this current study has found a significant positive relationship 
between Complex I-deficiency (protein expression) and homogenate heteroplasmy levels, 
both when analysing the Z_scores for all fibres analysed with the assay and also with the 
proportion of Complex I-deficient fibres only. Thus, these findings are consistent with those 
of Mariotti et al. (1995) and Hollingsworth et al. (2012) who found that Complex I activity 
decreased in skeletal muscle as the heteroplasmy level increased. This increase in biochemical 
deficiency observed in patient skeletal muscle sections has also been shown by Jeppensen et 
al. (2006) who found that the 25 patients (of 51) who displayed COX-deficient fibres and 
RRFs all had heteroplasmy level above 50% in skeletal muscle.  
In contrast, the level of Complex IV deficiency was not correlated to homogenate 
heteroplasmy in this cohort of patients. This was expected as the patients had very little 
deficiency in comparison to Complex I. In a larger cohort of patients, the power to detect an 
association between Complex IV and homogenate heteroplasmy would potentially be greater.  
Although increasing age has been associated with an accumulation of COX-deficient fibres in 
normal human skeletal muscle (Muller-Hocker et al. 1992), this study did not detect an 
association between age and biochemical deficiency (both Complex I and Complex IV). This 
could be because the m.3243A>G mutation is masking the effect of ageing, which could be 




homogenate heteroplasmy of this cohort (P =0.2296), which is consistent with the known 
literature (de Laat et al. 2012; Kaufmann et al. 2011).  
4.5.3. No correlation is observed between the biochemical deficiency and clinical 
phenotypes  
This current study has been able to investigate the relationship between phenotypes and the 
severity of the biochemical deficiency (the percentage of Complex I and or Complex IV- 
deficient fibres). Whilst no significant difference was found between the two categories 
(presence or absence of the phenotype) for myopathy, CPEO and ptosis, those over the 
threshold for myopathy had, on average, a higher proportion of Complex I-deficient fibres 
(31.6%). However, three of the six Group B patients (P03, P10 and P15) where no 
biochemical deficiency was detected, also showed myopathy. Therefore, it is difficult to 
conclude if the presence of myopathy in patients is linked to Complex I-deficiency in terms of 
protein expression, or not. This is further highlighted by the fact that only four patients with 
myopathy show higher Complex I deficiency compared to the other patients, whilst one 
patient without myopathy showed the highest percentage deficiency. Studies have either 
shown no or an inverse correlation between myopathy and m.3243A>G heteroplasmy levels, 
therefore it would be interesting to investigate further if this is similar for myopathy and the 
biochemical deficiency (Chinnery and Turnbull 1997; Kärppä et al. 2005). By undertaking 
this assessment in a larger cohort of patients, it would allow for a more robust conclusion to 
be drawn between the two groups.  
4.5.4. What is causing the difference in the biochemical status between patients in 
Group A and Group B?  
The most interesting finding from this study is the difference in the biochemical status 
between the patients in Group A and the patients in Group B. This has raised important 
questions; what is causing this difference between the two groups? Could this difference in 
the biochemical status be driving the wide spectrum of clinical phenotypes observed in 
m.3243A>G patients?  
A few factors, as mentioned in section 4.1.6 of this chapter, can be alluded to why this 
difference has been observed. Briefly, the age of the patients in both groups could have an 
impact, however, there was no correlation between age and biochemical deficiency. 
Moreover, the mean age of both groups is very similar; (mean = 43.3, SEM = 3.40 in Group A 
and mean = 42.1, SEM= 6.03 in Group B). In addition to this, there is no statistical difference 




There is a growing interest regarding the role of the nuclear DNA and nuclear factors in 
mitochondrial disease (Battersby et al. 2003; Hudson et al. 2005; Maeda et al. 2016). In vitro 
work by Dunbar et al. (1995) has shown the impact of nuclear genetic background on the 
m.3243A>G phenotypic and biochemical expression in different transmitochondrial cells. 
Furthermore, the work by Pickett et al. (2018), has shown a strong indication into the 
presence of nuclear effects in influencing the disease phenotype in m.3243A>G patients. 
Therefore, it could be likely that nuclear background is also influencing the biochemical 
status in these patients and is an aspect that needs to be investigated further. 
According to the threshold hypothesis (section 1.5.1 in Chapter 1), skeletal muscle fibres 
become biochemically deficient when mutant mtDNA reaches a specific proportion, in 
comparison to the wild-type mtDNA. The mosaic pattern observed in histochemical 
assessments show that different fibres have different levels of heteroplasmy, with some 
reaching the threshold and becoming deficient. Therefore, the difference in the biochemical 
status observed between the two groups is a strong indication of a difference in the 
heteroplasmy level at which the biochemical defect occurs; known as the critical threshold. 
Thereby, it is possible that fibres from patients in Group A have exceeded the threshold level 
in order to present with Complex I and (to a lesser extent) Complex IV deficiency, whilst this 
is not the case for fibres analysed from patients in Group B. These patients may have a higher 
threshold for deficiency in comparison, therefore the findings from this study poses another 
important question; is there a difference in the threshold between m.3243A>G patients?  
Both groups of patients have overlapping levels of homogenate heteroplasmy; Group A’s 
heteroplasmy levels range from 34% to 89% and Group B ranges from 46% and 84%. 
Homogenate heteroplasmy is the average level of m.3243A>G mutation across all fibres, both 
biochemically normal and deficient. Therefore, it is difficult to evaluate the relationship 
between the m.3243A>G mutation and the biochemical defects occurring within individual 
cells. As such, a single cell approach examining the heteroplasmy level in individual fibres in 
these patients could serve as a better approach in examining the relationship between the 
m.3243A>G mutation and the biochemical defect observed in patients in Group A. It will also 
allow for the investigation into the levels of m.3243A>G mutation in the biochemically 
normal fibres of Group B patients. This could then have the potential of deducing threshold 
for deficiency at an individual basis for these patient muscle sections.   
Single cell studies have already shown evidence of this principle. For example, Kärppä et al. 
(2018) utilised the approach to examine a patient harbouring m.15923A>G in the MT-TT gene 




The patient had a homogenate heteroplasmy level of 33% in skeletal muscle and following 
single cell analysis, it was found that COX-deficient fibres had an average heteroplasmy level 
of 92% whilst COX-positive fibres averaged at 43%. The authors concluded that the single 
cell analysis indicated that high heteroplasmy levels were required to cause a biochemical 
defect and therefore, a homogenate heteroplasmy level of 33% may not have been sufficient 
to cause a biochemical defect that would lead to a more severe phenotype – following the 
classic “higher heteroplamsy levels results in more severe phenotypes”. Studies have shown 
that the cellular threshold for m.3242A>G is between 80% and 90% (Petruzzella et al. 1994; 
Shoffner et al. 1990) whilst Miyabayashi et al. (1992) reported a lower threshold at 60%. 
Similar to the patient described by Kärppä et al. (2018), it can be hypothesised that different 
individuals have different thresholds. Therefore, perhaps Group B patients have higher 
threshold and thus have not reached the critical threshold for deficiency in skeletal muscle, 
which could be exemplified by P02 and P03 who have homogenate heteroplasmy levels of 
84% and 80% and so their threshold could be closer to or over 90%, as shown by Shoffner et 
al. (1990). Whilst, in Group A patients, the thresholds could be as low as the level reported by 
Miyabayashi et al. (1992). Although, it is important to recognise that three of the six Group B 
patients presented with myopathy in equal severity to those patients in Group A, according to 
the NMDAS.  
Another recent study by Rocha et al. (2018), utilised the quadruple immunofluorescence assay 
and a single cell approach to access single, large-scale mtDNA deletions. This approach was 
particularly valuable in showing that threshold levels differed in patients according to the site 
of deletions. Therefore, this same approach could be highly advantageous for accessing the 
difference between the two groups of patients defined in this current study, particularly for 
assessing heteroplasmy levels in the different populations of fibres and deducing a potential 
threshold in individual patients. Moreover, using this technique to assess the heteroplasmy 
levels in individual fibres between the two groups can potentially allow for investigation into 
the pattern of mutational segregation across the section. 
4.6. Limitations of this study 
Whilst this study has provided a more comprehensive evaluation of m.3243A>G patients, a 
number of limitations need to be discussed.  
Firstly, although this is currently the only study that has assessed the skeletal muscle of the 
m.3243A>G patients using the quadruple immunofluorescence assay targeting Complex I and 
Complex IV, the ability to draw statistically significant conclusions, particularly for the 




in the cohort. This is largely due to the heterogeneity on a clinical basis between these 
patients. In some patients, the use of skeletal muscle to draw these conclusions may not have 
been sufficient as they could be more neurologically affected in their phenotype.  
Secondly, the method by which the patients have been selected for this study is also a 
limitation. An approach to select patients likely to show deficiency through the assay was 
undertaken. Extending the application of the assay across the other available biopsies at 
random would serve a better approach in knowing how representative these findings are. 
Additionally, a larger cohort will allow a better assessment of the extent of Complex IV 
deficiency in m.3243A>G patients.   
Thirdly, this assay provides an invaluable insight into the expression of Complex I and 
Complex IV from a single 10µm section, which has huge advantages for the diagnosis 
algorithm or in terms of tissue availability, but it proves a limitation when accessing the 
biochemical status of skeletal muscle sections of patients. Work by Elson et al. (2002) showed 
striking variation in the length of COX-deficient segments across a length of a biopsy in 
individuals (ranging from 10µm to ≥1.2mm). Hence, biochemical deficiency (Complex I 
and/or Complex IV-deficiency) may appear at multiple sites along the length of the muscle 
fibre. Therefore, whilst findings have been insightful, they are/may not be representative of 
the entire biopsy, or indeed the whole muscle.  
Finally, the quadruple immunofluorescence assay has provided data on the protein expression 
of the complexes, rather than the enzymatic activity. So, although the Group B patients 
displayed normal expressions of both complexes, the enzymatic activity should be 
investigated for further confirmation. As discussed in Chapter 3, it could be that the 
m.3243A>G has variable effects on Complex I; either on assembly, enzymatic activity or 
both. However, this limited information has been provided in Table 4.2 and 4.4 but requires 
further investigation. 
4.7. Conclusion 
In conclusion, by assessing Complex I and Complex IV expression, the biochemical status in 
the skeletal muscle sections of 19 patients with the m.3243A>G pathogenic variant  has been 
extensively characterised in this study. This work presents the first study in which Complex I 
protein abundance, at a single cell level, has been assessed in a large cohort of patients, as 
previous studies have been restricted to the use of sequential COX/SDH, thereby this study 
has provided a more accurate characterisation of the biochemical profile in these patient 
skeletal muscles. Using the assay, the following findings have been determined; i) two groups 




showing a predominance of Complex I deficiency and patients in Group B who have shown 
no biochemical defect in their skeletal muscle section, ii) homogenate heteroplasmy is 
significantly correlated to the extent of Complex I deficiency. Moreover, from these findings, 
further questions have been raised; i) why is there a difference in the biochemical status 
between these groups, ii) is the critical threshold different between patients and iii) is this 
contributing to the phenotypic variation? These questions could potentially be answered using 






























Chapter 5: A single cell approach to estimate the heteroplasmic 
threshold for biochemical deficiency of Complex I in skeletal 































5.1. Introduction  
In Chapter 4, a cohort of 19 patients harbouring the m.3243A>G pathogenic variant was 
divided into two groups based on the OXPHOS biochemical profile (as determined by the 
quadruple immunofluorescence assay) of their skeletal muscle biopsy. Muscle biopsies from 
patients showing a Complex I deficiency were termed as Group A whilst those showing a 
normal biochemical profile were termed as Group B. These two groups of patients had 
overlapping homogenate heteroplasmy levels and clinical phenotypes. Thus, this difference in 
the biochemical status could be due to a difference in the critical m.3243A>G heteroplasmic 
threshold between these two groups of patients; do patients in Group A have a lower 
threshold hence a biochemical deficiency in their skeletal muscle? A single cell approach was 
used for this investigation, combining data from the quadruple immunofluorescence assay and 
a molecular genetics approach.  
Single cell studies investigating threshold levels for the m.3243A>G pathogenic variant:  
Estimates of the critical heteroplasmic threshold for the m.3243A>G mutation range from 50 
to 90% in the literature. This variability could have arisen because of variation between 
individuals or because of differences between experimental methods used to detect 
biochemical deficiency. Here, I consider the available data in the literature which have been 
obtained in an attempt to determine this critical threshold.  
Studies using transmitochondrial cells;  
Early studies investigating the threshold of the m.3243A>G variant utilised 
transmitochondrial cybrid cells, harbouring different levels of heteroplasmy. These studies 
demonstrated that the critical threshold level at which mitochondrial respiratory chain 
dysfunction was induced was at ∼90% (Attardi et al. 1995; Chomyn et al. 1992; Dunbar et al. 
1996; Koga et al. 1993; Yoneda et al. 1992). However, as described previously (section 4.13 
of Chapter 4), findings from studies using these cybrid cells need to be interpreted carefully. 
One difficulty with these observations is that transmitochondrial cell lines are cancerous 
(human osteosarcoma (143B-206) or lung carcinoma (A549)) and therefore do not accurately 
represent the in vivo conditions of most tissues in patients. Another reason to be cautious is 
that these studies have utilised different transmitochondrial cell lines which have different 
nuclear genetic backgrounds. It became evident that the confounding effects of difference in 
the nuclear backgrounds influenced the segregation of mutant and wild-type mtDNA present 
in these cells and therefore influenced the genotype-phenotype relationship being 




heteroplasmy level of 90% was required to cause a 30% decrease in COX-activity. Whilst, for 
the A549 cell line, a lower threshold of 55% resulted in a 50% reduction in COX-activity 
measured using biochemical enzymatic assay.  
Studies using patient fibroblast cells;  
Alternatively, a number of studies have utilised fibroblasts from patients to study the effect of 
high levels of the m.3243A>G variant. A study by Miyabayashi et al. (1992), cloned cells 
from fibroblasts of a MELAS patient and found that the activity of Complex I, as measured 
by NADH-cytochrome c reductase (NCR), decreased when heteroplasmy levels of the 
mutation increased to more than 60%. In contrast to this, Yokota et al. (2015), also used 
single cell derived clonal fibroblasts from two MELAS patients and found that the threshold 
for deficiency was at 90%, consistent with the findings observed in 143B-206 
transmitochondrial cell lines.  
Studies using single muscle fibres;  
A multitude of studies have used the single cell approach through isolating skeletal muscle 
fibres from affected patients. By using COX/SDH staining to identify the biochemical defect, 
these studies isolated RRFs, COX-positive and COX-deficient fibres, and the m.3243A>G 
heteroplasmy levels were determined in each. Some examples of these studies include the 
study by Tokunaga et al. (1994) who used single muscle fibres from three MELAS patients to 
show that the heteroplasmy levels were significantly higher in RRFs (88.1 ± 5.5%) than non-
RRFs (63.32% ± 21.6%). Petruzzella et al. (1994) isolated fibres from PEO and MELAS 
patients and showed that normal fibres had heteroplasmy levels of  56 ± 21%, COX-positive 
RRF fibres had high levels (90 ± 6%) and an almost complete segregation of the mutation in 
COX-deficient RRF (95 ± 3%). Similarly, Ozawa et al. (1998) investigated single fibres from 
five patients harbouring the mutation and RRFs had higher levels of heteroplasmy (average of 
89.8%) compared to non-RRF (average of 42.4%). Further to this, Kärppä et al. (2005) 
analysed fibres taken from 10 patients (a total of 251 biochemically normal fibres, 8 COX-
deficient fibres, 19 COX-positive RRF fibres and 13 COX-deficient RRF) and also showed 
that COX-deficient fibres had a mean heteroplasmy level of 90% (ranging between 81 to 
97%) and normal fibres had a mean of 50% (ranging from 3 to 92%). In line with the findings 
shown through the A549 cell line (Dunbar et al. 1995), Jeppesen et al. (2006) suggested 50% 
as the threshold for m.3243A>G in skeletal muscle whereby 25 out of 51 individuals who had 
heteroplasmy level above 50% showed abnormal histological findings on skeletal muscle 




These findings highlight the lack of consensus from these studies. Moreover, these studies 
have used single muscle fibres that have been isolated based on observations derived from the 
study of COX-deficient fibres. It is well known that in fact, Complex I is predominantly 
affected in these patients, further highlighted in the findings from Chapter 4 for this current 
cohort of patients. Therefore, a more precise approach to deduce the threshold level in these 
patients would be to investigate the heteroplasmy levels within Complex I positive and 
deficient fibres – the threshold for Complex I deficiency may differ to that for Complex IV. 
This has been alluded to by Dunbar et al. (1996) who showed that a decrease in oxygen 
consumption with pyruvate (Complex I substrate) occurred in transmitochondrial cells 
(A549) harbouring between 60-90% m.3243A>G heteroplasmy level, whilst only cells with 
over 95% heteroplasmy levels also showed Complex III and Complex IV deficiencies.  
5.2. Aims  
The first aim of this study was to characterise the distribution and relationship of m.3243A>G 
heteroplasmy level in both biochemically normal fibres and those deficient (in Complex I and 
Complex IV) from both Group A and Group B patient skeletal muscle sections.   
Following this, a second aim was to estimate a critical heteroplasmy threshold for Complex I 
deficiency in individual patients and to ascertain whether there is a difference in threshold 















5.3.1. Selecting patients for the single cell study  
Ten of the 13 skeletal muscle sections of Group A patients (P01, P04, P05, P06, P07, P11, 
P13, P15, P18 and P19) were selected based on the size of the biopsy that would allow for 
sufficient number of fibres to be isolated for the single cell study. The remaining three Group 
A patients were not used due to either insufficient number of fibres (for example P09; n= 104 
fibres) or folding of skeletal muscle sections which would interfere with matching fibres (see 
section 5.3.5). Three of the six skeletal muscle sections of Group B patients were selected at 
random.  
5.3.2. Single muscle fibre workflow 
The workflow for this single cell study is shown in Figure 5.1. The individual methods 
undertaken are also listed below.  
5.3.3. Tissue sectioning for fibre typing  
Serial transverse skeletal muscle cryosections were collected as shown in Figure 5.1; a 10µm 
section, which was used for the quadruple immunofluorescence assay (Chapter 4 and 
denoted by A in Figure 5.1) and a 20µm section which was used for fibre typing 
immunofluorescence (denoted by B). Sections were dried at RT for approximately 1 hour and 
then stored at -80°C until use.  
5.3.4. Fibre Typing 
Fibre types in the skeletal muscle sections were determined following an immunofluorescence 
protocol outlined in section 2.5.8.2 of Chapter 2. Following this, the skeletal muscle sections 
were imaged (see section 2.5.9, Chapter 2) and then stored at 20°C until laser 
microdissection. 
5.3.5. Matching fibres to OXHOS defect and fibre type:  
Muscle fibres in the 20µm fibre type section were manually matched to the 10µm OXPHOS 
section, so that each muscle fibre now had information on their OXPHOS status and their 







Figure 5.1: A schematic diagram of the single cell study experimental workflow. 
A) the quadruple immunofluorescence assay was undertaken on two 10µm sections (NPC and 
OXPHOS) followed by B) the fibre type immunofluorescence on a 20µm serial section C) fibres (a 
single fibre represented by the blue square) from this muscle section were isolated using laser 
microdissection, into 15µl cell lysis buffer. Fibres underwent single cell lysis reaction followed by D) 
PCR to amplify the DNA and E) molecular genetics investigation through quantitative pyrosequencing 





5.3.6. Section preparation for single muscle fibre isolation  
The 20µm sections stained for fibre typing were left to soak in PBS at 4°C overnight which 
allowed for coverslips to be easily removed. The slides were dehydrated in an ethanol 
gradient – 70% for 10 minutes, 95% for 10 minutes, 100% for 10 minutes and a further 10 
minutes in 100% ethanol. Sections were stored in -20°C for later use for laser 
microdissection. 
5.3.7. Isolation of single muscle fibres 
Single cell laser microdissection on the selected fibres was undertaken as described in detail 
in section 2.5.12 of Chapter 2 and depicted in Figure 5.1 (labelled C.). The single cell 
lysates were stored at -20°C until quantitative pyrosequencing was undertaken.   
5.3.8. Assessing the m.3243A>G heteroplasmy levels in single muscle fibres with 
quantitative pyrosequencing  
PCR was used to amplify a fragment of 210bp length of mtDNA, spanning the targeted 
mutation site (described in section 2.5.13 of Chapter 2) as depicted in Figure 5.1 (labelled 
D). Thereafter, the m.3243A>G heteroplasmy level of each single muscle fibre was assessed 
by quantitative pyrosequencing, performed using the Pyromark Q24 platform, Qiagen (Figure 
5.1, labelled E). This, alongside the interpretation of the sequencing using the Pyromark Q24 
software, is described in detail in section 2.5.13.7 of Chapter 2. Three mutation-positive 
controls with known levels of m.3243A>G heteroplasmy (18%, 48% and 72%) and one blank 
(no template) control were included within each experimental run. According to validated 
criteria set by the accredited NHS Highly Specialised Diagnostic Laboratory at the Wellcome 
Centre for Mitochondrial Research, Newcastle University, a ± 3% of the expected 







Figure 5.2: Matching OXHPOS status and fibre type. 
A) Quadruple immunofluorescence assay and B) Fibre type fluorescence staining showing 3 fibres as 
examples. Fibre 1 = OXPHOS status (panel A); normal for Complex I (NDUFB8, purple), normal for 
Complex IV (COX-1, green) and fibre type (panel B) = fibre type I (Mouse BA-F8-s (IgG2b) labelling 
myosin heavy chain (MHC) slow type I, green). Fibre 2 = OXPHOS status (panel A); deficient for 
Complex I, normal for Complex IV, and fibre type (panel B) = fibre type IIx (Mouse SC-71-s (IgG1 
labelling MHC type II, purple). Fibre 3 = OXPHOS status (panel A); deficient for Complex I, normal 
Complex IV and fibre type (panel B) = fibre type IIa (6H1-s (IgM) labelling MHC type IIx, red). The 




5.3.9. Selection of single muscle fibres for single cell study 
The method for selecting muscle fibres was based on the protocol outlined by Rocha et al. 
(2018). Briefly, muscle fibres were first categorised by their OXHOS status based on their 
level of deficiency in Complexes I and IV, as determined by their Z_scores. As shown in 
Chapter 4, the skeletal muscle sections of patients observed in this study predominantly 
showed four groups of fibres based on OXPHOS status, as depicted by the mitochondrial 
respiratory chain profiles in Figure 5.3, however some cases showed five groups of fibres. 
This study aimed to determine a threshold for biochemical deficiency, specifically for 
Complex I, which according to the quadruple immunofluorescence occurred between Group 1 
fibres (normal for both complexes) and Group 2 (these fibres are classified as intermediate 
positive and negative for Complex I) and therefore, more fibres were selected from these two 
groups. In addition, biochemically normal fibres were expected to have a wider distribution of 
heteroplasmy level based on previous findings using COX/SDH, therefore it was important to 
capture this to enable the threshold to be determined. Although these fibres were first 
categorised according to their OXPHOS status and their fibre type, fibres were selected at 
random for analysis from these resulting groups.  
 
Figure 5.3: The OXPHOS status groups seen in m.3243A>G patient mitochondrial respiratory 
chain profiles. 
Skeletal muscle section of patients predominantly showed four groups of fibres according to the 
mitochondrial respiratory chain profiles showing the Z_score categories of respiratory chain defects. 
This is shown by the coloured boxes and described in adjacent table; red = Group 1, green = Group 
2, blue = Group 3, purple = Group 4 and grey = Group 5. Fibres were coloured according to porin 




Table 5.1 summarises the target number of fibres to be selected for analysis per fibre type in 
each OXPHOS group. Each patient’s biopsy section presented differently in the number of 
fibres per group and the fibre type composition, thus where possible, the maximum number of 
fibres were taken from the outlined selection process (n=10). Due to low numbers present in 
the patient skeletal muscle sections, both Type IIa and Type IIx were grouped as Type II 
fibres. Where fibres were found to be fluorescently labelled for both Type IIa and Type IIx, 
they were accounted for as the third fibre type group (Type 11a/Type IIx). Examples of this 
occurrence include P06 and P13.   
Table 5.1: The number of fibres targeted for selection per OXHPOS status and fibre type 
 OXPHOS status 
Fibre Type Group 1 Group 2 Group 3 Group 4 Group 5 
I 20 20 10 10 10 
II (IIa +IIx) 20 20 10 10 10 
IIa/IIx 20 20 10 10 10 
Total:  210 fibres per patient   
 
Table 5.2: Overall number of fibres actually sampled per case per group of OXPHOS status in each 
patient and the final number included in the molecular genetics investigation 





Group A patients  
P01 37 39 20 10 - 106 106 
P04 40 37 40 10 2 129 116 
P05 40 51 11 2 - 104 120 
P06 65 37 13 13 - 128 128 
P07 40 35 25 2 - 102 89 
P11 26 17 21 21 3 88 77 
P13 65 23 5 11 - 104 89 
P16 80 23 13 11 5 132 106 
P18 40 35 19 20 17 131 115 
P19 20 15 18 12 - 65 55 
Group B patients 
P02 105 - - - - 105 105 
P10 107 - - - - 107 107 
P15 108 - - - - 108 108 
 
Following Table 5.2, Figure 5.4 shows examples of cases (P04 and P10) where the fibres 
actually sampled from the skeletal muscle sections are highlighted (remainder of the 11 
patients are shown in Appendix 4 (Figure 7.1, Chapter 7). As previously mentioned, fibres 
sampled from the three Group B patients (P02, P10 and P15) were all selected at complete 





Figure 5.4: Mitochondrial respiratory chain profiles highlighting sampled fibres. 
Examples of sampled fibres from a) from P04 (patient in Group A) and b) P10 (Group B patient). 
Coloured dots represent the fibres sampled and correspond to each OXHOS group; Group 1 = red, 




5.3.10.    Analysis   
Statistical analysis and graphs were produced in R version 3.5.2 (2018-12-20) using the 
following R packages; plyr (Wickham 2011), ggplot2 (Wickham 2016), matrixStats 
(Bengtsson 2017), ggforce (Pedersen, 2018), data.table (Dowle and Srinivasan 2017), 
fitdistrplus (Delignette-Muller and Dutang 2015) and gmp (Lucas et al. 2019).  
5.3.10.1. LOESS profiles 
The LOESS non-parametric model allows for an unbiased curve to be fitted to the data points, 
whereby it allows for the data to drive shape of the relationship (in this instance the 
relationship between heteroplasmy and biochemical deficiency as measured by z-score).  
The LOESS regression curve was fitted to the dataset of each patient using the LOESS 
function (loess) in R (R Core Team, 2018) as schematically depicted in Figure 5.5a. The 
estimates of the threshold were determined by the highest heteroplasmy level at which the 
curve intercepted the -3 Z_score deficiency cut off, as defined by Rocha et al. (2015). 
To capture uncertainty about the threshold estimate, the dataset was bootstrapped (a statistical 
test that relies on random sampling of data from each patient’s muscle section, with 
replacement) 10,000 times (Figure 5.5b). Essentially, this test allowed for 10,000 LOESS fits 
to occur and for 10,000 corresponding threshold estimates to be made. These bootstrapped 
estimates were also used to calculate the mean and 95% confidence intervals of the Z_score 
distribution across the full range of achievable heteroplasmy levels (0-100%). This final 
bootstrapped data (the mean) and the original dataset were plotted onto one LOESS profile for 
each patient. In addition, the heteroplasmy level at which the upper and lower 95% 
confidence intervals intercepted the y= -3 Z_score deficiency cut off were also plotted 





Figure 5.5: A schematic diagram of the LOESS regression and bootstrapping. 
A) LOESS model was fitted to the original data (green curve) and the estimate of threshold (black dot) 
was defined as the intercept between the curve and a Z-score of -3 – cut off for biochemical deficiency 
(dark blue dashed line at y=-3). B) bootstrapping of this data (example of 100 times); red dots = 
threshold estimates through bootstrapping, purple dots = examples of original data points and C) 
final LOESS profile with both original dataset (green curve) and the mean of final bootstrapped data 
(light blue). Grey dashed line = 95% confidence intervals of bootstrapped data, vertical red dashed 
line = heteroplasmy level at which the upper and lower 95% confidence intervals intercept -3 Z_score 




5.3.10.2. Hierarchical clustering  
To investigate an alternative method of fibre classification, unsupervised hierarchical 
clustering (Ward J 1963) of fibres into at most two populations, was carried out using the 
hclust function in R (R Core Team, 2018). This statistical method was coded by Dr Conor 
Lawless.  
This classification method used the optical density data (protein expression level of each 
target in each single fibre) generated from the quadruple immunofluorescence assay. Fibres in 
each individual patient were classified based on the log transformed data of porin (VDAC) 
and Complex I (NDUFB8) expression. By classifying fibres as either biochemically normal or 
deficient based solely on each patient’s Complex I – porin profile, it allowed the data to be 
clustered largely independent of the non-disease control data, in that the patient’s own fibres 
were used to identify two populations of fibres; biochemically normal and deficient. After 
segregating fibres into two populations by clustering, the population most similar to that of 
the control data was classified as “normal” while the remaining cluster was classified as 
“deficient”. 
Two-dimensional scatter (2D) plots, known as 2Dmito plots, were generated showing the 
biochemically normal fibres (blue) and the biochemically deficient fibres (red) after Complex 
I optical density values were log transformed and plotted against the log transformed porin 







Figure 5.6: Schematic illustration of two-dimensional scatter plot (2Dmito plot) after hierarchical 
clustering for fibre classification. 
Blue shows the cluster of biochemically normal fibres and red shows the biochemically deficient 
cluster. The solid grey line indicates a regression fitted to the non-disease control data, with a 95% 
confidence interval shown with dotted grey lines for comparison.  
 
5.3.10.3. Kernel density estimate plots 
Data from the sampled fibres (classified as biochemically normal fibres or deficient, 
according to the hierarchical clustering) from all patients were bootstrapped (n=10,000) and 
kernel density estimate models were fitted to each replicate, using the density function in R (R 
Core Team, 2018). The heteroplasmy level at which the mutation load distribution for the 
biochemically normal fibres intersected with the distribution for the deficient fibres was 
defined as the threshold, as depicted in Figure 5.7. Bootstrapping the estimates in this way 
allowed the uncertainly in the estimated thresholds to be measured. This aspect of the work 
was also coded by Dr Conor Lawless. 
 
 
Figure 5.7: Schematic illustration of kernel density estimate.  
The distributions of both the biochemically normal fibres (blue) and deficient fibres (red) were 
determined using kernel density estimates. The red vertical dashed line represents the heteroplasmy 





A total of 1,483 single fibres were isolated and analysed through quantitative pyrosequencing 
during this study, across the 13 patient muscle sections. These findings were used alongside 
the quantitative data from the quadruple immunofluorescence assay that was initially attained 
in Chapter 4.   
5.4.1. Optimisation of the single cell study  
5.4.1.1. Investigating the sampling method for single cell study  
The ideal method for sampling fibres for this study would have been complete random 
sampling from the skeletal muscle sections of patients from Group A, without knowing the 
OXPHOS groups. However, this project aimed to analyse and characterise the distribution in 
heteroplasmy levels in both the normal and deficient fibres from as many patient skeletal 
muscle sections, within a specific time frame. The aim thereafter was to deduce an estimated 
threshold and compare these between the different patients. Therefore, the selection strategy 
was based on that described by Rocha et al. (2018). This method allowed for sampling and 
characterisation of both normal and deficient fibres and it was ideal for the timeframe of the 
project.  
To emphasise this further, Table 5.3 highlights the number of fibres that would need to be 
sampled at complete random to achieve (at a probability of >0.5) the current number of 
deficient fibres already shown in Table 5.2 of section 5.3.9. For example, P13 had a total of 
1261 fibres analysed with the quadruple immunofluorescence assay, of which 75 fibres were 
below -3 Z_score and therefore deficient. A total of 89 fibres were selected for 
pyrosequencing of which 17 were the deficient fibres. In order to achieve this same number 
through complete random sampling, 279 fibres would need to be sampled. It is evident from 
the table that those patients (P11, P13, P18 and P19) who presented with much lower number 
of deficient fibres compared to normal in their skeletal muscle, would require sampling over 
250 fibres at random to achieve the current number of deficient fibres analysed. Therefore, 
given the aim of the study, to look at variability in threshold between individuals, the current 








Table 5.3: Random sampling compared to current sampling method 
 
5.4.1: Optimisation and validation of the pyrosequencing approach for the single cell study: 
Given the high number of single fibres per patient (ranging between 65 and 132 fibres in the 
13 patients), a cost and time effective approach was required for this study. Therefore, the 
reproducibility of pyrosequencing was investigated in 44 fibres (combining fibres from P01, 
P04, P11 and P19) to assess if one pyrosequencing assay per fibre was reliable. This was 
achieved with three different experiments; experiments 1 and 2 which assessed the variability 
of the pyrosequencing using the same PCR amplicons and experiment 3, which assessed the 
variability of the whole assay (new experimental set up). The variability between experiments 
1 and 2 were compared as well as 1 and 2 with experiment 3. Following set criteria, a ±3% 
range (equivalent to a range of 6%) was used to determine a heteroplasmy readout. The 
heteroplasmy level measurements per fibre (technical replicates) are shown in Figure 5.8 
and are further summarised in Appendix 5, Table 7.3 (Chapter 7). Overall, the total range 
observed across all of the experiments for individual fibres were within 6% of each other, 
apart from fibre 925 (total range of 9%). This is also reflected by the SD for each of the fibres 
which is within 3%. In addition, experiment 3 showed more variability in heteroplasmy levels 
compared to heteroplasmy levels determined in experiment 1 and 2, highlighting that as 
expected, variabilities are likely to occur from a new experimental set up (Chapter 7, 








Number of fibres sampled 
for pyrosequencing using 
sampling method from 







number of fibres 
required to get 
same number of 
deficient fibres  
P01 
 
871 597 106 47 68 
P04 
 
1179 710 114 66 109 
P06 
 
838 723 128 112 133 
P07 
 
546 247 89 52 131 
P11 
 
1464 295 77 53 261 
P13 
 
1261 75 89 17 279 
P18 
 
1258 387 115 76 331 
P19 
 





Figure 5.8: Heteroplasmy levels in fibres accessing inter and intra variability of pyrosequencing. 
The heteroplasmy levels of 44 fibres, taken from P01, P04, P11 and P19, were assessed from the same 
PCR amplicons (Experiment 1 (red) and 2 (green)) and from a new experimental set up (Experiment 3 
(blue)). All fibre triplicates, apart from fibre 925, fell within a range of 6%. SD was within 3%.  
 
Three controls of known heteroplasmy levels were also included in every pyrosequencing 
experiment undertaken for this study (n=89); 18% (control 1), 48% (control 2) and 72% 
(control 3). The spread of the heteroplasmy levels determined for each of these controls in all 
experiments is shown in Figure 5.9. The mean of the overall data for each control is within 
±3% of the expected heteroplasmy levels. The SD for all controls are between 1% and 1.4%. 
Control 1 shows the biggest range in the data (14% to 23%), however, as seen in Figure 5.9 
this wide range is due to only a few experimental runs (n=6). In these instances, the read outs 
for the other two controls were also checked and results were accepted on the basis the 
heteroplasmy levels of these controls were as expected, as well as the negative control 
showing no sequence read out. Therefore, from these findings it can be concluded that one 





Figure 5.9: Distribution of heteroplasmy levels in the three controls in all pyrosequencing 
experiments. 
The controls all show a tight distribution in the range. The summary data is as follows; total range in 
Control 1 = 14-23%, Control 2 = 44-48% and Control 3 = 72-77%. The mean of the controls are 
18.0%, 46.9% and 73.7% and SDs; 1.4%, 1.0% and 1.2% respectively.  
 
5.4.2. Heteroplasmy level and respiratory chain deficiency   
Heteroplasmy level of the m.3243A>G variant was determined by pyrosequencing in all 
sampled fibres from the 13 patient skeletal muscle sections. The range of the m.3243A>G 
heteroplasmy levels detected in individual fibres per OXPHOS group for each patient is 
highlighted in Table 5.4. This distribution of the data is shown in the boxplots in Figure 5.10.  
5.4.2.1.  m.3243A>G heteroplasmy levels increase in deficient fibres  
In all patients from Group A, apart from P05 and P19, Group 1 fibres (biochemically normal) 
show a broad distribution in the heteroplasmy levels determined, collectively ranging from 
3% to 98%. In comparison, the distributions of heteroplasmy levels in fibres sampled from 
Groups 2 to 4 and 5, were higher and had a narrower range. Therefore, fibres with respiratory 
chain deficiency tend to have higher heteroplasmy levels. Although Table 5.4 highlights that 
a number of fibres in Groups 2, 3 and 4 (and 5) have low heteroplasmy levels, Figure 5.10 
shows that this is only representative of a very small number of fibres, whilst the majority of 




The Group 1 fibres sampled from Group B patient skeletal muscle sections showed an overall 
range in heteroplasmy level between 14% and 97% (Table 5.4). However, the vast majority 
of the fibres analysed were clustered within a narrow range of heteroplasmy levels (Figure 
5.11) – contrasting with the larger range observed in the normal fibres from patients in Group 
A. This narrow range is also seen in the fibres sampled from P05, which despite showing 
deficiency and an increase in heteroplasmy level per OXPHOS group, had a range of 58-88% 
heteroplasmy levels in normal fibres.   
The fibres sampled from P19 showed a different distribution in the heteroplasmy levels. The 
heteroplasmy levels in Group 1 fibres ranged from 3% to 84%, however of the 20 fibres 
analysed in this group, 16 fibres were shown to have heteroplasmy levels ranging from 3% to 
22%. Therefore, in comparison to the other patients, P19 Group 1 fibres presented with lower 
levels of heteroplasmy. An increase of heteroplasmy level was observed in fibres within 
Groups 2, 3 and 4, however as shown in Figure 5.10, there are a number of fibres with much 
lower heteroplasmy levels within these groups. The boxplot highlights that there are 
seemingly two groups of fibres, fibres with very high levels of heteroplasmy and fibres with 
very low levels of heteroplasmy, irrespective of the biochemical deficiency. These findings 
could be alluding to this patient harbouring another mtDNA mutation (point mutation or 
possibly a mtDNA deletion) which could be influencing the heteroplasmy levels determined 
in the single fibres from the patients skeletal muscle section, particularly the normal fibres 









Figure 5.10: Distribution of single fibre heteroplasmy levels in each OXPHOS group observed in 
patients in Group A. 
Fibres from all Patients in Group A, apart from P05 and P19, show a broad distribution in 
heteroplasmy level in fibres in Group 1. Heteroplasmy level increases and narrows in range from 
Group 2 to 5. P05 shows a narrow range in heteroplasmy level in all groups. P19 shows fibres with 
both low and high levels of heteroplasmy in all groups. Each individual dot represents a single muscle 
fibre. OXPHOS groups = Group 1= normal Complex I and Complex IV; Group 2 = Intermediate 
positive and negative for Complex I, normal Complex IV; Group 3; Negative for Complex I and 
normal Complex IV; Group 4; Negative for Complex I, intermediate positive and negative for 




Figure 5.11: Distribution of single fibre heteroplasmy levels from Group B patient muscle sections. 
Heteroplasmy levels in Group 1 fibres sampled from patients in Group B are within a narrow range 
for each patient (P02, P10; P15) in comparison to the broad distribution observed in Group I fibres 
sampled from patients in Group A. Each individual dot represents a single muscle fibre. Heteroplasmy 




Table 5.4: The range of heteroplasmy level determined in single fibres per OXPHOS group from all patient skeletal muscle sections 
  
Heteroplasmy levels per OXPHOS status group (%) 
 














Lowest Highest Lowest Highest Lowest Highest Lowest Highest Lowest Highest 
































4 93 79 95 26 98 88 98 - - 88 75 78 
P05 
 
59 88 16 90 74 98 98  - - 82 81 78 
P06 
 
6 97 15 96 87 97 95 97 - - 89 81 77 
P07 
 
19 81 83 96 15 97 91 97 - - 88 76 74 
P11 
 
4 90 17 99 11 99 63 99 - - 93 76 64 
P13 
 
13 88 9 96 90 97 79 97 - - 69 67 62 
P16 
 
3 97 84 98 83 98 16 99 96 98 61 55 50 
P18 
 
5 98 9 96 79 97 89 98 71 98 91 73 39 
P19 
 
3 84 4 97 4 96 4 97 - - 66 49 34 

































33 77 - - - - - - - - 63 61 66 
P15 
 




5.4.2.2. The relationship between single cell m.3243A>G heteroplasmy levels and 
homogenate heteroplasmy levels   
The homogenate heteroplasmy levels previously measured for each patient is presented in 
Table 5.4. In 11 of the 13 patients, the mean and median heteroplasmy levels of the sampled 
muscle fibres were similar to their homogenate levels – which would be expected and 
indicative of the fact that the sampling strategy is representative of the whole section. 
However, the single cell work allows an insight into the distribution of heteroplasmy level in 
individual fibres, particularly for Group 1 fibres. Only P18 and P19 single muscle fibres had 
higher mean and median when compared to the homogenate heteroplasmy levels of 39% and 
35% respectively.  
5.4.2.3. Investigating the difference in porin levels between the two patient groups  
The quadruple immunofluorescence assay used porin as a marker for mitochondrial mass 
which can be indicative of mitochondrial biogenesis. The difference between the log(Porin) 
levels in patients from Group A and Group B was investigated using a linear mixed effects 
model to establish if this could be influencing the biochemical differences between fibres in 
the muscle sections from the two groups of patients (Figure 5.12). Fibres from patients in 
Group B (P02, P05, P10 and P15) were shown to have lower levels of log(Porin) compared to 
fibres from patients in Group A, however this was a small difference and not significant 
(coefficient = -0.035, SE = 0.031, P= 0.3000). Therefore, these data show that porin levels are 
not causing the difference in the biochemical status between the muscle fibres from these two 








Figure 5.12: Boxplot showing log(Porin) levels in muscle fibres from each patient muscle section. 
Variable levels of log(Porin) are seen between muscle fibres from patient sections but fibres sampled 
from patients in Group B (blue) were shown to have lower levels of porin in comparison to fibres 
sampled from patients in Group A (red), although this difference was not significant (SE = 0.031, P= 
0.3000). Individual dots = single muscle fibres that are outliers.    
 
5.4.2.4. Muscle fibre types and m.3243A>G heteroplasmy levels  
The sampling of fibres for single cell analysis was representative of the different muscle fibre 
types found in skeletal muscle sections. Of the 13 patient muscle sections, 11 sections had 
fibre type data matched with the OXPHOS status (see section 5.3.5). The difference in 
m.3243A>G heteroplasmy level was investigated between these two fibre types (Type I and 
Type II (consisted of Type IIa and IIx) fibres) using a linear mixed-effects model. There was a 
significant difference in heteroplasmy levels between the two types; Type II fibres had higher 
heteroplasmy levels than Type I, by 6% (SE = 1.600, P = 0.0002).  
However, of the 11 patients that had fibre type data collected from their skeletal muscle 
section, only three had significantly higher median heteroplasmy levels in Type II fibres than 
Type I; P11, P13 and P16 (P=0.053, P= 0.001 and P= 0.005 respectively), following a 
Wilcoxon rank sum test. This is shown in Figure 5.13 and also summarised in Table 5.5. 
Moreover, it can be seen that in some patients’ skeletal muscle section (P06, P07, P15 and 




significantly. This highlights the variability in these findings and indicates that the significant 
difference overall (as detailed above) is likely to be due to the influence of data from a small 
number of patient sections.    
 
 
Figure 5.13: Boxplot of m.3243A>G heteroplasmy level in Type I and Type II muscle fibres. 
A comparison of heteroplasmy levels in Type I (red) and Type II (blue) fibres per patient muscle 
section. The overlaid boxplot shows the median heteroplasmy level (black horizontal line in box) is 
higher in Type II fibres in  muscle sections of patients P01, P04, P05, P11, P13, P16 and P19 but only 
significantly different in P11 (P= 0.053), P13 (P= 0.001) and P16 (P= 0.005), as determined by a 
Wilcoxon test. Median heteroplasmy level is higher in Type I fibres than Type II fibres in patients P06, 











Table 5.5: Median, W and P-value showing differences in m.3243A>G heteroplasmy levels between 














I 6.00 59.25 90.50 75.06 93.00 97.00 
1155 0.132 
II 28.00 83.00 91.50 84.52 94.00 98.00 
P04 
I 11.00 65.50 87.50 77.07 93.75 98.00 
1689.5 0.700 
II 4.00 66.75 90.00 72.45 92.00 98.00 
P05 
I 16.00 77.00 80.00 78.56 84.00 97.00 
1466 0.059 
II 72.00 80.00 82.00 82.13 84.00 97.00 
P06 
I 6.00 79.00 90.00 79.73 93.00 97.00 
2194.5 0.697 
II 15.00 84.00 89.00 82.63 92.00 97.00 
P07 
I 4.00 58.50 90.00 73.43 93.00 97.00 
1018.5 0.684 
II 15.00 79.25 87.50 79.87 91.75 95.00 
P11 
I 4.00 36.75 70.00 64.18 96.25 99.00 
503.5 0.053 
II 6.00 80.00 94.00 82.00 97.00 99.00 
P13 
I 9.00 41.50 49.00 54.15 68.00 97.00 
477.5 0.001 
II 31.00 58.50 78.50 72.92 88.00 97.00 
P15 
I 22.00 50.50 56.00 56.47 63.50 97.00 
1384 0.098 
II 14.00 48.00 53.00 52.00 58.00 68.00 
P16 
I 3.00 9.00 22.50 44.15 91.00 99.00 
952 0.005 
II 7.00 19.00 88.00 65.07 96.00 98.00 
P18 
I 5.00 80.00 92.00 76.49 95.00 98.00 
353.5 0.350 
II 5.00 45.25 89.50 70.48 94.25 98.00 
P19 
I 2.00 4.00 5.00 34.87 78.50 98.00 
1939.5 0.202 
















5.4.3. Estimating the biochemical threshold for Complex I in the skeletal muscle of 
m.3243A>G patients 
In order to determine a biochemical threshold for Complex I deficiency (the predominant 
biochemical deficiency observed) in these patient muscle sections, various statistical methods 
were considered. Although the statistical details are not within the scope of this thesis, they 
are important to discuss in order to understand the final estimation of the threshold per 
patient.  
5.4.3.1. LOESS profiles using single fibre Z-scores and heteroplasmy level data 
Firstly, the NDUFB8_z values from each sampled single fibre were plotted against their 
associated heteroplasmy level. The LOESS non-parametric model (described previously in 
section 5.3.10.1) was fitted to the data (red curve in Figure 5.12). The mean and 95% 
confidence intervals of the bootstrapped model are also plotted (black curve in Figure 5.12). 
From this, estimates of the heteroplasmic threshold (where the mean bootstrapped curve 
intercepted the -3 Z_score deficiency cut off) were determined alongside both the lower and 
upper 95% confidence intervals (dark blue vertical lines). The heteroplasmy levels at which 
both the lower and upper 95% confidence intervals intercepted the y= -3 cut off was also 
plotted and determined. These are summarised in Table 5.6.  
The LOESS profiles of P01, P05, P07 and P19 are exemplified in Figure 5.14. As it can be 
seen in all four profiles, both the red and black curves are either identical or very similar in 
their fit along the x-axis. The LOESS profile for P07 (Figure 5.12a) shows an estimation in 
the heteroplasmic threshold for biochemical deficiency at of 87.2%, which is supported by a 
narrow upper and lower 95% confidence intervals (86.0% and 88.4% respectively) due to the 
good spread in the data attained from this patient’s skeletal muscle section.  
However, this was not the case for the sections from P01, P05 or P19 (Figure 5.14) or the 
remaining six patients in Group A (see Appendix 6 in Chapter 7, Figure 7.2). The curves 
(red and black) in P01 LOESS profile intercepted the -3 Z_score cut off twice, leading to 
inaccuracy in the estimation of threshold (mean at 88.8%) (Figure 5.12b). The 95% 
confidence intervals are also wide due to the uneven spread of data and the lower and upper 
intervals intercept -3 cut off at heteroplasmy levels of 18.9% and 91.1% respectively. P05 
LOESS profile shows the dominant effect of one data point on the LOESS model and 
calculation of only the heteroplasmy level at which the upper confidence interval intercepts 
the -3 Z_score (82.9%) whilst the lower confidence interval did not intercept the cut off and 
so no heteroplasmy level for this was determined. Interestingly, the profile for P05 further 




uneven spread of data between low and high heteroplasmy levels in both deficient and normal 
fibres, the curve intercepted the -3 Z_score cut off at a lower heteroplasmy level (19.7%) and 
similarly to P05, only the upper confidence interval intercepted the -3 cut-off (77.7), whilst 
the lower confidence interval was below the -3 cut-off and therefore no heteroplasmy level 
value determined.  
The threshold estimates deduced using this statistical method for patients in Group A are 
presented in Table 5.6. The 95% confidence intervals of the threshold estimates were wide 
for most of the patients; P01, P04, P05, P06, P11, P18 and P19, highlighting the high 
uncertainty of the threshold estimates for these patients 
 
Table 5.6: Threshold estimates and upper and lower confidence intervals for selected patients using 
LOESS model fitted to the bootstrapped data 




P01 88.8 18.9 91.1 
P04 74.5 47.2 82.3 
P05 78.2 0.00 82.9 
P06 83.9 36.5 91.8 
P07 87.2 86.0 88.4 
P11 68.3 45.1 85.8 
P13 80.1 75.0 83.4 
P16 84.7 76.6 89 
P18 75.3 35.8 85.3 
P19 19.7 0.00 77.7 
  
Overall, the LOESS profiles for these patients highlight the heterogeneity of the data and the 
disadvantages of this statistical method in determining the critical heteroplasmic threshold for 
Complex I deficiency. The most important disadvantage is the reliance on the use of Z_scores 
and the arbitrary -3 Z_score cut-off that defines the biochemical deficiency, which are all 










Figure 5.14: LOESS profiles showing the Z_score and heteroplasmy level distribution of single 
fibres and the estimated heteroplasmic threshold for deficiency. 
Profiles are representative of fibres from skeletal muscle sections of patients in Group A and 
estimated threshold defined at point at which models curves cross the deficiency cut off at Z_score of -
3 (y=-3). A) P07 shows a good spread of data across the heteroplasmy levels and narrow confidence 
intervals around the estimated threshold where curves intercept the y=3. B) P01 curve crosses y=-3 
twice and wide confidence intervals and heteroplasmy levels at which these intercept the y= -3, C) 
P05 profile shows the influence of one data point (representing one fibre) on the shape of the curve 
and no intercept of the lower confidence interval at y=-3 and D) P19 shows wide confidence intervals 
around spread of the data and no intercept of lower confidence interval at y= -3. Each white dot 
represents a single fibre. The blue dashed line (y=-3) is the Z_score deficiency cut off. The black curve 
represents the model fitted to the mean of the bootstrapped data and the red curve represents the 
model fitted to the original data. The dotted black line around the curves = 95% confidence intervals 
of bootstrapped estimate. Solid dark blue lines represent the heteroplasmy levels at which the 










5.4.3.2. Control-free classifications using hierarchical clustering: 
The analysis of the data with the LOESS model made it apparent that using the Z_scores, 
particularly the -3 Z_score cut off to determine the heteroplasmic threshold level for 
biochemical deficiency, was not a stringent way to investigate the heterogeneous dataset to 
achieve the aim of this project. Taking this into account and the fact that Z_score 
classification of fibres is based on the non-disease control group (not representative of the 
diseased group), a control-free classification of fibres was investigated. Thus, there was no 
reliance on Z_score measures for biochemical deficiency (only requiring the available protein 
expression (immunoreactivity) data) and therefore no direct reliance on the non-disease 
control groups. As described and depicted in Figure 5.6 in section 5.3.10.2, unsupervised 
hierarchical clustering was applied to the optical density values (the raw expression values) 
attained from the assay, to provide a control-free classification of the fibres, based on the 
patient’s own population of fibres. The classification of fibres was solely based on the 
Complex I/porin expression profile. The data could be split into two branches/clusters (V-
shaped data) representing two different populations of fibres; biochemically normal (branch 
1) and biochemically deficient fibres (branch 2) based on Complex I. Fibres were classified as 
deficient only when the frequency of this population was >5% of the total number of fibres 
analysed.  
The 2Dmito plots of log Complex I expression level against log porin for P04 (Group A 
patient) and P10 (Group B patient) is shown in Figure 5.15, as examples. The colouring of 
the fibres in panel B and D of Figure 5.15 (Complex IV panels) is based on Complex I 
clustering - the red fibres within the Complex IV plot are those fibres that are deficient for 
Complex I. The plot of P04 shows a definitive splitting (branching – V-shaped) of the fibre 
populations into two different clusters – blue cluster representing the biochemically normal 
fibres and red cluster representing the biochemically deficient fibres. The red cluster of fibres 
show a decrease in Complex I expression in relation to the porin level (Figure 5.15a). This 
definitive split in the Complex I data is also seen in the following Group A patients; P01, P07, 
P11, P13, P16, P18 and P19 (plots shown in Appendix 7 (Figure 7.3). As expected, the 
Complex IV data in these patients showed no splitting in the data, but rather all being within 
one cluster, representing fibres with normal CIV expression. To provide the confirmation that 
the biochemically normal fibres were similar to what is seen in the non-disease controls, the 
regression line which was fitted to the control data and the 95% confidence intervals (shown 




As represented by the 2Dmito plot of P10 in Figure 5.15c, fibres from Group B patients (P02, 
P10 and P15), also showed no splitting in their data (only one cluster present from the 
clustering method) and therefore only showed fibres that are biochemically normal. This was 
expected, as previously demonstrated with the Z_score analysis of the data. The majority of 
these fibres fall within the 95% confidence intervals of the non-disease control data, showing 
that although this classification is independent from these controls, both are still comparable. 
The 2Dmito plots for the following patient sections are shown in Appendix 7 (Appendix 
Figure 7.3, Chapter 7); P01, P07, P11, P13, P16, P18 (Group A) and P02 and P15 from 
Group B.  
 
 
Figure 5.15: Two-dimensional scatterplots (2Dmito plots) comparing Complex I protein expression 
with mitochondrial mass. 
(A – B) P04 and (C-D) P10. A) Complex I (CI) data in P04 shows clustering of fibres into two 
branches after hierarchical clustering; blue = biochemically normal fibres and red = biochemically 




porin). B) Complex IV data in P04 shows only one cluster, therefore, no deficient fibres for Complex 
IV (CIV). Red fibres are indicative of Complex I deficient fibres in that cluster. C) P10 data also 
shows only one cluster in the data for either Complex I or D) Complex IV therefore all fibres are 
biochemically normal (blue). Sampled fibres have been colour co-ordinated according to the original 
Z_score classification; red = Group 1 fibres, green = Group 2 fibres, blue = Group 3 fibres, purple = 
Group 4 fibres. Grey solid and dashed line showing the regression line fitted to the control data and 
the 95% confidence intervals, for comparison.  
 
Although the clustering was achievable for the majority of patients, as listed above, it was less 
convincing for P06. This is shown through the 2Dmito plot of P06 where the data appeared to 
have split into two populations of fibres (V-shape) as shown through the blue and red 
coloured fibres. However, deficient fibres are shown to have levels of Complex I that are 
comparable to the levels that would be expected of the non-disease controls (indicated by the 
95% confidence interval) (Figure 5.14, panel C). Therefore, this shows that the clustering has 
not successfully identified between the biochemically normal fibres and the deficient.  
Intriguingly, P05 was shown to have a Complex I- deficient mitochondrial respiratory chain 
profile from the Z_score analysis (58.71% Complex I- deficient fibres) (panel E of Figure 
5.16). However, hierarchical clustering classified all of the fibres as normal for Complex I on 
the 2Dmito plot (panel A and B in Figure 5.16) as the shape of the data does not show two 
clear populations, but rather a shift down in relation to the control regression. This highlights 
how the difference in the classification methods can cause discrepancy in the proportion of 
fibres classified as normal or deficient. This comparison between the two classification 
methods is shown in Table 5.7. In all cases, aside from P05 and P06, the proportion of total 












Figure 5.16: 2Dmito plots and mitochondrial respiratory chain profiles representing the data for 
P05 and P06. 
A) In comparison to the mitochondrial profile for P05 (shown in E), hierarchical clustering classified 
all fibres as biochemically normal for Complex I and B) Complex IV. Only one cluster was identified 
in the data but there is a shift downwards from the control regression (in grey). C) P06 data shows 
two clusters (V-shape) however clustering has failed to identify the biochemically normal fibres which 
are in line with the control regression. Fibres have been classified as deficient for Complex I. F) 
Complex IV data shows a shift down from the control regression. Blue fibres in A, B, C and D = 
biochemically normal fibres, red fibres = deficient fibres. Coloured dots are representative of Z_score 
classification of fibres into OXPHOS groups = red = Group 1 fibres, green = Group 2 fibres, blue = 
Group 3 fibres, purple = Group 4 fibres. Regression line fitted to the control data and the 95% 




Both methods of fibre classification showed similarities and differences in regard to the level 
of Complex I deficiency determined. The small differences in the results between the two 
methods can be explained by the fact that hierarchical clustering only determines either 
biochemically normal or deficient fibres. Therefore, the fibres that were initially classified as 
intermediate positive or negative through the Z_score analysis, were now classified as normal 
or deficient. This is exemplified by the previous 2Dmito plots (Figure 5.13) where the 
sampled fibres were coloured according to their stated OXPHOS groups, (as defined by the 
Z_score) and highlighting P04 as an example, it can be seen that the intermediate positive 
fibres (highlighted green) were classified as normal or deficient . Despite this, both methods 
of fibre classification were comparable for 11 of the 13 patients, showing that hierarchical 
clustering detected expected levels of Complex I deficiency in these patients, but most 
importantly, without reliance on the non-disease control data (Table 5.7).  
Furthermore, whilst the sampled fibres were selected based on Z_score classifications into the 
different OXPHOS groups, the 2Dmito plots show that these sampled fibres (as coloured by 
their representative OXPHOS group) provide a good spread of sampling when placed into the 
context of the hierarchical clustering method.  
 
Table 5.7: Differences in the proportion of fibres (%) classified as Complex I and Complex IV 
deficient through Z_scores classification and Complex I deficient with hierarchical clustering 
 Proportion of deficient fibres (%) 
Patient 
Hierarchical clustering based on  
Complex I/Porin expression levels 
Z_score  -  
Complex I 
Z_score –  
Complex IV 
Group A patients  
P01 69.3 79.45 2.07 
P04 61.2 63.61 3.73 
P05 0 58.71 0.70 
P06 90.4 69.45 29.95 
P07 36.2 39.19 1.28 
P11 21.9 21.93 6.97 
P13 6.9 8.41 4.28 
P16 15.5 16.38 3.67 
P18 22.3 19.87 11.69 
P19 10.5 11.50 2.42 
Group B Patients 
P02 0 2.20 0.48 
P10 0 0.00 0.00 





5.4.3.3. The heteroplasmy levels in the biochemically normal and deficient fibres  
As shown previously through the Z_score analysis, the sampled biochemically normal fibres 
(as now classified by the hierarchical clustering) of the following patients in Group A; P01, 
P04, P07, P11, P13, P16 and P18, have a broad distribution in the heteroplasmy levels whilst 
the sampled deficient fibres have high heteroplasmy levels within a narrower distribution 
(Figure 5.17). Although, P01 and P11 both have a number of fibres that are deficient but 
showing lower levels of heteroplasmy.  
However, both P06 and P19 do not follow this pattern. Instead, the deficient fibres show a 
wider spread in the heteroplasmy levels compared to the normal fibres. This further confirms 
that the hierarchical clustering method was not successful in identifying the difference 
between the biochemically normal or deficient fibres for P06 data. Conversely, the data for 
P19 were as expected, and as previously highlighted by the Z_score analysis, – the uneven 
spread of the data showed normal fibres with low levels of heteroplasmy whilst the deficient 
fibres showed both low and high levels of heteroplasmy.   
Additionally, as already stated, fibres sampled from P05 skeletal muscle section showed the 
same pattern as the fibres sampled from patients P02, P10 and P15 (Figure 5.15), whereby 
normal fibres harboured heteroplasmy levels within a narrower range compared to the patients 
in Group A. In this instance, P05 was classed as Group B based on hierarchical clustering 






















Figure 5.17: Boxplot distribution of heteroplasmy levels in biochemically normal and deficient 
fibres from patients in Group A and B. 
A) In all patients in Group A, apart from P06 and P19, the biochemically normal fibres show a broad 
distribution in heteroplasmy levels whilst deficient fibres show a narrow distribution of high 
heteroplasmy levels. P06 and P19 show the contrasting distribution; normal fibres show narrow range 
and deficient fibres show a broad distribution in heteroplasmy level. B) Single fibres sampled from all 
patients in Group B show a narrow distribution in heteroplasmy levels. Each single dot is 
representative of a single fibre. Blue dashed line = homogenate heteroplasmy level of each patient. 
Red dashed line = point at which two kernel densities intersect to determine the threshold estimate. 
Dots (fibres) have been coloured according to Z_score classification of fibres into OXPHOS groups; 
red = Group 1 fibres, green = Group 2 fibres, blue = Group 3 fibres, purple = Group 4 fibres.  







5.4.3.4. Kernel density estimate for threshold levels 
Kernel density distributions were fitted to the heteroplasmy data from both the normal and 
deficient groups of sampled fibres. The heteroplasmic threshold estimate for each patient was 
then defined as the point at which these two distributions intersected, as indicated by the red 
dashed line in Figure 5.17. These data were bootstrapped (n=10,000) to produce a range of 
threshold estimates for each patient. The heteroplasmic threshold estimate and the distribution 
in the uncertainty of this estimate as determined by bootstrapping is shown for each patient in 
Figure 5.18. This uncertainty is shown by the overlay of the boxplots as well as the R 
summary data from the kernel density estimate, shown in Table 5.8.  
The median threshold estimates (as shown by the middle black line within the overlaid 
boxplots) is seen to differ between patients (Figure 5.18), with P01 showing the highest 
estimate in comparison to the other eight patients in Group A. Moreover, Figure 5.18 also 
highlights the multimodal distribution that is present in the data for two patients, P06 and P19; 
the distribution of the data is either bimodal (P06) or trimodal (P19) in comparison to the 
other seven patients in Group A. As previously stated, the distribution for P06 highlights that 
the clustering has failed to accurately classify fibres, therefore the threshold estimate for P06 
is not accurate. The trimodal distribution seen for P19 also further highlights the uneven 
spread in the heteroplasmy levels determined in the single muscle fibres for this section. 
Therefore, the median estimates for these two patients could not be assumed to be entirely 
accurate in this instance and so were not included in further analysis.  Similarly, to the 
LOESS model, P07 shows a narrow variance (minimum; 79.50, mean; 84.34 and maximum; 
86.90) whilst the remainder of the now six patients in Group A show bigger variances.  
Group B patients show no data points as they only harbour biochemical normal fibres, 






Figure 5.18: Kernel density estimate plot showing heteroplasmic threshold estimates of Complex I 
deficiency in all patients. 
Each single red dot is a threshold estimate from one bootstrapped sample (undertaken 10,000 times). 
The middle black solid line of overlaid box plot indicates the median threshold estimates for each 
patient. P01 shows the highest median threshold estimate. P06 and P19 have multimodal 
distributions; P06 = bimodal, P19 = trimodal. Patients in Group B (P02, P05, P10 and P15) show no 
threshold estimates as all fibres in skeletal muscle sections were classified as being biochemically 






Table 5.8: Summary data for heteroplasmic threshold estimates (%) as plotted on kernel density 
estimate plot (Figure 5.18) 
 Summary 
Patient Minimum 1st Quartile Median Mean 3rd Quartile Maximum 
P01 73.50 87.80 88.80 88.63 89.70 93.70 
P04 55.60 76.30 79.70 78.36 81.70 85.60 
P07 79.50 83.90 84.40 84.34 84.90 86.70 
P11 56.40 73.30 75.40 76.9 81.70 89.90 
P13 70.90 75.40 77.25 77.33 79.40 85.20 
P16 63.40 74.70 76.20 76.18 77.70 86.20 
P18 54.30 79.30 81.30 80.14 82.30 86.30 
 
The median threshold estimates for the seven Group A patients (P01, P04, P07, P11, P13, P16 
and P18), range from 75.40% (P11) to 88.80% (P01) (Table 5.8).  
5.4.3.5: Patients show significant differences in estimated heteroplasmic thresholds 
Following this analysis, it was important to determine if these median threshold estimates 
were significantly different between these individual patients. To obtain a probability-based 
estimate of the differences between the median estimate thresholds of these patients’ muscle 
sections (P01, P04, P07, P11, P13, P16 and P18), bootstrapping was undertaken on the 
threshold estimates. Briefly, 1,000 bootstrapped estimates were taken from P01 and 1,000 
bootstrapped estimates from P04. This generated 106 pairwise comparisons between the two 
sets of estimates. For example, the proportion of times that the estimated threshold for P01 
(row P01) was greater than that of P04 (column P04) was calculated – this proportion is the 
probability that the threshold for P01 is greater than that for P04. A probability > 0.95 was 
deemed to be a significant difference (equivalent to P<0.05). These values are highlighted by 
blue in Table 5.9 (top half of table). The corresponding magnitude of the difference (%) in 









Table 5.9: Probability-based estimates of the difference in threshold between the seven patients in 
Group A. The top half shows probability estimates and the bottom half shows the corresponding 























) P01  0.992 0.972 0.988 0.996 0.997 0.989 
P04 9.4  0.029 0.604 0.642 0.715 0.348 
P07 4.4 -4.8  0.883 0.995 0.996 0.923 
P11 12.8 2.3 2.2  0.425 0.486 0.305 
P13 11.3 2.0 7.0 -1.3  0.607 0.206 
P16 12.5 3.0 8.1 -0.2 1.0  0.055 
P18 7.6 --1.6 3.0 -4.9 -3.8 -4.9  
 
Interestingly, significant differences in the threshold estimates were found between patients 
harbouring the m.3243A>G pathogenic variant in this study. The median threshold estimate 
of P01 is significantly higher than that for the six Group A patients (P04, P07, P11, P13, P16 
and P18) – the difference in heteroplasmy levels ranging between 4.4% (P07) and 12.8% 
(P11) (Table 5.7). Additionally, the median threshold estimate of P07 is significantly higher 
than P13 (by 7%) and P16 (by 8%).  
Overall, these findings have shown that not only do these patient skeletal muscle sections 
differ in their biochemical status in terms of Complex I expression (thus level of deficiency), 
but (significant) differences in the median heteroplasmic threshold between patient muscle 
sections have also been determined. Patient 01 has the highest heteroplasmic threshold, 
requiring heteroplasmy levels to exceed 88.80% in order for a respiratory chain defect to 
occur (in this instance, defect in Complex I) whilst P11 required a lower level of 
heteroplasmy (75.40%) to lead to a biochemical defect. These differences in the 
heteroplasmic threshold could therefore be a potential mechanism that drives a wide 
phenotypic spectrum in these patients.  
Given that differences in threshold occur between patients from Group A, it could be 
proposed that patients from Group B also have varying thresholds. Whilst it was hypothesised 
that patients in Group A have a lower critical threshold, hence a biochemical deficiency in 




could have a threshold lower than that of one from Group A but, due to the narrow 
distribution of heteroplasmy levels in individual fibres, this threshold may not have been 
exceeded and so a biochemical deficiency does not occur. As already discussed in section 5.1, 
this could be linked to nuclear background. Thus, not only does this suggest that differences 
in heteroplasmic thresholds could influence phenotypic differences, but also that there may be 
differences between individuals in the underlying mechanisms that modulate heteroplasmy 








5.5. Discussion  
The heteroplasmic m.3243A>G MT-TL1 gene variant is well known for causing clinical 
heterogeneity. Taking forward the findings from the quadruple immunofluorescence assay in 
Chapter 4, this study used a single cell approach to investigate the distribution of 
heteroplasmy levels in both biochemically normal and deficient fibres. Thereafter, the 
approach was used to determine an estimate of the heteroplasmic threshold beyond which 
biochemical deficiency is apparent for Complex I in the skeletal muscle cryosections of 13 
patients harbouring the m.3243A>G mutation (a subset of the original 19 from Chapter 4). 
Skeletal muscle sections from 10 of these 13 patients presented with profiles representing a 
biochemical deficiency (dominated by Complex I) and three showed normal biochemical 
profiles. A total of 1,483 single muscle fibres from patient muscle sections were isolated by 
laser microdissection and molecular genetic analysis was undertaken through pyrosequencing 
to determine the m.3243A>G heteroplasmy levels in each individual fibre.  
5.5.1. Increased m.3243A>G heteroplasmy levels in deficient fibres 
Single muscle fibres from all Group A patients, aside from P19 (and P06 if based on 
hierarchical clustering), showed an obvious increase in the m.3243A>G heteroplasmy levels 
from biochemically normal fibres (Group 1 according to Z_score analysis) to the deficient 
fibres (Group 2 to Group 4/5), demonstrating that respiratory chain function becomes 
increasingly impaired as heteroplasmy level increases. This finding is consistent with 
previous single cell studies, where it is already well established in literature that fibres 
deficient in Complex IV (COX-deficient fibres), have higher heteroplasmy levels (Kärppä et 
al. 2005; Moraes et al. 1992; Petruzzella et al. 1994; Tokunaga et al. 1994).  
However, it is shown in Chapter 4, as well as in the literature (Kirino et al. 2005), that 
Complex I is the predominating biochemical deficiency observed with the m.3243A>G 
mutation. Therefore, by using the quadruple immunofluorescence assay, this current study has 
had the advantage of analysing fibres based on both Complex I and Complex IV protein 
expression; allowing for the identification of fibres that were normal or deficient in Complex 
I, normal or deficient in Complex IV and normal or deficient for both. Therefore, I was able 
to sample fibres from a wider range of OXPHOS deficiency in comparison to the studies that 
had used sequential COX/SDH.   
The range of heteroplasmy levels observed in the normal fibres from Group A patients 
(ranging from 3% to 98%) is also in line with the findings from previous single cell studies 




example, Kärppä et al. (2005) showed the range of heteroplasmy to be 3% to 92% in 251 
normal fibres, based on normal COX-activity as determined by sequential COX/SDH 
histochemistry. 
The only exception to this observation is P19. It was shown that there was an increase in the 
heteroplasmy level between Group 1 and Group 3 fibres, however there were many fibres that 
were biochemically deficient yet harboured very low levels of m.3243A>G heteroplasmy. A 
total of 55 fibres were analysed from this patient’s section; increasing this number could 
provide a clearer picture of the distribution of fibre heteroplasmy. However, it is also likely 
that this difference in heteroplasmy distribution in comparison to the other patients in Group 
A could be due to an additional underlying mutation, alongside the m.3243A>G mutation. 
Essentially, could the biochemical deficiency observed in the sampled fibres from P19 be due 
to another point mutation or an mtDNA rearrangement? In order to investigate this, the 
Newcastle Highly Specialised Mitochondrial Diagnostic Laboratory undertook long-range 
PCR screening of this patient’s DNA sample to assess the presence of large-scale mtDNA 
rearrangements, confirming that this was not the case (results not presented in this thesis). In 
fact, this patient was confirmed again as having 34% m.3243A>G heteroplasmy in a 
homogenate skeletal muscle DNA sample. Screening the patient’s full mitochondrial genome 
sequence could potentially identify an additional point mutation contributing to the 
phenotype, but this must be rather unlikely.  
5.5.2. Type II fibres harbour higher levels of m.3243A>G heteroplasmy levels 
The selection of fibres for single cell analysis included the representation of different muscle 
fibre types; Type I and Type II fibres which was a combination of both Type IIa and IIx. 
Overall, Type II fibres harboured higher levels of heteroplasmy in comparison to Type I 
fibres, by 6%. This is in line with previous finding by Rocha et al. (2018). However, this was 
only representative of three of the 11 patients who were shown to have significant difference 
between the median heteroplasmy level in Type I and Type II fibres, whilst the remaining 
patients showed no consistent or significant differences between the two fibre types. 
Therefore, this study has provided further evidence that there is no consistent relationship 
observed between muscle fibre types and heteroplasmy level (Rocha et al. 2018). 
5.5.3. Difference in tissue segregation of the m.3243A>G mutation between patients in 
Group A and Group B;  
Unlike previous single cell studies which examined fibres from patient skeletal muscle 
sections that harboured both COX-positive and COX-deficient fibres, this current study has 




of Complex I and Complex IV (biochemically normal) in their skeletal muscle sections. This 
was undertaken to assess if there were any differences in the distribution in the heteroplasmy 
level that could help distinguish why patients in Group B showed no biochemical deficiency, 
compared to patients in Group A.  
Interestingly, a difference was observed between the two groups of patients. The 
heteroplasmy levels determined in the normal fibres sampled from skeletal muscle sections of 
patients from Group B, were clustered within a narrow range, unlike the broad distribution 
observed in the normal fibres from patients in Group A. This indicates that the broad 
distribution in heteroplasmy levels may be linked to the presence of deficient fibres whilst the 
narrow distribution is linked to patients with no deficiency in their skeletal muscle. To the 
best of knowledge, this has not yet been reported in the literature.  
The most obvious explanation for the difference between these two groups of normal fibres is 
that fibres from patients in Group B have not yet reached the critical threshold for 
biochemical deficiency. However, what is causing these fibres to stay within a certain range 
of heteroplasmy levels without exceeding that threshold? A number of aspects can be 
considered, though these are predominantly based on studies undertaken on 
transmitochondrial cell lines or mitotic cells such as colonic crypts.  
Could this difference in distribution be due to the difference in nuclear genetic 
background?  
These two patterns of heteroplasmy levels have been reported in transmitochondrial cell lines 
– either stable (within a range) (Lehtinen et al. 2000; Shoubridge 1995) or shifts towards 
either low or high levels of heteroplasmy (Dunbar et al. 1995). This shift in heteroplasmy and 
segregation was owed to the difference in nuclear background of the cells (Dunbar et al. 1995; 
Raap et al. 2012; Shoubridge 1995). Although it was also recognised that the differences in 
experimental procedures in such studies could also be accountable for these differing 
outcomes, for example the number of passages undertaken and the length of time that the cells 
were cultured (Bentlage and Attardi 1996; Shoubridge 1995). Nonetheless, the change in 
heteroplasmy levels in post-mitotic cells is due to the continuous recycling of mtDNA 
molecules in a process called relaxed replication (Stewart and Chinnery 2015) and like the 
transmitochondrial cell lines, heteroplasmy level within a given cell is thought to be able to  
increase, decrease or remain stable over time. Again, it is thought to be influenced by nuclear 
genes. Thus, a likely hypothesis for this difference in heteroplasmy distribution is that the 




discussed in Chapter 4, studies have shown strong indication towards the role of the nuclear 
DNA and nuclear factors in mitochondrial disease (Battersby et al. 2003; Hudson et al. 2005; 
Maeda et al. 2016; Pickett et al. 2018). 
Could this difference in distribution be due to clonal expansion?  
Another aspect that can be considered in understanding these findings is clonal expansion; the 
process by which the proportion of the mutated mtDNA (caused by either a point mutation or 
deletions), increases and eventually exceeds the critical threshold that is required to induce a 
biochemical deficiency. The mechanism that drives mtDNA molecules to undergo clonal 
expansion is of longstanding interest in research with current mechanisms that have been 
suggested including random genetic drift (Baines et al. 2014; Elson et al. 2002; Greaves et al. 
2014) and preferential selection of mutant mtDNA due to increased biogenesis in the 
perinuclear region of the skeletal muscle section (Vincent et al. 2018).  
It could be postulated that the mutant mtDNA in the fibres of patients in Group A have 
clonally expanded to high levels and exceeded the threshold to then consequently cause the 
Complex I (and Complex IV) deficiency that has been observed in the skeletal muscle 
sections. In addition to this, the broad distribution of heteroplasmy levels observed in these 
normal fibres includes the many fibres that harbour very low levels of heteroplasmy in 
comparison to the overall homogenate level. This is potentially a result of random segregation 
(distribution) of mutant mtDNA molecules into skeletal muscle progenitor cells during 
embryogenesis, which results in a broad distribution of heteroplasmy levels in the resulting 
skeletal muscle fibres. Clonal expansion, potentially in response to exceeding threshold for 
deficiency, within individual fibres could then contribute to this spread becoming even 
broader. In contrast, fibres from Group B patients may not have undergone clonal expansion 
to the same extent, resulting in narrower ranges of heteroplasmy. 
Furthermore, this narrow range could potentially be indicating that the process of segregation 
during embryogenesis may not be random in these patients as all fibres that have been 
sampled harbour similar levels of heteroplasmy levels.  
Could this difference in distribution be due to mtDNA copy number?  
The quadruple immunofluorescence assay allowed for the determination of mitochondrial 
mass through the immunoreactivity/expression of porin. Interestingly, it was found in this 




levels than fibres in sections from patients in Group A, but this difference was not significant. 
The direct measure of mtDNA copy number in these patients would clarify this finding better.  
Differences in mtDNA copy number in these single muscle fibres could also account for the 
differences observed, particularly in those fibres that show very high levels of heteroplasmy 
yet remain biochemically normal. At a population level, Grady et al. (2018) showed an 
association between low homogenate skeletal muscle mtDNA copy number and increased 
disease severity and progression. Therefore, at a single cell level, it could be hypothesised that 
low copy number also drives the existence of deficient fibres. A recent study by Filograna et 
al. (2019) demonstrated that mice (carrying the m.5024C>T mutation on the tRNAAla gene (the 
so called “C5024T” mice)) with an increase in mtDNA copy number (achieved by 
overexpressing (OE) TFAM in Tfam+/OE C5024T mice) decreased the frequency of COX-
deficient cardiomyocytes compared to mice with low mtDNA copy number (knock out (KO) 
Tfam; Tfam+/KO C5024T mice) – thereby concluding that an increase in mtDNA copy number 
was sufficient to decrease the biochemical defect in cells owed to slowing down the process 
of clonal expansion. This decrease was not observed in the skeletal muscle sections of these 
mice, however, this may have been influenced by the fact that these mice had very low 
frequency of COX-deficient fibres. Therefore, normal fibres from patients in Group B may 
have a higher mtDNA copy number in comparison to the fibres in patients in Group A, 
therefore potentially decreasing the process of clonal expansion of the m.3243A>G variant to 
reach the threshold for deficiency and consequently not display a biochemical defect.  
Heteroplasmic mutations involving various tRNA genes have been shown to be associated 
with mtDNA proliferation (Moraes et al. 1992; Shoubridge 1998; Tokunaga et al. 1994) – 
represented by increased total mtDNA copy number in the classic RRF observed in the 
skeletal muscle sections of patients (Tokunaga et al. 1994). This proliferation in mtDNA is 
indicative of a compensatory mechanism which is known as the “maintenance of the wild-
type hypothesis” (Chinnery et al. 1999; Durham et al. 2007; Stewart and Chinnery 2015). This 
theory proposes that in the presence of mutated mtDNA, the mtDNA pool is replicated in the 
cell as a way of restabilising an adequate level of wild-type mtDNA. However, this also leads 
to non-selective replication and so an increased amount of mutated mtDNA molecules. The 
heteroplasmy level would then increase in the post-mitotic tissue with time, potentially 
leading to respiratory chain deficiency. Alternatively, this theory of proliferation of wild-type 
mtDNA is not supported by the findings from the study by Durham et al. (2007) who 
investigated muscle fibres from a patient harbouring the m.3243A>G mutation and showed 




enough to halt the respiratory chain deficiency. The authors concluded that the pathogenic 
mechanism of the m.3243A>G mutation involves interference with the function of the wild-
type mtDNA or the wild-type mt-tRNALeu(UUR), as previously described in Chapter 4, section 
4.1.3. This is further exemplified by the presence of RRF that are COX-deficient – evidence 
of the fact that proliferation of mtDNA copy number in these fibres is not capable of 
compensating for the high levels of heteroplasmy (Petruzzella et al. 1994). 
This leads to notion that it could be possible that fibres from different individuals vary in their 
ability to compensate for the presence of the mutation (Apabhai et al. 2011; Cao et al. 2001; 
Grady et al. 2018). Thus, it could be suggested that the compensatory mechanism of 
proliferation has been compromised in fibres from patients in Group A whilst fibres from 
patients in Group B are able to compensate in the presence of the m.3243A>G mutation, 
hence show no biochemical defect.  
5.5.4. Differences in the estimated heteroplasmic threshold for Complex I deficiency 
between patients  
Using both hierarchical clustering and kernel density estimates, this study was able to 
determine the estimated critical threshold for biochemical deficiency (Complex I deficiency) 
in patients harbouring the m.3243A>G pathogenic variant. In line with the literature, the 
threshold estimates determined for patients were shown to be between 74% and 89%. 
This is the first study that has been able to statistically demonstrate significant differences in 
estimated thresholds between the patients, in particular patient P01 who was shown to have 
higher thresholds in comparison to the remainder of the six patients. These differences may be 
biologically meaningful given their magnitude (up to 12.8% difference in heteroplasmy level), 
particularly in terms of a clinical outlook. It also supports the hypothesis that thresholds are 
different between individuals, and could be responsible, in part, for the phenotypic variation 
observed. Therefore, it would be interesting to investigate the association between these 
differences in threshold levels and the clinical data of these patients. Unfortunately, in this 
current study, this could not be investigated further due to the small cohort of patients in 
whom the threshold was determined (n= 7). However, it has paved way for further patients to 
be investigated in order to determine the exact clinical relevance of these significant 
differences in threshold levels.  
5.6. Limitations of this study 
This single cell study is the first study to investigate single muscle fibres from patients with 




large number of fibres have been analysed in 13 patients, four of whom had biochemically 
normal skeletal muscle sections (based on the hierarchical clustering).  Although the 
combination of the quantitative immunofluorescence assay data and molecular genetics 
(pyrosequencing data) has improved the understanding of genetic and respiratory chain 
defects, there are some limitations to consider. 
The fibre sampling strategy could be biased as fibres were selected from known OXPHOS 
groups, despite random sampling from within these groups. However, given the time-
constraint, it was the better option over random sampling which was also shown to be 
inadequate for sampling a sufficient number of fibres in some cases without sampling more 
than 250 fibres. The sampling of fibres was limited by the fibre type groupings, especially as 
each patient presented differently with their fibre type composition. For example, some 
sections had more Type I fibres whilst others had more Type IIa/x fibres. Although it was 
found that heteroplasmy level was 6% higher in Type II fibres than Type I, the linear 
regression model seemed to be influenced by three patients in particular, whilst in the 
remaining 8 patients, there was no consistency. Moreover, due to the different levels of 
deficiency and fibre type composition, each patient had their own individual selection method 
– dependent on the fibres per OXPHOS group and the number of fibres per fibre type. 
Random sampling from these OXPHOS groups without taking into account fibre type may 
have been a better selection method. 
Whilst muscle sections from 13 patients have been used in this study, it was only possible to 
determine the threshold for seven of these. This small group size did not allow for the 
correlation between these threshold findings and the clinical phenotypes of these patients, 
which would have been particularly interesting given the phenotypic heterogeneity in the 
cohort. 
The statistical work up allowed for the estimates of thresholds to be determined, however, 
hierarchical clustering failed to classify fibres in P06 which then could not be compared to the 
remaining patients after the summary from kernel density plots. This highlights that the 
classification needs to be refined to ensure it can be applied for all patients, particularly for 
patients who show a substantial amount of Complex IV deficiency. 
This study has utilised fibres sampled from the 20µm fibre type section for pyrosequencing, 
rather than sampling directly from the 10µm OXPHOS section. Although fibres were 




sections, given that COX-deficiency occurs segmentally across the muscle. However, the 
fibres did show the expected levels of heteroplasmy according to their OXPHOS group.  
Similarly, the threshold estimates for Complex I deficiency, were determined from fibres 
sampled from one skeletal muscle section. It would be ideal to take a section from further 
down the biopsy and/or from a different biopsy and repeat the experimental procedure to 
investigate if similar levels of heteroplasmy are found, as well as how similar the estimated 
threshold is to the initial finding.  
As this current study has only investigated fibres based on protein expression for Complex I 
and Complex IV, it could be suggested that the activity of the complexes need to be 
investigated in order to accurately determine the Group B patients as being biochemically 
normal. However, measuring the activity of complexes at a single cell level is not possible, 
therefore this would be investigated using homogenate skeletal muscle sample and 
spectrophotometric assays.  
Lastly, due to the time constraint of this project, the assessment of the heteroplasmy levels in 
the single muscle fibres was only undertaken once, rather than in duplicates or triplicates. 
However, by investigating a sample of fibres as duplicates from the same experimental run as 
well as from a new experimental set up, showed that the heteroplasmy levels of most of these 
fibres fell within a 6% range. In addition, controls of known heteroplasmy level were included 
in order to validate each pyrosequencing run. 
5.7. Conclusion  
In conclusion, through using quantitative data from the quadruple immunofluorescence assay 
combined with laser capture microdissection and pyrosequencing, this study has been able to 
assess m.3243A>G heteroplasmy levels in fibres deficient in Complex I and Complex IV in 
muscle sections from patients harbouring the m.3243A>G pathogenic variant. The following 
findings have been determined; i) based on Complex I and Complex IV expression, fibres 
have shown an increase in heteroplasmy level with increased biochemical deficiency, ii) 
biochemically normal fibres from skeletal muscle sections of patients from Group A and 
Group B show a difference in heteroplasmy distribution; normal fibres from patients in Group 
A show a wide distribution whilst normal fibres from patients in Group B show a narrow 
distribution. Furthermore, this study has used stringent statistical methods including using 
bootstrapping, hierarchical clustering, kernel density estimates, followed by probability paired 
calculations to show the following findings; i) estimated threshold levels could be determined 




between some of the patients. Overall, this study has been able to demonstrate the difference 
in threshold for Complex I deficiency in patients with the m.3243A>G mutation. Further 
research into whether these differences can account for the phenotypic variability in these 
patients is warranted – this will be discussed further in the final discussion of this thesis 


































































































6.1. Conclusions  
Mitochondrial diseases are caused by pathogenic variants which reside within genes that are 
either encoded by the nuclear DNA or the mtDNA. Thus, affected individuals present with 
genetic, clinical and biochemical heterogeneity and for those who are affected by pathogenic 
mtDNA variants, this is further confounded by heteroplasmy. The studies described in this 
thesis had the aim of improving the diagnosis of mitochondrial disease and improving the 
understanding of molecular mechanisms underlying mitochondrial disease and the expression 
of a biochemical defect. These aims have been achieved with the use of the quadruple 
immunofluorescence assay which allowed for the assessment of Complex I (NDUFB8), 
Complex IV (COX-1) and porin (mitochondrial mass) protein expression in individual fibres, 
within 10µm skeletal muscle sections from patients. 
There are several areas in which this thesis has presented novel findings that contribute 
towards the ongoing advancement in the knowledge and understanding of mitochondrial 
disease. These key findings are described below.  
6.1.1. The quadruple immunofluorescence assay is a beneficial tool in the diagnosis of 
Complex I deficiency: 
Complex I deficiency is the most frequently observed biochemical defect in patients with 
mitochondrial disease. Prior to the quadruple immunofluorescence assay (Rocha et al. 2015), 
there were no histochemical tests that interrogated Complex I expression in skeletal muscle in 
a diagnostic setting. Therefore, following on from work undertaken by Rocha et al. (2015), it 
was important to validate the assay and its ability to detect Complex I deficiency in a 
heterogeneous cohort of patients (n= 25) with genetically-proven pathogenic variants within 
mtDNA or nuclear-encoded genes. 
This study demonstrated the clear diagnostic potential of the assay in detecting Complex I 
deficiency, particularly within patients harbouring pathogenic variants of nuclear-encoded 
genes (encoding either structural subunits or assembly factors). Moreover, this study also 
showed that in some cases, the assay cannot detect Complex I deficiency, using antibodies 
against NDUFB8 and NDUFS3. This is most likely because the mutation is only affecting the 
enzymatic activity of the complex rather than assembly, or the mutation has variable effects 
on either the assembly, activity or both.  Although, in some instances, the assay was able to 
give further insight into the effect of the mutation on Complex I, for example, in one patient 
harbouring the m.13513G>A, p.(Asp393Asn) variant (P25), the protein expression of 




Complex I were detected (with BN-PAGE) as well as normal residual biochemical Complex I 
activity. Combining these findings, it could be concluded that this variant may have no effect 
on the activity or assembly of Complex I in skeletal muscle, despite the relatively high level 
of mtDNA heteroplasmy and severe clinical phenotypes.  
Overall, these findings highlight the key advantage that this assay has introduced to the 
diagnostic pathway for mitochondrial diseases - Complex I expression can be interrogated in 
the single fibres of a 10µm skeletal muscle section and provide essential information on the 
status of the complex; a decrease in the expression (deficiency) or a normal expression. 
Importantly, these findings add further importance to the multidisciplinary approach required 
in the diagnosis of mitochondrial diseases, for example the necessity of the 
spectrophotometric assay to measure the activity of Complex I in cases where protein 
expression is normal in skeletal muscle sections, as well as BN-PAGE to assess the assembly 
of Complex I. In addition, these findings show the importance of completing mitochondrial 
genome sequencing in those patients where the immunofluorescence assay was unable to 
detect a deficiency.  
6.1.2. Skeletal muscle sections of patients harbouring the m.3243A>G pathogenic 
variant show variable biochemical status based on Complex I expression  
The m.3243A>G mutation, located within the MT-TLI gene (encoding mitochondrial tRNALeu 
(UUR)), is the most prevalent, pathogenic mitochondrial point mutation. It is associated with a 
broad clinical spectrum, from asymptomatic individuals to patients with MELAS. This is due 
to a number of factors that include heteroplasmy, age, mtDNA copy number and nuclear 
factors (Boggan et al. 2019). The study in this thesis focused on the role of heteroplasmy. 
Previous studies have used the classic sequential COX/SDH histochemical assessment to 
investigate skeletal muscle of patients with m.3243A>G variant. However, the 
downregulation of Complex I is of predominance in these patients (Fornuskova et al. 2008; 
Goto et al. 1992; Kobayashi et al. 1990; Morgan-Hughes et al. 1995) and so would go 
undetected using this method. Therefore, in order to provide novel findings to progress the 
knowledge of the m.3243A>G mutation, the study described in Chapter 4 used the quadruple 
immunofluorescence assay to characterise – at a single cell level - the biochemical status 





Firstly, the findings from this study showed that Complex I is indeed the predominant 
biochemical defect observed in patients, particularly within this current cohort of patients. 
Only three of the 19 patients showed Complex IV deficiency at a single cell level.  
Secondly, the study identified two groups of patients based on Complex I expression in the 
skeletal muscle biopsies; those patients showing Complex I deficiency were termed as Group 
A whilst those showing a normal biochemical profile were termed as Group B. Previous 
studies have shown a decrease in Complex I activity in patient samples, owed to the fact that 
the m.3243A>G mutation directly impacts both ND6 and ND5 (Chomyn et al. 2000; Dunbar 
et al. 1996; Kirino et al. 2004; Sasarman et al. 2008). A preliminary study by Rocha et al. 
(2015) used the quadruple immunofluorescence assay to assess Complex I and Complex IV 
deficiency in muscle sections from a heterogeneous group of mitochondrial disease patients, 
including five carriers of m.3243A>G. By interrogating a larger cohort of m.3243A>G 
carriers, this current study has given insight into the variable levels of Complex I deficiency 
found in patient skeletal muscle sections, as well as showing that some patients can present 
with normal levels of Complex I (and Complex IV) expression in single muscle fibres, despite 
the severe clinical presentations or high homogenate heteroplasmy levels in some cases. 
6.1.3. m.3243A>G heteroplasmy distribution differs in biochemically normal fibres 
between patients in Group A and B 
The findings from Chapter 4 initiated the investigation into why this difference was observed 
between these two groups of patients. It was hypothesised that the difference in the critical 
heteroplasmic threshold for deficiency was different between the two groups of patients. 
Isolation of single muscle fibres from 13 of the 19 patients enabled investigation of the 
relationship between biochemical deficiency and single fibre m.3243A>G heteroplasmy, as 
described in Chapter 5.  
The first novel finding from this study is the difference in the heteroplasmy distribution 
observed in the biochemically normal fibres sampled from patients in Group A and the 
normal fibres sampled from the patients in Group B; fibres from Group A patients have a 
broad distribution in heteroplasmy levels whilst fibres from patients in Group B have a 
narrower distribution. Therefore, this difference appears to determine the skeletal muscle 
biopsy biochemical profile, as detected by the quadruple immunofluorescence assay. 
6.1.4. Patients showed a difference in their biochemical threshold  
The second novel finding in this study is the differences in the critical heteroplasmic threshold 




difference is statistically significant. P01 was shown to have a significantly higher threshold 
estimate than all patients analysed whilst P07 was shown to have a higher heteroplasmic 
threshold level than P13 and P16. These findings have paved the way to asking further 
questions such as; do these differences in threshold cause the phenotypic differences observed 
in these patients? Do those patients that have a significantly higher threshold level have a less 
severe phenotype than patients with lower thresholds?  
6.2. Future work and potential studies  
A discussion of potential future research is described below. These proposed studies would 
allow for better understanding of these current findings and the understanding of the 
complexity that is associated with the m.3243A>G pathogenic variant. 
Future work after expanding the size of the cohort:  
One of the limitations to the study undertaken on the m.3243A>G pathogenic variant is the 
relatively small cohort size (n=19). Therefore, one crucial next step is to undertake the 
quadruple immunofluorescence assay in the remaining biopsies of patients with the 
m.3243A>G mutation. The MitoCohort contains approximately 60 patient muscle biopsies; 
increasing the number of patients investigated will allow for confirmation of the findings 
described in Chapter 4. Would biopsies from these patients also present with muscle biopsies 
that are either deficient for Complex I or normal for both Complex I and Complex IV 
expression, or could some of these patients present with a much a higher degree of Complex 
IV deficiency compared to those in this current cohort? Thus, increasing the cohort size will 
allow a further insight into the biochemical status of Complex I and Complex IV in single 
fibres of patients harbouring the m.3243A>G pathogenic variant. Further to this, once the 
assay has been performed on the muscle biopsies, family members can be targeted to 
investigate whether deficient or normal Complex I and Complex IV cluster in families. In this 
current cohort of patients, there are three family members; P03 is the first cousin of P15; P04 
is the sister of P05 and P08 is the first cousin, once removed of P10. The protein expression of 
Complex I and Complex IV is normal in both P03 and P15 skeletal muscle sections. However, 
the skeletal muscle section of P08 had Complex I-deficient fibres whilst P10 displayed normal 
expression of both OXPHOS complexes. According to the Z_score analysis, P05 displayed 
deficiency which would be in line with the findings for P04, however the hierarchical 
clustering defined P05 as all normal fibres. This could potentially be indicative of the role of 




clustering. However, this could be by chance and therefore, to investigate this relationship 
further, a larger sample size would be needed. 
Increasing the cohort size would also provide more statistical power to detect a relationship 
between the phenotypes observed in these individuals (as scored by the NMDAS) and the 
level of Complex I deficiency (and potentially Complex IV).  In addition to this, increasing 
the number of muscle sections with single fibre data would also help to confirm the findings 
with regards to critical threshold estimates. Working alongside Dr Conor Lawless, I have only 
investigated two of many statistical models that can be used to interrogate these single cell 
findings in the given time length of this project. Whilst the hierarchical clustering was an 
effective alternative approach to Z_score analysis, future work will include working with 
other statistical models, one being the Gaussian clustering method, to allow for an informed 
decision on how to best approach such heterogeneous data attained from these patients.  
The inclusion of more patients would also allow the correlation of phenotypes with threshold 
estimates to answer the question: does the difference in threshold level for deficiency of 
Complex I account for the phenotypic variation observed in these patients? By correlating 
these estimates with NMDAS data (total and scores for individual phenotypes), it would allow 
an insight into how these differences (particularly the significant differences) can impact these 
patients in a clinical setting,  
Investigating mtDNA copy number, signalling pathways and nuclear factors alongside the 
heteroplasmy levels 
Mitochondrial DNA copy number was not investigated in this study as the main aim was to 
determine the heteroplasmic threshold differences in this cohort of patients. In light of the 
findings from this study, particularly the difference in heteroplasmy distribution in 
biochemically normal fibres between two groups of patients, determining the mtDNA copy 
number in the single muscle fibres is another essential molecular genetic investigation that 
should be undertaken. By determining copy number; total and wild-type mtDNA copy 
number, the interplay between these, heteroplasmy levels and biochemical deficiency can be 
investigated.  
One suggestion for potential research that could be linked to mtDNA copy number, is to 
investigate the difference between the biochemically normal fibres (in Group A patients) that 
show very high levels of heteroplasmy (for example 98% as shown in this current study) and 
the deficient fibres with same or similar heteroplasmy levels (also in Group A patients). This 




tolerate high heteroplasmy levels without reaching threshold to cause a respiratory chain 
deficiency?” This latter question could then be linked to the investigation into why there is a 
difference in distribution of heteroplasmy levels between the normal fibres sampled from 
patients in Group A and the normal fibres sampled from patients in Group B. Why have some 
patients’ fibres reached high heteroplasmy levels and exceeded the critical threshold for 
deficiency, whilst other patients’ fibres have maintained a narrow range of heteroplasmy 
levels and have not yet reached the threshold?  
A recent development with Imaging Mass Cytometry (IMC) at the Wellcome Centre for 
Mitochondria Research could potentially be used to investigate these research questions. IMC 
is a single cell ‘omics’ technique that combines time of flight mass cytometry (CyTOF) and 
immunohistochemistry with a high resolution ablation system (Giesen et al. 2014). It utilises 
rare earth metals as reporters on antibodies instead of fluorophores and therefore allows for 
the labelling of up to 40 different proteins on a single tissue section, for example the muscle 
or the brain. Antibodies targeting a number of proteins in various signalling pathways are 
currently being investigated and optimised at the Centre, including TFAM and PGC1-α 
(implicated in mitochondrial biogenesis) which could be linked to mtDNA copy number and 
helpful in investigating potential compensatory mechanisms within individual fibres of 
m.3242A>G patients. IMC would also allow for assessment of brain tissue (post-mortem) of a 
subset of these patients to decipher if similar findings of respiratory chain defects are 
observed in this tissue. In addition to this, the inclusion of antibodies targeting mtDNA-
encoded subunits of the respiratory chain enzymes (for example, ND1 and ND4 for Complex 
I, CYTB for Complex III and also ATP6 and ATP8 for Complex V), alongside the antibodies 
that target nuclear-encoded subunits, would expand our understanding of the biochemical 
deficiency in these patients’ muscle fibres. This could also prove beneficial at a diagnostic 
level when looking to expand the panel of antibodies to interrogate the mitochondrial 
respiratory chain.   
Additionally, an investigation similar to that described by Vincent et al. (2018) could be 
undertaken on muscle sections from patients with m.3243A>G pathogenic variant. They 
investigated the presence of focal regions of respiratory chain deficiency in the perinuclear 
region of the cell/fibre in skeletal muscle sections of patient with mtDNA deletions. From 
this, Vincent and colleagues were able to propose a model to explain clonal expansion by 
showing that these focal regions showed local elevations of both mitochondrial mass and 
mtDNA copy number and therefore were associated with a local increase in mitochondrial 




potentially give insight into clonal expansion of the mutation in single fibres of patients with 
m.3243A>G. Furthermore, investigating whether deficient focal regions exist in muscle fibres 
of patients who presented with biochemically normal muscle sections could help determine 
whether these truly are biochemically normal fibres or if clonal expansion of a foci is to occur 
in muscle fibres of this subset of patients.   
Finally, this work has further highlighted the importance of understanding the effect of 
nuclear background on the biochemical and clinical heterogeneity observed in patients 
harbouring the m.3243A>G pathogenic variant. This further encourages studies that are 
currently underway, for example, those using whole genome sequencing (WGS) and genetic 
linkage and association to identify nuclear variation influencing phenotypic differences and 
the segregation and modulation of heteroplasmy levels in these patients (Boggan et al. 2019). 
Therefore, whilst this current study has investigated heteroplasmy and determined differences 
in the critical thresholds between individual patients, it has also highlighted that indeed, 
multiple factors contribute to the complexity of the m.3243A>G pathogenic variant and 
mitochondrial disease in general.  
6.3. Final conclusion 
In conclusion, the studies detailed in this thesis have utilised the quadruple 
immunofluorescence assay to contribute towards the current diagnostic process of 
mitochondrial disease and also to improve the understanding of the pathogenesis of the 
m.3243A>G variant. In addition, this work has also highlighted a number of important 
research questions, which together with these current findings, will hopefully contribute 
towards the ongoing research aiming to advance the understanding of the different 
mechanisms underlying the disease pathology of mitochondrial disease, particularly those 












































Appendix 1: Newcastle Adult Mitochondrial Disease scale (NMDAS) questionnaire 
which is used to assess mitochondrial disease severity and progression in the Newcastle 



























THE NEWCASTLE  
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Age at assessment:      
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Raw Score Scaled Score  Centile 
 
❑ SF-12v2 self completion questionnaire          
 
❑ WTAR reading test (1 minute)          
 
❑ Symbol Search (2 minutes)          
 
❑ Speed of comprehension test (2 minutes)            
 
 
Disease score (sections I-III)    
 


















Section I- Current Function 
Rate function over the preceding 4 week period, according to patient and/or caregiver interview only. 
The clinician’s subjective judgement of functional ability should not be taken into account. 
 
 
1. Vision with usual glasses or contact lenses 
 
0. Normal. 
1. No functional impairment but aware of worsened acuities. 
2. Mild - difficulty with small print or text on television. 
3. Moderate - difficulty outside the home (e.g. bus numbers, road signs or shopping). 
4. Severe - difficulty recognising faces. 
5. Unable to navigate without help (e.g. carer, dog, cane). 
 
 
2. Hearing with or without hearing aid 
 
0. Normal. 
1. No communication problems but aware of tinnitus or deterioration from prior ‘normal’ hearing. 
2. Mild deafness (e.g. missing words in presence of background noise). Fully corrected with hearing aid. 
3. Moderate deafness (e.g. regularly requiring repetition). Not fully corrected with hearing aid. 
4. Severe deafness - poor hearing even with aid (see 3 above). 
5. End stage - virtually no hearing despite aid. Relies heavily on non-verbal communication 






1. Communication unaffected but patient or others aware of changes in speech patterns or quality. 
2. Mild difficulties - usually understood and rarely asked to repeat things. 
3. Moderate difficulties - poorly understood by strangers and frequently asked to repeat things. 
4. Severe difficulties - poorly understood by family or friends. 






1. Mild - sensation of solids ‘sticking’ (occasional). 
2. Sensation of solids ‘sticking’ (most meals) or need to modify diet (e.g. avoidance of steak/salad). 
3. Difficulty swallowing solids - affecting meal size or duration. Coughing, choking or 
nasal regurgitation infrequent (1 to 4 times per month) but more than peers. 
4. Requires adapted diet - regular coughing, choking, or nasal regurgitation (more than once per week). 






1. Writing speed unaffected but aware of increasing untidiness. 
2. Mild – Has to write slower to maintain tidiness/legibility. 
3. Moderate – Handwriting takes at least twice as long or resorts to printing (must previously have 
used joined writing). 
4. Severe – Handwriting mostly illegible. Printing very slow and untidy (e.g. ‘THE BLACK CAT’ 
takes in excess of 30 seconds). 




6. Cutting food and handling utensils (irrespective of contributory factors – e.g. weakness, 
coordination, cognitive function etc. This is also true for questions 7-10) 
 
0. Normal. 
1. Slightly slow and/or clumsy but minimal effect on meal duration. 
2. Slow and/or clumsy with extended meal duration, but no help required. 
3. Difficulty cutting up food and inaccuracy of transfer pronounced. Can manage alone but 
avoids problem foods (egg peas) or carer typically offers minor assistance (e.g. cutting up 
steak). 
4. Unable to cut up food. Can pass food to mouth with great effort or inaccuracy. Resultant 
intake minimal. Requires major assistance. 





1. Occasional difficulties (e.g. shoe laces, buttons etc.) but no real impact on time or effort taken to dress. 
2. Mild – Dressing takes longer and requires more effort than expected at the patient’s age. No 
help required. 
3. Moderate - Can dress unaided but takes at least twice as long and is a major effort. Carer 
typically helps with difficult tasks such as shoe laces or buttons. 
4. Severe – Unable to dress without help but some tasks completed unaided. 
5. Needs to be dressed. 
 
7. Hygiene  
 
0. Normal. 
1. Occasional difficulties only but no real impact on time or effort required. 
2. Mild – hygienic care takes longer but quality unaffected. 
3. Moderate - bathes and showers alone with difficulty or needs bath chair / modifications. 
Dextrous tasks (e.g. brushing teeth, combing hair) performed poorly. 
4. Severe - unable to bathe or shower without help. Major difficulty using toilet alone. Dextrous 
tasks require help. 
5. Dependent upon carers to wash, bathe, and toilet. 
 
8. Exercise Tolerance  
 
0. Normal. 
1. Unlimited on flat - symptomatic on inclines or stairs. 
2. Able to walk < 1000m on the flat. Restricted on inclines or stairs - rest needed after 1 flight (12 steps). 
3. Able to walk < 500m on the flat. Rest needed after 8 steps on stairs. 
4. Able to walk < 100m on the flat. Rest needed after 4 steps on stairs. 
5. Able to walk < 25m on the flat. Unable to do stairs alone. 
 
9. Gait stability 
 
0. Normal. 
1. Normal gait - occasional difficulties on turns, uneven ground, or if required to balance on narrow base. 
2. Gait reasonably steady. Aware of impaired balance. Occasionally off balance when walking. 
3. Unsteady gait. Always off balance when walking. Occasional falls. Gait steady with support of 
stick or person. 
4. Gait grossly unsteady without support. High likelihood of falls. Can only walk short distances (< 
10m) without support. 




Section II – System Specific Involvement 
Rate function according to patient and/or caregiver interview and consultation with the medical notes. Each 
inquiry should take into account the situation for the preceding 12 month period only, unless otherwise 
stated in the question. 
 
1. Psychiatric  
 
0. None. 
1. Mild & transient (e.g. reactive depression) - lasting less than 3 months. 
2. Mild & persistent (lasting more than 3 months) or recurrent. Patient has consulted GP. 
3. Moderate & warranting specialist treatment (e.g. from a psychiatrist) - e.g. bipolar disorder 
or depression with vegetative symptoms (insomnia, anorexia, abulia etc.). 
4. Severe (e.g. self harm - psychosis etc.). 
5. Institutionalised or suicide attempt. 
 
2. Migraine Headaches. During the last 3 months, how many days have headaches prevented the patient from 
functioning normally at school, work, or in the home? 
 
0. No past history. 
1. Asymptomatic but past history of migraines. 
2. One day per month. 
3. Two days per month. 
4. Three days per month. 
5. Four days per month or more. 
 
3. Seizures  
 
0. No past history. 
1. Asymptomatic but past history of epilepsy. 
2. Myoclonic or simple partial seizures only. 
3. Multiple absence, complex partial, or myoclonic seizures affecting function or single 
generalised seizure. 
4. Multiple generalised seizures. 
5. Status epilepticus. 
 
4. Stroke-like-episodes (exclude focal deficits felt to be of vascular aetiology) 
 
0. None. 
1. Transient focal sensory symptoms only (less than 24 hours). 
2. Transient focal motor symptoms only (less than 24 hours). 
3. Single stroke-like episode affecting one hemisphere (more than 24 hours). 
4. Single stroke-like episode affecting both hemispheres (more than 24 hours). 
5. Multiple stroke-like episodes (more than 24 hours each). 
 
5. Encephalopathic episodes  
 
0. No past history. 
1. Asymptomatic but past history of encephalopathy. 
2. Mild - single episode of personality or behavioural change but retaining orientation 
in time/place/person. 
3. Moderate - single episode of confusion or disorientation in time, place or person. 
4. Severe – multiple moderate episodes (as above) or emergency hospital admission due 
to encephalopathy without associated seizures or stroke-like episodes. 












6. Gastro-intestinal symptoms 
 
0. None. 
1. Mild constipation only or past history of bowel resection for dysmotility. 
2. Occasional symptoms of ‘irritable bowel’ (pain, bloating or diarrhoea) with long spells of normality. 
3. Frequent symptoms (as above) most weeks or severe constipation with bowels open less 
than once/week or need for daily medications. 
4. Dysmotility requiring admission or persistent and/or recurrent anorexia/vomiting/weight loss. 
5. Surgical procedures or resections for gastrointestinal dysmotility. 
 
7. Diabetes mellitus  
 
0. None. 
1. Past history of gestational diabetes or transient glucose intolerance related to intercurrent illness. 
2. Impaired glucose tolerance (in absence of intercurrent illness). 
3. NIDDM (diet). 
4. NIDDM (tablets). 
5. DM requiring insulin (irrespective of treatment at onset). 
 
8. Respiratory muscle weakness  
 
0. FVC normal (≥ 85% predicted). 
1. FVC < 85% predicted. 
2. FVC < 75% predicted. 
3. FVC < 65% predicted. 
4. FVC < 55% predicted. 
5. FVC < 45% predicted or ventilatory support for over 6 hours per 24 hr period (not for OSA alone). 
 
9. Cardiovascular system  
 
0. None. 
1. Asymptomatic ECG change. 
2. Asymptomatic LVH on echo or non-sustained brady/tachyarrhythmia on ECG. 
3. Sustained or symptomatic arrhythmia, LVH or cardiomyopathy. Dilated chambers or 
reduced function on echo. Mobitz II AV block or greater. 
4. Requires pacemaker, defibrillator, arrhythmia ablation, or LVEF < 35% on echocardiogram. 
5. Symptoms of left ventricular failure with clinical and/or x-ray evidence of pulmonary oedema or 




Section III – Current Clinical Assessment 
Rate current status according to examination performed at the time of assessment 
 
 
1. Visual acuity with usual glasses, contact lenses or pinhole. 
 
0. CSD ≤ 12 (i.e. normal vision - 6/6, 6/6 or 
better). 1. CSD ≤ 18 (e.g. 6/9, 6/9). 
2. CSD ≤ 36 (e.g. 6/12, 6/24). 
3. CSD ≤ 60 (e.g. 6/24, 6/36). 
4. CSD ≤ 96 (e.g. 6/60, 6/36). 
5. CSD ≥ 120 (e.g. 6/60, 6/60 or worse). 
 
2. Ptosis  
 
0. None. 
1. Mild ptosis - not obscuring either pupil. 
2. Unilateral ptosis obscuring < 1/3 of pupil. 
3. Bilateral ptosis obscuring < 1/3 or unilateral ptosis obscuring > 1/3 of pupil or prior unilateral surgery. 
4. Bilateral ptosis obscuring > 1/3 of pupils or prior bilateral surgery. 
5. Bilateral ptosis obscuring >2/3 of pupils or >1/3 of pupils despite prior bilateral surgery. 
 
3. Chronic Progressive External Ophthalmoplegia  
 
0. None. 
1. Some restriction of eye movement (any direction). Abduction complete. 
2. Abduction of worst eye incomplete. 
3. Abduction of worst eye below 60% of normal. 
4. Abduction of worst eye below 30% of normal. 
5. Abduction of worst eye minimal (flicker). 
 
4. Dysphonia/Dysarthria  
 
0. None. 
1. Minimal - noted on examination only. 
2. Mild – clear impairment but easily understood. 
3. Moderate – some words poorly understood and infrequent repetition needed. 
4. Severe – many words poorly understood and frequent repetition needed. 
5. Not understood. Requires communication aid. 
 
5. Myopathy  
 
0. Normal. 
1. Minimal reduction in hip flexion and/or shoulder abduction only (e.g. MRC 4+/5). 
2. Mild but clear proximal weakness in hip flexion and shoulder abduction (MRC 4/5). Minimal 
weakness in elbow flexion and knee extension (MRC 4+/5 - both examined with joint at 90 
degrees). 
3. Moderate proximal weakness including elbow flexion & knee extension (MRC 4/5 or 4 -/5) 
or difficulty rising from a 90 degree squat. 
4. Waddling gait. Unable to rise from a 90 degree squat (=a chair) unaided. 















6. Cerebellar ataxia  
 
0. None. 
1. Normal gait but hesitant heel-toe. 
2. Gait reasonably steady. Unable to maintain heel-toe walking or mild UL dysmetria. 
3. Ataxic gait (but walks unaided) or UL intention tremor & past-pointing. Unable to walk heel-toe - 
falls immediately. 
4. Severe - gait grossly unsteady without support or UL ataxia sufficient to affect feeding. 
5. Wheelchair dependent primarily due to ataxia or UL ataxia prevents feeding. 
7. Neuropathy  
 
0. None. 
1. Subtle sensory symptoms or areflexia. 
2. Sensory impairment only (e.g. glove & stocking sensory loss). 
3. Motor impairment (distal weakness) or sensory ataxia. 
4. Sensory ataxia or motor effects severely limit ambulation. 
5. Wheelchair bound primarily due to sensory ataxia or neurogenic weakness. 
 
8. Pyramidal Involvement  
 
0. None. 
1. Focal or generalised increase in tone or reflexes only. 
2. Mild focal weakness, sensory loss or fine motor impairment (e.g. cortical hand). 
3. Moderate hemiplegia allowing unaided ambulation or dense UL monoplegia. 
4. Severe hemiplegia allowing ambulation with aids or moderate tetraplegia (ambulant). 
5. Wheelchair dependent primarily due to hemiplegia or tetraplegia. 
 
9. Extrapyramidal  
 
0. Normal. 
1. Mild and unilateral. Not disabling (H&Y stage 1). 
2. Mild and bilateral. Minimal disability. Gait affected (H&Y stage 2). 
3. Moderate. Significant slowing of body movements (H&Y stage 3) 
4. Severe. Rigidity and bradykinesia. Unable to live alone. Can walk to limited extent (H&Y stage 4). 
5. Cannot walk or stand unaided. Requires constant nursing care (H&Y stage 5). 
 
10. Cognition  
 
Patients undergo testing using WTAR, Symbol Search and Speed of Comprehension Test. 
 
0. Combined centiles 100 or more. 
1. Combined centiles 60 - 99 
2. Combined centiles 30 - 59 
3. Combined centiles 15 - 29 
4. Combined centiles 5 - 14 












Appendix 2:  























SLE Cardio Ptosis CPEO Myopathy 
Threshold 4 1 2 2 2 2 
P01 12.4  0 0 0 0 0 1 
P02 20.7 1 0 0 0 0 1 
P03 20.4 3 0 1 0 0 2 
P04 23.2 3 0 - 0 0 3 
P05 27.9 2 0 0 0 0 2 
P06 33.5 3 3  0 0 3 
P07 21.8 2 0 0 3 0 2 
P08 26.9 2 0 1 1 0 1 
P09 45.1 2 0 1 1 0 2 
P10 21.5 2 0 0 1 0 2 
P11 - - - - - - - 
P12 4.1 0 0 0 0 0 0 
P13 9.7 0 0 0 0 0 0 
P14 26.9 4 0 2 3 2 1 
P15 22.8 3 0 0 0 1 2 
P16 49.7 4 0 0 0 2 1 
P17 14 0 0 - 0 0 0 
P18 49.7 4 0 0 0 2 1 
P19 - - - - - - - 




Appendix 3:  
Table 7.2: Quantification of Complex I (NDUFB8) and Complex IV (COX-I) deficiency in 

















Complex I (NDUFB8) Levels (%) 
 
 

























C01 99.85 0.15 0.00 0.00 0.15 100.00 0.00 0.00 0.00 0.00 1988 
C02 99.91 0.04 0.00 0.04 0.09 99.91 0.04 0.00 0.04 0.09 2295 
C03 99.73 0.09 0.09 0.09 0.27 99.91 0.09 0.00 0.00 0.09 1103 
C04 100.00 0.00 0.00 0.00 0.00 99.65 0.35 0.00 0.00 0.35 1986 
C05 100.00 0.00 0.00 0.00 0.00 99.97 0.03 0.00 0.00 0.03 3401 
Experiment 2 
C01 100.00 0.00 0.00 0.00 0.00 99.72 0.28 0.00 0.00 0.28 2174 
C02 99.94 0.06 0.00 0.00 0.06 99.88 0.12 0.00 0.00 0.12 1691 
C03 99.71 0.19 0.10 0.00 0.29 99.81 0.10 0.10 0.00 0.19 1026 
C04 100.00 0.00 0.00 0.00 0.00 98.23 1.72 0.06 0.00 0.00 1084 
C05 100.00 0.00 0.00 0.00 0.00 99.72 0.22 0.04 0.00 0.00 2680 
Experiment 3 
C01 99.92 0.08 0.00 0.00 0.08 100.00 0.00 0.00 0.00 0.00 1313 
C02 98.65 1.28 0.07 0.00 1.35 99.93 0.07 0.00 0.00 0.07 1479 
C03 100.00 0.00 0.00 0.00 0.00 99.38 0.62 0.00 0.00 0.62 950 
C04 100.00 0.00 0.00 0.00 0.00 99.26 0.75 0.00 0.00 0.75 989 
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Figure 7.1: Mitochondrial respiratory chain profiles highlighting sampled fibres from all patients. 
Coloured dots represent the fibres sampled and correspond to each OXHOS group; Group 1 = red, 






















Table 7.3: The m.3243A>G heteroplasmy levels through inter and intra-variability testing of pyrosequencing 










23 63 63 59 0 4 62 2 
28 91 92 93 1 2 92 1 
49 24 22 19 2 5 22 3 
67 93 92 93 1 1 93 1 
76 73 73 71 0 2 72 1 
118 76 76 75 0 1 76 1 
129 90 90 94 0 4 91 2 
154 93 93 94 0 1 93 1 
158 4 4 4 0 0 4 0 
189 95 94 94 1 1 94 1 
199 23 22 21 1 2 22 1 
201 96 96 95 0 1 96 1 
239 98 97 97 1 1 97 1 
258 88 88 92 0 4 89 2 
261 10 10 6 0 4 9 2 
262 95 96 96 1 1 96 1 
263 95 94 96 1 1 95 1 
269 86 88 85 2 2 86 2 
276 13 14 15 1 2 14 1 
283 77 75 76 2 2 76 1 
295 76 73 73 3 3 74 2 
312 80 82 81 2 2 81 1 
336 6 8 3 2 5 6 3 




368 82 83 83 1 1 83 1 
373 92 90 95 2 5 92 3 
401 69 68 74 1 6 70 3 
432 82 83 82 1 1 82 1 
490 4 3 3 1 1 3 1 
496 91 90 91 1 1 91 1 
498 95 95 97 0 2 96 1 
521 78 78 80 0 2 79 1 
552 93 93 91 0 2 92 1 
595 8 7 3 1 5 6 3 
615 8 8 5 0 3 7 2 
631 9 10 8 1 2 9 1 
640 92 92 92 0 0 92 0 
663 5 4 2 1 3 4 2 
668 2 5 0 3 5 2 3 
683 8 6 4 2 4 6 2 
694 6 6 2 0 4 5 2 
709 84 84 84 0 0 84 0 
843 95 95 94 0 1 95 1 




Appendix 6:  
LOESS profiles showing the Z_score and heteroplasmy level distribution of single fibres and 















Figure 7.2: LOESS profiles showing the Z_score and heteroplasmy level distribution of single fibres 
and the estimated heteroplasmic threshold for deficiency. 
Profiles are representative of fibres from skeletal muscle sections of patients in Group A (A, B, C, D, 
E, F) and patients in Group B (G, H, I) and the estimated threshold defined at the point which model 
curves cross the deficiency cut off at Z_score of -3 (y=-3.  Each white dot represents a single fibre. 
The blue dashed line (y=-3) is the Z_score deficiency cut off. The black curve represents the model 
fitted to the mean of the bootstrapped data and the red curve represents the model fitted to the original 
data. The dotted black line around the curves = 95% confidence intervals of bootstrapped estimate. 
Solid dark blue lines represent the heteroplasmy levels at which the confidence intervals for the model 
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Figure 7.3: Two-dimensional scatterplots (2Dmito plots) comparing Complex I protein expression 
with mitochondrial mass. 
Patients from Group A (A – B) P01, (C-D) P07, (E-F) P11, (G-H) P13, (I-J) P16, (K-L) P18, (M-N) 
P19 show clustering of fibres into two cluster populations for Complex I  after hierarchical clustering; 
blue = biochemically normal fibres and red = biochemically deficient fibres for Complex I which is 
indicated by the decrease in Complex I in relation to log of porin). But only on cluster for Complex IV, 




show only one cluster in the data for both Complex I and Complex IV therefore all fibres are 
biochemically normal (blue). Sampled fibres have been colour co-ordinated according to the original 
Z_score classification; red = Group 1 fibres, green = Group 2 fibres, blue = Group 3 fibres, purple = 
Group 4 fibres. Grey solid and dashed line showing the regression line fitted to the control data and 
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